0001493152-23-020868.txt : 20230612 0001493152-23-020868.hdr.sgml : 20230612 20230612111434 ACCESSION NUMBER: 0001493152-23-020868 CONFORMED SUBMISSION TYPE: 10-K/A PUBLIC DOCUMENT COUNT: 60 CONFORMED PERIOD OF REPORT: 20220731 FILED AS OF DATE: 20230612 DATE AS OF CHANGE: 20230612 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Hartford Great Health Corp. CENTRAL INDEX KEY: 0001482554 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-COMPUTER PROCESSING & DATA PREPARATION [7374] IRS NUMBER: 205422795 STATE OF INCORPORATION: NV FISCAL YEAR END: 0731 FILING VALUES: FORM TYPE: 10-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-54439 FILM NUMBER: 231007387 BUSINESS ADDRESS: STREET 1: 8832 GLENDON WAY CITY: ROSEMEAD STATE: CA ZIP: 91770 BUSINESS PHONE: 626-656-6192 MAIL ADDRESS: STREET 1: 8832 GLENDON WAY CITY: ROSEMEAD STATE: CA ZIP: 91770 FORMER COMPANY: FORMER CONFORMED NAME: Photoamigo, Inc. DATE OF NAME CHANGE: 20100128 10-K/A 1 form10-ka.htm
0001482554 true FY 0001482554 2021-08-01 2022-07-31 0001482554 2022-01-31 0001482554 2023-05-27 0001482554 2022-07-31 0001482554 2021-07-31 0001482554 2020-08-01 2021-07-31 0001482554 us-gaap:CommonStockMember 2020-07-31 0001482554 us-gaap:AdditionalPaidInCapitalMember 2020-07-31 0001482554 us-gaap:RetainedEarningsMember 2020-07-31 0001482554 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-31 0001482554 us-gaap:NoncontrollingInterestMember 2020-07-31 0001482554 2020-07-31 0001482554 us-gaap:CommonStockMember 2021-07-31 0001482554 us-gaap:AdditionalPaidInCapitalMember 2021-07-31 0001482554 us-gaap:RetainedEarningsMember 2021-07-31 0001482554 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-31 0001482554 us-gaap:NoncontrollingInterestMember 2021-07-31 0001482554 us-gaap:CommonStockMember 2020-08-01 2021-07-31 0001482554 us-gaap:AdditionalPaidInCapitalMember 2020-08-01 2021-07-31 0001482554 us-gaap:RetainedEarningsMember 2020-08-01 2021-07-31 0001482554 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-08-01 2021-07-31 0001482554 us-gaap:NoncontrollingInterestMember 2020-08-01 2021-07-31 0001482554 us-gaap:CommonStockMember 2021-08-01 2022-07-31 0001482554 us-gaap:AdditionalPaidInCapitalMember 2021-08-01 2022-07-31 0001482554 us-gaap:RetainedEarningsMember 2021-08-01 2022-07-31 0001482554 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-08-01 2022-07-31 0001482554 us-gaap:NoncontrollingInterestMember 2021-08-01 2022-07-31 0001482554 us-gaap:CommonStockMember 2022-07-31 0001482554 us-gaap:AdditionalPaidInCapitalMember 2022-07-31 0001482554 us-gaap:RetainedEarningsMember 2022-07-31 0001482554 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-31 0001482554 us-gaap:NoncontrollingInterestMember 2022-07-31 0001482554 HFUS:HangzhouLongjingQiaoFuVacationHotelCoLtdMember 2020-12-31 0001482554 HFUS:ShanghaiHartfordComprehensiveHealthManagementLtdMember 2020-12-31 0001482554 HFUS:ShanghaiHongkouHaiDeFuDeChildcareCoLtdMember 2020-03-23 0001482554 HFUS:PudongHaojinChildhoodEducationLtdMember 2019-07-24 0001482554 HFUS:ShanghaiHdfdZhongliEducationTechnologyCoLtdMember 2021-08-31 0001482554 HFUS:ShanghaiJingyuEducationTechLtdMember 2021-08-31 0001482554 HFUS:HangzhouLongjingQiaoFuVacationHotelCoLtdMember us-gaap:SubsequentEventMember 2022-08-01 0001482554 HFUS:ShanghaiOverseaMember HFUS:HartfordInternationalEducationTechnologyCoLtdMember us-gaap:SubsequentEventMember 2022-08-01 0001482554 HFUS:HangzhouHartfordComprehensiveHealthManagementLtdMember us-gaap:SubsequentEventMember 2022-08-01 0001482554 HFUS:ShanghaiOverseaMember HFUS:HangzhouHartfordComprehensiveHealthManagementLtdMember us-gaap:SubsequentEventMember 2022-08-01 0001482554 HFUS:PeoplesBankOfChinaFinancialStabilityBureauMember 2022-07-31 0001482554 2017-12-01 2017-12-22 0001482554 HFUS:EarlyChildhoodEducationServicesMember 2021-08-01 2022-07-31 0001482554 HFUS:EarlyChildhoodEducationServicesMember 2020-08-01 2021-07-31 0001482554 us-gaap:LeaseholdImprovementsMember 2021-08-01 2022-07-31 0001482554 HFUS:ROUAssetsFinanceLeaseMember 2021-08-01 2022-07-31 0001482554 us-gaap:FurnitureAndFixturesMember srt:MinimumMember 2021-08-01 2022-07-31 0001482554 us-gaap:FurnitureAndFixturesMember srt:MaximumMember 2021-08-01 2022-07-31 0001482554 HFUS:OfficeEquipmentVehiclesMember srt:MinimumMember 2021-08-01 2022-07-31 0001482554 HFUS:OfficeEquipmentVehiclesMember srt:MaximumMember 2021-08-01 2022-07-31 0001482554 HFUS:ComputerSoftwareMember srt:MinimumMember 2021-08-01 2022-07-31 0001482554 HFUS:ComputerSoftwareMember srt:MaximumMember 2021-08-01 2022-07-31 0001482554 HFUS:ShareholderMember 2020-11-23 2020-11-24 0001482554 HFUS:ShareholderMember 2020-11-24 0001482554 HFUS:JointVentureAgreementMember 2019-03-22 0001482554 HFUS:ShareholderMember HFUS:HartfordInternationalEducationTechnologyCoLtdMember 2020-07-31 0001482554 HFUS:JointVentureAgreementMember srt:MaximumMember 2020-06-19 0001482554 HFUS:JointVentureAgreementMember srt:MinimumMember 2020-06-19 0001482554 HFUS:JointVentureAgreementMember HFUS:HartfordInternationalEducationTechnologyCoLtdMember HFUS:SevenEducationTextbooksMember 2019-03-22 0001482554 HFUS:JointVentureAgreementMember HFUS:HartfordInternationalEducationTechnologyCoLtdMember HFUS:TenHaiDeFuDeMember 2019-03-22 0001482554 HFUS:JointVentureAgreementMember HFUS:HartfordInternationalEducationTechnologyCoLtdMember srt:ChiefExecutiveOfficerMember 2021-03-31 0001482554 HFUS:ShanghaiGelinkeChildcareEducationCenterMember 2021-07-31 0001482554 HFUS:ShanghaiSeniorHealthConsultingLtdMember 2019-01-31 0001482554 HFUS:ShanghaiSeniorHealthConsultingLtdMember 2019-02-28 0001482554 HFUS:ShanghaiPasadenaLtdMember 2019-01-31 0001482554 HFUS:ShanghaiPasadenaLtdMember 2019-02-28 0001482554 HFUS:ShanghaiLuoShengInternationalTradeLtdMember 2019-01-31 0001482554 HFUS:HangzhouHartfordComprehensiveHealthManagementLtdMember 2020-12-31 0001482554 HFUS:HangzhouHartfordComprehensiveHealthManagementLtdMember 2020-12-30 2020-12-31 0001482554 HFUS:ShanghaiGelinkeChildcareEducationCenterMember 2020-07-20 0001482554 HFUS:ShanghaiGelinkeChildcareEducationCenterMember 2020-07-19 2020-07-20 0001482554 HFUS:QiaoGardenIntelTravelMember 2020-12-31 0001482554 HFUS:QiaoGardenIntelTravelMember 2020-12-29 2020-12-31 0001482554 HFUS:EducationAndHospitalitySegmentsMember us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember 2022-07-31 0001482554 HFUS:EducationAndHospitalitySegmentsMember us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember 2021-07-31 0001482554 HFUS:HartfordInternationalEducationTechnologyCoLtdMember us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember 2021-08-01 2022-07-31 0001482554 HFUS:HartfordInternationalEducationTechnologyCoLtdMember us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember 2020-08-01 2021-07-31 0001482554 HFUS:SHQiahongMember 2022-07-31 0001482554 HFUS:SHQiahongMember 2021-07-31 0001482554 HFUS:ShanghaiOverseaChineseCultureMediaLtdMember 2022-07-31 0001482554 HFUS:ShanghaiOverseaChineseCultureMediaLtdMember 2021-07-31 0001482554 HFUS:HartfordHotelInvestmentIncMember 2022-07-31 0001482554 HFUS:HartfordHotelInvestmentIncMember 2021-07-31 0001482554 HFUS:HartfordHotelInvestmentIncMember 2021-08-01 2022-07-31 0001482554 HFUS:HartfordHotelInvestmentIncMember 2020-08-01 2021-07-31 0001482554 HFUS:IntellectualPropertiesMember HFUS:HartfordInternationalEducationTechnologyCoLtdMember 2021-08-01 2022-07-31 0001482554 HFUS:IntellectualPropertiesMember HFUS:HartfordInternationalEducationTechnologyCoLtdMember 2022-07-31 0001482554 HFUS:HartfordInternationalEducationTechnologyCoLtdMember us-gaap:LicenseMember 2021-08-01 2022-07-31 0001482554 HFUS:HartfordInternationalEducationTechnologyCoLtdMember us-gaap:LicenseMember 2020-08-01 2021-07-31 0001482554 HFUS:HospitalityMember us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember 2021-08-01 2022-07-31 0001482554 HFUS:EducationMember us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember 2021-08-01 2022-07-31 0001482554 HFUS:CorporateAndUnallocatedMember 2021-08-01 2022-07-31 0001482554 HFUS:HospitalityMember us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember 2022-07-31 0001482554 HFUS:EducationMember us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember 2022-07-31 0001482554 HFUS:CorporateAndUnallocatedMember 2022-07-31 0001482554 HFUS:HospitalityMember us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember 2020-08-01 2021-07-31 0001482554 HFUS:EducationMember us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember 2020-08-01 2021-07-31 0001482554 HFUS:CorporateAndUnallocatedMember 2020-08-01 2021-07-31 0001482554 HFUS:HospitalityMember us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember 2021-07-31 0001482554 HFUS:EducationMember us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember 2021-07-31 0001482554 HFUS:CorporateAndUnallocatedMember 2021-07-31 0001482554 HFUS:HangzhouLongjingQiaoFuVacationHotelCoLtdMember 2022-08-01 0001482554 us-gaap:SubsequentEventMember HFUS:ShangaiLuoShengInternationalTradeLtdMember 2022-08-01 0001482554 HFUS:RelatedPartyMember us-gaap:SubsequentEventMember 2022-08-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure iso4217:CNY

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.

 

FORM 10-K/A

Amendment No.1

 

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the fiscal year ended July 31, 2022

 

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _____ to _____

 

Commission file number 000-54439

 

Hartford Great Health Corp.

(Exact name of registrant as specified in its charter)

 

Nevada   51-0675116
(State or other jurisdiction of   (I.R.S. Employer
incorporation or organization)   Identification No.)

 

8832 Glendon Way, Rosemead, California   91770
(Address of principal executive offices)   (Zip Code)

 

(626) 321-1915

(Registrant’s telephone number, including area code)

 

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes ☐ No

 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

Yes ☒ No ☐

 

Indicate by check mark whether the issuer (1) filed all reports required to be filed by Sections 13 or 15(d) of the Securities Exchange Act of 1934 during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by checkmark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§ 229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☒

 

January 31, 2022, the last business day of the Registrant’s most recently completed second fiscal quarter, the aggregate market value of the voting common stock held by non-affiliates of the Registrant (without admitting that any person whose shares are not included in such calculation is an affiliate) was $5,002,840.

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer ☐ Accelerated filer ☐
Non-accelerated filer Smaller reporting company
Emerging growth company  

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common stock, par value $0.001 par value   HFUS   OTC Markets Group

 

Securities registered pursuant to Section 12(g) of the Act: Common Stock, Par value $0.001

 

State the number of shares outstanding of each of the issuer’s classes of common equity, as of the latest practicable date: 100,108,000 shares of common stock outstanding as of May 27, 2023.

 

 

 

 

 

 

EXPLANATORY NOTE

 

This Amendment No. 1 to our Annual Report on Form 10-K for the annual period from August 1, 2021 to July 31, 2022, which was filed with the U.S. Securities and Exchange Commission (the “SEC”) on November 14, 2022 (the “Original Filing”), is being filed for the following purposes:

 

(a) for Consolidated balance sheets on Item 8, Financial Statements, of Part II of Form 10-K, to reclass the balance of Non-current assets held for sale, as of July 31, 2022, to Current assets held for sale.

 

(b) for Consolidated statements of operations on Item 8, Financial Statements, of Part II of Form 10-K, to separately disclose the discontinued operation results for years ended July 31, 2022 and 2021.

 

(c) for Liquidity and Capital Resources section on Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operation, of Part II of Form 10-K, to update the negative working capital comparison due to above (a) reclassification.

 

(d) for Results of Operations section on Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operation, of Part II of Form 10-K, to update Results of Operations- Year Ended July 31, 2022 Compared to Year Ended July 31, 2021 due to above (b) disclosure.

 

Except as described above, this Amendment No. 1 does not amend, modify, or otherwise update any other information in the Original 2022 Form 10-K and does not reflect events occurring after the filing of the Original 2022 Form 10-K.

 

 
 

 

TABLE OF CONTENTS

 

PART I    
     
ITEM 1: BUSINESS 4
ITEM 1A: RISK FACTORS 6
ITEM 1B: UNRESOLVED STAFF COMMENTS 6
ITEM 2: PROPERTIES 6
ITEM 3: LEGAL PROCEEDINGS 6
ITEM 4: MINE SAFETY DISCLOSURES 6
     
PART II    
     
ITEM 5: MARKET FOR COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND PURCHASES OF EQUITY SECURITIES 7
ITEM 6: SELECTED FINANCIAL DATA 8
ITEM 7: MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION 9
ITEM 7A. QUANTATIVE AND QUALATATIVE DISCLOSURES ABOUT MARKET RISK 13
ITEM 8: FINANCIAL STATEMENTS 14
ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANS ON ACCOUNTING AND FINANCIAL DISCLOSURE 28
ITEM 9A. CONTROLS AND PROCEDURES 28
ITEM 9B: OTHER INFORMATION 29
     
PART III    
     
ITEM 10: DIRECTORS, EXECUTIVE OFFICERS, AND CORPORATE GOVERNANCE 29
ITEM 11: EXECUTIVE COMPENSATION 31
ITEM 12: SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS 32
ITEM 13: CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE 32
ITEM 14: PRINCIPAL ACCOUNTING FEES AND SERVICES 33
     
PART IV    
     
ITEM 15: EXHIBITS 33
   
SIGNATURES 34

 

ADDITIONAL INFORMATION

 

Descriptions of agreements or other documents contained in this report are intended as summaries and are not necessarily complete. Please refer to the agreements or other documents filed or incorporated herein by reference as exhibits. Please see the exhibit index at the end of this report for a complete list of those exhibits.

 

2
 

 

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

This report contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties and are based on the beliefs and assumptions of management and information currently available to management. The use of words such as “believes”, “expects”, “anticipates”, “intends”, “plans”, “estimates”, “should”, “likely” or similar expressions, indicates a forward-looking statement.

 

The identification in this report of factors that may affect future performance and the accuracy of forward-looking statements is meant to be illustrative and by no means exhaustive. All forward-looking statements should be evaluated with the understanding of their inherent uncertainty.

 

Factors that could cause actual results to differ materially from those expressed or implied by forward-looking statements include, but are not limited to:

 

The worldwide economic situation;
Any change in interest rates or inflation;
The willingness and ability of third parties to honor their contractual commitments;
The Company’s ability to raise additional capital, as it may be affected by current conditions in the stock market and competition for risk capital;
The Company’s capital costs, as they may be affected by delays or cost overruns;
The Company’s costs of production;
Environmental and other regulations, as the same presently exist or may later be amended;
The Company’s ability to identify, finance and integrate any future acquisitions; and
The volatility of the Company’s stock price.

 

3
 

 

PART I

 

ITEM 1. BUSINESS.

 

General

 

Hartford Great Health Corp. (“the Company”, “Hartford” “we”, “us” or our”) was incorporated in the State of Nevada on April 2, 2008 (“Inception) under the name PhotoAmigo, Inc. It changed its name to Hartford Great Health Corp. on August 20, 2018, and since then we have been engaged in activities to formulate and implement our business plan as set forth below.

 

Overview

 

Up until August 2018, we provided social networking and photo sharing from the website PhotoAmigo.com. We also maintained the domain names PhotoAmigo.net, fotoamigo.com and fotoamigo.net. These domain names all redirect incoming traffic to our main website, PhotoAmigo.com.

 

In August 2018, the Company changed its future plans of operations. Through its wholly owned subsidiary - Hangzhou Hartford Comprehensive Health Management, Ltd (“HZHF) and HZHF’s 60 percent owned subsidiary - Hangzhou Longjing Qiao Fu Vacation Hotel Co., Ltd. (“HZLJ”), and through Shanghai Hartford Comprehensive Health Management, Ltd. (“HFSH”) and its 90 percent owned subsidiary - Shanghai Qiao Garden International Travel Agency (“Qiao Garden Int’l Travel”), the Company engages in hospitality industry in China. Qiao Garden Int’l Travel was disposed on December 31, 2020, see note 4 Acquisitions, Joint Ventures and Deconsolidation.

 

The Company started to engage in early childhood education industry at Hartford International Education Technology Co., Ltd (“HF Int’l Education”). HFSH originally held 75.5% ownership of HF Int’l Education and maintains control over HF Int’l Education. During the board meeting in 2021, SH Jingyu and another noncontrolling shareholders sold a total of 14.5% equity at zero value to HFSH. As a result, HFSH holds 90% of HF Int’l Education and a total of 10% equity is held by two individual noncontrolling shareholders. On July 24, 2019 and March 23, 2020, HF Int’l Education established two 100% owned subsidiaries, Pudong Haojin Childhood Education Ltd. (“PDHJ”) and Shanghai Hongkou HaiDeFuDe Childcare Co., Ltd.(“HDFD”), respectively, to operate the early childhood education service under the brand name of “HaiDeFuDe” in Shanghai, China. On July 20, 2020, HF Int’l Education entered an agreement with two individuals to acquire the whole ownership of Shanghai Gelinke Childcare Education Center (“Gelinke”). Gelinke temporally ceased its operations by the end of August 2021. On August 31, 2021, PDHJ established one 96% owned subsidiary, Shanghai HDFD Zhongli Education Technology Co., Ltd. (“Zhongli”), two individual investors hold the remaining 4% ownership, see note 4 Acquisitions, Joint Ventures and Deconsolidation.

 

In March 2021, HF Int’l Education entered agreements with Hartford Health Management (Shanghai), Co. Ltd. (“HFHM”). HFHM purchased seven education & intellectual property copy rights and ten “HaiDeFuDe” registered trademarks from HF Int’l Education for a total amount of RMB1.2M and RMB1.0M, respectively. As a part of the purchase agreement, HFHM was originally agreed to be paid the 90% of gross tuition income from the three childcare centers. Due to impacts from the pandemic and new regulations issued by Chinese government in education industry, HF Int’l Education occurred significant loss from operation. Both parties mutually agreed to amend the fee to 20% on July 2022, the amended rate is retrospectively applicable to June 1, 2021.

 

The following business plan is based on research and discussions between the board and third party suppliers and experts. Only preliminary activities relating to the following objectives have been undertaken and therefore, there is no assurance that any of the proposed activities set forth below will be started by the Company or if started will be successful.

 

Strategy

 

The initial plan focuses on the development of the Sino-U.S. health industry in the following four areas:

 

A. International Anti-Aging Membership Program,

B. Artificial Intelligence and Medical Equipment Sales,

C. Mobile Lifestyle Health & Wellness Management Platform,

D. Integrated Health Management of Metabolic Diseases.

 

4
 

 

The Company has also expanded its strategy into the hospitality industry, focusing on hotels, restaurants, and travel arrangements. The Company plans to integrate hospitality with health management through its membership-based program by arranging travel accommodations for Chinese citizen members to the United States to obtain stem cell beauty treatments.

 

The initial plan in early 2019 that focused on the development of the Sino-U.S. health industry in the areas of International Anti-Aging membership based program; Artificial Intelligence and Medical Equipment Sales; Mobile Lifestyle Management Platform; and Integrated management of metabolic diseases have been put on hold due to economic uncertainties caused by the increasing tension between the US and China international relation.

 

Near the end of 2019, the Company has found another opportunity to expand its market reach in the Chinese childhood education industry. The Company plans to formulate a proprietary early childhood education center management model beginning with the opening of several early childhood education centers in the greater Shanghai area with the goal of demonstrating the management model in action in order to attract interest from potential franchisees. Currently, there are three early child education and development center in operation despite the economic slowdown during the pandemic. The recent “Three-child policy” announced on May 1, 2021, by Chinese government further increases the market opportunities in early childhood education industry. On July 24, 2021, the Chinese government announced a “Double-Reduction” education policy to be taken effective on August 31, 2021. This new education policy has since impacted the Company’s early childhood education business. Due to China’s zero-Covid policy implementation during the pandemic as well as Covid-19 lockdown for over two months in Greater Shanghai, childcare and childhood education center were forced to halt operations; therefore, the Company decides to divert its plan from childcare and childhood educational development industry. In the near future, the company is looking into wholesale distribution of herbal supplement health products in China.

 

There can be no assurance following consummation of any of the business ventures will develop into a going concern or, if the business is already operating, that it will continue to operate successfully. Many of the potential business opportunities available to the Company may involve new and untested products, processes or market strategies which may not ultimately prove successful.

 

The Company’s independent auditors have issued a report raising substantial doubt about the Company’s ability to continue as a going concern. At present, the Company has limited operations and the continuation of the Company as a going concern is dependent upon financial support from its stockholders, its ability to obtain necessary equity financing to continue operations and/or to successfully locate and negotiate with a business entity for the combination of that target company with the Company. There is no assurance that the Company will ever be profitable.

 

5
 

 

Employees

 

As of November 14, 2022, we have 14 employees.

 

ITEM 1A. RISK FACTORS

 

As a “smaller reporting company” as defined by Item 8 of Regulation S-K, the Company is not required to provide information required by this Item.

 

ITEM 1B. UNRESOLVED STAFF COMMENTS

 

None.

 

ITEM 2. PROPERTIES

 

Hartford Great Health Corp. uses the offices of its Chief Executive Officer, at 8832 Glendon Way, Rosemead, CA 91770, for its minimal office facility needs for no consideration.

 

Each newly acquired or formed entity maintains its own leased office building and property. We lease spaces in Shanghai and Hangzhou, China under leases that expire at various times between 2023 and 2051 with various term extensions available.

 

We lease all of our facilities and do not own any real property.

 

ITEM 3. LEGAL PROCEEDINGS

 

On March 21, 2022, HF Int’l Education filed a civil case against the landlord demanding reductions of office rent due to mandatory business lockdown ordered by Shanghai health officials. The case has been accepted by the court and pending court date.

 

We were not subject to any other legal proceedings during the twelve months ended July 31, 2022, and are not currently subject to any legal proceedings, and to the best of our knowledge, no such proceeding is threatened, the results of which would have a material impact on our results of operation or financial condition. Nor, to the best of our knowledge, are any of our officers or directors involved in any legal proceedings in which we are an adverse party.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable to our Company.

 

6
 

 

PART II

 

ITEM 5. MARKET FOR COMMON EQUITY. RELATED STOCKHOLDER MATTERS AND PURCHASES OF EQUITY SECURITIES

 

Market Information

 

There has only been limited trading for the Company’s Common Stock since it was quoted on OTC Markets. There is no assurance that an active trading market will ever develop or, if such a market does develop, that it will continue. The Securities and Exchange Commission has adopted Rule 15g-9 which establishes the definition of a “penny stock,” for purposes relevant to the Company, as any equity security that has a market price of less than $5.00 per share or with an exercise price of less than $5.00 per share, subject to certain exceptions. For any transaction involving a penny stock, unless exempt, the rules require: (i) that a broker or dealer approve a person’s account for transactions in penny stocks and (ii) the broker or dealer receive from the investor a written agreement to the transaction, setting forth the identity and quantity of the penny stock to be purchased. In order to approve a person’s account for transactions in penny stocks, the broker or dealer must (i) obtain financial information and investment experience and objectives of the person and (ii) make a reasonable determination that the transactions in penny stocks are suitable for that person and that person has sufficient knowledge and experience in financial matters to be capable of evaluating the risks of transactions in penny stocks. The broker or dealer must also deliver, prior to any transaction in a penny stock, a disclosure schedule prepared by the Commission relating to the penny stock market, which, in highlight form, (i) sets forth the basis on which the broker or dealer made the suitability determination and (ii) that the broker or dealer received a signed, written agreement from the investor prior to the transaction. Disclosure also has to be made about the risks of investing in penny stocks in both public offerings and in secondary trading, and about commissions payable to both the broker-dealer and the registered representative, current quotations for the securities and the rights and remedies available to an investor in cases of fraud in penny stock transactions. Finally, monthly statements have to be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stocks.

 

Because of these regulations, broker-dealers may encounter difficulties in their attempt to buy or sell shares of our common stock, which may affect the ability of our shareholders to sell their shares in the secondary market and have the effect of reducing the level of trading activity in the secondary market. These additional sales practice and disclosure requirements could impede the sale of our common stock in the market place. In addition, the liquidity for our common stock may be decreased, with a corresponding decrease in the price of our common stock. Our shares are likely to be subject to such penny stock rules for the foreseeable future.

 

On November 14, 2022, the closing price of our common stock reported on the OTC Markets was $0.16 per share. The following table sets forth, for each of the quarterly periods indicated, the high and low sales prices of our common stock, as reported on the OTC Markets.

 

Fiscal 2021  Low   High 
First Quarter  $0.16   $0.95 
Second Quarter  $0.16   $0.16 
Third Quarter  $0.03   $1.00 
Fourth Quarter  $0.03   $0.16 

 

Fiscal 2022  Low   High 
First Quarter  $0.16   $0.16 

 

Holders

 

As of November 14, 2021, a total of 100,108,000 shares of our common stock were outstanding and there were approximately 52 holders of record.

 

7
 

 

Penny Stock Rules

 

Due to the price of our common stock, as well as the fact that we are not listed on Nasdaq or a national securities exchange, our stock is characterized as “penny stocks” under applicable securities regulations. Our stock will therefore be subject to rules adopted by the Securities and Exchange Commission (“SEC”) regulating broker-dealer practices in connection with transactions in penny stocks. The broker or dealer proposing to affect a transaction in a penny stock must furnish his customer a document containing information prescribed by the SEC and obtain from the customer an executed acknowledgment of receipt of that document. The broker or dealer must also provide the customer with pricing information regarding the security prior to the transaction and with the written confirmation of the transaction. The broker or dealer must also disclose the aggregate amount of any compensation received or receivable by him in connection with such transaction prior to consummating the transaction and with the written confirmation of the trade. The broker or dealer must also send an account statement to each customer for which he has executed a transaction in a penny stock each month in which such security is held for the customer’s account. The existence of these rules may have an effect on the price of our stock, and the willingness of certain brokers to effect transactions in our stock.

 

Transfer Agent

 

We have appointed EQ by Equiniti, as the transfer agent for our common stock. The principal office of EQ is located at 1110 Centre Pointe Curve #101, Mendota Heights, MN 55120 and its telephone number is (612) 209-9006.  

 

Dividend Policy

 

We have never declared or paid dividends on our common stock. Payment of future dividends, if any, will be at the discretion of our Board of Directors after taking into account various factors, including the terms of any credit arrangements, our financial condition, operating results, current and anticipated cash needs and plans for expansion. At the present time, we intend to retain any earning in our business, and therefore do not anticipate paying dividends in the foreseeable future.

 

Recent Sales of Unregistered Securities; Use of Proceeds from Unregistered Securities

 

None

 

ITEM 6. SELECTED FINANCIAL DATA

 

As a “smaller reporting company” as defined by Item 8 of Regulation S-K, the Company is not required to provide information required by this Item.

 

8
 

 

ITEM 7. MANAGEMENTS’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION

 

The following discussion and analysis were prepared to supplement information contained in the accompanying financial statements and is intended to explain certain items regarding the financial condition as of July 31, 2022, and the results of operations for the years ended July 31, 2022, and 2021. It should be read in conjunction with the audited financial statements and notes thereto contained in this report.

 

Overview of the Business

 

Hartford Great Health Corp. was originally incorporated in the State of Nevada on April 2, 2008, under the name PhotoAmigo, Inc. It changed its name to Hartford Great Health Corp. on August 22, 2018, and since then we have been engaged in activities to formulate and implement our business plan as set forth below.

 

Ability to continue as a “going concern”.

 

The independent registered public accounting firms’ reports on our financial statements as of July 31, 2022 and 2021, includes a “going concern” explanatory paragraph that describes substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to the factors prompting the explanatory paragraph are discussed in the financial statements, including footnotes thereto.

 

Plan of Operation

 

As of July 31, 2022, the company has issued a total of 100,108,000 shares of common stock. On December 11, 2018, 96,090,000 shares of common stock were issued at the price of $0.02 per share to raise an additional $1,921,800 in capital. On November 24, 2020, the Company issued additional 1,000,000 shares of common stock to a significant shareholder of the Company at $0.02 per share.

 

On December 28, 2018, the Company acquired Hangzhou Hartford Comprehensive Health Management, Ltd (“HZHF”). On March 22, 2019, the Company acquired 60 percent of Hangzhou Longjing Qiao Fu Vacation Hotel Co., Ltd. (“HZLJ”). On March 20, 2019, the Company acquired Shanghai Hartford Comprehensive Health Management, Ltd. (“HFSH”) with 90 percent of Shanghai Qiao Garden International Travel Agency (“Qiao Garden Int’l Travel”), which was disposed on December 31, 2020, and formed a joint venture entity, Hartford International Education Technology Co., Ltd (“HF Int’l Education”).

 

The subsidiary of HFUS in Shanghai (HFSH) advances operating funds from two related party entities, SH Qiao Hong and SH Oversea Chinese Culture Media Ltd. The main purpose of the funding is to invest in Hartford International Education Technology (Shanghai) Co., Ltd. (HF Int’l Education). Upon signing of supplemental agreement, HFUS currently holds 75.5% ownership of HF Int’l Education and maintains control over HF Int’l Education. On July 24, 2019, HF Int’l Education established a 100% owned subsidiary, Pudong Haojin Childhood Education Ltd. (“PDHJ”). On October 28, 2019, PDHJ had its childhood education center opened. On March 23, 2020, HF Int’l Education established Shanghai Hongkou HaiDeFuDe Childcare Co., Ltd.(“HDFD”) and was approved the business license to conduct childcare operations in Shanghai, China. On July 20, 2020, HF Int’l Education entered an agreement with two individuals to acquire the whole ownership of Shanghai Gelinke Childcare Education Center (“Gelinke”). During the board meeting, SH Jingyu and another noncontrolling shareholders also sold a total of 14.5% equity at zero value to HFSH. As a result, HFSH holds 90% of HF Int’l Education and a total of 10% equity is held by two individual noncontrolling shareholders.

 

HF Int’l Education has developed an enhanced model of childcare franchise management program and registered a new brand name, “HaiDeFuDe”. HF Int’l Education has recruited a team of knowledgeable childcare teachers to develop series of independent textbooks designed to targeted age of young children and register for the copyrights for these textbooks in September of 2020. Since then, HF Int’l Education has begun marketing and promoting the enhanced model of franchise operation and management packaged program, under “HaiDeFuDe” brand, to an initial of 50 franchisees throughout different regions of China. To achieve that, HF Int’l Education has incorporated existing market resources throughout other major cities and provinces in China. The promotion of HF Int’l Education franchise operation and management model was expected to attract other childcare education centers to join the “HaiDeFuDe” brand, and HF Int’l Education expected to generate revenue from franchise and management fees.

 

9
 

 

Due to continued market uncertainties during the pandemic, the board of HFSH adopted a new management approach to ease cash flow and reduce operation loss. In March 2021, HF Int’l Education entered agreements with Hartford Health Management (Shanghai), Co. Ltd. (“HFHM”). HFHM purchased seven education & intellectual property copy rights and ten “HaiDeFuDe” registered trademarks from HF Int’l Education for a total amount of RMB1.2M and RMB1.0M, respectively. In June 2021, HF Int’l Education and its three subsidiaries entered license agreements with HFHM for the rights to use the intellectual Properties (the “IPs”) HFHM owns. The IPs cover in the license agreements are four sets of curriculum structure designed and fifteen trademarks including “HaiDeFuDe” registered trademarks purchased from HF Int’l Education. As a return, on a monthly basis, HF Int’l Education and its subsidiaries pays 20% of its tuition revenue generated to HFHM as license usage fee.

 

However, due to China’s continual of zero-Covid policy implementation this year as well as Covid-19 lockdown for over two months in Greater Shanghai, childcare and childhood education center were forced to halt operations; therefore, the Company decides to divert its plan from childcare and childhood educational development industry. In the near future, the company is looking into wholesale distribution of herbal supplement health products in China.

 

Liquidity and Capital Resources

 

As of July 31, 2022, we had negative working capital of $6,440,655 comprised of current assets of $4,530,350 and current liabilities of $10,971,005. This represents a decrease of $892,063 in the working capital balance from the July 31, 2021 negative amount of $5,548,592. During the year-ended July 31, 2022, our working capital deficit increased primarily because additional advances from related parties for business operating.

 

We believe that our funding requirements for the next twelve months will be in excess of $150,000. We are currently seeking for further funding through related parties’ loan and finance.

 

On December 11, 2018, the Company sold 96,090,000 shares of its common stock (the “Shares”) to 15 individuals. The selling price was $0.02 per share for an aggregate of $1,921,800. All 15 investors executed subscription agreements. As of April 30, 2019, all proceeds have collected. Twelve of the 15 investors are Chinese citizens and purchased the shares in China. Due to the strict monitoring of China’s foreign exchange investment policy, funds are not able to be transferred directly to HFUS. As a result, amount of $657,000 were collected in RMB from the Chinese investors. The Shares were sold in a private placement pursuant to an exemption from registration in accordance with Section 4(2) and/or Regulation S under the Securities Act of 1933, as amended. The Shares are all restricted shares and accordingly all stock certificates evidencing the Shares have been affixed with the appropriate legend restricting sales and transfers.

 

On November 24, 2020, the Company issued additional 1,000,000 shares of common stock to a significant shareholder of the Company at $0.02 per share.

 

We will seek additional financing in the form of debt or equity. There is no assurance that we will be able to obtain any needed financing on favorable terms, or at all, or that we will find qualified purchasers for the sale of our stock. Any sales of our securities would dilute the ownership of our existing investors.

 

Cash Flows – Year Ended July 31, 2022 Compared to Year Ended July 31, 2021

 

Operating Activities

 

During the year ended July 31, 2022, $860,832 used in operating activities compared to $2,381,575 used in the operations during the year ended July 31, 2021.

 

During the year ended July 31, 2022, we recorded losses including noncontrolling interests of $1,772,582 , incurred non-cash depreciation of $122,065 , prepaid and other current receivables decreased by $225,428 , inventory decreased by $5,327 , other assets decreased by $24,078 , contract liabilities increased by $26,466 , other current payable increased by $102,526 , related party payables net with receivables decreased by $81,013 , other liabilities increased by $27,880 and operating lease liabilities net with operating lease assets increased by $458,993 as a result from the delayed rent payments.

 

During the year ended July 31, 2021, we recorded losses including noncontrolling interests of $2,842,339, incurred non-cash depreciation of $85,103, Loss absorbed from subsidiary restructure $403,131, gain on disposal of subsidiary of $104,317, including noncontrolling interest, goodwill impairment loss of $70,514, prepaid and other current receivables increased by $87,977, inventory increased by $299,588, other assets decreased by $10,435, contract liabilities increased by $373,413, other current payable increased by $312,902, related party payables net with receivables decreased by $185,693, other liabilities increased by $27,108 and operating lease liabilities net with operating lease assets increased by $17,779 as a result from the adoption of new lease guidance ASU No. 2016-02.

 

10
 

 

Investing activities

 

Cash used in investing activities was $145,048 for the year ended July 31, 2022 as compared to $185,682 cash used in investing activities for the corresponding period in 2021.

 

During the year ended July 31, 2022, the Company purchased Property and equipment of $145,048.

 

During the year ended July 31, 2021, HF Int’l Education acquired a new entity, Gelinke with cash net inflow of $12,721, HFSH disposed its 90 percent owned subsidiary - Qiao Garden Int’l Travel with cash net outflow of $30,116, and Property and equipment purchases of $168,287.

 

Financing activities

 

Cash provided by financing activities was $972,267 for the year ended July 31, 2022 as compared to $2,549,984 for the year ended July 31, 2021. The cash flows provided by financing activities for the year ended July 31, 2022 was primarily attributable to $788,673 funding support from related parties, $145,000 notes payable from one related party, $61,750 contribution from noncontrolling interest, offset by $23,156 finance lease principal payment.

 

The cash flows provided by financing activities for the year ended July 31, 2021 was primarily attributable to $2,407,033 funding support from related parties, $145,000 notes payable from one related party, $20,000 proceeds from stock issuance, offset by $22,049 finance lease principal payment.

 

Equity and Capital Resources

 

We have incurred losses since inception of our business and, as of July 31, 2022, we had an accumulated deficit of $7,400,620 compared to $5,821,519 at the previous year end. To date, we have funded our operations through short-term debt and equity financing.

 

We   expect our expenses will decrease in the foreseeable future because of the decrease in operational expenses and because of closure of the childcare education centers. The two remaining childcare education centers with our Chinese subsidiaries were generating limited revenues during the pandemic and were forced to halt operations due to Covid-19 lockdown since March 2022. The generated revenue is not expected to be sufficient to cover our marketing needs in the foreseeable future due to the uncertainties affected by the Zero-Covid policy in China. Consequently, we are dependent on the proceeds from future debt or equity investments to sustain our operations and implement our business plan. If we are unable to raise sufficient capital, we will be required to delay or forego most of our business plan, which would have a material adverse effect on our anticipated results from operations and financial condition. There is no assurance that we will be able to obtain necessary amounts of additional capital or that our estimates of our capital requirements will prove to be accurate.

 

Future Capital Expenditures

 

On January 2019, HFSH entered an agreement to acquire 100 percent equity interest of Shanghai Luo Sheng International Trade Ltd. (“SH Luosheng”). As of July 31, 2022, the agreement has not yet taken effective as no consideration has been paid toward those acquisitions. The agreement will be executed when the Company is financially ready to move forward, and the purchase price will be calculated based on the net assets of each entity on execute dates. There was no penalty levied or to be levied due to delayed execution or inexecution of this agreement.  

 

Off-Balance Sheet Arrangements

 

As of and subsequent to July 31, 2022, we have no off-balance sheet arrangements.

 

Contractual Commitments

 

As of July 31, 2022, we have no other material contractual commitments except the office building and property leases which are included Note 13 Leases. (see note 7. Commitments and contingencies)

 

11
 

 

Results of Operations- Year Ended July 31, 2022 Compared to Year Ended July 31, 2021 (restated)

 

Operating Expenses: Operating expenses decreased to $177,913 for the year ended July 31, 2022, compared to $255,655 during the comparable period of 2021. The decrease of operating expenses was due to the reduction of payroll and professional expenses occurred in US as a result of the downsize of business operation.

 

Other Income (Expense): Other expense, net amount of $11,717 for the year ended July 31, 2022, compared to $174,727 of other income for the corresponding period of 2021. Other expense for the year ended July 31, 2022 was mainly resulted from interest expenses. Other income for the year ended July 31, 2021 was mainly resulted from $104,317 gain on disposal of subsidiary, as well as $55,604 gain of the lease payable write-off as a result of the legal settlement (see note 7. Commitments and contingencies).

 

Net Loss from continuing operations: Net loss from continuing operations increased to $190,430 for the year ended July 31, 2022, compared to $81,728 for the corresponding period of 2021 as result of above.

 

Net Loss from discontinued operations, net of tax: We realized $1,582,152 net operation loss, including $561,262 revenue, $234,118 cost of revenue and $2,022,897 operating expenses and $113,601 other income for the year ended July 31, 2022, from two industry segments, the hospitality housing in HZLJ and childhood education care services in HF Int’l Education. We realized $2,760,611 net operation loss, including $553,459 revenue, $308,413 cost of revenue and $3,005,657 operating expenses and others for the year ended July 31, 2021, from two industry segments, the hospitality housing in HZLJ and childhood education care services in HF Int’l Education. These two business operations have been disposed on August 1, 2022. (see note 4 Acquisitions, Joint Ventures and Deconsolidation)

 

Net Loss Attributable to Noncontrolling Interest: For the year ended July 31, 2022, we recorded a net loss attributable to Noncontrolling interest of $193,481 compared to $589,005 for the corresponding period of 2021. The loss was allocated based on the ownership percentage of noncontrolling interest, which was mainly acquired through the acquisitions and Joint Ventures.

 

Net Loss Attributable to Hartford Great Health Corp: We recorded a net loss of $1,579,101 or $ (0.02) per share for the year ended July 31, 2022, compared to a net loss of $2,253,334 or $(0.02) per share for the year ended July 31, 2021, a decrease in losses of $674,233 due to the factors discussed above.

 

Discontinued Operations (restated): Subsequently on August 1, 2022, we entered a contract with a related party, Shanghai Oversea Chinese Culture Media Ltd. (“SH Oversea”), to sell 90 percent ownership of HF Int’l Education and its subsidiaries. We also entered a contract with SH Oversea and another individual, to sell 100 percent ownership of HZHF and its subsidiaries. See “Note 5. Discontinued Operation” to our consolidated financial statements included in this report. As of July 31, 2022, the assets and liabilities grouped under Education and Hospitality segments classified as assets and/or liabilities held for sale, and it is the Company’s intention to complete the sales of these assets within the upcoming year. The transactions meet the criteria to be reported as a discontinued operation as they constitute significant strategic business shifts for the Company.

 

12
 

 

Accounting Policies and Pronouncements

 

Critical Accounting Policies and Estimates

 

Our consolidated financial statements are prepared in accordance with GAAP. GAAP requires us to make estimates and assumptions that affect the reported amounts in our consolidated financial statements. Critical accounting estimates are those that management believes are the most important to the portrayal of our financial condition and results and require the most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain and that have had, or are reasonably likely to have, a material impact on our financial condition or results of operations. Judgments and uncertainties may result in materially different amounts being reported under different conditions or using different assumptions. See “Part II, Item 8 – Financial Statements – Note 1 –Summary of Significant Accounting Policies” for a summary of our significant accounting policies.

 

The following summarizes our most significant critical accounting estimates:

 

Foreign Currency: The accounts of the Company’s foreign subsidiaries are translated in accordance with FASB ASC 830. Foreign currency transaction gains and losses are recognized in other expense, net, at the time they occur. Net foreign currency exchange gains or losses resulting from the translation of assets and liabilities of foreign subsidiaries whose functional currency is not the U.S. dollar are recorded as a part of accumulated other comprehensive loss in stockholders’ equity. The Company does not undertake hedging transactions to cover its foreign currency exposure.

 

Revenue Recognition: The Company adopted ASC Topic 606 Revenue from Contracts with Customers (“Topic 606) on August 1, 2019, applying the modified retrospective method to all contracts that were not completed as of August 1, 2019. The Company is building up its core business upon the completion of multiple acquisitions in March 2019 and impact of COVID-19 pandemic, limited operations occurred during the years ended July 31, 2022 and 2021. The revenue during the year ended July 31, 2022 and 2021 was mainly generated from HZLJ and HF Int’l Education.

 

Revenue is recognized when control of promised goods or services is transferred to our customers in an amount of consideration to which we expect to be entitled to in exchange for those goods or services. We follow the five steps approach for revenue recognition under Topic 606: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) we satisfy a performance obligation. Billings to customers for which services are not rendered are considered deferred revenue. ASC 606 has no material impacts on the Company’s financial positions. The Company’s revenue is recognized when it satisfies a single performance obligation by transferring control of its products or providing services to a customer. The Company’s general payment terms are short-term in duration. The Company does not have significant financing components or payment terms.

 

a.Early childhood education services: HF Int’l Education generates revenue from childhood education classes provided to its customers. The educational services consist of parent-child and bilingual childcare classes. Each contract of educational classes is accounted for as a single performance obligation which is satisfied proportionately over the service period. Tuition fee is generally collected in advance and is initially recorded as deferred revenue and transferred to contract liabilities after trial period. Refunds are provided to parents if they decide within the trial period that they no longer want to take the class. After the trial period, if a parent withdraws from a class, usually only that unearned portion of the fee is available to be returned. For the year ended July 31, 2022 and 2021, $509,920 and $435,149, respectively, of revenue were derived from early childhood education classes provided.

 

b.Hospitality services: HZLJ generates revenue primarily from the room rentals, sale of food and beverage and other miscellaneous hospitality services. The Company recognizes room rental and services daily as services are provided. Under ASC 606, the pattern and timing of recognition of income from hotel facility is consistent with the prior accounting model.

 

Recent Accounting Pronouncements.

 

See “Part II, Item 8 – Financial Statements – Note 1 –Summary of Significant Accounting Policies – Recent Accounting Pronouncements” for a full description of recent accounting pronouncements including the respective expected dates of adoption and expected effects on the Company’s consolidated financial position, results of operations or liquidity.

 

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

 

As a “smaller reporting Company” as defined by Item 8 of Regulation S-K, the Company is not required to provide information required by this Item.

 

13
 

 

ITEM 8. FINANCIAL STATEMENTS

 

 

Report of Independent Registered Public Accounting Firm

 

Shareholders and Board of Directors

Hartford Great Health Corp.

 

Opinion on the Consolidated Financial Statements

 

We have audited the accompanying consolidated balance sheets of Hartford Great Health Corp. and subsidiary (the “Company”) as of July 31, 2022 and 2021, the related consolidated statements of operation and comprehensive income (loss), changes in stockholders’ equity, and cash flows for each of the two years in the period ended July 31, 2022, and the related notes to the consolidated financial statements. In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of July 31, 2022 and 2021, and the results of its operations and its cash flows for each of the two years in the period ended July 31, 2022, in conformity with accounting principles generally accepted in the United States of America.

 

Going Concern Uncertainty

 

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As described in Note 2 to the consolidated financial statements, the Company has suffered recurring losses from operations and has a net capital deficiency that raise substantial doubt about its ability to continue as a going concern. Management’s evaluation of the events and conditions and management’s plans regarding these matters are also described in Note 2. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

 

Basis for Opinion

 

These consolidated financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

 

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud.

 

Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.

 

Critical Audit Matter

 

The critical audit matter communicated below is a matter arising from the current period audit of the consolidated financial statements that was communicated or required to be communicated to the audit committee and that: (1) relates to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing separate opinions on the critical audit matter or on the accounts or disclosures to which it relates.

 

Revenue recognition

 

As described in Note 1 to the consolidated financial statements, the Company generates its revenue mainly from early childhood educational classes provided to its customers. The Company evaluates its early childhood education contracts and determines each contract of educational classes is accounted for a single performance obligation which is satisfied proportionately over the service period. Performance obligation is satisfied when a educational class are consumed.

 

We identified the revenue recognition as a critical audit matter. Auditor judgement is involved in performing our audit procedures to evaluate the timing the Company transfers the control of the promised service to its customers in an amount of consideration to which the Company expects to be entitled to in exchange for the services per the contracts.

 

The primary procedures we performed to address this critical audit matter included:

 

We evaluated management’s significant accounting policies related to these early childhood educational class contracts executed for reasonableness.

 

We selected a sample of educational class contracts and performed the following procedures:

 

  Obtained and read contract for each selection
     
  Tested management’s identification and the determination of the timing of revenue recognition
     
  Traced to the evidence the management uses to apply their accounting policies
     
  Evaluated the appropriateness of management’s application of their accounting policies, along with their use of estimates, in the determination of revenue recognition conclusions
     
  We tested the mathematical accuracy of management’s calculations of revenue and the associated timing of revenue recognized in the financial statements

 

/s/ Simon & Edward, LLP

 

We have served as the Company’s auditor since 2019.

PCAOB ID: 2485

Rowland Heights, California

November 14, 2022, except Note #10 on June 12, 2023.

 

14
 

 

HARTFORD GREAT HEALTH CORP.

CONSOLIDATED BALANCE SHEETS

 

   July 31, 2022

(restated)

   July 31, 2021 
ASSETS        
Current Assets          
Cash and cash equivalents  $15,227   $12,739 
Prepaid and Other current receivables   1,154    1,203 
Related party receivable   14,233    309 
Current assets held for sale   4,499,736    975,837 
Total Current Assets   4,530,350    990,088 
Non-current Assets          
Property and equipment, net   8,006    8,357 
Non-current assets held for sale   -    4,744,153 
Total Non-current Assets   8,006    4,752,510 
TOTAL ASSETS  $4,538,356   $5,742,598 
           
LIABILITIES AND STOCKHOLDERS’ EQUITY          
Current Liabilities          
Related party loan and payables  $4,481,524   $3,711,606 
Other current payable   144,760    145,435 
Current liabilities held for sale   6,344,721    2,681,639 
Total Current Liabilities   10,971,005    6,538,680 
           
Long-term liabilities held for sale   -    4,190,368 
TOTAL LIABILITIES   10,971,005    10,729,048 
Commitments and contingencies (Note 7)   -    - 
Stockholders’ Equity (Deficit)          
Preferred stock - $0.001 par value, 5,000,000 shares authorized, no shares issued and outstanding   -    - 
Common stock - $0.001 par value, 300,000,000 shares authorized, 100,108,000 shares outstanding at both of July 31, 2022 and 2021.   100,108    100,108 
Additional paid-in capital   2,173,521    2,173,521 
Accumulated deficit   (7,400,620)   (5,821,519)
Accumulated other comprehensive loss   (16,742)   (233,487)
Noncontrolling interest   (1,288,916)   (1,205,073)
Total Stockholders’ Deficit   (6,432,649)   (4,986,450)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT  $4,538,356   $5,742,598 

 

The accompanying notes are an integral part of these financial statements.

 

15
 

 

HARTFORD GREAT HEALTH CORP.

CONSOLIDATED STATEMENTS OF OPERATIONS

 

           
   Years ended 
   July 31, 
   2022

(restated)

   2021

(restated)

 
Selling, general and administrative   177,913     255,655 
Total operating cost and expenses   177,913    255,655 
Operating Loss   (177,913)   (255,655)
Other Income (Expense)          
Interest (expense) income, net   (11,857)   14,806 
Gain on disposal of subsidiary   -    104,317 
Other income, net   140    55,604 
Other (expense) income, net   (11,717)   174,727 
(Loss) income before income taxes   (189,630)   (80,928)
Income Tax Expense   800    800 
Net (loss) income from continuing operations   (190,430)   (81,728)
Less: net income from continuing operations attributable to noncontrolling Interest   -    - 
Net (loss) income from continuing operations Attributable to Hartford Great Health Corp  $(190,430)  $(81,728)
           
Income loss from discontinued operations, net of income taxes   (1,582,152)   (2,760,611)
Less: net loss from discontinued operations attributable to noncontrolling Interest   (193,481)   (589,005)
Net loss from discontinued operations Attributable to Hartford Great Health Corp  $(1,388,671)  $(2,171,606)
           
Net loss per common share:          
Continuing operations   (0.00)   0.00 
Discontinued operations   (0.01)   (0.02)
Basic and Diluted  $(0.02)  $(0.02)
Weighted average shares outstanding:          
Basic and diluted   100,108,000    99,790,192 

 

The accompanying notes are an integral part of these financial statements.

 

16
 

 

HARTFORD GREAT HEALTH CORP.

 

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS

 

           
  

Years ended

July 31,

 
   2022   2021 
Net Loss  $(1,579,101)  $(2,253,334)
Other Comprehensive income (loss), net of income tax          
Foreign currency translation adjustments   267,073    (217,953)
Total other comprehensive loss   267,073    (217,953)
Less: total other comprehensive loss attributable to noncontrolling interest   50,328    (39,612)
Total Other Comprehensive Loss Attributable to Hartford Great Health Corp   216,745    (178,341)
Total Comprehensive Loss  $(1,362,356)  $(2,431,675)

 

The accompanying notes are an integral part of these financial statements.

 

17
 

 

HARTFORD GREAT HEALTH CORP.

CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY (DEFICIT)

for the years ended July 31, 2022 and 2021

 

                   Accumulated       Total 
           Additional       Other       Stockholders’ 
   Common Stock   Paid - in   Accumulated   Comprehensive   Noncontrolling   Equity 
   Shares   Amount   Capital   (Deficit)   loss   Interest   (Deficit) 
Balance, July 31, 2020   99,108,000    99,108    2,154,521    (3,568,185)   (55,146)   (917,489)   (2,287,191)
Net (loss)   -    -    -    (2,253,334)   -    (589,005)   (2,842,339)
Issuance of common stock   1,000,000    1,000    19,000    -    -    -    20,000 
Restructure of subsidiary   -    -    -    -    -    403,131    403,131 
Disposal of subsidiary   -    -    -    -    -    (62,098)   (62,098)
Foreign currency translation adjustment   -    -    -    -    (178,341)   (39,612)   (217,953)
Balance, July 31, 2021   100,108,000    100,108    2,173,521    (5,821,519)   (233,487)   (1,205,073)   (4,986,450)
Net (loss)   -    -    -    (1,579,101)   -    (193,481)   (1,772,582)
Investment from noncontrolling interest   -    -    -    -    -    59,310    59,310 
Foreign currency translation adjustment   -    -    -    -    216,745    50,328    267,073 
Balance, July 31, 2022   100,108,000    100,108    2,173,521    (7,400,620)   (16,742)   (1,288,916)   (6,432,649)

 

The accompanying notes are an integral part of these financial statements.

 

18
 

 

HARTFORD GREAT HEALTH CORP.

CONSOLIDATED STATEMENTS OF CASH FLOWS

 

           
   Years ended 
   July 31, 
   2022   2021 
Cash flows from operating activities:          
Net loss including noncontrolling interests  $(1,772,582)  $(2,842,339)
Adjustments to reconcile net loss including noncontrolling interests to net cash provided by (used in) operating activities:          
Depreciation and amortization   122,065    85,103 
Disposal of subsidiary, including noncontrolling interest   -    (104,316)
Debts forgiveness per court ruling   -    (162,806)
Loss from restructure   -    403,131 
Loss on disposal of property and equipment   -    760 
Impairment loss   -    70,514 
Changes in operating assets and liabilities:          
Prepaid and Other current receivables   225,428    (87,978)
Inventory   5,327    (299,588)
Other assets   24,078    10,435 
Related party receivables and payables   (81,013)   (185,693)
Contract liabilities   26,466    373,413 
Other current payable   102,526    312,902 
Operating lease assets and liabilities   458,993    17,779 
Other liabilities   27,880    27,108 
Net cash used in operating activities   (860,832)   (2,381,575)
           
Cash flows from investing activities:          
Cash proceeds from Acquisitions   -    27,927 
Cash used in Acquisitions   -    (15,206)
Disposal of subsidiary   -    (30,116)
Purchases of property and equipment   (145,048)   (168,287)
Net cash used in investing activities   (145,048)   (185,682)
           
Cash flows from financing activities:          
Contribution from noncontrolling interest   61,750    - 
Proceeds from issuance of common stock   -    20,000 
Proceeds of related party notes payable   145,000    145,000 
Principal payments on finance lease   (23,156)   (22,049)
Advances from related parties   788,673    2,407,033 
Net cash provided by financing activities   972,267    2,549,984 
           
Effect of exchange rate changes on cash   (400)   6,174 
Net change in Cash, cash equivalents and restricted cash   (34,013)   (11,099)
Cash, cash equivalents and restricted cash at beginning of period   54,178    65,277 
Cash, cash equivalents and restricted cash at end of period  $20,165   $54,178 
           
Supplemental Cash Flow Information          
Interest paid  $-   $- 
Income taxes paid  $800   $800 
Non-cash investing and financing activities:          
Payable to acquiree  $-   $10,462 
Investment return through three-party settlement  $-   $765,131 

 

The accompanying notes are an integral part of these financial statements.

 

19
 

 

HARTFORD GREAT HEALTH CORP.

Notes to Financial Statements

For the Years Ended July 31, 2022 and 2021

 

NOTE 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

This summary of significant accounting policies is presented to assist in understanding the Company’s financial statements. The financial statements and notes are the responsibility of the Company’s management. These accounting policies conform to accounting principles generally accepted in the United States of America (“US GAAP”) and have been consistently applied in the preparation of the financial statements.

 

Organization

 

Hartford Great Health Corp. was originally incorporated in the State of Nevada on April 2, 2008 under the name PhotoAmigo, Inc. It changed its name to Hartford Great Health Corp. on August 22, 2018 and since then we have been engaged in activities to formulate and implement our business plans.

 

Through its wholly owned subsidiary - Hangzhou Hartford Comprehensive Health Management, Ltd (“HZHF) and HZHF’s 60 percent owned subsidiary - Hangzhou Longjing Qiao Fu Vacation Hotel Co., Ltd. (“HZLJ”), and through Shanghai Hartford Comprehensive Health Management, Ltd. (“HFSH”) and its 90 percent owned subsidiary - Shanghai Qiao Garden International Travel Agency (“Qiao Garden Int’l Travel”), the Company engages in hospitality industry in China. Qiao Garden Int’l Travel was disposed on December 31, 2020, see note 4 Acquisitions, Joint Ventures and Deconsolidation.

 

The Company started to engage in early childhood education industry at Hartford International Education Technology Co., Ltd (“HF Int’l Education”). On July 24, 2019 and March 23, 2020, HF Int’l Education established two 100% owned subsidiaries, Pudong Haojin Childhood Education Ltd. (“PDHJ”) and Shanghai Hongkou HaiDeFuDe Childcare Co., Ltd.(“HDFD”), respectively, to operate the early childhood education service under the brand name of “HaiDeFuDe” in Shanghai, China. On July 20, 2020, HF Int’l Education entered an agreement with two individuals to acquire the whole ownership of Shanghai Gelinke Childcare Education Center (“Gelinke”). Gelinke temporally ceased its operations by the end of August 2021. On August 31, 2021, PDHJ established one 96% owned subsidiary, Shanghai HDFD Zhongli Education Technology Co., Ltd. (“Zhongli”), two individual investors hold the remaining 4% ownership, see note 4 Acquisitions, Joint Ventures and Deconsolidation.

 

Impacted by the government regulation newly implemented in education industry and the restrictions posted by the Chinese government to control the pandemic in China since 2021, to avoid further operation losses, subsequently on August 1, 2022, HFSH entered a contract with a related party, Shanghai Oversea Chinese Culture Media Ltd. (“SH Oversea”), to sell 90 percent ownership of HF Int’l Education and its subsidiaries for $900 (RMB 5,850). On August 1, 2022, HFUS entered a contract with SH Oversea and another individual, to sell 100 percent ownership of HZHF and its subsidiaries for $1,000 (RMB 6,500). As of July 31, 2022, the asset group in Education segment and the asset group in Hospitality segment classified as assets and liabilities held for sale, and it is the Company’s intention to complete the sales of these assets within the upcoming year.

 

Basis of Presentation: The consolidated financial statements include the accounts of Hartford Great Health Corp, its wholly-owned subsidiaries and subsidiaries in which it has a controlling interest. The Company reports noncontrolling interests of the consolidated entities as a component of equity separate from the Company’s equity. All material inter-company transactions between and among the Company and its consolidated subsidiaries have been eliminated in the consolidation. The Company’s net income (loss) excludes income (loss) attributable to the noncontrolling interests.

 

Use of Estimates: The preparation of financial statements in conformity with US GAAP requires the Company’s management to make estimates and assumptions that affect the amounts of assets and liabilities, the identification and disclosure of impaired assets and contingent liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

 

Foreign Currency: The accounts of the Company’s foreign subsidiaries are translated in accordance with FASB ASC 830. Foreign currency transaction gains and losses are recognized in other expense, net, at the time they occur. Net foreign currency exchange gains or losses resulting from the translation of assets and liabilities of foreign subsidiaries whose functional currency is not the U.S. dollar are recorded as a part of accumulated other comprehensive loss in stockholders’ equity. The Company does not undertake hedging transactions to cover its foreign currency exposure.

 

Comprehensive Income (loss): For the year ended July 31, 2022 and 2021, the Company included its foreign currency translation gain or loss as part of its comprehensive income (loss).

 

Fair value measurement: Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Accounting Standard Codification (“ASC”) 820, Fair Value Measurements and Disclosures (“ASC 820”), describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value, which are the following:

 

Level 1 - Quoted prices in active markets for identical assets or liabilities or funds.

Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

 

The Company’s financial instruments consist of cash and cash equivalents, accounts receivable, related party receivable, prepaid and other current receivable, accounts payable, related party payable and other current payable. The carrying amounts of afore-mentioned accounts approximate fair value because of their short-term nature.

 

20
 

 

Cash and Cash Equivalents: The Company maintains cash with banks in the USA and China. Should any bank holding cash become insolvent, or if the Company is otherwise unable to withdraw funds, the Company would lose the cash with that bank; however, the Company has not experienced any losses in such accounts and believes it is not exposed to any significant risks on its cash in bank accounts. In China, a depositor has up to RMB500,000 insured by the People’s Bank of China Financial Stability Bureau (“FSD”). In the United States, the standard insurance amount is USD250,000 per depositor in a bank insured by the Federal Deposit Insurance Corporation (“FDIC”). Financial instruments that potentially subject the Company to significant concentrations of credit risk are cash and cash equivalents and accounts receivable. As of July 31, 2022 and 2021, respectively, none of the Company’s cash and cash equivalents held by financial institutions was uninsured. With respect to accounts receivable, the Company generally does not require collateral and does not have an allowance for doubtful accounts.

 

Receivables: The Company evaluates the collectability of its receivables based on a number of factors. In circumstances where the Company becomes aware of a specific customer’s or borrower’s inability to meet its financial obligations to the Company, a specific reserve for bad debts is estimated and recorded, which reduces the recognized receivable to the estimated amount the Company believes will ultimately be collected. As of July 31, 2022 and 2021, all balances are collectable based on management’s assessment.

 

Property and equipment, net: Property and equipment, net, are stated at cost. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the assets. The estimated useful lives of property and equipment are as follows:

 

   Years
Leasehold improvements  Lesser of lease term or estimated useful life
ROU assets-Finance lease  Lease term
Furniture and fixtures  3-5
Office equipment and vehicles  3-5
Computer software  3-5

 

Expenditures for repairs and maintenance are charged to expense as incurred.

 

Goodwill and Long-lived Assets: Goodwill, which represents the excess of the purchase price over the fair value of identifiable net assets acquired, is not amortized, in accordance with Accounting Standards Codification (ASC) 350, Intangibles—Goodwill and Other. ASC 350 requires that goodwill be tested for impairment at the reporting unit level on an annual basis and between annual tests, if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. These events or circumstances could include a significant change in the business climate, legal factors, operating performance indicators, competition, or sale or disposition of a significant portion of a reporting unit.

 

The Company has the option to assess goodwill for possible impairment by performing a qualitative analysis to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. A quantitative assessment is performed if the qualitative assessment results in a more-likely-than-not determination or if a qualitative assessment is not performed. The quantitative assessment considers whether the carrying amount of a reporting unit exceeds its fair value, in which case an impairment charge is recorded to the extent that the reporting unit’s carrying value exceeds its fair value. The Company’s goodwill was mainly generated from the acquisitions during the year ended July 31, 2019. We currently have two reporting units - Hospitality and Early Childhood Education. Given the impact of COVID-19 pandemic and the unfavorable operation results, an interim goodwill impairment assessment was performed as of January 31, 2020. Based on the assessment result, management determined that the goodwill generated from acquisitions was fully impaired as of July 31, 2021.

 

Business Combinations: If an acquired set of activities and assets is capable of being operated as a business consisting of inputs and processes from the viewpoint of a market participant, the assets acquired and liabilities assumed are a business. Business combinations are accounted for using the acquisition method of accounting, which requires an acquirer to recognize the assets acquired and the liabilities assumed at the acquisition date measured at their fair values as of that date. Fair value determinations are based on discounted cash flow analyses or other valuation techniques. In determining the fair value of the assets acquired and liabilities assumed in a material acquisition, the Company may utilize appraisals from third party valuation firms to determine fair values of some or all of the assets acquired and liabilities assumed, or may complete some or all of the valuations internally. In either case, the Company takes full responsibility for the determination of the fair value of the assets acquired and liabilities assumed. The value of goodwill reflects the excess of the fair value of the consideration conveyed to the seller over the fair value of the net assets received. Acquisition-related costs that the Company incurs to affect a business combination are expensed in the periods in which the costs are incurred.

 

Noncontrolling interest: The Company adopted ASC 810, Noncontrolling Interests in Consolidated Financial Statements—an Amendment of Accounting Research Bulletin No. 51, as of January 1, 2009. ASC 810 establishes accounting and reporting standards for ownership interests in subsidiaries held by parties other than the parent, the amount of consolidated net income attributable to the parent and to the noncontrolling interest, changes in a parent’s ownership interest and the valuation of retained noncontrolling equity investments when a subsidiary is deconsolidated. ASC 810 also establishes reporting requirements that provide sufficient disclosures that clearly identify and distinguish between the interest of the parent and the interests of the noncontrolling owner.

 

Advertising costs: Advertising costs are expensed as incurred. During the year ended July 31, 2022 and 2021, amount of $10,540 and $65,406 advertising expenses were incurred, respectively.

 

21
 

 

Income Taxes: The Company accounts for income taxes using the asset and liability method in accordance with ASC 740, Accounting for Income Taxes. The asset and liability method provides that deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using the currently enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company records a valuation allowance to reduce deferred tax assets to the amount that is believed more likely than not to be realized.

 

On December 22, 2017, the President of the United States signed into law the Tax Reform Act. The Tax Reform Act permanently reduces the U.S. corporate income tax rate from a maximum of 35% to a flat 21% rate, effective January 1, 2018. In addition, the 2017 Tax Act also creates a new requirement that certain income (i.e., Global Intangible Low-Taxed Income (“GILTI”)) earned by controlled foreign corporations (“CFCs”) must be included in the gross income of the CFCs’ U.S. shareholder income. The tax law in PRC applies an income tax rate of 25% to all enterprises. The Company’s subsidiary does not receive any preferential tax treatment from local government. The Company has been in loss position for years and zero balances of tax provisions, deferred tax assets and liabilities as of the reporting periods ended. The tax reforms have no significant impacts on the Company.

 

Revenue Recognition: The Company adopted ASC Topic 606 Revenue from Contracts with Customers (“Topic 606) on August 1, 2019, applying the modified retrospective method to all contracts that were not completed as of August 1, 2019. The Company is building up its core business upon the completion of multiple acquisitions in March 2019 and impact of COVID-19 pandemic, limited operations occurred during the years ended July 31, 2022 and 2021. The revenue during the years ended July 31, 2022 and 2021 were mainly generated from HZLJ and HF Int’l Education.

 

Revenue is recognized when control of promised goods or services is transferred to our customers in an amount of consideration to which we expect to be entitled to in exchange for those goods or services. We follow the five steps approach for revenue recognition under Topic 606: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) we satisfy a performance obligation. Billings to customers for which services are not rendered are considered deferred revenue. ASC 606 has no material impacts on the Company’s financial positions. The Company’s revenue is recognized when it satisfies a single performance obligation by transferring control of its products or providing services to a customer. The Company’s general payment terms are short-term in duration. The Company does not have significant financing components or payment terms.

 

a.Early childhood education services: HF Int’l Education generates revenue from childhood education classes provided to its customers. The educational services consist of parent-child and bilingual childcare classes. Each contract of educational classes is accounted for as a single performance obligation which is satisfied proportionately over the service period. Tuition fee is generally collected in advance and is initially recorded as deferred revenue and transferred to contract liabilities after trial period. Refunds are provided to parents if they decide within the trial period that they no longer want to take the class. After the trial period, if a parent withdraws from a class, usually only that unearned portion of the fee is available to be returned. For the year ended July 31, 2022 and 2021, $509,920 and $435,149, respectively, of revenue were derived from early childhood education classes provided.

 

b.Hospitality services: HZLJ generates revenue primarily from the room rentals, sale of food and beverage and other miscellaneous hospitality services. The Company recognizes room rental and services daily as services are provided. Under ASC 606, the pattern and timing of recognition of income from hotel facility is consistent with the prior accounting model.

 

Income (Loss) Per Share: Basic earnings per share include no dilution and are computed by dividing net income (or loss) by the weighted- average number of shares outstanding during the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of the Company, assuming the issuance of an equivalent number of common shares pursuant to options, warrants, or convertible debt arrangements. Diluted earnings per share are not shown for periods in which the Company incurs a loss because it would be anti-dilutive. Similarly, potential common stock equivalents are not included in the calculation if the effect would be anti-dilutive. No potentially dilutive debt or equity securities were issued or outstanding during the years ended July 31, 2022 or 2021.

 

Reclassifications

 

Certain amounts on the prior-year consolidated balance sheet, consolidated statement of operations and cash flows were reclassified to conform to current-year presentation, with no effect on ending stockholders’ equity.

 

22
 

 

Recent Accounting Pronouncements.

 

Recently adopted accounting pronouncements

 

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes which is intended to simplify various aspects related to accounting for income taxes. The standard is effective for fiscal years, and interim periods within those years, beginning after December 15, 2020, with early adoption permitted. The adoption of ASU 2019-12 had an immaterial impact on the Company’s consolidated statement of operation and consolidated statement of cash flows for the year ended July 31, 2022.

 

Recently issued accounting pronouncements not yet adopted

 

In June 2016, the FASB issued ASU 2016-13, “Financial Instruments—Credit Losses”. The standard, including subsequently issued amendments (ASU 2018-19, ASU 2019-04, ASU 2019-05, ASU 2019-10 and ASU 2019-11), requires a financial asset measured at amortized cost basis, such as accounts receivable and certain other financial assets, to be presented at the net amount expected to be collected based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. In November 2019, the FASB issued ASU No. 2019-10 to postpone the effective date of ASU No. 2016-13 for public business entities eligible to be smaller reporting companies defined by the SEC to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company is evaluating the impact of this guidance on its consolidated financial statements.

 

23
 

 

NOTE 2. GOING CONCERN

 

The accompanying financial statements were prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of obligations in the normal course of business. However, Hartford Great Health Corp. has incurred losses since inception, resulting in an accumulated deficit of $7,400,620 as of July 31, 2022. These conditions raise substantial doubt about the ability of Hartford Great Health Corp. to continue as a going concern.

 

In view of these matters, continuation as a going concern is dependent upon several factors, including the availability of debt or equity funding upon terms and conditions acceptable to Hartford Great Health Corp., and ultimately achieving profitable operations. Management believes that Hartford Great Health Corp.’s business plan provides it with an opportunity to continue as a going concern. However, management cannot provide assurance that Hartford Great Health Corp. will meet its objectives and be able to continue in operation.

 

The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of Hartford Great Health Corp. to continue as a going concern.

 

NOTE 3. STOCKHOLDERS’ EQUITY

 

Preferred Stock

 

The Company is authorized to issue 5,000,000 shares of preferred stock with a par value of $0.001 per share. No shares of preferred stock have been issued or outstanding since Inception (April 2, 2008).

 

Common Stock

 

The Company is authorized to issue 300,000,000 shares of common stock with a par value of $0.001 per share. On November 24, 2020, the Company issued 1,000,000 shares of common stock to a significant shareholder of the Company at $0.02 per share. The company had a total of 100,108,000 shares of common stock issued and outstanding at both of July 31, 2022 and 2021.

 

NOTE 4. ACQUISITIONS, JOINT VENTURES AND DECONSOLIDATION

 

Joint Venture – HF Int’l Education

 

On March 22, 2019, HFSH entered into a joint venture agreement (the “JV agreement”) with Shanghai Jingyu Education Tech Ltd. (“SH Jingyu”) and one individual investor, to form a new entity - HF Int’l Education to provide childcare education services. HFSH initially owned 65.0% ownership HF Int’l Education, and reduced to 61.0% during the year ended on July 31, 2020 because of equity transactions between noncontrolling shareholders. On June 19, 2020, the board of HF Int’l Education decided to increase registered capital to RMB10 million from RMB5 million, and three out of four noncontrolling shareholders gave up the subscription rights. As a result, HFSH held 75.5% of HF Int’l Education and a total of 24.5% equity was held by noncontrolling shareholders. Pursuant to the board meeting held on June 1, 2021, the noncontrolling shareholders sold a total 14.5% equity at zero consideration to HFSH. As a result, HFSH holds 90.0% of HF Int’l Education and $403,131 noncontrolling loss was absorbed by HFSH as a result of the ownership restructure at HF Int’l Education.

 

Continuous operation losses caused by the market uncertainties including pandemic and government regulations, HF Int’l Education entered agreements to sell the copyrights of seven education textbooks and ten “HaiDeFuDe” registered trademarks owned for RMB1.2 million and RMB1.0 million, respectively, to Hartford Health Management (Shanghai) Co., Ltd (“HFHM”) in March 2021 with approval of the board of directors. The CEO of HFHM is a shareholder of the Company who owns more than 5% of the Company’s common stocks.

 

Operation result of HF Int’l Education are included in the Company’s consolidated financial statements commencing on the formation date. The Company classifies the ownership interest held by other four parties as “Noncontrolling interest” on the consolidated balance sheet.

 

Acquisition of Gelinke

 

On July 20, 2020, HF Int’l Education entered an agreement with two individuals to acquire the whole ownership of Gelinke, who engages at early childhood education services in Changning District, Shanghai. The results of operations of the acquired entities are included in the Company’s consolidated financial statements commencing on the acquisition date. The Company has recorded an allocation of purchase price to Gelinke’s tangible and identifiable intangible assets acquired and liabilities assumed based on their fair value at the acquisition date. The Company accounted the acquisition transaction in accordance with FASB ASC 805, Business Combinations, under acquisition accounting method. The related transaction costs were immaterial and included in General and administrative expenses in the accompanying consolidated statements of operations. The acquisition was completed on August 31, 2021. The calculation of purchase price and purchase price allocation is as follows:

 

   Assets Acquired and 
   Liabilities Assumed 
Cash and cash equivalents   1,809 
Restricted Cash   25,009 
Prepaid and Other current receivables   4,696 
Property and Equipment, net   4,294 
Unearned revenue   (78,696)
Goodwill   67,712 
Total consideration*   24,824 

 

*$10,462 (RMB70,000) payable to the acquiree plus $14,362 (RMB100,000) cash payment totaled $24,824 consideration for the acquisition.

 

Goodwill is mainly attributable to synergies expected from the acquisition of license, list of customers and teacher workforce. Due to unfavorable operation result of Gelinke during the year ended July 31, 2021, management determined that $67,712 goodwill generated from Gelinke Acquisition was fully impaired.

 

24
 

 

Other Acquisitions

 

In January and February 2019, HFSH entered agreements to acquire 85 percent ownership of Shanghai Senior Health Consulting Ltd. (“SH Senior”) and 55 percent ownership of Shanghai Pasadena Ltd. (“SH Pasadena”). On December 31, 2020, HFSH withdrew from the two acquisition agreements. No penalty results from the withdrawn.

 

In January 2019, HFSH entered agreements to acquire 100 percent equity interest of Shanghai Luo Sheng International Trade Ltd. (“SH Luosheng”)  and the agreement has not yet taken effect. On August 1, 2022, HFSH decided to withdraw from the agreement. There was no penalty levied or to be levied due to delayed execution or inexecution.  

 

Disposal of subsidiary

 

On December 31, 2020, HFSH disposed its 90 percent owned subsidiary - Qiao Garden Int’l Travel to an individual (the “Disposal”). The individual is a relative of the CEO, Qiao Garden Int’l Travel became a related party after deconsolidation. The operation results, assets and liabilities, and cash flows of Qiao Garden Int’l Travel were deconsolidated from the Company’s consolidated financial statements effective on December 31, 2020. The Disposal of Qiao Garden was consummated through a three-party settlement among HFSH, SH Qiaohong and Qiao Garden Int’l Travel (the “Three-Party Settlement”): the original investment RMB 4.5 million plus RMB 0.5 million investment income were agreed to returned from Qiao Garden Int’l Travel as a result of the Disposal and settled with a payable due to SH Qiaohong at SHHF, who was a debtor of Qiao Garden Int’l Travel, see Note 14, Related Party Transactions.

 

Net assets (liabilities) disposed of:

 

    1 
Net assets (liabilities) disposed of:    
Cash and cash equivalents   172 
Restricted cash   29,944 
Related party receivable   782,224 
Related party payable   (98,615)
Other current payable   (3,876)
Noncontrolling interest   (60,812)
Net assets of the subsidiary, excluding noncontrolling interest   649,037 
Consideration   753,354 
Gain on disposal of the subsidiary   (104,317)
Gain on disposal of noncontrolling interest   (60,812)
Gain on disposal of the subsidiary, excluding noncontrolling interest   (43,505)

 

Net inflow / (outflow) of cash and cash equivalents in respect of the disposal subsidiary:

 

    1 
Cash and cash equivalents   (172)
Restricted cash   (29,944)
Cash and cash equivalents deconsolidated   (30,116)

 

NOTE 5. DISCONTINUED OPERATION

 

Impacted by the government regulation newly implemented in education industry and the restrictions posted by the Chinese government to control the pandemic in China since 2021, the Company’s business hasn’t been developed as planned and occurred significant loss from the early child education practice. To avoid further operation losses, subsequently on August 1, 2022, HFSH entered a contract with a related party, Shanghai Oversea Chinese Culture Media Ltd. (“SH Oversea”), to sell 90 percent ownership of HF Int’l Education and its subsidiaries for $900 (RMB 5,850). On August 1, 2022, HFUS entered a contract with SH Oversea and another individual, to sell 100 percent ownership of HZHF and its subsidiaries for $1,000 (RMB 6,500).

 

As of July 31, 2022, the assets and liabilities grouped under Education and Hospitality segments classified as assets and/or liabilities held for sale, and it is the Company’s intention to complete the sales of these assets within the upcoming year. The transactions meet the criteria to be reported as a discontinued operation as they constitute significant strategic business shifts for the Company. We have reported, for all periods presented, the financial condition, results of operations, and cash flows of the operation segments as discontinued operations in the accompanying consolidated financial statements.

 

25
 

 

The total assets and liabilities of Education and hospitality segments that are classified as held for sale on the Companys consolidated balance sheet as of July 31, 2022, are as follows: 

 

SCHEDULE OF DISCONTINUED OPERATIONS OF FINANCIAL STATEMENTS

     July 31, 2022     July 31, 2021 
Assets          
Current Assets          
Cash and cash equivalents  $4,938   $14,873 
Prepaid and Other current receivables   45,532    311,594 
Related party receivable   428,519    325,555 
Inventory   305,124    323,815 
Property and equipment, net   582,707    585,160 
ROU assets-operating lease   2,836,698    3,837,187 
Other assets   296,218    321,806 
Total Assets held for sale  $4,499,736   $5,719,990 
Liabilities          
Current Liabilities          
Related party loan and payables  $1,321,549   $1,332,338 
Contract liabilities   547,906    545,346 
Lease liabilities, current and noncurrent   3,715,688    4,071,767 
Other current payable   401,782    553,841 
Other liabilities   357,796    368,715 
Total Liabilities held for sale  $6,344,721   $6,872,007 

 

For the years ended July 31, 2022 and 2021, results of operations from HF Intel Education and its subsidiaries, and HZHF and its subsidiary were as follows:

 

For the years ended July 31, 

2022

(restated)

  

2021

(restated)

 
Net sales  $561,262   $553,459 
Cost of sales   677,093    722,838 
Gross profit   (115,831)   (169,379)
Operating expenses:          
Selling, general, and administrative expenses   1,579,922    2,520,817 
Impairment   -    70,514 
Total operating expenses   1,579,922    2,591,331 
Loss from operations of discontinued operations   (1,695,753)   (2,760,710)
Interest expense   (54,730)   (45,692)
Other Income   168,331    45,791 
Loss from discontinued operations before income taxes   (1,582,152)   (2,760,611)
Income tax benefit (expense)   -    - 
Income (loss) from discontinued operations, net of taxes before gain from sale of discontinued operations   (1,582,152)   (2,760,611)
Loss from sale of discontinued operations, net of taxes   -    - 
Income from discontinued operations, net of taxes  $(1,582,152)  $(2,760,611)

 

For the years ended July 31, 2022 and 2021, net cash used in discontinued operations - HF Intel Education and its subsidiaries, and HZHF and its subsidiary were as follows:

 

           
   Years ended July 31, 
Cash flow of discontinued operations:  2022   2021 
Operating cash flows  $(656,663)  $(2,455,829)
Investing cash flows   (145,048)   (155,566)
Net cash used in discontinued operations  $(801,711)  $(2,611,395)

 

NOTE 6. RELATED PARTY TRANSACTIONS

 

Related Party Receivables

 

As of July 31, 2022, $ 428,519 and $325,555 related party receivables were allocated to current assets held for sales, see Note 5, under “Assets and liabilities held for sale”.

 

Related Party Payables

 

As of July 31, 2022 and 2021, amounts of $620,876 and $616,159, are payable to SH Qiaohong, respectively. The balances were mainly funding support from SH Qiaohong for operation. The funding support bears no interest and due on demand.

 

HFSH had payable balances to Shanghai Oversea Chinese Culture Media Ltd. (“SH Oversea”), an entity managed by the same management team, in the amounts of $3,531,064 and $2,926,782 as of July 31, 2022 and 2021, respectively. The payable is funding support from SH Oversea for operation, bears no interest and due on demand.

 

As of July 31, 2022 and 2021, amount of $290,000 and $145,000, respectively, borrowed in form of a short-term loan at 5% per annum from a related party, Hartford Hotel Investment Inc., an entity managed by the same management team. $11,857 and $3,856 of interest expenses were recorded during the year ended July 31, 2022 and 2021, respectively. The unpaid principal and interest will be due on demand.

 

The remaining related party payable of $39,583 and $80,477 as of July 31, 2022 and 2021, respectively, represents the unpaid portion of operating advances made to the Company by affiliates which are managed by the same management team. These advances do not bear interest and are considered due on demand.

 

As of July 31, 2022, $1,317,690 and $1,332,338 related party payables were allocated to current liabilities held for sales, see Note 5, under “Assets and liabilities held for sale”.

 

Other Related Party Transactions

 

Office space at Rosemead, CA is provided to Hartford Great Health Corp. at no cost by the sole executive officer. No provision for these costs has been included in these financial statements as the amounts are not material.

 

26
 

 

NOTE 7. COMMITMENTS AND CONTINGENCIES

 

There has been below material contractual obligations and other commitments except the lease commitments disclosed in Note 12 Leases.

 

License agreements

 

In June 2021, HF Int’l Education and its three subsidiaries: PDHJ, HDFD and Gelinke entered license agreements with HFHM for the rights to use the intellectual Properties (the “IPs”) HFHM owns. The IPs cover in the license agreements are four set of curriculum structure designed and fifteen trademarks including “HaiDeFuDe” registered trademarks purchased from HF Int’l Education. As a return, on a monthly basis, HF Int’l Education and its subsidiaries pays 90% of its tuition revenue generated to HFHM as license usage fee. Due to impacts from the pandemic and new regulations issued by Chinese government in education industry, HF Int’l Education occurred significant loss from operation. On July 2022, both parties mutually agreed to amend the fee to 20%, the amended rate is retrospectively applicable since June 1, 2021 and recaptured in 2022. As a result, the Company incurred $6,664 and $161,783 license fees to HFHM for the year ended July 31, 2022 and 2021 reported under discontinued operation, respectively.

 

NOTE 8. INCOME TAXES

 

We recorded income tax expense of $800 for both of the years ended July 31, 2022 and 2021, due to the loss position for the years since inception.

 

Hartford Great Health Corp.’s deferred tax assets, valuation allowance, and change in valuation allowance are as follows:

 

           Estimated tax             
   Net NOL       benefit from NOL       Change in   Net 
   carry-   NOL   and other tax   Valuation   valuation   deferred 
Period Ending  forward   expires   benefits (21%)   allowance   allowance   tax asset 
31-Jul-21  $6,634,644    2041   $1,990,393   $(1,990,393)  $(919,938)  $- 
31-Jul-22  $7,400,620    2042   $2,220,186   $(2,220,186)  $(229,793)  $- 

 

Income taxes at the statutory rate are reconciled to reported income tax expense (benefit) as follows:

 

   2022   2021 
Federal income tax rate   21.0%   21.0%
State income tax rate   8.8%   8.8%
Foreign tax difference   (4.8)%   (4.1)%
Non-taxable item adjustment   -%   (3.2)%
GILTI   -%   -%
Valuation allowance   (25.0)%   (22.5)%
Others   -%   -%
Effective tax rate   0.0%   0.0%

 

At this time, the Company is unable to determine if it will be able to benefit from its deferred tax asset. There are limitations on the utilization of net operating loss carry-forwards, including a requirement that losses be offset against future taxable income, if any. In addition, there are limitations imposed by certain transactions which are deemed to be ownership changes. Accordingly, a full valuation allowance has been established for the entire deferred tax asset. Other temporary differences and estimated permanent differences are considered immaterial. Open tax years subject to examination by the IRS range from August 1, 2017 to the present. The Company has no uncertain tax positions.

 

The Company has been in loss position for years since inception and zero balances of deferred tax assets and liabilities as of the reporting periods ended. There was no GILTI tax for the Company for the years ended July 31, 2022 and 2021 due to the operation losses incurred.

 

NOTE 9. SEGMENT INFORMATION (restated)

 

The Company currently operates in following industry segments: hospitality (hotel and travel agency) and early childhood education industry in China.

 

Segment information on assets as of July 31, 2022 and revenue generated during the year ended July 31, 2022, as follows:

 

                     
  

Hospitality

(Discontinued Operation)

  

Education

(Discontinued Operation)

   Corporate and Unallocated (Continued operation)   Total 
Revenue  $51,342   $509,920   $-   $561,262 
Operating loss   (129,352)   (1,566,401)   (177,913)   (1,873,666)
Loss before tax   (182,980)   (1,399,172)   (189,630)   (1,771,782)
Net Loss Attributable to Hartford Great Health Corp   (129,422)   (1,259,249)   (190,430)   (1,579,101)
Total assets (excluding Intercompany balances)   303,703    4,196,033    38,620    4,538,356 
Assets allocated to held for sale   (303,703)   (4,196,033)   -    (4,499,736)

 

Segment information on assets as of July 31, 2021 and revenue generated during the year ended July 31, 2021, as follows:

 

                     
                 
  

Hospitality

(Discontinued Operation)

  

Education

(Discontinued Operation)

  

Corporate and Unallocated

(Continued operation)

   Total 
Revenue  $118,309   $435,150   $-   $553,459 
Operating loss   (172,536)   (2,588,174)   (255,655)   (3,016,365)
Loss before tax   (216,303)   (2,544,308)   (80,928)   (2,841,539)
Net Loss Attributable to Hartford Great Health Corp   (174,018)   (1,997,588)   (81,728)   (2,253,334)
Total assets (excluding Intercompany balances)   384,747    5,335,244    22,607    5,742,598 
Assets allocated to held for sale   (384,747)   (5,335,244)   -    (5,719,991)

 

NOTE 10. RESTATEMENT

 

The Company restated its Annual Report on Form 10-K for the annual period from August 1, 2021 to July 31, 2022, which was filed with the U.S. Securities and Exchange Commission (the “SEC”) on November 14, 2022 (the “Original Filing”), is being filed for the following purposes:

 

(a) for Consolidated balance sheets on Item 8, Financial Statements, of Part II of Form 10-K, to reclass the balance of Non-current assets held for sale, as of July 31, 2022, to Current assets held for sale.

 

(b) for Consolidated statements of operations on Item 8, Financial Statements, of Part II of Form 10-K, to separately disclose the discontinued operation results for years ended July 31, 2022 and 2021.

 

The restatements above have been incorporated into the consolidated statements of operation, Note #5 and #9, respectively.

 

NOTE 11. SUBSEQUENT EVENTS

 

In accordance with ASC 855, “Subsequent Events”, the Company has evaluated subsequent events through the date of issuance of these financial statements and has noted the following subsequent events to be disclosed.

 

On August 1, 2022, see note 5, under section “Assets and liabilities held for sale”, HFSH entered a contract with a related party, SH Oversea, to sell 90 percent ownership of HF Int’l Education and its subsidiaries for $900 (RMB 5,850). On August 1, 2022, HFUS entered a contract with SH Oversea and another individual, to sell 100 percent ownership of HZHF and its subsidiaries for $1,000 (RMB 6,500).

 

On August 1, 2022, HFSH decided to withdraw from the agreement entered in January 2019 to acquire 100 percent equity interest of Shanghai Luo Sheng International Trade Ltd. (“SH Luosheng”). There was no penalty levied or to be levied due to delayed execution or inexecution.

 

On August 17, 2022, the Company borrowed a note in a total amount of $30,000, in form of a short-term loan at 5% per annum from a related party.

 

27
 

 

ITEM 9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE

 

Not Applicable.

 

Item 9A. Controls and Procedures.

 

Evaluation of Disclosure Controls and Procedures

 

An evaluation was performed under the supervision of our management, including our Chief Executive Officer and Chief Financial Officer (principal financial officer), of the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) as of the end of the period covered by this Annual Report. Based on that evaluation, our management, including our Chief Executive Officer and Chief Financial Officer, concluded that, as of July 31, 2022, our disclosure controls and procedures were not effective to ensure that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms due to material weaknesses in our internal controls described below.

 

Management’s Annual Report on Internal Control Over Financial Reporting.

 

Our management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Exchange Act Rule 13a-15(f). Our internal control system is intended to provide reasonable assurance to our management and board of directors regarding the preparation and fair presentation of published financial statements and that we have controls and procedures designed to ensure that the information required to be disclosed by us in our reports that we will be required to file under the Exchange Act is accumulated and communicated to our management as appropriate to allow timely and informed decisions regarding financial disclosure.

 

Our management assessed the effectiveness of our internal control over financial reporting as of July 31, 2022. Based on this assessment, management believes that as of July 31, 2022, our internal control over financial reporting was not effective based on those criteria.

 

Management’s assessment identified several material weaknesses in our internal control over financial reporting. These material weaknesses include the following:

 

Lack of proper authorization and approval procedures on significant business transactions.

 

Lack of competence accounting personnel at entity level and proper segregation of duties implemented.

 

Inherent Limitations Over Internal Controls

 

Our management, including our Chief Executive Officer and Chief Financial Officer, does not expect that our disclosure controls and procedures or our internal controls will prevent all errors and all fraud. A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Our control systems are designed to provide such reasonable assurance of achieving their objectives. Further, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our Company have been detected. These inherent limitations include, but are not limited to, the realities that judgments in decision-making can be faulty and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the likelihood of future events and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, controls may become inadequate because of changes in conditions, or the degree of compliance with the policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

 

28
 

 

Changes in Internal Control Over Financial Reporting.

 

We have made no change in our internal control over financial reporting during the last fiscal year that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

Attestation Report of the Registered Public Accounting Firm.

 

This annual report does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting. Management’s report was not subject to attestation by our independent registered public accounting firm pursuant to temporary rules of the SEC that permit us to provide only management’s report in this annual report on Form 10-K.

 

ITEM 9B. OTHER INFORMATION

 

None.

 

PART III

 

ITEM 10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE

 

Directors and Executive Officers

 

The following individual presently serves as our officers and directors:

 

            Board
Name and           Position
Municipality of Residence   Age   Positions With the Company   Held Since
        President, Chief Executive Officer    
Rose Hong Wang Los Angeles, CA   50   and Director   2021
        Chief Financial Officer, Secretary and    
Sheng-Yih Chang Los Angeles, CA   51   Director   2018
Yuan Lu Shanghai, CHINA   36   Director   2019
Xin Dong Los Angeles, CA   38   Director   2018

 

Each of the directors will serve until the next annual meeting of stockholders of the Company and until such director’s successor is elected and qualified or until such director’s earlier death, resignation or removal. The following is information concerning the business backgrounds of each member of the board of directors:

 

Rose Hong Wang. From March 2018 to the present Ms. Wang has been Chief Financial Officer and Director of Hartford Hotel Investment Inc., Rosemead, CA, USA. In addition, since June 2010 to the present she has been Vice President and Director of Shanghai Qiao Garden Group Overseas Branch, CA, USA. From September 2006 to May 2010 she was the Assistant General Manager of Qiao Garden Group Investment Inc., CA, USA, In December 1998 Ms. Wang immigrated to the USA. From December 1996 to September 1998, she was the Assistant General Manager of Shanghai Watanabe Asset Management Co., Ltd., China. From September 1993 thru July 1995, she Studied Language and Literature at Shanghai International Studies University, China. In July 1990, Ms. Wang received her Bachelor’s Degree with Music Major from Xinjiang Normal University, China.

 

29
 

 

Sheng Yih Chang. Mr. Chang has served as the General Manager at Hartford Hotel, a commercial hotel in Rosemead California since March 2018. Mr. Chang served as a Product Manager at Jowett Group, a textile manufacturing company in the USA, from November 2015 through September 2017, as an Operational Manager and General Manager at A-Concepts Designs, a houseware supplier company in the USA, from January 2004 through October 2015, as a General Manager at Long Arch International, a carving crafts supplier in the USA, from December 2000 through December 2003, as a Sales Manager at EZ Wholesale, a general merchandise wholesaler in the USA, from July 1998 through November 2000, and as a technician at Richcom Computer Corporation, a computer service provider in China, from July 1996 through November 1997. Mr. Chang studied electrical engineering at the University of British Columbia and holds a Bachelor of Science in Electrical Engineering from California State University, Northridge.

 

Yuan Lu. Ms. Lu graduated in 2008 with a Bachelor’s Degree from Anhui University of Technology in China majoring in International Trade and Economics. In 2013, Ms. Lu earned a Master’s Degree in International Language Arts from Shanghai University of Finance and Economics in China. From 2008-2009, Ms. Lu was an Assistant Teacher at New Channel International Educated Group, Ltd. From 2009-2010, Ms. Lu was a Customs Broker and Procurement Buyer at Shanghai Pan-Resources Imp&Exp Co., Ltd. From 2010 through the present, Ms. Lu has served as the Assistant CEO at Shanghai Overseas Chinese Culture Media Co., Ltd.

 

Xin Dong. Mr. Dong has served as the Executive Director and General Manager of Shanghai Huitong Health Management Company, a senior care and traditional health management company, in China since September 2017. From July 2016 through August 2017, Mr. Dong acted as the Vice President and General Manager of Shanghai Huicai Financial Information Service Co., Ltd., a financial service and small loan company, in China. Mr. Dong has also served as the General Manager of Shenzhen Maoli International Trading Co., Ltd., an international trading company in Shenzhen, China, from April 2012 through June 2016, and as a Project Manager and Market Representative at Nanjing Hongyuan Electronic Technology Company, an electronics manufacturing company, from July 2007 through March 2012. Mr. Dong holds a Masters in International Finance and Trade from Shanghai Jiaotong University and a degree in Computer Science from Jiangsu University.

 

Term of office

 

All officers and directors listed above will remain in office until the next annual meeting of our stockholders, and until their successors have been duly elected and qualified or until removed from office in accordance with our bylaws. There are no agreements with respect to the election of Directors. We have not compensated our Directors for service on our Board of Directors, any committee thereof, or reimbursed for expenses incurred for attendance at meetings of our Board of Directors and/or any committee of our Board of Directors. Officers are appointed annually by our Board of Directors and each Executive Officer serves at the discretion of our Board of Directors. We do not have any standing committees. Our Board of Directors may in the future determine to pay Directors’ fees and reimburse Directors for expenses related to their activities.

 

None of our Officers and/or Directors have filed any bankruptcy petition, been convicted of or been the subject of any criminal proceedings or the subject of any order, judgment or decree involving the violation of any state or federal securities laws within the past five (5) years.

 

Director Independence

 

The Board consists of four members, of which Yuan Lu and Xin Dong meet the independence requirements of the Nasdaq Stock Market as currently in effect.

 

30
 

 

Committees and Terms

 

The Board of Directors (the “Board”) has not established any committees. The Company will notify its shareholders for an annual shareholder meeting and that they may present proposals for inclusion in the Company’s proxy statement to be mailed in connection with any such annual meeting; such proposals must be received by the Company at least 90 days prior to the meeting. No other specific policy has been adopted in regard to the inclusion of shareholder nominations to the Board of Directors.

 

Code of Ethics

 

To date, we have not adopted a Code of Ethics applicable to our principal executive officer and principal financial officer because the Company has no meaningful operations within the United States of America. The Company does not believe that a formal written code of ethics is necessary at this time. We expect that the Company will adopt a code of ethics if and when the Company successfully completes a business combination that results in the acquisition of an on-going business and thereby commences operations within the United States.

 

ITEM 11. EXECUTIVE COMPENSATION

 

Beginning January 1, 2019, a monthly payroll salary of $3,000 has been offered to Sheng-Yih Chang, the Company’s CFO. No other officer or director has received annual compensation. There has been no compensation awarded to, earned by, or paid to the named executive officer or director other than the CFO’s wage. There is no compensation to the executive officers planned for the next year. Such compensations will be brought to discussion in next board meeting.

 

Employment Agreements

 

As of July 31, 2022, all employees and officers in China have entered into employment agreements with the Company’s subsidiaries. However, the Company has not entered into employment agreements with any of its executive officers in the US as of July 31, 2022.

 

Anticipated Officer and Director Remuneration

 

Except for the monthly wage paid to the CFO, the Company has not to date paid any other compensation owed to any officer or director as of date hereto. The Company intends to begin to pay annual salaries to all its officers and will pay an annual stipend to its directors when, and if, it completes a primary public offering for the sale of securities and/or the Company reaches profitability, experiences positive cash flow and/or obtains additional funding. At such time, the Company anticipates offering cash and non-cash compensation to officers and directors. In addition, although not presently offered, the Company anticipates that its officers and directors will be provided with a group health, vision and dental insurance program at subsidizes rates, or at the sole expense of the Company, as may be determined on a case-by-case basis by the Company in its sole discretion.

 

Stock Option Plan

 

We do not have a stock option plan and we have not issued any warrants, options or other rights to acquire our securities. However, we may adopt an incentive and non-statutory stock option plan in the future.

 

Employee Pension, Profit Sharing or other Retirement Plans

 

We do not have a defined benefit, pension plan, profit sharing or other retirement plan, although we may adopt one or more of such plans in the future.

 

Section 16(a) Beneficial Ownership Reporting Compliance

 

We are not registered under the Securities Exchange Act of 1934, as amended, and are not subject to the reporting requirements of Section 16(a).

 

31
 

 

ITEM 12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS

 

As of November 14, 202, there are a total of 100,108,000   shares of our common stock outstanding, our only class of voting securities currently outstanding. The following table describes the ownership of our voting securities by: (i) each of our officers and directors; (ii) all of our officers and directors as a group; and (iii) each shareholder known to us to own beneficially more than 5% of our common stock. All ownership is direct, unless otherwise stated.

 

      Shares     
      Beneficially   Percentage 
Name of Beneficial Owner  Address of Beneficial Owner  Owned Number   (%) 
   RM 3806 218 WUSONG RD, HONGKOU DISTRICT          
YUAN LU  SHANGHAI, CHINA   32,440,000    32.4%
ROSE HONG WANG  729 CARRIAGE HOUSE DRIVE, ARCADIA, CA 91006   11,000,000    11.0%
XIN DONG  8832 GLENDON WAY, ROSEMEAD, CA 91770   2,400,000    2.4%
SHENG-YIH CHANG  8832 GLENDON WAY, ROSEMEAD, CA 91770   1,000,000    1.0%
   Total Officers and Directors (4)   46,840,000    46.8%

 

Each shareholder known to us to own beneficially more than 5% of our common stock:

 

      Shares Beneficially   Percentage 
Name of Beneficial Owner  Address of Beneficial Owner  Owned Number   (%) 
LIANYUE SONG  8832 GLENDON WAY, ROSEMEAD, CA 91770   20,000,000.00    20.0%
   RM 218 WUSONG ROAD, HONGKOU DISTRICT,          
DANFENG GU  SHANGHAI, CHINA   8,300,000.00    8.3%
   1F QIAO GARDEN 73 WUHUA RD, HONGKOU          
JIAMIN ZHU  DISTRICT, SHANGHAI, CHINA   8,000,000.00    8.0%

 

ITEM 13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE

 

US office space is provided to Hartford Great Health Corp. at no additional cost by the sole executive officer. No provision for these costs has been included in these financial statements as the amounts are not material.

 

32
 

 

ITEM 14. PRINCIPAL ACCOUNTING FEES AND SERVICES

 

The following table sets forth fees billed by our principal accounting firms of Simon & Edward, LLP and Haynie & Company in the last two years ended July 31, 2022:

 

   2022   2021 
Audit Fees  $26,000   $26,000 
Audit Related Fees   13,500    13,500 
All other fees   -    2,000 
Total Fees  $39,500   $41,500 

 

It is the policy of our Board of Directors to engage the principal accounting firm selected to conduct the financial audit for our company and to confirm, prior to such engagement, that such principal accounting firm is independent of our company. All services of the principal accounting firm reflected above were approved by the Board of Directors.

 

PART IV

 

ITEM 15. EXHIBITS AND FINANCIAL STATEMENTS SCHEDULES

 

The following documents are filed as part of this Annual Report:

 

1.Consolidated Financial Statements

 

Our consolidated financial statements are listed under Part II, Item 8, of this Annual Report.

 

2.Financial Statement Schedules

 

All financial statement schedules have been omitted because they are not required or are not applicable, or the required information is shown in our Consolidated Financial Statements or the notes thereto.

 

3.Exhibits

 

The following exhibits are filed with or incorporated by referenced in this report:

 

21.1* Subsidiaries of the Company
 
31.1* Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 for Rose Hong Wang.
 
31.2* Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 for Sheng-Yih Chang
 
32* Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 for Rose Hong Wang and Sheng-Yih Chang

 

101.INS* Inline XBRL Instance Document
101.SCH* Inline XBRL Taxonomy Extension Schema Document
101.CAL* Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF* Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB* Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE* Inline XBRL Taxonomy Extension Presentation Linkbase Document
104* Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

* Filed herewith

 

33
 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  HARTFORD GREAT HEALTH CORP.
   
Date: June 12, 2023 By: /s/ ROSE HONG WANG
    Rose Hong Wang
    Chief Executive Officer

 

Pursuant to the requirements of the Securities Exchange Act of 1934 this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

 

Name   Title   Date
         
/s/ Rose Hong Wang   Chief Executive Officer, President, Dir. June 12, 2023
Rose Hong Wang   (Principal Executive Officer)  
       
/s/ Sheng-Yih Chang   Chief Financial Officer June 12, 2023
Sheng-Yih Chang   (Principal Accounting Officer)  
       
/s/ Yuan Lu   Director June 12, 2023
Yuan Lu        
         
/s/ Xin Dong   Director June 12, 2023
Xin Dong        

 

34

GRAPHIC 2 form10-k_001.jpg begin 644 form10-k_001.jpg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end EX-21.1 3 ex21-1.htm

 

Exhibit 21.1

 

SUBSIDIARIES OF THE COMPANY

 

The following is a list of subsidiaries of the Company as of July 31, 2022, omitting subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary.

 

    State or Other Jurisdiction
    of Incorporation or
Subsidiaries   Organization
     
Hartford Great Health Management (Shanghai) Ltd. (“HFSH”)   Shanghai, China
Hartford International Education Technology (Shanghai) Co. Ltd. (“HF Int’l Education”)   Shanghai, China
Hangzhou Hartford Comprehensive Health Management, Ltd. (“HZHF”)   Hangzhou, China
Hangzhou Longjing Qiao Fu Vacation Hotel Co., Ltd (“HZLJ”)   Hangzhou, China
Pudong Haojin Childhood Education Ltd. (“PDHJ”)   Shanghai, China
Shanghai Hongkou HaiDeFuDe Childcare Co., Ltd.(“HDFD”)   Shanghai, China
Shanghai Gelinke Childcare Education Center (“Gelinke”)   Shanghai, China
HDFD Zhongli Education Technology Co., Ltd. (“Zhongli”)   Shanghai, China

 

 

EX-31.1 4 ex31-1.htm

 

Exhibit 31.1

 

Certification of Chief Executive Officer

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

and Rules 13a-14 and 15d-14 under the Securities Exchange Act of 1934

 

I, Rose Hong Wang, certify that:

 

1. I have reviewed this Annual Report on Form 10-K/A of Hartford Great Health Corp.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f)) for the registrant and have:

 

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)Designed such internal control over financing reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: June 12, 2023

 

  /s/ ROSE HONG WANG
  Rose Hong Wang
  Chief Executive Officer

 

 

 

EX-31.2 5 ex31-2.htm

 

Exhibit 31.2

 

Certification of Chief Financial Officer

Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

and Rules 13a-14 and 15d-14 under the Securities Exchange Act of 1934

 

I, Sheng-Yih Chang, certify that:

 

1. I have reviewed this Annual Report on Form 10-K/A of Hartford Great Health Corp.;

 

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15(d)-15(f)) for the registrant and have:

 

(a)Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

(b)Designed such internal control over financing reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

(c)Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

(d)Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

 

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

(b)Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Date: June 12, 2023

 

  /s/ Sheng-Yih Chang
  Sheng-Yih Chang
  Chief Financial Officer

 

 

 

EX-32 6 ex32.htm

 

Exhibit 32

 

Certification of Periodic Financial Report by the Chief Executive Officer and

Chief Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

 

Solely for the purposes of complying with 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, we, the undersigned Chief Executive Officer and Chief Financial Officer of Hartford Great Health Corp. (the “Company”), hereby certify, based on our knowledge, that the Annual Report on Form 10-K/A of the Company for the year ended July 31, 2022 (the “Report”) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 

Date: June 12, 2023 /s/ ROSE HONG WANG
  Rose Hong Wang
  Chief Executive Officer
   
Date: June 12, 2023 /s/ SHENG-YIH CHANG
  Sheng-Yih Chang
  Chief Financial Officer

 

 

 

EX-101.SCH 7 hfus-20220731.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 00000002 - Statement - Consolidated Balance Sheets link:presentationLink link:calculationLink link:definitionLink 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000004 - Statement - Consolidated Statements of Operations link:presentationLink link:calculationLink link:definitionLink 00000005 - Statement - Consolidated Statements of Comprehensive Loss link:presentationLink link:calculationLink link:definitionLink 00000006 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Deficit) link:presentationLink link:calculationLink link:definitionLink 00000007 - Statement - Consolidated Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES link:presentationLink link:calculationLink link:definitionLink 00000009 - Disclosure - GOING CONCERN link:presentationLink link:calculationLink link:definitionLink 00000010 - Disclosure - STOCKHOLDERS’ EQUITY link:presentationLink link:calculationLink link:definitionLink 00000011 - Disclosure - ACQUISITIONS, JOINT VENTURES AND DECONSOLIDATION link:presentationLink link:calculationLink link:definitionLink 00000012 - Disclosure - DISCONTINUED OPERATION link:presentationLink link:calculationLink link:definitionLink 00000013 - Disclosure - RELATED PARTY TRANSACTIONS link:presentationLink link:calculationLink link:definitionLink 00000014 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 00000015 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 00000016 - Disclosure - SEGMENT INFORMATION (restated) link:presentationLink link:calculationLink link:definitionLink 00000017 - Disclosure - RESTATEMENT link:presentationLink link:calculationLink link:definitionLink 00000018 - Disclosure - SUBSEQUENT EVENTS link:presentationLink link:calculationLink link:definitionLink 00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) link:presentationLink link:calculationLink link:definitionLink 00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000021 - Disclosure - ACQUISITIONS, JOINT VENTURES AND DECONSOLIDATION (Tables) link:presentationLink link:calculationLink link:definitionLink 00000022 - Disclosure - DISCONTINUED OPERATION (Tables) link:presentationLink link:calculationLink link:definitionLink 00000023 - Disclosure - INCOME TAXES (Tables) link:presentationLink link:calculationLink link:definitionLink 00000024 - Disclosure - SEGMENT INFORMATION (restated) (Tables) link:presentationLink link:calculationLink link:definitionLink 00000025 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE (Details) link:presentationLink link:calculationLink link:definitionLink 00000026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000027 - Disclosure - GOING CONCERN (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000028 - Disclosure - STOCKHOLDERS’ EQUITY (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000029 - Disclosure - SCHEDULE OF RECOGNIZED IDENTIFIED ASSETS ACQUIRED AND LIABILITIES ASSUMED (Details) link:presentationLink link:calculationLink link:definitionLink 00000030 - Disclosure - SCHEDULE OF RECOGNIZED IDENTIFIED ASSETS ACQUIRED AND LIABILITIES ASSUMED (Details) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 00000031 - Disclosure - SCHEDULE OF NET ASSETS (LIABILITIES) DISPOSED OF SUBSIDIARY (Details) link:presentationLink link:calculationLink link:definitionLink 00000032 - Disclosure - SCHEDULE OF NET INFLOW (OUTFLOW) OF CASH AND CASH EQUIVALENTS OF DISPOSAL SUBSIDIARY (Details) link:presentationLink link:calculationLink link:definitionLink 00000033 - Disclosure - ACQUISITIONS, JOINT VENTURES AND DECONSOLIDATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000034 - Disclosure - SCHEDULE OF DISCONTINUED OPERATIONS OF FINANCIAL STATEMENTS (Details) link:presentationLink link:calculationLink link:definitionLink 00000035 - Disclosure - DISCONTINUED OPERATION (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000036 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000037 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000038 - Disclosure - SCHEDULE OF INCOME TAX VALUATION (Details) link:presentationLink link:calculationLink link:definitionLink 00000039 - Disclosure - SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION (Details) link:presentationLink link:calculationLink link:definitionLink 00000040 - Disclosure - INCOME TAXES (Details Narrative) link:presentationLink link:calculationLink link:definitionLink 00000041 - Disclosure - SCHEDULE OF SEGMENT INFORMATION (Details) link:presentationLink link:calculationLink link:definitionLink 00000042 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 8 hfus-20220731_cal.xml XBRL CALCULATION FILE EX-101.DEF 9 hfus-20220731_def.xml XBRL DEFINITION FILE EX-101.LAB 10 hfus-20220731_lab.xml XBRL LABEL FILE Equity Components [Axis] Common Stock [Member] Additional Paid-in Capital [Member] Retained Earnings [Member] AOCI Attributable to Parent [Member] Noncontrolling Interest [Member] Business Acquisition [Axis] Hangzhou Longjing Qiao Fu Vacation Hotel Co., Ltd. [Member] Shanghai Hartford Comprehensive Health Management, Ltd. [Member] Investment, Name [Axis] Shanghai Hongkou Hai De Fu De Childcare Co Ltd [Member] Pudong Haojin Childhood Education Ltd [Member] Shanghai HDFD Zhongli Education Technology Co Ltd [Member] Ownership [Axis] Shanghai Jingyu Education Tech Ltd [Member] Subsequent Event Type [Axis] Subsequent Event [Member] Related Party [Axis] Shanghai Oversea [Member] Hartford International Education Technology Co., Ltd [Member] Hangzhou Hartford Comprehensive Health Management Ltd [Member] Legal Entity [Axis] People's Bank of China Financial Stability Bureau [Member] Product and Service [Axis] Early Childhood Education Services [Member] Long-Lived Tangible Asset [Axis] Leasehold Improvements [Member] ROU Assets-Finance Lease [Member] Furniture and Fixtures [Member] Statistical Measurement [Axis] Minimum [Member] Maximum [Member] Office Equipment and Vehicles [Member] Computer Software [Member] Shareholder [Member] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Joint Venture Agreement [Member] Title of Individual [Axis] Indefinite-Lived Intangible Assets [Axis] Seven Education Textbooks [Member] Ten “HaiDeFuDe” [Member] Chief Executive Officer [Member] Shanghai Gelinke Childcare Education Center [Member] Shanghai Senior Health Consulting Ltd. [Member] Shanghai Pasadena Ltd. [Member] Shanghai Luo Sheng International Trade Ltd. [Member] Consolidated Entities [Axis] Qiao Garden Intel Travel [Member] Segments [Axis] Education and Hospitality Segments [Member] Disposal Group Classification [Axis] Discontinued Operations, Held-for-sale or Disposed of by Sale [Member] SHQiahong [Member] Shanghai Oversea Chinese Culture Media Ltd [Member] Hartford Hotel Investment Inc [Member] Finite-Lived Intangible Assets by Major Class [Axis] Intellectual Properties [Member] License [Member] Hospitality [Member] Education [Member] Corporate And Unallocated [Member] Shangai Luo Sheng International Trade Ltd [Member] Related Party [Member] Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] Auditor Name Auditor Firm ID Auditor Location Statement of Financial Position [Abstract] ASSETS Cash and cash equivalents Prepaid and Other current receivables Related party receivable Current assets held for sale Total Current Assets Non-current Assets Property and equipment, net Non-current assets held for sale Total Non-current Assets TOTAL ASSETS LIABILITIES AND STOCKHOLDERS’ EQUITY Current Liabilities Related party loan and payables Other current payable Current liabilities held for sale Total Current Liabilities Long-term liabilities held for sale TOTAL LIABILITIES Commitments and contingencies (Note 7) Stockholders’ Equity (Deficit) Preferred stock - $0.001 par value, 5,000,000 shares authorized, no shares issued and outstanding Common stock - $0.001 par value, 300,000,000 shares authorized, 100,108,000 shares outstanding at both of July 31, 2022 and 2021. Additional paid-in capital Accumulated deficit Accumulated other comprehensive loss Noncontrolling interest Total Stockholders’ Deficit TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT Preferred stock, par value Preferred stock, shares authorized Preferred stock, shares issued Preferred stock, shares outstanding Common stock, par value Common stock, shares authorized Common stock, shares outstanding Income Statement [Abstract] Selling, general and administrative Total operating cost and expenses Operating Loss Other Income (Expense) Interest (expense) income, net Gain on disposal of subsidiary Other income, net Other (expense) income, net (Loss) income before income taxes Income Tax Expense Net (loss) income from continuing operations Less: net income from continuing operations attributable to noncontrolling Interest Net (loss) income from continuing operations Attributable to Hartford Great Health Corp Income loss from discontinued operations, net of income taxes Less: net loss from discontinued operations attributable to noncontrolling Interest Net loss from discontinued operations Attributable to Hartford Great Health Corp Net loss per common share: Continuing operations Discontinued operations Basic and Diluted Weighted average shares outstanding: Basic and diluted Net Loss Other Comprehensive income (loss), net of income tax Foreign currency translation adjustments Total other comprehensive loss Less: total other comprehensive loss attributable to noncontrolling interest Total Other Comprehensive Loss Attributable to Hartford Great Health Corp Total Comprehensive Loss Statement [Table] Statement [Line Items] Balance Balance, shares Net (loss) Issuance of common stock Issuance of common stock, shares Restructure of subsidiary Disposal of subsidiary Foreign currency translation adjustment Investment from noncontrolling interest Balance Balance, shares Statement of Cash Flows [Abstract] Cash flows from operating activities: Net loss including noncontrolling interests Adjustments to reconcile net loss including noncontrolling interests to net cash provided by (used in) operating activities: Depreciation and amortization Disposal of subsidiary, including noncontrolling interest Debts forgiveness per court ruling Loss from restructure Loss on disposal of property and equipment Impairment loss Changes in operating assets and liabilities: Prepaid and Other current receivables Inventory Other assets Related party receivables and payables Contract liabilities Other current payable Operating lease assets and liabilities Other liabilities Net cash used in operating activities Cash flows from investing activities: Cash proceeds from Acquisitions Cash used in Acquisitions Disposal of subsidiary Purchases of property and equipment Net cash used in investing activities Cash flows from financing activities: Contribution from noncontrolling interest Proceeds from issuance of common stock Proceeds of related party notes payable Principal payments on finance lease Advances from related parties Net cash provided by financing activities Effect of exchange rate changes on cash Net change in Cash, cash equivalents and restricted cash Cash, cash equivalents and restricted cash at beginning of period Cash, cash equivalents and restricted cash at end of period Supplemental Cash Flow Information Interest paid Income taxes paid Non-cash investing and financing activities: Payable to acquiree Investment return through three-party settlement Accounting Policies [Abstract] SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Organization, Consolidation and Presentation of Financial Statements [Abstract] GOING CONCERN Equity [Abstract] STOCKHOLDERS’ EQUITY Business Combination and Asset Acquisition [Abstract] ACQUISITIONS, JOINT VENTURES AND DECONSOLIDATION Discontinued Operations and Disposal Groups [Abstract] DISCONTINUED OPERATION Related Party Transactions [Abstract] RELATED PARTY TRANSACTIONS Commitments and Contingencies Disclosure [Abstract] COMMITMENTS AND CONTINGENCIES Income Tax Disclosure [Abstract] INCOME TAXES Segment Reporting [Abstract] SEGMENT INFORMATION (restated) Accounting Changes and Error Corrections [Abstract] RESTATEMENT Subsequent Events [Abstract] SUBSEQUENT EVENTS Organization Basis of Presentation Use of Estimates Foreign Currency Comprehensive Income (loss) Fair value measurement Cash and Cash Equivalents Receivables Property and equipment, net Goodwill and Long-lived Assets Business Combinations Noncontrolling interest Advertising costs Income Taxes Revenue Recognition Income (Loss) Per Share Reclassifications Recent Accounting Pronouncements SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE SCHEDULE OF RECOGNIZED IDENTIFIED ASSETS ACQUIRED AND LIABILITIES ASSUMED SCHEDULE OF NET ASSETS (LIABILITIES) DISPOSED OF SUBSIDIARY SCHEDULE OF NET INFLOW (OUTFLOW) OF CASH AND CASH EQUIVALENTS OF DISPOSAL SUBSIDIARY SCHEDULE OF DISCONTINUED OPERATIONS OF FINANCIAL STATEMENTS SCHEDULE OF INCOME TAX VALUATION SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION SCHEDULE OF SEGMENT INFORMATION Property, Plant and Equipment [Table] Property, Plant and Equipment [Line Items] Description of estimated useful lives of property and equipment Property, plant and equipment, useful life Schedule of Product Information [Table] Product Information [Line Items] Business acquisition, percentage of voting interests acquired Equity ownership percentage Equity ownership percentage Related party FDIC insured amount Advertising cost Income tax examination description Revenue Accumulated deficit Schedule of Defined Benefit Plans Disclosures [Table] Defined Benefit Plan Disclosure [Line Items] Share price Common stock, shares issued Schedule of Business Acquisitions, by Acquisition [Table] Business Acquisition [Line Items] Cash and cash equivalents Restricted Cash Prepaid and Other current receivables Property and Equipment, net Unearned revenue Goodwill Total consideration Purchase price Cash payments to acquire business Total consideration Cash and cash equivalents Restricted cash Related party receivable Related party payable Other current payable Noncontrolling interest Net assets of the subsidiary, excluding noncontrolling interest Consideration Gain on disposal of the subsidiary Gain on disposal of noncontrolling interest Gain on disposal of the subsidiary, excluding noncontrolling interest Cash and cash equivalents Restricted cash Cash and cash equivalents deconsolidated Joint venture acquired ownership interest Noncontrolling ownership interest Registered capital Noncontrolling shareholders, description Goodwill Business acquired ownership interest Investment from noncontrolling interest Investment income Disposal Groups, Including Discontinued Operations [Table] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Current Assets Prepaid and Other current receivables Related party receivable Inventory Property and equipment, net ROU assets-operating lease Other assets Total Assets held for sale Current Liabilities Related party loan and payables Contract liabilities Lease liabilities, current and noncurrent Other current payable Other liabilities Total Liabilities held for sale Net sales Cost of sales Gross profit Selling, general, and administrative expenses Impairment Total operating expenses Loss from operations of discontinued operations Interest expense Other Income Income tax benefit (expense) Income (loss) from discontinued operations, net of taxes before gain from sale of discontinued operations Loss from sale of discontinued operations, net of taxes Cash flow of discontinued operations: Operating cash flows Investing cash flows Net cash used in discontinued operations Schedule of Restructuring and Related Costs [Table] Restructuring Cost and Reserve [Line Items] Schedule of Related Party Transactions, by Related Party [Table] Related Party Transaction [Line Items] Accounts payable, related parties Short term debt Debt instrument, interest rate, stated percentage Interest expense, related party Product Liability Contingency [Table] Product Liability Contingency [Line Items] Licencse description Amed fee percentage Incrrued license fees Net NOL carry-forward NOL expires Estimated tax benefit from NOL and other tax benefits (21%) Valuation allowance Change in valuation allowance Net deferred tax asset Federal income tax rate State income tax rate Foreign tax difference Non-taxable item adjustment GILTI Valuation allowance Others Effective tax rate Income tax expense Schedule of Segment Reporting Information, by Segment [Table] Segment Reporting Information [Line Items] Operating loss Loss before tax Net Loss Attributable to Hartford Great Health Corp Total assets (excluding Intercompany balances) Assets allocated to held for sale Subsequent Event [Table] Subsequent Event [Line Items] Equity method investment ownership, perentage Joint venture acquired ownership interest. Joint Venture Agreement [Member] Hartford Great Health Management (Shanghai) Ltd. [Member] Noncontrolling shareholders, description. Hartford International Education Technology Co., Ltd [Member] Seven Education Textbooks [Member] Ten “HaiDeFuDe” [Member] Shanghai Gelinke Childcare Education Center [Member] Business combination recognized identifiable assets acquired and liabilities assumed current assets restricted cash. Business combination, recognized identifiable assets acquired and liabilities assumed, current assets, goodwill. Shanghai Senior Health Consulting Ltd [Member] Shanghai Pasadena Ltd. [Member] Shanghai Luo Sheng International Trade Ltd. [Member] Investment from Noncontrolling Interest. Qiao Garden Intel Travel [Member] Disposal group, including discontinued operation, restricted cash. Disposal group, including discontinued operation, related party receivable. Disposal Group, Including Discontinued Operation, Related party payable. Disposal group, including discontinued operation, noncontrolling interest. Disposal group, including discontinued operation, net assets of the subsidiary. Disposal group, including discontinued operation, cash and cash equivalents and restricted cash. Disposal of subsidiary. Increase decrease in operating lease assets and liabilities. Advances from related parties. Investment return through threeparty settlement. SHQiahong [Member] Shanghai Hartford Comprehensive Health Management, Ltd. [Member] Shanghai Hongkou Hai De FuDeChildcareCoLtdMember Shanghai Hdfd Zhongli Education Technology Co Ltd [Member] People's Bank of China Financial Stability Bureau [Member] ROU Assets-Finance Lease [Member] Office Equipment and Vehicles [Member] Computer Software [Member] License Description Intellectual Properties [Member] Net operating loss expires. Effective Income Tax Rate Nontaxable Item Adjustment Effective Income Tax Rate Reconciliation Global Intangible Low Taxed Income Shareholder [Member] Related Party [Member] Hangzhou Longjing Qiao Fu Vacation Hotel Co., Ltd [Member] Schedule Of Net Assets Liabilities Disposed Of Subsidiary [Table Text Block]. Debts forgiveness per court ruling. Gain loss from restructure. Shanghai Oversea Chinese Culture Media Ltd [Member] Hangzhou Hartford Comprehensive Health Management Ltd [Member] Restructure of subsidiary. Noncontrolling Interest Policy Text [Block] Schedule Of Property And Equipment Useful Lives [Table Text Block] Reclassifications [Policy Text Block] Hospitality [Member] Education [Member] Corporate And Unallocated [Member] Shanghai Oversea [Member] Shangai Luo Sheng International Trade Ltd [Member] Disposal group including discontinued operation right of use assets operating lease. Disposal group including discontinued operation lease liabilities. Disposal group including discontinued operation contract liabilities current. Disposal group including discontinued operation related party loan and payables current. Education and Hospitality Segments [Member]. Disposal group including discontinued operation impairment expense. Pudong Haojin Childhood Education Ltd [Member] Shanghai Jingyu Education Tech Ltd [Member] Early Childhood Education Services [Member] Hartford Hotel Investment Inc [Member] Amend fee percentage. Gain on disposal of subsidiary. Disposal group including discontinued operation contract liiabilities current. Income loss from continuing and discontinued operations before income taxes extraordinary items. Operating income loss including continued and discontinued operations. Assets, Current Assets, Noncurrent Liabilities, Current Liabilities Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest Liabilities and Equity Operating Costs and Expenses Operating Income (Loss) Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Other Comprehensive Income (Loss), Net of Tax Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Comprehensive Income (Loss), Net of Tax, Attributable to Parent Shares, Outstanding Gain (Loss) on Disposition of Stock in Subsidiary DebtsForgivenessPerCourtRuling Gain (Loss) on Disposition of Property Plant Equipment Increase (Decrease) in Prepaid Expense and Other Assets Increase (Decrease) in Inventories Increase (Decrease) in Other Operating Assets Increase (Decrease) in Broker-Dealer Related Receivables (Payables), Net Increase (Decrease) in Other Accounts Payable IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities Net Cash Provided by (Used in) Operating Activities Payments for Previous Acquisition Cash Divested from Deconsolidation Payments to Acquire Property, Plant, and Equipment Net Cash Provided by (Used in) Investing Activities Finance Lease, Principal Payments Net Cash Provided by (Used in) Financing Activities Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Property, Plant and Equipment, Policy [Policy Text Block] NoncontrollingInterestPolicyTextBlock Noncontrolling Interest, Ownership Percentage by Parent Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents DisposalGroupIncludingDiscontinuedOperationRelatedPartyReceivable Disposal Group, Including Discontinued Operation, Other Liabilities, Current DisposalGroupIncludingDiscontinuedOperationNoncontrollingInterest Cash and cash equivalents deconsolidated Goodwill [Default Label] InvestmentFromNoncontrollingInterests Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current Disposal Group, Including Discontinued Operation, Assets DisposalGroupIncludingDiscontinuedOperationRelatedPartyLoanAndPayablesCurrent DisposalGroupIncludingDiscontinuedOperationContractLiiabilitiesCurrent Disposal Group, Including Discontinued Operation, Accounts Payable, Current Disposal Group, Including Discontinued Operation, Gross Profit (Loss) Disposal Group, Including Discontinued Operation, Operating Expense Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax Net Cash Provided by (Used in) Discontinued Operations Deferred Tax Assets, Valuation Allowance Deferred Tax Assets, Net of Valuation Allowance Assets Held-for-sale, Not Part of Disposal Group EX-101.PRE 11 hfus-20220731_pre.xml XBRL PRESENTATION FILE XML 12 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover - USD ($)
12 Months Ended
Jul. 31, 2022
May 27, 2023
Jan. 31, 2022
Cover [Abstract]      
Document Type 10-K/A    
Amendment Flag true    
Amendment Description This Amendment No. 1 to our Annual Report on Form 10-K for the annual period from August 1, 2021 to July 31, 2022, which was filed with the U.S. Securities and Exchange Commission (the “SEC”) on November 14, 2022 (the “Original Filing”), is being filed for the following purposes    
Document Annual Report true    
Document Transition Report false    
Document Period End Date Jul. 31, 2022    
Document Fiscal Period Focus FY    
Document Fiscal Year Focus 2022    
Current Fiscal Year End Date --07-31    
Entity File Number 000-54439    
Entity Registrant Name Hartford Great Health Corp.    
Entity Central Index Key 0001482554    
Entity Tax Identification Number 51-0675116    
Entity Incorporation, State or Country Code NV    
Entity Address, Address Line One 8832 Glendon Way    
Entity Address, City or Town Rosemead    
Entity Address, State or Province CA    
Entity Address, Postal Zip Code 91770    
City Area Code (626)    
Local Phone Number 321-1915    
Title of 12(b) Security Common stock, par value $0.001 par value    
Trading Symbol HFUS    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers Yes    
Entity Current Reporting Status Yes    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company true    
Elected Not To Use the Extended Transition Period false    
Entity Shell Company false    
Entity Public Float     $ 5,002,840
Entity Common Stock, Shares Outstanding   100,108,000  
Auditor Name Simon & Edward, LLP    
Auditor Firm ID 2485    
Auditor Location Rowland Heights, California    
XML 13 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Balance Sheets - USD ($)
Jul. 31, 2022
Jul. 31, 2021
ASSETS    
Cash and cash equivalents $ 15,227 $ 12,739
Prepaid and Other current receivables 1,154 1,203
Related party receivable 14,233 309
Current assets held for sale 4,499,736 975,837
Total Current Assets 4,530,350 990,088
Non-current Assets    
Property and equipment, net 8,006 8,357
Non-current assets held for sale 4,744,153
Total Non-current Assets 8,006 4,752,510
TOTAL ASSETS 4,538,356 5,742,598
Current Liabilities    
Related party loan and payables 4,481,524 3,711,606
Other current payable 144,760 145,435
Current liabilities held for sale 6,344,721 2,681,639
Total Current Liabilities 10,971,005 6,538,680
Long-term liabilities held for sale 4,190,368
TOTAL LIABILITIES 10,971,005 10,729,048
Commitments and contingencies (Note 7)
Stockholders’ Equity (Deficit)    
Preferred stock - $0.001 par value, 5,000,000 shares authorized, no shares issued and outstanding
Common stock - $0.001 par value, 300,000,000 shares authorized, 100,108,000 shares outstanding at both of July 31, 2022 and 2021. 100,108 100,108
Additional paid-in capital 2,173,521 2,173,521
Accumulated deficit (7,400,620) (5,821,519)
Accumulated other comprehensive loss (16,742) (233,487)
Noncontrolling interest (1,288,916) (1,205,073)
Total Stockholders’ Deficit (6,432,649) (4,986,450)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT $ 4,538,356 $ 5,742,598
XML 14 R3.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Balance Sheets (Parenthetical) - $ / shares
Jul. 31, 2022
Jul. 31, 2021
Statement of Financial Position [Abstract]    
Preferred stock, par value $ 0.001 $ 0.001
Preferred stock, shares authorized 5,000,000 5,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value $ 0.001 $ 0.001
Common stock, shares authorized 300,000,000 300,000,000
Common stock, shares outstanding 100,108,000 100,108,000
XML 15 R4.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Operations - USD ($)
12 Months Ended
Jul. 31, 2022
Jul. 31, 2021
Income Statement [Abstract]    
Selling, general and administrative $ 177,913 $ 255,655
Total operating cost and expenses 177,913 255,655
Operating Loss (177,913) (255,655)
Other Income (Expense)    
Interest (expense) income, net (11,857) 14,806
Gain on disposal of subsidiary 104,317
Other income, net 140 55,604
Other (expense) income, net (11,717) 174,727
(Loss) income before income taxes (189,630) (80,928)
Income Tax Expense 800 800
Net (loss) income from continuing operations (190,430) (81,728)
Less: net income from continuing operations attributable to noncontrolling Interest
Net (loss) income from continuing operations Attributable to Hartford Great Health Corp (190,430) (81,728)
Income loss from discontinued operations, net of income taxes (1,582,152) (2,760,611)
Less: net loss from discontinued operations attributable to noncontrolling Interest (193,481) (589,005)
Net loss from discontinued operations Attributable to Hartford Great Health Corp $ (1,388,671) $ (2,171,606)
Net loss per common share:    
Continuing operations $ (0.00) $ 0.00
Discontinued operations (0.01) (0.02)
Basic and Diluted $ (0.02) $ (0.02)
Weighted average shares outstanding:    
Basic and diluted 100,108,000 99,790,192
XML 16 R5.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Comprehensive Loss - USD ($)
12 Months Ended
Jul. 31, 2022
Jul. 31, 2021
Income Statement [Abstract]    
Net Loss $ (1,579,101) $ (2,253,334)
Other Comprehensive income (loss), net of income tax    
Foreign currency translation adjustments 267,073 (217,953)
Total other comprehensive loss 267,073 (217,953)
Less: total other comprehensive loss attributable to noncontrolling interest 50,328 (39,612)
Total Other Comprehensive Loss Attributable to Hartford Great Health Corp 216,745 (178,341)
Total Comprehensive Loss $ (1,362,356) $ (2,431,675)
XML 17 R6.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Changes in Stockholders' Equity (Deficit) - USD ($)
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
AOCI Attributable to Parent [Member]
Noncontrolling Interest [Member]
Total
Balance at Jul. 31, 2020 $ 99,108 $ 2,154,521 $ (3,568,185) $ (55,146) $ (917,489) $ (2,287,191)
Balance, shares at Jul. 31, 2020 99,108,000          
Net (loss) (2,253,334) (589,005) (2,842,339)
Issuance of common stock $ 1,000 19,000 20,000
Issuance of common stock, shares 1,000,000          
Restructure of subsidiary 403,131 403,131
Disposal of subsidiary (62,098) (62,098)
Foreign currency translation adjustment (178,341) (39,612) (217,953)
Balance at Jul. 31, 2021 $ 100,108 2,173,521 (5,821,519) (233,487) (1,205,073) (4,986,450)
Balance, shares at Jul. 31, 2021 100,108,000          
Net (loss) (1,579,101) (193,481) (1,772,582)
Foreign currency translation adjustment 216,745 50,328 267,073
Investment from noncontrolling interest 59,310 59,310
Balance at Jul. 31, 2022 $ 100,108 $ 2,173,521 $ (7,400,620) $ (16,742) $ (1,288,916) $ (6,432,649)
Balance, shares at Jul. 31, 2022 100,108,000          
XML 18 R7.htm IDEA: XBRL DOCUMENT v3.23.1
Consolidated Statements of Cash Flows - USD ($)
12 Months Ended
Jul. 31, 2022
Jul. 31, 2021
Cash flows from operating activities:    
Net loss including noncontrolling interests $ (1,772,582) $ (2,842,339)
Adjustments to reconcile net loss including noncontrolling interests to net cash provided by (used in) operating activities:    
Depreciation and amortization 122,065 85,103
Disposal of subsidiary, including noncontrolling interest (104,316)
Debts forgiveness per court ruling (162,806)
Loss from restructure 403,131
Loss on disposal of property and equipment 760
Impairment loss 70,514
Changes in operating assets and liabilities:    
Prepaid and Other current receivables 225,428 (87,978)
Inventory 5,327 (299,588)
Other assets 24,078 10,435
Related party receivables and payables (81,013) (185,693)
Contract liabilities 26,466 373,413
Other current payable 102,526 312,902
Operating lease assets and liabilities 458,993 17,779
Other liabilities 27,880 27,108
Net cash used in operating activities (860,832) (2,381,575)
Cash flows from investing activities:    
Cash proceeds from Acquisitions 27,927
Cash used in Acquisitions (15,206)
Disposal of subsidiary (30,116)
Purchases of property and equipment (145,048) (168,287)
Net cash used in investing activities (145,048) (185,682)
Cash flows from financing activities:    
Contribution from noncontrolling interest 61,750
Proceeds from issuance of common stock 20,000
Proceeds of related party notes payable 145,000 145,000
Principal payments on finance lease (23,156) (22,049)
Advances from related parties 788,673 2,407,033
Net cash provided by financing activities 972,267 2,549,984
Effect of exchange rate changes on cash (400) 6,174
Net change in Cash, cash equivalents and restricted cash (34,013) (11,099)
Cash, cash equivalents and restricted cash at beginning of period 54,178 65,277
Cash, cash equivalents and restricted cash at end of period 20,165 54,178
Supplemental Cash Flow Information    
Interest paid
Income taxes paid 800 800
Non-cash investing and financing activities:    
Payable to acquiree 10,462
Investment return through three-party settlement $ 765,131
XML 19 R8.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
12 Months Ended
Jul. 31, 2022
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

This summary of significant accounting policies is presented to assist in understanding the Company’s financial statements. The financial statements and notes are the responsibility of the Company’s management. These accounting policies conform to accounting principles generally accepted in the United States of America (“US GAAP”) and have been consistently applied in the preparation of the financial statements.

 

Organization

 

Hartford Great Health Corp. was originally incorporated in the State of Nevada on April 2, 2008 under the name PhotoAmigo, Inc. It changed its name to Hartford Great Health Corp. on August 22, 2018 and since then we have been engaged in activities to formulate and implement our business plans.

 

Through its wholly owned subsidiary - Hangzhou Hartford Comprehensive Health Management, Ltd (“HZHF) and HZHF’s 60 percent owned subsidiary - Hangzhou Longjing Qiao Fu Vacation Hotel Co., Ltd. (“HZLJ”), and through Shanghai Hartford Comprehensive Health Management, Ltd. (“HFSH”) and its 90 percent owned subsidiary - Shanghai Qiao Garden International Travel Agency (“Qiao Garden Int’l Travel”), the Company engages in hospitality industry in China. Qiao Garden Int’l Travel was disposed on December 31, 2020, see note 4 Acquisitions, Joint Ventures and Deconsolidation.

 

The Company started to engage in early childhood education industry at Hartford International Education Technology Co., Ltd (“HF Int’l Education”). On July 24, 2019 and March 23, 2020, HF Int’l Education established two 100% owned subsidiaries, Pudong Haojin Childhood Education Ltd. (“PDHJ”) and Shanghai Hongkou HaiDeFuDe Childcare Co., Ltd.(“HDFD”), respectively, to operate the early childhood education service under the brand name of “HaiDeFuDe” in Shanghai, China. On July 20, 2020, HF Int’l Education entered an agreement with two individuals to acquire the whole ownership of Shanghai Gelinke Childcare Education Center (“Gelinke”). Gelinke temporally ceased its operations by the end of August 2021. On August 31, 2021, PDHJ established one 96% owned subsidiary, Shanghai HDFD Zhongli Education Technology Co., Ltd. (“Zhongli”), two individual investors hold the remaining 4% ownership, see note 4 Acquisitions, Joint Ventures and Deconsolidation.

 

Impacted by the government regulation newly implemented in education industry and the restrictions posted by the Chinese government to control the pandemic in China since 2021, to avoid further operation losses, subsequently on August 1, 2022, HFSH entered a contract with a related party, Shanghai Oversea Chinese Culture Media Ltd. (“SH Oversea”), to sell 90 percent ownership of HF Int’l Education and its subsidiaries for $900 (RMB 5,850). On August 1, 2022, HFUS entered a contract with SH Oversea and another individual, to sell 100 percent ownership of HZHF and its subsidiaries for $1,000 (RMB 6,500). As of July 31, 2022, the asset group in Education segment and the asset group in Hospitality segment classified as assets and liabilities held for sale, and it is the Company’s intention to complete the sales of these assets within the upcoming year.

 

Basis of Presentation: The consolidated financial statements include the accounts of Hartford Great Health Corp, its wholly-owned subsidiaries and subsidiaries in which it has a controlling interest. The Company reports noncontrolling interests of the consolidated entities as a component of equity separate from the Company’s equity. All material inter-company transactions between and among the Company and its consolidated subsidiaries have been eliminated in the consolidation. The Company’s net income (loss) excludes income (loss) attributable to the noncontrolling interests.

 

Use of Estimates: The preparation of financial statements in conformity with US GAAP requires the Company’s management to make estimates and assumptions that affect the amounts of assets and liabilities, the identification and disclosure of impaired assets and contingent liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

 

Foreign Currency: The accounts of the Company’s foreign subsidiaries are translated in accordance with FASB ASC 830. Foreign currency transaction gains and losses are recognized in other expense, net, at the time they occur. Net foreign currency exchange gains or losses resulting from the translation of assets and liabilities of foreign subsidiaries whose functional currency is not the U.S. dollar are recorded as a part of accumulated other comprehensive loss in stockholders’ equity. The Company does not undertake hedging transactions to cover its foreign currency exposure.

 

Comprehensive Income (loss): For the year ended July 31, 2022 and 2021, the Company included its foreign currency translation gain or loss as part of its comprehensive income (loss).

 

Fair value measurement: Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Accounting Standard Codification (“ASC”) 820, Fair Value Measurements and Disclosures (“ASC 820”), describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value, which are the following:

 

Level 1 - Quoted prices in active markets for identical assets or liabilities or funds.

Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

 

The Company’s financial instruments consist of cash and cash equivalents, accounts receivable, related party receivable, prepaid and other current receivable, accounts payable, related party payable and other current payable. The carrying amounts of afore-mentioned accounts approximate fair value because of their short-term nature.

 

 

Cash and Cash Equivalents: The Company maintains cash with banks in the USA and China. Should any bank holding cash become insolvent, or if the Company is otherwise unable to withdraw funds, the Company would lose the cash with that bank; however, the Company has not experienced any losses in such accounts and believes it is not exposed to any significant risks on its cash in bank accounts. In China, a depositor has up to RMB500,000 insured by the People’s Bank of China Financial Stability Bureau (“FSD”). In the United States, the standard insurance amount is USD250,000 per depositor in a bank insured by the Federal Deposit Insurance Corporation (“FDIC”). Financial instruments that potentially subject the Company to significant concentrations of credit risk are cash and cash equivalents and accounts receivable. As of July 31, 2022 and 2021, respectively, none of the Company’s cash and cash equivalents held by financial institutions was uninsured. With respect to accounts receivable, the Company generally does not require collateral and does not have an allowance for doubtful accounts.

 

Receivables: The Company evaluates the collectability of its receivables based on a number of factors. In circumstances where the Company becomes aware of a specific customer’s or borrower’s inability to meet its financial obligations to the Company, a specific reserve for bad debts is estimated and recorded, which reduces the recognized receivable to the estimated amount the Company believes will ultimately be collected. As of July 31, 2022 and 2021, all balances are collectable based on management’s assessment.

 

Property and equipment, net: Property and equipment, net, are stated at cost. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the assets. The estimated useful lives of property and equipment are as follows:

 

   Years
Leasehold improvements  Lesser of lease term or estimated useful life
ROU assets-Finance lease  Lease term
Furniture and fixtures  3-5
Office equipment and vehicles  3-5
Computer software  3-5

 

Expenditures for repairs and maintenance are charged to expense as incurred.

 

Goodwill and Long-lived Assets: Goodwill, which represents the excess of the purchase price over the fair value of identifiable net assets acquired, is not amortized, in accordance with Accounting Standards Codification (ASC) 350, Intangibles—Goodwill and Other. ASC 350 requires that goodwill be tested for impairment at the reporting unit level on an annual basis and between annual tests, if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. These events or circumstances could include a significant change in the business climate, legal factors, operating performance indicators, competition, or sale or disposition of a significant portion of a reporting unit.

 

The Company has the option to assess goodwill for possible impairment by performing a qualitative analysis to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. A quantitative assessment is performed if the qualitative assessment results in a more-likely-than-not determination or if a qualitative assessment is not performed. The quantitative assessment considers whether the carrying amount of a reporting unit exceeds its fair value, in which case an impairment charge is recorded to the extent that the reporting unit’s carrying value exceeds its fair value. The Company’s goodwill was mainly generated from the acquisitions during the year ended July 31, 2019. We currently have two reporting units - Hospitality and Early Childhood Education. Given the impact of COVID-19 pandemic and the unfavorable operation results, an interim goodwill impairment assessment was performed as of January 31, 2020. Based on the assessment result, management determined that the goodwill generated from acquisitions was fully impaired as of July 31, 2021.

 

Business Combinations: If an acquired set of activities and assets is capable of being operated as a business consisting of inputs and processes from the viewpoint of a market participant, the assets acquired and liabilities assumed are a business. Business combinations are accounted for using the acquisition method of accounting, which requires an acquirer to recognize the assets acquired and the liabilities assumed at the acquisition date measured at their fair values as of that date. Fair value determinations are based on discounted cash flow analyses or other valuation techniques. In determining the fair value of the assets acquired and liabilities assumed in a material acquisition, the Company may utilize appraisals from third party valuation firms to determine fair values of some or all of the assets acquired and liabilities assumed, or may complete some or all of the valuations internally. In either case, the Company takes full responsibility for the determination of the fair value of the assets acquired and liabilities assumed. The value of goodwill reflects the excess of the fair value of the consideration conveyed to the seller over the fair value of the net assets received. Acquisition-related costs that the Company incurs to affect a business combination are expensed in the periods in which the costs are incurred.

 

Noncontrolling interest: The Company adopted ASC 810, Noncontrolling Interests in Consolidated Financial Statements—an Amendment of Accounting Research Bulletin No. 51, as of January 1, 2009. ASC 810 establishes accounting and reporting standards for ownership interests in subsidiaries held by parties other than the parent, the amount of consolidated net income attributable to the parent and to the noncontrolling interest, changes in a parent’s ownership interest and the valuation of retained noncontrolling equity investments when a subsidiary is deconsolidated. ASC 810 also establishes reporting requirements that provide sufficient disclosures that clearly identify and distinguish between the interest of the parent and the interests of the noncontrolling owner.

 

Advertising costs: Advertising costs are expensed as incurred. During the year ended July 31, 2022 and 2021, amount of $10,540 and $65,406 advertising expenses were incurred, respectively.

 

 

Income Taxes: The Company accounts for income taxes using the asset and liability method in accordance with ASC 740, Accounting for Income Taxes. The asset and liability method provides that deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using the currently enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company records a valuation allowance to reduce deferred tax assets to the amount that is believed more likely than not to be realized.

 

On December 22, 2017, the President of the United States signed into law the Tax Reform Act. The Tax Reform Act permanently reduces the U.S. corporate income tax rate from a maximum of 35% to a flat 21% rate, effective January 1, 2018. In addition, the 2017 Tax Act also creates a new requirement that certain income (i.e., Global Intangible Low-Taxed Income (“GILTI”)) earned by controlled foreign corporations (“CFCs”) must be included in the gross income of the CFCs’ U.S. shareholder income. The tax law in PRC applies an income tax rate of 25% to all enterprises. The Company’s subsidiary does not receive any preferential tax treatment from local government. The Company has been in loss position for years and zero balances of tax provisions, deferred tax assets and liabilities as of the reporting periods ended. The tax reforms have no significant impacts on the Company.

 

Revenue Recognition: The Company adopted ASC Topic 606 Revenue from Contracts with Customers (“Topic 606) on August 1, 2019, applying the modified retrospective method to all contracts that were not completed as of August 1, 2019. The Company is building up its core business upon the completion of multiple acquisitions in March 2019 and impact of COVID-19 pandemic, limited operations occurred during the years ended July 31, 2022 and 2021. The revenue during the years ended July 31, 2022 and 2021 were mainly generated from HZLJ and HF Int’l Education.

 

Revenue is recognized when control of promised goods or services is transferred to our customers in an amount of consideration to which we expect to be entitled to in exchange for those goods or services. We follow the five steps approach for revenue recognition under Topic 606: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) we satisfy a performance obligation. Billings to customers for which services are not rendered are considered deferred revenue. ASC 606 has no material impacts on the Company’s financial positions. The Company’s revenue is recognized when it satisfies a single performance obligation by transferring control of its products or providing services to a customer. The Company’s general payment terms are short-term in duration. The Company does not have significant financing components or payment terms.

 

a.Early childhood education services: HF Int’l Education generates revenue from childhood education classes provided to its customers. The educational services consist of parent-child and bilingual childcare classes. Each contract of educational classes is accounted for as a single performance obligation which is satisfied proportionately over the service period. Tuition fee is generally collected in advance and is initially recorded as deferred revenue and transferred to contract liabilities after trial period. Refunds are provided to parents if they decide within the trial period that they no longer want to take the class. After the trial period, if a parent withdraws from a class, usually only that unearned portion of the fee is available to be returned. For the year ended July 31, 2022 and 2021, $509,920 and $435,149, respectively, of revenue were derived from early childhood education classes provided.

 

b.Hospitality services: HZLJ generates revenue primarily from the room rentals, sale of food and beverage and other miscellaneous hospitality services. The Company recognizes room rental and services daily as services are provided. Under ASC 606, the pattern and timing of recognition of income from hotel facility is consistent with the prior accounting model.

 

Income (Loss) Per Share: Basic earnings per share include no dilution and are computed by dividing net income (or loss) by the weighted- average number of shares outstanding during the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of the Company, assuming the issuance of an equivalent number of common shares pursuant to options, warrants, or convertible debt arrangements. Diluted earnings per share are not shown for periods in which the Company incurs a loss because it would be anti-dilutive. Similarly, potential common stock equivalents are not included in the calculation if the effect would be anti-dilutive. No potentially dilutive debt or equity securities were issued or outstanding during the years ended July 31, 2022 or 2021.

 

Reclassifications

 

Certain amounts on the prior-year consolidated balance sheet, consolidated statement of operations and cash flows were reclassified to conform to current-year presentation, with no effect on ending stockholders’ equity.

 

 

Recent Accounting Pronouncements.

 

Recently adopted accounting pronouncements

 

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes which is intended to simplify various aspects related to accounting for income taxes. The standard is effective for fiscal years, and interim periods within those years, beginning after December 15, 2020, with early adoption permitted. The adoption of ASU 2019-12 had an immaterial impact on the Company’s consolidated statement of operation and consolidated statement of cash flows for the year ended July 31, 2022.

 

Recently issued accounting pronouncements not yet adopted

 

In June 2016, the FASB issued ASU 2016-13, “Financial Instruments—Credit Losses”. The standard, including subsequently issued amendments (ASU 2018-19, ASU 2019-04, ASU 2019-05, ASU 2019-10 and ASU 2019-11), requires a financial asset measured at amortized cost basis, such as accounts receivable and certain other financial assets, to be presented at the net amount expected to be collected based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. In November 2019, the FASB issued ASU No. 2019-10 to postpone the effective date of ASU No. 2016-13 for public business entities eligible to be smaller reporting companies defined by the SEC to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company is evaluating the impact of this guidance on its consolidated financial statements.

 

 

XML 20 R9.htm IDEA: XBRL DOCUMENT v3.23.1
GOING CONCERN
12 Months Ended
Jul. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
GOING CONCERN

NOTE 2. GOING CONCERN

 

The accompanying financial statements were prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of obligations in the normal course of business. However, Hartford Great Health Corp. has incurred losses since inception, resulting in an accumulated deficit of $7,400,620 as of July 31, 2022. These conditions raise substantial doubt about the ability of Hartford Great Health Corp. to continue as a going concern.

 

In view of these matters, continuation as a going concern is dependent upon several factors, including the availability of debt or equity funding upon terms and conditions acceptable to Hartford Great Health Corp., and ultimately achieving profitable operations. Management believes that Hartford Great Health Corp.’s business plan provides it with an opportunity to continue as a going concern. However, management cannot provide assurance that Hartford Great Health Corp. will meet its objectives and be able to continue in operation.

 

The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of Hartford Great Health Corp. to continue as a going concern.

 

XML 21 R10.htm IDEA: XBRL DOCUMENT v3.23.1
STOCKHOLDERS’ EQUITY
12 Months Ended
Jul. 31, 2022
Equity [Abstract]  
STOCKHOLDERS’ EQUITY

NOTE 3. STOCKHOLDERS’ EQUITY

 

Preferred Stock

 

The Company is authorized to issue 5,000,000 shares of preferred stock with a par value of $0.001 per share. No shares of preferred stock have been issued or outstanding since Inception (April 2, 2008).

 

Common Stock

 

The Company is authorized to issue 300,000,000 shares of common stock with a par value of $0.001 per share. On November 24, 2020, the Company issued 1,000,000 shares of common stock to a significant shareholder of the Company at $0.02 per share. The company had a total of 100,108,000 shares of common stock issued and outstanding at both of July 31, 2022 and 2021.

 

XML 22 R11.htm IDEA: XBRL DOCUMENT v3.23.1
ACQUISITIONS, JOINT VENTURES AND DECONSOLIDATION
12 Months Ended
Jul. 31, 2022
Business Combination and Asset Acquisition [Abstract]  
ACQUISITIONS, JOINT VENTURES AND DECONSOLIDATION

NOTE 4. ACQUISITIONS, JOINT VENTURES AND DECONSOLIDATION

 

Joint Venture – HF Int’l Education

 

On March 22, 2019, HFSH entered into a joint venture agreement (the “JV agreement”) with Shanghai Jingyu Education Tech Ltd. (“SH Jingyu”) and one individual investor, to form a new entity - HF Int’l Education to provide childcare education services. HFSH initially owned 65.0% ownership HF Int’l Education, and reduced to 61.0% during the year ended on July 31, 2020 because of equity transactions between noncontrolling shareholders. On June 19, 2020, the board of HF Int’l Education decided to increase registered capital to RMB10 million from RMB5 million, and three out of four noncontrolling shareholders gave up the subscription rights. As a result, HFSH held 75.5% of HF Int’l Education and a total of 24.5% equity was held by noncontrolling shareholders. Pursuant to the board meeting held on June 1, 2021, the noncontrolling shareholders sold a total 14.5% equity at zero consideration to HFSH. As a result, HFSH holds 90.0% of HF Int’l Education and $403,131 noncontrolling loss was absorbed by HFSH as a result of the ownership restructure at HF Int’l Education.

 

Continuous operation losses caused by the market uncertainties including pandemic and government regulations, HF Int’l Education entered agreements to sell the copyrights of seven education textbooks and ten “HaiDeFuDe” registered trademarks owned for RMB1.2 million and RMB1.0 million, respectively, to Hartford Health Management (Shanghai) Co., Ltd (“HFHM”) in March 2021 with approval of the board of directors. The CEO of HFHM is a shareholder of the Company who owns more than 5% of the Company’s common stocks.

 

Operation result of HF Int’l Education are included in the Company’s consolidated financial statements commencing on the formation date. The Company classifies the ownership interest held by other four parties as “Noncontrolling interest” on the consolidated balance sheet.

 

Acquisition of Gelinke

 

On July 20, 2020, HF Int’l Education entered an agreement with two individuals to acquire the whole ownership of Gelinke, who engages at early childhood education services in Changning District, Shanghai. The results of operations of the acquired entities are included in the Company’s consolidated financial statements commencing on the acquisition date. The Company has recorded an allocation of purchase price to Gelinke’s tangible and identifiable intangible assets acquired and liabilities assumed based on their fair value at the acquisition date. The Company accounted the acquisition transaction in accordance with FASB ASC 805, Business Combinations, under acquisition accounting method. The related transaction costs were immaterial and included in General and administrative expenses in the accompanying consolidated statements of operations. The acquisition was completed on August 31, 2021. The calculation of purchase price and purchase price allocation is as follows:

 

   Assets Acquired and 
   Liabilities Assumed 
Cash and cash equivalents   1,809 
Restricted Cash   25,009 
Prepaid and Other current receivables   4,696 
Property and Equipment, net   4,294 
Unearned revenue   (78,696)
Goodwill   67,712 
Total consideration*   24,824 

 

*$10,462 (RMB70,000) payable to the acquiree plus $14,362 (RMB100,000) cash payment totaled $24,824 consideration for the acquisition.

 

Goodwill is mainly attributable to synergies expected from the acquisition of license, list of customers and teacher workforce. Due to unfavorable operation result of Gelinke during the year ended July 31, 2021, management determined that $67,712 goodwill generated from Gelinke Acquisition was fully impaired.

 

 

Other Acquisitions

 

In January and February 2019, HFSH entered agreements to acquire 85 percent ownership of Shanghai Senior Health Consulting Ltd. (“SH Senior”) and 55 percent ownership of Shanghai Pasadena Ltd. (“SH Pasadena”). On December 31, 2020, HFSH withdrew from the two acquisition agreements. No penalty results from the withdrawn.

 

In January 2019, HFSH entered agreements to acquire 100 percent equity interest of Shanghai Luo Sheng International Trade Ltd. (“SH Luosheng”)  and the agreement has not yet taken effect. On August 1, 2022, HFSH decided to withdraw from the agreement. There was no penalty levied or to be levied due to delayed execution or inexecution.  

 

Disposal of subsidiary

 

On December 31, 2020, HFSH disposed its 90 percent owned subsidiary - Qiao Garden Int’l Travel to an individual (the “Disposal”). The individual is a relative of the CEO, Qiao Garden Int’l Travel became a related party after deconsolidation. The operation results, assets and liabilities, and cash flows of Qiao Garden Int’l Travel were deconsolidated from the Company’s consolidated financial statements effective on December 31, 2020. The Disposal of Qiao Garden was consummated through a three-party settlement among HFSH, SH Qiaohong and Qiao Garden Int’l Travel (the “Three-Party Settlement”): the original investment RMB 4.5 million plus RMB 0.5 million investment income were agreed to returned from Qiao Garden Int’l Travel as a result of the Disposal and settled with a payable due to SH Qiaohong at SHHF, who was a debtor of Qiao Garden Int’l Travel, see Note 14, Related Party Transactions.

 

Net assets (liabilities) disposed of:

 

    1 
Net assets (liabilities) disposed of:    
Cash and cash equivalents   172 
Restricted cash   29,944 
Related party receivable   782,224 
Related party payable   (98,615)
Other current payable   (3,876)
Noncontrolling interest   (60,812)
Net assets of the subsidiary, excluding noncontrolling interest   649,037 
Consideration   753,354 
Gain on disposal of the subsidiary   (104,317)
Gain on disposal of noncontrolling interest   (60,812)
Gain on disposal of the subsidiary, excluding noncontrolling interest   (43,505)

 

Net inflow / (outflow) of cash and cash equivalents in respect of the disposal subsidiary:

 

    1 
Cash and cash equivalents   (172)
Restricted cash   (29,944)
Cash and cash equivalents deconsolidated   (30,116)

 

XML 23 R12.htm IDEA: XBRL DOCUMENT v3.23.1
DISCONTINUED OPERATION
12 Months Ended
Jul. 31, 2022
Discontinued Operations and Disposal Groups [Abstract]  
DISCONTINUED OPERATION

NOTE 5. DISCONTINUED OPERATION

 

Impacted by the government regulation newly implemented in education industry and the restrictions posted by the Chinese government to control the pandemic in China since 2021, the Company’s business hasn’t been developed as planned and occurred significant loss from the early child education practice. To avoid further operation losses, subsequently on August 1, 2022, HFSH entered a contract with a related party, Shanghai Oversea Chinese Culture Media Ltd. (“SH Oversea”), to sell 90 percent ownership of HF Int’l Education and its subsidiaries for $900 (RMB 5,850). On August 1, 2022, HFUS entered a contract with SH Oversea and another individual, to sell 100 percent ownership of HZHF and its subsidiaries for $1,000 (RMB 6,500).

 

As of July 31, 2022, the assets and liabilities grouped under Education and Hospitality segments classified as assets and/or liabilities held for sale, and it is the Company’s intention to complete the sales of these assets within the upcoming year. The transactions meet the criteria to be reported as a discontinued operation as they constitute significant strategic business shifts for the Company. We have reported, for all periods presented, the financial condition, results of operations, and cash flows of the operation segments as discontinued operations in the accompanying consolidated financial statements.

 

 

The total assets and liabilities of Education and hospitality segments that are classified as held for sale on the Companys consolidated balance sheet as of July 31, 2022, are as follows: 

 

SCHEDULE OF DISCONTINUED OPERATIONS OF FINANCIAL STATEMENTS

     July 31, 2022     July 31, 2021 
Assets          
Current Assets          
Cash and cash equivalents  $4,938   $14,873 
Prepaid and Other current receivables   45,532    311,594 
Related party receivable   428,519    325,555 
Inventory   305,124    323,815 
Property and equipment, net   582,707    585,160 
ROU assets-operating lease   2,836,698    3,837,187 
Other assets   296,218    321,806 
Total Assets held for sale  $4,499,736   $5,719,990 
Liabilities          
Current Liabilities          
Related party loan and payables  $1,321,549   $1,332,338 
Contract liabilities   547,906    545,346 
Lease liabilities, current and noncurrent   3,715,688    4,071,767 
Other current payable   401,782    553,841 
Other liabilities   357,796    368,715 
Total Liabilities held for sale  $6,344,721   $6,872,007 

 

For the years ended July 31, 2022 and 2021, results of operations from HF Intel Education and its subsidiaries, and HZHF and its subsidiary were as follows:

 

For the years ended July 31, 

2022

(restated)

  

2021

(restated)

 
Net sales  $561,262   $553,459 
Cost of sales   677,093    722,838 
Gross profit   (115,831)   (169,379)
Operating expenses:          
Selling, general, and administrative expenses   1,579,922    2,520,817 
Impairment   -    70,514 
Total operating expenses   1,579,922    2,591,331 
Loss from operations of discontinued operations   (1,695,753)   (2,760,710)
Interest expense   (54,730)   (45,692)
Other Income   168,331    45,791 
Loss from discontinued operations before income taxes   (1,582,152)   (2,760,611)
Income tax benefit (expense)   -    - 
Income (loss) from discontinued operations, net of taxes before gain from sale of discontinued operations   (1,582,152)   (2,760,611)
Loss from sale of discontinued operations, net of taxes   -    - 
Income from discontinued operations, net of taxes  $(1,582,152)  $(2,760,611)

 

For the years ended July 31, 2022 and 2021, net cash used in discontinued operations - HF Intel Education and its subsidiaries, and HZHF and its subsidiary were as follows:

 

           
   Years ended July 31, 
Cash flow of discontinued operations:  2022   2021 
Operating cash flows  $(656,663)  $(2,455,829)
Investing cash flows   (145,048)   (155,566)
Net cash used in discontinued operations  $(801,711)  $(2,611,395)

 

XML 24 R13.htm IDEA: XBRL DOCUMENT v3.23.1
RELATED PARTY TRANSACTIONS
12 Months Ended
Jul. 31, 2022
Related Party Transactions [Abstract]  
RELATED PARTY TRANSACTIONS

NOTE 6. RELATED PARTY TRANSACTIONS

 

Related Party Receivables

 

As of July 31, 2022, $ 428,519 and $325,555 related party receivables were allocated to current assets held for sales, see Note 5, under “Assets and liabilities held for sale”.

 

Related Party Payables

 

As of July 31, 2022 and 2021, amounts of $620,876 and $616,159, are payable to SH Qiaohong, respectively. The balances were mainly funding support from SH Qiaohong for operation. The funding support bears no interest and due on demand.

 

HFSH had payable balances to Shanghai Oversea Chinese Culture Media Ltd. (“SH Oversea”), an entity managed by the same management team, in the amounts of $3,531,064 and $2,926,782 as of July 31, 2022 and 2021, respectively. The payable is funding support from SH Oversea for operation, bears no interest and due on demand.

 

As of July 31, 2022 and 2021, amount of $290,000 and $145,000, respectively, borrowed in form of a short-term loan at 5% per annum from a related party, Hartford Hotel Investment Inc., an entity managed by the same management team. $11,857 and $3,856 of interest expenses were recorded during the year ended July 31, 2022 and 2021, respectively. The unpaid principal and interest will be due on demand.

 

The remaining related party payable of $39,583 and $80,477 as of July 31, 2022 and 2021, respectively, represents the unpaid portion of operating advances made to the Company by affiliates which are managed by the same management team. These advances do not bear interest and are considered due on demand.

 

As of July 31, 2022, $1,317,690 and $1,332,338 related party payables were allocated to current liabilities held for sales, see Note 5, under “Assets and liabilities held for sale”.

 

Other Related Party Transactions

 

Office space at Rosemead, CA is provided to Hartford Great Health Corp. at no cost by the sole executive officer. No provision for these costs has been included in these financial statements as the amounts are not material.

 

 

XML 25 R14.htm IDEA: XBRL DOCUMENT v3.23.1
COMMITMENTS AND CONTINGENCIES
12 Months Ended
Jul. 31, 2022
Commitments and Contingencies Disclosure [Abstract]  
COMMITMENTS AND CONTINGENCIES

NOTE 7. COMMITMENTS AND CONTINGENCIES

 

There has been below material contractual obligations and other commitments except the lease commitments disclosed in Note 12 Leases.

 

License agreements

 

In June 2021, HF Int’l Education and its three subsidiaries: PDHJ, HDFD and Gelinke entered license agreements with HFHM for the rights to use the intellectual Properties (the “IPs”) HFHM owns. The IPs cover in the license agreements are four set of curriculum structure designed and fifteen trademarks including “HaiDeFuDe” registered trademarks purchased from HF Int’l Education. As a return, on a monthly basis, HF Int’l Education and its subsidiaries pays 90% of its tuition revenue generated to HFHM as license usage fee. Due to impacts from the pandemic and new regulations issued by Chinese government in education industry, HF Int’l Education occurred significant loss from operation. On July 2022, both parties mutually agreed to amend the fee to 20%, the amended rate is retrospectively applicable since June 1, 2021 and recaptured in 2022. As a result, the Company incurred $6,664 and $161,783 license fees to HFHM for the year ended July 31, 2022 and 2021 reported under discontinued operation, respectively.

 

XML 26 R15.htm IDEA: XBRL DOCUMENT v3.23.1
INCOME TAXES
12 Months Ended
Jul. 31, 2022
Income Tax Disclosure [Abstract]  
INCOME TAXES

NOTE 8. INCOME TAXES

 

We recorded income tax expense of $800 for both of the years ended July 31, 2022 and 2021, due to the loss position for the years since inception.

 

Hartford Great Health Corp.’s deferred tax assets, valuation allowance, and change in valuation allowance are as follows:

 

           Estimated tax             
   Net NOL       benefit from NOL       Change in   Net 
   carry-   NOL   and other tax   Valuation   valuation   deferred 
Period Ending  forward   expires   benefits (21%)   allowance   allowance   tax asset 
31-Jul-21  $6,634,644    2041   $1,990,393   $(1,990,393)  $(919,938)  $- 
31-Jul-22  $7,400,620    2042   $2,220,186   $(2,220,186)  $(229,793)  $- 

 

Income taxes at the statutory rate are reconciled to reported income tax expense (benefit) as follows:

 

   2022   2021 
Federal income tax rate   21.0%   21.0%
State income tax rate   8.8%   8.8%
Foreign tax difference   (4.8)%   (4.1)%
Non-taxable item adjustment   -%   (3.2)%
GILTI   -%   -%
Valuation allowance   (25.0)%   (22.5)%
Others   -%   -%
Effective tax rate   0.0%   0.0%

 

At this time, the Company is unable to determine if it will be able to benefit from its deferred tax asset. There are limitations on the utilization of net operating loss carry-forwards, including a requirement that losses be offset against future taxable income, if any. In addition, there are limitations imposed by certain transactions which are deemed to be ownership changes. Accordingly, a full valuation allowance has been established for the entire deferred tax asset. Other temporary differences and estimated permanent differences are considered immaterial. Open tax years subject to examination by the IRS range from August 1, 2017 to the present. The Company has no uncertain tax positions.

 

The Company has been in loss position for years since inception and zero balances of deferred tax assets and liabilities as of the reporting periods ended. There was no GILTI tax for the Company for the years ended July 31, 2022 and 2021 due to the operation losses incurred.

 

XML 27 R16.htm IDEA: XBRL DOCUMENT v3.23.1
SEGMENT INFORMATION (restated)
12 Months Ended
Jul. 31, 2022
Segment Reporting [Abstract]  
SEGMENT INFORMATION (restated)

NOTE 9. SEGMENT INFORMATION (restated)

 

The Company currently operates in following industry segments: hospitality (hotel and travel agency) and early childhood education industry in China.

 

Segment information on assets as of July 31, 2022 and revenue generated during the year ended July 31, 2022, as follows:

 

                     
  

Hospitality

(Discontinued Operation)

  

Education

(Discontinued Operation)

   Corporate and Unallocated (Continued operation)   Total 
Revenue  $51,342   $509,920   $-   $561,262 
Operating loss   (129,352)   (1,566,401)   (177,913)   (1,873,666)
Loss before tax   (182,980)   (1,399,172)   (189,630)   (1,771,782)
Net Loss Attributable to Hartford Great Health Corp   (129,422)   (1,259,249)   (190,430)   (1,579,101)
Total assets (excluding Intercompany balances)   303,703    4,196,033    38,620    4,538,356 
Assets allocated to held for sale   (303,703)   (4,196,033)   -    (4,499,736)

 

Segment information on assets as of July 31, 2021 and revenue generated during the year ended July 31, 2021, as follows:

 

                     
                 
  

Hospitality

(Discontinued Operation)

  

Education

(Discontinued Operation)

  

Corporate and Unallocated

(Continued operation)

   Total 
Revenue  $118,309   $435,150   $-   $553,459 
Operating loss   (172,536)   (2,588,174)   (255,655)   (3,016,365)
Loss before tax   (216,303)   (2,544,308)   (80,928)   (2,841,539)
Net Loss Attributable to Hartford Great Health Corp   (174,018)   (1,997,588)   (81,728)   (2,253,334)
Total assets (excluding Intercompany balances)   384,747    5,335,244    22,607    5,742,598 
Assets allocated to held for sale   (384,747)   (5,335,244)   -    (5,719,991)

 

XML 28 R17.htm IDEA: XBRL DOCUMENT v3.23.1
RESTATEMENT
12 Months Ended
Jul. 31, 2022
Accounting Changes and Error Corrections [Abstract]  
RESTATEMENT

NOTE 10. RESTATEMENT

 

The Company restated its Annual Report on Form 10-K for the annual period from August 1, 2021 to July 31, 2022, which was filed with the U.S. Securities and Exchange Commission (the “SEC”) on November 14, 2022 (the “Original Filing”), is being filed for the following purposes:

 

(a) for Consolidated balance sheets on Item 8, Financial Statements, of Part II of Form 10-K, to reclass the balance of Non-current assets held for sale, as of July 31, 2022, to Current assets held for sale.

 

(b) for Consolidated statements of operations on Item 8, Financial Statements, of Part II of Form 10-K, to separately disclose the discontinued operation results for years ended July 31, 2022 and 2021.

 

The restatements above have been incorporated into the consolidated statements of operation, Note #5 and #9, respectively.

 

XML 29 R18.htm IDEA: XBRL DOCUMENT v3.23.1
SUBSEQUENT EVENTS
12 Months Ended
Jul. 31, 2022
Subsequent Events [Abstract]  
SUBSEQUENT EVENTS

NOTE 11. SUBSEQUENT EVENTS

 

In accordance with ASC 855, “Subsequent Events”, the Company has evaluated subsequent events through the date of issuance of these financial statements and has noted the following subsequent events to be disclosed.

 

On August 1, 2022, see note 5, under section “Assets and liabilities held for sale”, HFSH entered a contract with a related party, SH Oversea, to sell 90 percent ownership of HF Int’l Education and its subsidiaries for $900 (RMB 5,850). On August 1, 2022, HFUS entered a contract with SH Oversea and another individual, to sell 100 percent ownership of HZHF and its subsidiaries for $1,000 (RMB 6,500).

 

On August 1, 2022, HFSH decided to withdraw from the agreement entered in January 2019 to acquire 100 percent equity interest of Shanghai Luo Sheng International Trade Ltd. (“SH Luosheng”). There was no penalty levied or to be levied due to delayed execution or inexecution.

 

On August 17, 2022, the Company borrowed a note in a total amount of $30,000, in form of a short-term loan at 5% per annum from a related party.

XML 30 R19.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
12 Months Ended
Jul. 31, 2022
Accounting Policies [Abstract]  
Organization

Organization

 

Hartford Great Health Corp. was originally incorporated in the State of Nevada on April 2, 2008 under the name PhotoAmigo, Inc. It changed its name to Hartford Great Health Corp. on August 22, 2018 and since then we have been engaged in activities to formulate and implement our business plans.

 

Through its wholly owned subsidiary - Hangzhou Hartford Comprehensive Health Management, Ltd (“HZHF) and HZHF’s 60 percent owned subsidiary - Hangzhou Longjing Qiao Fu Vacation Hotel Co., Ltd. (“HZLJ”), and through Shanghai Hartford Comprehensive Health Management, Ltd. (“HFSH”) and its 90 percent owned subsidiary - Shanghai Qiao Garden International Travel Agency (“Qiao Garden Int’l Travel”), the Company engages in hospitality industry in China. Qiao Garden Int’l Travel was disposed on December 31, 2020, see note 4 Acquisitions, Joint Ventures and Deconsolidation.

 

The Company started to engage in early childhood education industry at Hartford International Education Technology Co., Ltd (“HF Int’l Education”). On July 24, 2019 and March 23, 2020, HF Int’l Education established two 100% owned subsidiaries, Pudong Haojin Childhood Education Ltd. (“PDHJ”) and Shanghai Hongkou HaiDeFuDe Childcare Co., Ltd.(“HDFD”), respectively, to operate the early childhood education service under the brand name of “HaiDeFuDe” in Shanghai, China. On July 20, 2020, HF Int’l Education entered an agreement with two individuals to acquire the whole ownership of Shanghai Gelinke Childcare Education Center (“Gelinke”). Gelinke temporally ceased its operations by the end of August 2021. On August 31, 2021, PDHJ established one 96% owned subsidiary, Shanghai HDFD Zhongli Education Technology Co., Ltd. (“Zhongli”), two individual investors hold the remaining 4% ownership, see note 4 Acquisitions, Joint Ventures and Deconsolidation.

 

Impacted by the government regulation newly implemented in education industry and the restrictions posted by the Chinese government to control the pandemic in China since 2021, to avoid further operation losses, subsequently on August 1, 2022, HFSH entered a contract with a related party, Shanghai Oversea Chinese Culture Media Ltd. (“SH Oversea”), to sell 90 percent ownership of HF Int’l Education and its subsidiaries for $900 (RMB 5,850). On August 1, 2022, HFUS entered a contract with SH Oversea and another individual, to sell 100 percent ownership of HZHF and its subsidiaries for $1,000 (RMB 6,500). As of July 31, 2022, the asset group in Education segment and the asset group in Hospitality segment classified as assets and liabilities held for sale, and it is the Company’s intention to complete the sales of these assets within the upcoming year.

 

Basis of Presentation

Basis of Presentation: The consolidated financial statements include the accounts of Hartford Great Health Corp, its wholly-owned subsidiaries and subsidiaries in which it has a controlling interest. The Company reports noncontrolling interests of the consolidated entities as a component of equity separate from the Company’s equity. All material inter-company transactions between and among the Company and its consolidated subsidiaries have been eliminated in the consolidation. The Company’s net income (loss) excludes income (loss) attributable to the noncontrolling interests.

 

Use of Estimates

Use of Estimates: The preparation of financial statements in conformity with US GAAP requires the Company’s management to make estimates and assumptions that affect the amounts of assets and liabilities, the identification and disclosure of impaired assets and contingent liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.

 

Foreign Currency

Foreign Currency: The accounts of the Company’s foreign subsidiaries are translated in accordance with FASB ASC 830. Foreign currency transaction gains and losses are recognized in other expense, net, at the time they occur. Net foreign currency exchange gains or losses resulting from the translation of assets and liabilities of foreign subsidiaries whose functional currency is not the U.S. dollar are recorded as a part of accumulated other comprehensive loss in stockholders’ equity. The Company does not undertake hedging transactions to cover its foreign currency exposure.

 

Comprehensive Income (loss)

Comprehensive Income (loss): For the year ended July 31, 2022 and 2021, the Company included its foreign currency translation gain or loss as part of its comprehensive income (loss).

 

Fair value measurement

Fair value measurement: Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Accounting Standard Codification (“ASC”) 820, Fair Value Measurements and Disclosures (“ASC 820”), describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value, which are the following:

 

Level 1 - Quoted prices in active markets for identical assets or liabilities or funds.

Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.

Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

 

The Company’s financial instruments consist of cash and cash equivalents, accounts receivable, related party receivable, prepaid and other current receivable, accounts payable, related party payable and other current payable. The carrying amounts of afore-mentioned accounts approximate fair value because of their short-term nature.

 

 

Cash and Cash Equivalents

Cash and Cash Equivalents: The Company maintains cash with banks in the USA and China. Should any bank holding cash become insolvent, or if the Company is otherwise unable to withdraw funds, the Company would lose the cash with that bank; however, the Company has not experienced any losses in such accounts and believes it is not exposed to any significant risks on its cash in bank accounts. In China, a depositor has up to RMB500,000 insured by the People’s Bank of China Financial Stability Bureau (“FSD”). In the United States, the standard insurance amount is USD250,000 per depositor in a bank insured by the Federal Deposit Insurance Corporation (“FDIC”). Financial instruments that potentially subject the Company to significant concentrations of credit risk are cash and cash equivalents and accounts receivable. As of July 31, 2022 and 2021, respectively, none of the Company’s cash and cash equivalents held by financial institutions was uninsured. With respect to accounts receivable, the Company generally does not require collateral and does not have an allowance for doubtful accounts.

 

Receivables

Receivables: The Company evaluates the collectability of its receivables based on a number of factors. In circumstances where the Company becomes aware of a specific customer’s or borrower’s inability to meet its financial obligations to the Company, a specific reserve for bad debts is estimated and recorded, which reduces the recognized receivable to the estimated amount the Company believes will ultimately be collected. As of July 31, 2022 and 2021, all balances are collectable based on management’s assessment.

 

Property and equipment, net

Property and equipment, net: Property and equipment, net, are stated at cost. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the assets. The estimated useful lives of property and equipment are as follows:

 

   Years
Leasehold improvements  Lesser of lease term or estimated useful life
ROU assets-Finance lease  Lease term
Furniture and fixtures  3-5
Office equipment and vehicles  3-5
Computer software  3-5

 

Expenditures for repairs and maintenance are charged to expense as incurred.

 

Goodwill and Long-lived Assets

Goodwill and Long-lived Assets: Goodwill, which represents the excess of the purchase price over the fair value of identifiable net assets acquired, is not amortized, in accordance with Accounting Standards Codification (ASC) 350, Intangibles—Goodwill and Other. ASC 350 requires that goodwill be tested for impairment at the reporting unit level on an annual basis and between annual tests, if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. These events or circumstances could include a significant change in the business climate, legal factors, operating performance indicators, competition, or sale or disposition of a significant portion of a reporting unit.

 

The Company has the option to assess goodwill for possible impairment by performing a qualitative analysis to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. A quantitative assessment is performed if the qualitative assessment results in a more-likely-than-not determination or if a qualitative assessment is not performed. The quantitative assessment considers whether the carrying amount of a reporting unit exceeds its fair value, in which case an impairment charge is recorded to the extent that the reporting unit’s carrying value exceeds its fair value. The Company’s goodwill was mainly generated from the acquisitions during the year ended July 31, 2019. We currently have two reporting units - Hospitality and Early Childhood Education. Given the impact of COVID-19 pandemic and the unfavorable operation results, an interim goodwill impairment assessment was performed as of January 31, 2020. Based on the assessment result, management determined that the goodwill generated from acquisitions was fully impaired as of July 31, 2021.

 

Business Combinations

Business Combinations: If an acquired set of activities and assets is capable of being operated as a business consisting of inputs and processes from the viewpoint of a market participant, the assets acquired and liabilities assumed are a business. Business combinations are accounted for using the acquisition method of accounting, which requires an acquirer to recognize the assets acquired and the liabilities assumed at the acquisition date measured at their fair values as of that date. Fair value determinations are based on discounted cash flow analyses or other valuation techniques. In determining the fair value of the assets acquired and liabilities assumed in a material acquisition, the Company may utilize appraisals from third party valuation firms to determine fair values of some or all of the assets acquired and liabilities assumed, or may complete some or all of the valuations internally. In either case, the Company takes full responsibility for the determination of the fair value of the assets acquired and liabilities assumed. The value of goodwill reflects the excess of the fair value of the consideration conveyed to the seller over the fair value of the net assets received. Acquisition-related costs that the Company incurs to affect a business combination are expensed in the periods in which the costs are incurred.

 

Noncontrolling interest

Noncontrolling interest: The Company adopted ASC 810, Noncontrolling Interests in Consolidated Financial Statements—an Amendment of Accounting Research Bulletin No. 51, as of January 1, 2009. ASC 810 establishes accounting and reporting standards for ownership interests in subsidiaries held by parties other than the parent, the amount of consolidated net income attributable to the parent and to the noncontrolling interest, changes in a parent’s ownership interest and the valuation of retained noncontrolling equity investments when a subsidiary is deconsolidated. ASC 810 also establishes reporting requirements that provide sufficient disclosures that clearly identify and distinguish between the interest of the parent and the interests of the noncontrolling owner.

 

Advertising costs

Advertising costs: Advertising costs are expensed as incurred. During the year ended July 31, 2022 and 2021, amount of $10,540 and $65,406 advertising expenses were incurred, respectively.

 

 

Income Taxes

Income Taxes: The Company accounts for income taxes using the asset and liability method in accordance with ASC 740, Accounting for Income Taxes. The asset and liability method provides that deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using the currently enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company records a valuation allowance to reduce deferred tax assets to the amount that is believed more likely than not to be realized.

 

On December 22, 2017, the President of the United States signed into law the Tax Reform Act. The Tax Reform Act permanently reduces the U.S. corporate income tax rate from a maximum of 35% to a flat 21% rate, effective January 1, 2018. In addition, the 2017 Tax Act also creates a new requirement that certain income (i.e., Global Intangible Low-Taxed Income (“GILTI”)) earned by controlled foreign corporations (“CFCs”) must be included in the gross income of the CFCs’ U.S. shareholder income. The tax law in PRC applies an income tax rate of 25% to all enterprises. The Company’s subsidiary does not receive any preferential tax treatment from local government. The Company has been in loss position for years and zero balances of tax provisions, deferred tax assets and liabilities as of the reporting periods ended. The tax reforms have no significant impacts on the Company.

 

Revenue Recognition

Revenue Recognition: The Company adopted ASC Topic 606 Revenue from Contracts with Customers (“Topic 606) on August 1, 2019, applying the modified retrospective method to all contracts that were not completed as of August 1, 2019. The Company is building up its core business upon the completion of multiple acquisitions in March 2019 and impact of COVID-19 pandemic, limited operations occurred during the years ended July 31, 2022 and 2021. The revenue during the years ended July 31, 2022 and 2021 were mainly generated from HZLJ and HF Int’l Education.

 

Revenue is recognized when control of promised goods or services is transferred to our customers in an amount of consideration to which we expect to be entitled to in exchange for those goods or services. We follow the five steps approach for revenue recognition under Topic 606: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) we satisfy a performance obligation. Billings to customers for which services are not rendered are considered deferred revenue. ASC 606 has no material impacts on the Company’s financial positions. The Company’s revenue is recognized when it satisfies a single performance obligation by transferring control of its products or providing services to a customer. The Company’s general payment terms are short-term in duration. The Company does not have significant financing components or payment terms.

 

a.Early childhood education services: HF Int’l Education generates revenue from childhood education classes provided to its customers. The educational services consist of parent-child and bilingual childcare classes. Each contract of educational classes is accounted for as a single performance obligation which is satisfied proportionately over the service period. Tuition fee is generally collected in advance and is initially recorded as deferred revenue and transferred to contract liabilities after trial period. Refunds are provided to parents if they decide within the trial period that they no longer want to take the class. After the trial period, if a parent withdraws from a class, usually only that unearned portion of the fee is available to be returned. For the year ended July 31, 2022 and 2021, $509,920 and $435,149, respectively, of revenue were derived from early childhood education classes provided.

 

b.Hospitality services: HZLJ generates revenue primarily from the room rentals, sale of food and beverage and other miscellaneous hospitality services. The Company recognizes room rental and services daily as services are provided. Under ASC 606, the pattern and timing of recognition of income from hotel facility is consistent with the prior accounting model.

 

Income (Loss) Per Share

Income (Loss) Per Share: Basic earnings per share include no dilution and are computed by dividing net income (or loss) by the weighted- average number of shares outstanding during the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of the Company, assuming the issuance of an equivalent number of common shares pursuant to options, warrants, or convertible debt arrangements. Diluted earnings per share are not shown for periods in which the Company incurs a loss because it would be anti-dilutive. Similarly, potential common stock equivalents are not included in the calculation if the effect would be anti-dilutive. No potentially dilutive debt or equity securities were issued or outstanding during the years ended July 31, 2022 or 2021.

 

Reclassifications

Reclassifications

 

Certain amounts on the prior-year consolidated balance sheet, consolidated statement of operations and cash flows were reclassified to conform to current-year presentation, with no effect on ending stockholders’ equity.

 

 

Recent Accounting Pronouncements

Recent Accounting Pronouncements.

 

Recently adopted accounting pronouncements

 

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes which is intended to simplify various aspects related to accounting for income taxes. The standard is effective for fiscal years, and interim periods within those years, beginning after December 15, 2020, with early adoption permitted. The adoption of ASU 2019-12 had an immaterial impact on the Company’s consolidated statement of operation and consolidated statement of cash flows for the year ended July 31, 2022.

 

Recently issued accounting pronouncements not yet adopted

 

In June 2016, the FASB issued ASU 2016-13, “Financial Instruments—Credit Losses”. The standard, including subsequently issued amendments (ASU 2018-19, ASU 2019-04, ASU 2019-05, ASU 2019-10 and ASU 2019-11), requires a financial asset measured at amortized cost basis, such as accounts receivable and certain other financial assets, to be presented at the net amount expected to be collected based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. In November 2019, the FASB issued ASU No. 2019-10 to postpone the effective date of ASU No. 2016-13 for public business entities eligible to be smaller reporting companies defined by the SEC to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company is evaluating the impact of this guidance on its consolidated financial statements.

XML 31 R20.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
12 Months Ended
Jul. 31, 2022
Accounting Policies [Abstract]  
SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE

 

   Years
Leasehold improvements  Lesser of lease term or estimated useful life
ROU assets-Finance lease  Lease term
Furniture and fixtures  3-5
Office equipment and vehicles  3-5
Computer software  3-5
XML 32 R21.htm IDEA: XBRL DOCUMENT v3.23.1
ACQUISITIONS, JOINT VENTURES AND DECONSOLIDATION (Tables)
12 Months Ended
Jul. 31, 2022
Business Combination and Asset Acquisition [Abstract]  
SCHEDULE OF RECOGNIZED IDENTIFIED ASSETS ACQUIRED AND LIABILITIES ASSUMED

 

   Assets Acquired and 
   Liabilities Assumed 
Cash and cash equivalents   1,809 
Restricted Cash   25,009 
Prepaid and Other current receivables   4,696 
Property and Equipment, net   4,294 
Unearned revenue   (78,696)
Goodwill   67,712 
Total consideration*   24,824 

 

*$10,462 (RMB70,000) payable to the acquiree plus $14,362 (RMB100,000) cash payment totaled $24,824 consideration for the acquisition.
SCHEDULE OF NET ASSETS (LIABILITIES) DISPOSED OF SUBSIDIARY

Net assets (liabilities) disposed of:

 

    1 
Net assets (liabilities) disposed of:    
Cash and cash equivalents   172 
Restricted cash   29,944 
Related party receivable   782,224 
Related party payable   (98,615)
Other current payable   (3,876)
Noncontrolling interest   (60,812)
Net assets of the subsidiary, excluding noncontrolling interest   649,037 
Consideration   753,354 
Gain on disposal of the subsidiary   (104,317)
Gain on disposal of noncontrolling interest   (60,812)
Gain on disposal of the subsidiary, excluding noncontrolling interest   (43,505)
SCHEDULE OF NET INFLOW (OUTFLOW) OF CASH AND CASH EQUIVALENTS OF DISPOSAL SUBSIDIARY

Net inflow / (outflow) of cash and cash equivalents in respect of the disposal subsidiary:

 

    1 
Cash and cash equivalents   (172)
Restricted cash   (29,944)
Cash and cash equivalents deconsolidated   (30,116)
XML 33 R22.htm IDEA: XBRL DOCUMENT v3.23.1
DISCONTINUED OPERATION (Tables)
12 Months Ended
Jul. 31, 2022
Discontinued Operations and Disposal Groups [Abstract]  
SCHEDULE OF DISCONTINUED OPERATIONS OF FINANCIAL STATEMENTS

The total assets and liabilities of Education and hospitality segments that are classified as held for sale on the Companys consolidated balance sheet as of July 31, 2022, are as follows: 

 

SCHEDULE OF DISCONTINUED OPERATIONS OF FINANCIAL STATEMENTS

     July 31, 2022     July 31, 2021 
Assets          
Current Assets          
Cash and cash equivalents  $4,938   $14,873 
Prepaid and Other current receivables   45,532    311,594 
Related party receivable   428,519    325,555 
Inventory   305,124    323,815 
Property and equipment, net   582,707    585,160 
ROU assets-operating lease   2,836,698    3,837,187 
Other assets   296,218    321,806 
Total Assets held for sale  $4,499,736   $5,719,990 
Liabilities          
Current Liabilities          
Related party loan and payables  $1,321,549   $1,332,338 
Contract liabilities   547,906    545,346 
Lease liabilities, current and noncurrent   3,715,688    4,071,767 
Other current payable   401,782    553,841 
Other liabilities   357,796    368,715 
Total Liabilities held for sale  $6,344,721   $6,872,007 

 

For the years ended July 31, 2022 and 2021, results of operations from HF Intel Education and its subsidiaries, and HZHF and its subsidiary were as follows:

 

For the years ended July 31, 

2022

(restated)

  

2021

(restated)

 
Net sales  $561,262   $553,459 
Cost of sales   677,093    722,838 
Gross profit   (115,831)   (169,379)
Operating expenses:          
Selling, general, and administrative expenses   1,579,922    2,520,817 
Impairment   -    70,514 
Total operating expenses   1,579,922    2,591,331 
Loss from operations of discontinued operations   (1,695,753)   (2,760,710)
Interest expense   (54,730)   (45,692)
Other Income   168,331    45,791 
Loss from discontinued operations before income taxes   (1,582,152)   (2,760,611)
Income tax benefit (expense)   -    - 
Income (loss) from discontinued operations, net of taxes before gain from sale of discontinued operations   (1,582,152)   (2,760,611)
Loss from sale of discontinued operations, net of taxes   -    - 
Income from discontinued operations, net of taxes  $(1,582,152)  $(2,760,611)

 

For the years ended July 31, 2022 and 2021, net cash used in discontinued operations - HF Intel Education and its subsidiaries, and HZHF and its subsidiary were as follows:

 

           
   Years ended July 31, 
Cash flow of discontinued operations:  2022   2021 
Operating cash flows  $(656,663)  $(2,455,829)
Investing cash flows   (145,048)   (155,566)
Net cash used in discontinued operations  $(801,711)  $(2,611,395)

 

XML 34 R23.htm IDEA: XBRL DOCUMENT v3.23.1
INCOME TAXES (Tables)
12 Months Ended
Jul. 31, 2022
Income Tax Disclosure [Abstract]  
SCHEDULE OF INCOME TAX VALUATION

Hartford Great Health Corp.’s deferred tax assets, valuation allowance, and change in valuation allowance are as follows:

 

           Estimated tax             
   Net NOL       benefit from NOL       Change in   Net 
   carry-   NOL   and other tax   Valuation   valuation   deferred 
Period Ending  forward   expires   benefits (21%)   allowance   allowance   tax asset 
31-Jul-21  $6,634,644    2041   $1,990,393   $(1,990,393)  $(919,938)  $- 
31-Jul-22  $7,400,620    2042   $2,220,186   $(2,220,186)  $(229,793)  $- 
SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION

Income taxes at the statutory rate are reconciled to reported income tax expense (benefit) as follows:

 

   2022   2021 
Federal income tax rate   21.0%   21.0%
State income tax rate   8.8%   8.8%
Foreign tax difference   (4.8)%   (4.1)%
Non-taxable item adjustment   -%   (3.2)%
GILTI   -%   -%
Valuation allowance   (25.0)%   (22.5)%
Others   -%   -%
Effective tax rate   0.0%   0.0%
XML 35 R24.htm IDEA: XBRL DOCUMENT v3.23.1
SEGMENT INFORMATION (restated) (Tables)
12 Months Ended
Jul. 31, 2022
Segment Reporting [Abstract]  
SCHEDULE OF SEGMENT INFORMATION

Segment information on assets as of July 31, 2022 and revenue generated during the year ended July 31, 2022, as follows:

 

                     
  

Hospitality

(Discontinued Operation)

  

Education

(Discontinued Operation)

   Corporate and Unallocated (Continued operation)   Total 
Revenue  $51,342   $509,920   $-   $561,262 
Operating loss   (129,352)   (1,566,401)   (177,913)   (1,873,666)
Loss before tax   (182,980)   (1,399,172)   (189,630)   (1,771,782)
Net Loss Attributable to Hartford Great Health Corp   (129,422)   (1,259,249)   (190,430)   (1,579,101)
Total assets (excluding Intercompany balances)   303,703    4,196,033    38,620    4,538,356 
Assets allocated to held for sale   (303,703)   (4,196,033)   -    (4,499,736)

 

Segment information on assets as of July 31, 2021 and revenue generated during the year ended July 31, 2021, as follows:

 

                     
                 
  

Hospitality

(Discontinued Operation)

  

Education

(Discontinued Operation)

  

Corporate and Unallocated

(Continued operation)

   Total 
Revenue  $118,309   $435,150   $-   $553,459 
Operating loss   (172,536)   (2,588,174)   (255,655)   (3,016,365)
Loss before tax   (216,303)   (2,544,308)   (80,928)   (2,841,539)
Net Loss Attributable to Hartford Great Health Corp   (174,018)   (1,997,588)   (81,728)   (2,253,334)
Total assets (excluding Intercompany balances)   384,747    5,335,244    22,607    5,742,598 
Assets allocated to held for sale   (384,747)   (5,335,244)   -    (5,719,991)
XML 36 R25.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE (Details)
12 Months Ended
Jul. 31, 2022
Leasehold Improvements [Member]  
Property, Plant and Equipment [Line Items]  
Description of estimated useful lives of property and equipment Lesser of lease term or estimated useful life
ROU Assets-Finance Lease [Member]  
Property, Plant and Equipment [Line Items]  
Description of estimated useful lives of property and equipment Lease term
Furniture and Fixtures [Member] | Minimum [Member]  
Property, Plant and Equipment [Line Items]  
Property, plant and equipment, useful life 3 years
Furniture and Fixtures [Member] | Maximum [Member]  
Property, Plant and Equipment [Line Items]  
Property, plant and equipment, useful life 5 years
Office Equipment and Vehicles [Member] | Minimum [Member]  
Property, Plant and Equipment [Line Items]  
Property, plant and equipment, useful life 3 years
Office Equipment and Vehicles [Member] | Maximum [Member]  
Property, Plant and Equipment [Line Items]  
Property, plant and equipment, useful life 5 years
Computer Software [Member] | Minimum [Member]  
Property, Plant and Equipment [Line Items]  
Property, plant and equipment, useful life 3 years
Computer Software [Member] | Maximum [Member]  
Property, Plant and Equipment [Line Items]  
Property, plant and equipment, useful life 5 years
XML 37 R26.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)
1 Months Ended 12 Months Ended
Dec. 22, 2017
Jul. 31, 2022
USD ($)
Jul. 31, 2021
USD ($)
Aug. 01, 2022
USD ($)
Aug. 01, 2022
CNY (¥)
Jul. 31, 2022
CNY (¥)
Aug. 31, 2021
Dec. 31, 2020
Mar. 23, 2020
Jul. 24, 2019
Product Information [Line Items]                    
FDIC insured amount   $ 250,000                
Advertising cost   10,540 $ 65,406              
Income tax examination description On December 22, 2017, the President of the United States signed into law the Tax Reform Act. The Tax Reform Act permanently reduces the U.S. corporate income tax rate from a maximum of 35% to a flat 21% rate, effective January 1, 2018. In addition, the 2017 Tax Act also creates a new requirement that certain income (i.e., Global Intangible Low-Taxed Income (“GILTI”)) earned by controlled foreign corporations (“CFCs”) must be included in the gross income of the CFCs’ U.S. shareholder income. The tax law in PRC applies an income tax rate of 25% to all enterprises                  
Revenue   561,262 553,459              
Early Childhood Education Services [Member]                    
Product Information [Line Items]                    
Revenue   $ 509,920 $ 435,149              
People's Bank of China Financial Stability Bureau [Member]                    
Product Information [Line Items]                    
FDIC insured amount | ¥           ¥ 500,000        
Shanghai Jingyu Education Tech Ltd [Member]                    
Product Information [Line Items]                    
Equity ownership percentage             4.00%      
Shanghai Hongkou Hai De Fu De Childcare Co Ltd [Member]                    
Product Information [Line Items]                    
Equity ownership percentage                 100.00%  
Pudong Haojin Childhood Education Ltd [Member]                    
Product Information [Line Items]                    
Equity ownership percentage                   100.00%
Shanghai HDFD Zhongli Education Technology Co Ltd [Member]                    
Product Information [Line Items]                    
Equity ownership percentage             96.00%      
Hangzhou Longjing Qiao Fu Vacation Hotel Co., Ltd. [Member]                    
Product Information [Line Items]                    
Business acquisition, percentage of voting interests acquired       90.00% 90.00%     60.00%    
Hangzhou Longjing Qiao Fu Vacation Hotel Co., Ltd. [Member] | Subsequent Event [Member]                    
Product Information [Line Items]                    
Business acquisition, percentage of voting interests acquired       90.00% 90.00%          
Shanghai Hartford Comprehensive Health Management, Ltd. [Member]                    
Product Information [Line Items]                    
Business acquisition, percentage of voting interests acquired               90.00%    
Hartford International Education Technology Co., Ltd [Member] | Subsequent Event [Member] | Shanghai Oversea [Member]                    
Product Information [Line Items]                    
Related party       $ 900 ¥ 5,850          
Hangzhou Hartford Comprehensive Health Management Ltd [Member]                    
Product Information [Line Items]                    
Business acquisition, percentage of voting interests acquired               90.00%    
Hangzhou Hartford Comprehensive Health Management Ltd [Member] | Subsequent Event [Member]                    
Product Information [Line Items]                    
Business acquisition, percentage of voting interests acquired       100.00% 100.00%          
Hangzhou Hartford Comprehensive Health Management Ltd [Member] | Subsequent Event [Member] | Shanghai Oversea [Member]                    
Product Information [Line Items]                    
Related party       $ 1,000 ¥ 6,500          
XML 38 R27.htm IDEA: XBRL DOCUMENT v3.23.1
GOING CONCERN (Details Narrative) - USD ($)
Jul. 31, 2022
Jul. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Accumulated deficit $ 7,400,620 $ 5,821,519
XML 39 R28.htm IDEA: XBRL DOCUMENT v3.23.1
STOCKHOLDERS’ EQUITY (Details Narrative) - $ / shares
Nov. 24, 2020
Jul. 31, 2022
Jul. 31, 2021
Defined Benefit Plan Disclosure [Line Items]      
Preferred stock, shares authorized   5,000,000 5,000,000
Preferred stock, par value   $ 0.001 $ 0.001
Preferred stock, shares issued   0 0
Preferred stock, shares outstanding   0 0
Common stock, shares authorized   300,000,000 300,000,000
Common stock, par value   $ 0.001 $ 0.001
Common stock, shares issued   100,108,000 100,108,000
Common stock, shares outstanding   100,108,000 100,108,000
Shareholder [Member]      
Defined Benefit Plan Disclosure [Line Items]      
Issuance of common stock, shares 1,000,000    
Share price $ 0.02    
XML 40 R29.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF RECOGNIZED IDENTIFIED ASSETS ACQUIRED AND LIABILITIES ASSUMED (Details) - Shanghai Gelinke Childcare Education Center [Member]
Jul. 20, 2020
USD ($)
Business Acquisition [Line Items]  
Cash and cash equivalents $ 1,809
Restricted Cash 25,009
Prepaid and Other current receivables 4,696
Property and Equipment, net 4,294
Unearned revenue (78,696)
Goodwill 67,712
Total consideration $ 24,824 [1]
[1] $10,462 (RMB70,000) payable to the acquiree plus $14,362 (RMB100,000) cash payment totaled $24,824 consideration for the acquisition.
XML 41 R30.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF RECOGNIZED IDENTIFIED ASSETS ACQUIRED AND LIABILITIES ASSUMED (Details) (Parenthetical) - Jul. 20, 2020 - Shanghai Gelinke Childcare Education Center [Member]
USD ($)
CNY (¥)
Business Acquisition [Line Items]    
Purchase price $ 10,462 ¥ 70,000
Cash payments to acquire business 14,362 ¥ 100,000
Total consideration [1] $ 24,824  
[1] $10,462 (RMB70,000) payable to the acquiree plus $14,362 (RMB100,000) cash payment totaled $24,824 consideration for the acquisition.
XML 42 R31.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF NET ASSETS (LIABILITIES) DISPOSED OF SUBSIDIARY (Details) - USD ($)
12 Months Ended
Dec. 31, 2020
Jul. 31, 2022
Jul. 31, 2021
Gain on disposal of the subsidiary, excluding noncontrolling interest   $ (1,388,671) $ (2,171,606)
Qiao Garden Intel Travel [Member]      
Cash and cash equivalents $ 172    
Restricted cash 29,944    
Related party receivable 782,224    
Related party payable (98,615)    
Other current payable (3,876)    
Noncontrolling interest (60,812)    
Net assets of the subsidiary, excluding noncontrolling interest 649,037    
Consideration 753,354    
Gain on disposal of the subsidiary (104,317)    
Gain on disposal of noncontrolling interest (60,812)    
Gain on disposal of the subsidiary, excluding noncontrolling interest $ (43,505)    
XML 43 R32.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF NET INFLOW (OUTFLOW) OF CASH AND CASH EQUIVALENTS OF DISPOSAL SUBSIDIARY (Details) - Qiao Garden Intel Travel [Member]
Dec. 31, 2020
USD ($)
Cash and cash equivalents $ (172)
Restricted cash (29,944)
Cash and cash equivalents deconsolidated $ (30,116)
XML 44 R33.htm IDEA: XBRL DOCUMENT v3.23.1
ACQUISITIONS, JOINT VENTURES AND DECONSOLIDATION (Details Narrative)
¥ in Millions
12 Months Ended
Dec. 31, 2020
CNY (¥)
Jul. 31, 2022
Jul. 31, 2021
USD ($)
Mar. 31, 2021
Jul. 31, 2020
Jun. 19, 2020
CNY (¥)
Mar. 22, 2019
CNY (¥)
Feb. 28, 2019
Jan. 31, 2019
Business Acquisition [Line Items]                  
Noncontrolling shareholders, description   As a result, HFSH held 75.5% of HF Int’l Education and a total of 24.5% equity was held by noncontrolling shareholders. Pursuant to the board meeting held on June 1, 2021, the noncontrolling shareholders sold a total 14.5% equity at zero consideration to HFSH. As a result, HFSH holds 90.0% of HF Int’l Education and $403,131 noncontrolling loss was absorbed by HFSH as a result of the ownership restructure at HF Int’l Education.              
Shanghai Gelinke Childcare Education Center [Member]                  
Business Acquisition [Line Items]                  
Goodwill | $     $ 67,712            
Shanghai Senior Health Consulting Ltd. [Member]                  
Business Acquisition [Line Items]                  
Business acquired ownership interest               85.00% 85.00%
Shanghai Pasadena Ltd. [Member]                  
Business Acquisition [Line Items]                  
Business acquired ownership interest               55.00% 55.00%
Shanghai Luo Sheng International Trade Ltd. [Member]                  
Business Acquisition [Line Items]                  
Business acquired ownership interest                 100.00%
Hangzhou Hartford Comprehensive Health Management Ltd [Member]                  
Business Acquisition [Line Items]                  
Business acquired ownership interest 90.00%                
Hangzhou Hartford Comprehensive Health Management Ltd [Member]                  
Business Acquisition [Line Items]                  
Investment from noncontrolling interest ¥ 4.5                
Investment income ¥ 0.5                
Shareholder [Member] | Hartford International Education Technology Co., Ltd [Member]                  
Business Acquisition [Line Items]                  
Noncontrolling ownership interest         61.00%        
Joint Venture Agreement [Member]                  
Business Acquisition [Line Items]                  
Joint venture acquired ownership interest             65.00%    
Joint Venture Agreement [Member] | Hartford International Education Technology Co., Ltd [Member] | Seven Education Textbooks [Member]                  
Business Acquisition [Line Items]                  
Registered capital             ¥ 1.2    
Joint Venture Agreement [Member] | Hartford International Education Technology Co., Ltd [Member] | Ten “HaiDeFuDe” [Member]                  
Business Acquisition [Line Items]                  
Registered capital             ¥ 1.0    
Joint Venture Agreement [Member] | Maximum [Member]                  
Business Acquisition [Line Items]                  
Registered capital           ¥ 10.0      
Joint Venture Agreement [Member] | Minimum [Member]                  
Business Acquisition [Line Items]                  
Registered capital           ¥ 5.0      
Joint Venture Agreement [Member] | Chief Executive Officer [Member] | Hartford International Education Technology Co., Ltd [Member]                  
Business Acquisition [Line Items]                  
Joint venture acquired ownership interest       5.00%          
XML 45 R34.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF DISCONTINUED OPERATIONS OF FINANCIAL STATEMENTS (Details) - USD ($)
12 Months Ended
Jul. 31, 2022
Jul. 31, 2021
Current Assets    
Related party receivable $ 428,519 $ 325,555
Current Liabilities    
Related party loan and payables 1,317,690 1,332,338
Total Liabilities held for sale 6,344,721 2,681,639
Interest expense (11,857) 14,806
Other Income (11,717) 174,727
Income loss from discontinued operations, net of income taxes (1,582,152) (2,760,611)
Discontinued Operations, Held-for-sale or Disposed of by Sale [Member] | Hartford International Education Technology Co., Ltd [Member]    
Current Liabilities    
Net sales 561,262 553,459
Cost of sales 677,093 722,838
Gross profit (115,831) (169,379)
Selling, general, and administrative expenses 1,579,922 2,520,817
Impairment 70,514
Total operating expenses 1,579,922 2,591,331
Loss from operations of discontinued operations (1,695,753) (2,760,710)
Interest expense (54,730) (45,692)
Other Income 168,331 45,791
Income loss from discontinued operations, net of income taxes (1,582,152) (2,760,611)
Income tax benefit (expense)
Income (loss) from discontinued operations, net of taxes before gain from sale of discontinued operations (1,582,152) (2,760,611)
Loss from sale of discontinued operations, net of taxes
Cash flow of discontinued operations:    
Operating cash flows (656,663) (2,455,829)
Investing cash flows (145,048) (155,566)
Net cash used in discontinued operations (801,711) (2,611,395)
Education and Hospitality Segments [Member] | Discontinued Operations, Held-for-sale or Disposed of by Sale [Member]    
Current Assets    
Cash and cash equivalents 4,938 14,873
Prepaid and Other current receivables 45,532 311,594
Related party receivable 428,519 325,555
Inventory 305,124 323,815
Property and equipment, net 582,707 585,160
ROU assets-operating lease 2,836,698 3,837,187
Other assets 296,218 321,806
Total Assets held for sale 4,499,736 5,719,990
Current Liabilities    
Related party loan and payables 1,321,549 1,332,338
Contract liabilities 547,906 545,346
Lease liabilities, current and noncurrent 3,715,688 4,071,767
Other current payable 401,782 553,841
Other liabilities 357,796 368,715
Total Liabilities held for sale $ 6,344,721 $ 6,872,007
XML 46 R35.htm IDEA: XBRL DOCUMENT v3.23.1
DISCONTINUED OPERATION (Details Narrative)
Aug. 01, 2022
USD ($)
Aug. 01, 2022
CNY (¥)
Dec. 31, 2020
Hangzhou Longjing Qiao Fu Vacation Hotel Co., Ltd. [Member]      
Restructuring Cost and Reserve [Line Items]      
Business acquired ownership interest 90.00% 90.00% 60.00%
Hangzhou Longjing Qiao Fu Vacation Hotel Co., Ltd. [Member] | Subsequent Event [Member]      
Restructuring Cost and Reserve [Line Items]      
Business acquired ownership interest 90.00% 90.00%  
Hartford International Education Technology Co., Ltd [Member] | Subsequent Event [Member] | Shanghai Oversea [Member]      
Restructuring Cost and Reserve [Line Items]      
Related party $ 900 ¥ 5,850  
Hangzhou Hartford Comprehensive Health Management Ltd [Member]      
Restructuring Cost and Reserve [Line Items]      
Business acquired ownership interest     90.00%
Hangzhou Hartford Comprehensive Health Management Ltd [Member] | Subsequent Event [Member]      
Restructuring Cost and Reserve [Line Items]      
Business acquired ownership interest 100.00% 100.00%  
Hangzhou Hartford Comprehensive Health Management Ltd [Member] | Subsequent Event [Member] | Shanghai Oversea [Member]      
Restructuring Cost and Reserve [Line Items]      
Related party $ 1,000 ¥ 6,500  
XML 47 R36.htm IDEA: XBRL DOCUMENT v3.23.1
RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($)
12 Months Ended
Jul. 31, 2022
Jul. 31, 2021
Related Party Transaction [Line Items]    
Related party receivable $ 428,519 $ 325,555
Accounts payable, related parties 39,583 80,477
Related party loan and payables 1,317,690 1,332,338
SHQiahong [Member]    
Related Party Transaction [Line Items]    
Accounts payable, related parties 620,876 616,159
Shanghai Oversea Chinese Culture Media Ltd [Member]    
Related Party Transaction [Line Items]    
Accounts payable, related parties 3,531,064 2,926,782
Hartford Hotel Investment Inc [Member]    
Related Party Transaction [Line Items]    
Short term debt $ 290,000 145,000
Debt instrument, interest rate, stated percentage 5.00%  
Interest expense, related party $ 11,857 $ 3,856
XML 48 R37.htm IDEA: XBRL DOCUMENT v3.23.1
COMMITMENTS AND CONTINGENCIES (Details Narrative) - Hartford International Education Technology Co., Ltd [Member] - USD ($)
12 Months Ended
Jul. 31, 2022
Jul. 31, 2021
License [Member]    
Product Liability Contingency [Line Items]    
Incrrued license fees $ 6,664 $ 161,783
Intellectual Properties [Member]    
Product Liability Contingency [Line Items]    
Licencse description As a return, on a monthly basis, HF Int’l Education and its subsidiaries pays 90% of its tuition revenue generated to HFHM as license usage fee. Due to impacts from the pandemic and new regulations issued by Chinese government in education industry, HF Int’l Education occurred significant loss from operation  
Amed fee percentage 20.00%  
XML 49 R38.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF INCOME TAX VALUATION (Details) - USD ($)
12 Months Ended
Jul. 31, 2022
Jul. 31, 2021
Income Tax Disclosure [Abstract]    
Net NOL carry-forward $ 7,400,620 $ 6,634,644
NOL expires 2042 2041
Estimated tax benefit from NOL and other tax benefits (21%) $ 2,220,186 $ 1,990,393
Valuation allowance (2,220,186) (1,990,393)
Change in valuation allowance (229,793) (919,938)
Net deferred tax asset
XML 50 R39.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION (Details)
12 Months Ended
Jul. 31, 2022
Jul. 31, 2021
Income Tax Disclosure [Abstract]    
Federal income tax rate 21.00% 21.00%
State income tax rate 8.80% 8.80%
Foreign tax difference (480.00%) (410.00%)
Non-taxable item adjustment (3.20%)
GILTI
Valuation allowance (25.00%) (22.50%)
Others
Effective tax rate 0.00% 0.00%
XML 51 R40.htm IDEA: XBRL DOCUMENT v3.23.1
INCOME TAXES (Details Narrative) - USD ($)
12 Months Ended
Jul. 31, 2022
Jul. 31, 2021
Income Tax Disclosure [Abstract]    
Income tax expense $ 800 $ 800
XML 52 R41.htm IDEA: XBRL DOCUMENT v3.23.1
SCHEDULE OF SEGMENT INFORMATION (Details) - USD ($)
12 Months Ended
Jul. 31, 2022
Jul. 31, 2021
Segment Reporting Information [Line Items]    
Revenue $ 561,262 $ 553,459
Operating loss (1,873,666) (3,016,365)
Loss before tax (1,771,782) (2,841,539)
Net Loss Attributable to Hartford Great Health Corp (1,579,101) (2,253,334)
Total assets (excluding Intercompany balances) 4,538,356 5,742,598
Assets allocated to held for sale (4,499,736) (5,719,991)
Hospitality [Member] | Discontinued Operations, Held-for-sale or Disposed of by Sale [Member]    
Segment Reporting Information [Line Items]    
Revenue 51,342 118,309
Operating loss (129,352) (172,536)
Loss before tax (182,980) (216,303)
Net Loss Attributable to Hartford Great Health Corp (129,422) (174,018)
Total assets (excluding Intercompany balances) 303,703 384,747
Assets allocated to held for sale (303,703) (384,747)
Education [Member] | Discontinued Operations, Held-for-sale or Disposed of by Sale [Member]    
Segment Reporting Information [Line Items]    
Revenue 509,920 435,150
Operating loss (1,566,401) (2,588,174)
Loss before tax (1,399,172) (2,544,308)
Net Loss Attributable to Hartford Great Health Corp (1,259,249) (1,997,588)
Total assets (excluding Intercompany balances) 4,196,033 5,335,244
Assets allocated to held for sale (4,196,033) (5,335,244)
Corporate And Unallocated [Member]    
Segment Reporting Information [Line Items]    
Revenue
Operating loss (177,913) (255,655)
Loss before tax (189,630) (80,928)
Net Loss Attributable to Hartford Great Health Corp (190,430) (81,728)
Total assets (excluding Intercompany balances) 38,620 22,607
Assets allocated to held for sale
XML 53 R42.htm IDEA: XBRL DOCUMENT v3.23.1
SUBSEQUENT EVENTS (Details Narrative)
Aug. 17, 2022
USD ($)
Aug. 01, 2022
USD ($)
Aug. 01, 2022
CNY (¥)
Dec. 31, 2020
Subsequent Event [Member] | Related Party [Member]        
Subsequent Event [Line Items]        
Short term debt $ 30,000      
Debt instrument, interest rate, stated percentage 5.00%      
Subsequent Event [Member] | Shangai Luo Sheng International Trade Ltd [Member]        
Subsequent Event [Line Items]        
Equity method investment ownership, perentage   100.00% 100.00%  
Hangzhou Longjing Qiao Fu Vacation Hotel Co., Ltd. [Member]        
Subsequent Event [Line Items]        
Business acquisition, percentage of voting interests acquired   90.00% 90.00% 60.00%
Hangzhou Longjing Qiao Fu Vacation Hotel Co., Ltd. [Member] | Subsequent Event [Member]        
Subsequent Event [Line Items]        
Business acquisition, percentage of voting interests acquired   90.00% 90.00%  
Hartford International Education Technology Co., Ltd [Member] | Shanghai Oversea [Member] | Subsequent Event [Member]        
Subsequent Event [Line Items]        
Related party   $ 900 ¥ 5,850  
Hangzhou Hartford Comprehensive Health Management Ltd [Member]        
Subsequent Event [Line Items]        
Business acquisition, percentage of voting interests acquired       90.00%
Hangzhou Hartford Comprehensive Health Management Ltd [Member] | Subsequent Event [Member]        
Subsequent Event [Line Items]        
Business acquisition, percentage of voting interests acquired   100.00% 100.00%  
Hangzhou Hartford Comprehensive Health Management Ltd [Member] | Shanghai Oversea [Member] | Subsequent Event [Member]        
Subsequent Event [Line Items]        
Related party   $ 1,000 ¥ 6,500  
XML 54 form10-ka_htm.xml IDEA: XBRL DOCUMENT 0001482554 2021-08-01 2022-07-31 0001482554 2022-01-31 0001482554 2023-05-27 0001482554 2022-07-31 0001482554 2021-07-31 0001482554 2020-08-01 2021-07-31 0001482554 us-gaap:CommonStockMember 2020-07-31 0001482554 us-gaap:AdditionalPaidInCapitalMember 2020-07-31 0001482554 us-gaap:RetainedEarningsMember 2020-07-31 0001482554 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-07-31 0001482554 us-gaap:NoncontrollingInterestMember 2020-07-31 0001482554 2020-07-31 0001482554 us-gaap:CommonStockMember 2021-07-31 0001482554 us-gaap:AdditionalPaidInCapitalMember 2021-07-31 0001482554 us-gaap:RetainedEarningsMember 2021-07-31 0001482554 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-07-31 0001482554 us-gaap:NoncontrollingInterestMember 2021-07-31 0001482554 us-gaap:CommonStockMember 2020-08-01 2021-07-31 0001482554 us-gaap:AdditionalPaidInCapitalMember 2020-08-01 2021-07-31 0001482554 us-gaap:RetainedEarningsMember 2020-08-01 2021-07-31 0001482554 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-08-01 2021-07-31 0001482554 us-gaap:NoncontrollingInterestMember 2020-08-01 2021-07-31 0001482554 us-gaap:CommonStockMember 2021-08-01 2022-07-31 0001482554 us-gaap:AdditionalPaidInCapitalMember 2021-08-01 2022-07-31 0001482554 us-gaap:RetainedEarningsMember 2021-08-01 2022-07-31 0001482554 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-08-01 2022-07-31 0001482554 us-gaap:NoncontrollingInterestMember 2021-08-01 2022-07-31 0001482554 us-gaap:CommonStockMember 2022-07-31 0001482554 us-gaap:AdditionalPaidInCapitalMember 2022-07-31 0001482554 us-gaap:RetainedEarningsMember 2022-07-31 0001482554 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-07-31 0001482554 us-gaap:NoncontrollingInterestMember 2022-07-31 0001482554 HFUS:HangzhouLongjingQiaoFuVacationHotelCoLtdMember 2020-12-31 0001482554 HFUS:ShanghaiHartfordComprehensiveHealthManagementLtdMember 2020-12-31 0001482554 HFUS:ShanghaiHongkouHaiDeFuDeChildcareCoLtdMember 2020-03-23 0001482554 HFUS:PudongHaojinChildhoodEducationLtdMember 2019-07-24 0001482554 HFUS:ShanghaiHdfdZhongliEducationTechnologyCoLtdMember 2021-08-31 0001482554 HFUS:ShanghaiJingyuEducationTechLtdMember 2021-08-31 0001482554 HFUS:HangzhouLongjingQiaoFuVacationHotelCoLtdMember us-gaap:SubsequentEventMember 2022-08-01 0001482554 HFUS:HartfordInternationalEducationTechnologyCoLtdMember HFUS:ShanghaiOverseaMember us-gaap:SubsequentEventMember 2022-08-01 0001482554 HFUS:HangzhouHartfordComprehensiveHealthManagementLtdMember us-gaap:SubsequentEventMember 2022-08-01 0001482554 HFUS:HangzhouHartfordComprehensiveHealthManagementLtdMember HFUS:ShanghaiOverseaMember us-gaap:SubsequentEventMember 2022-08-01 0001482554 HFUS:PeoplesBankOfChinaFinancialStabilityBureauMember 2022-07-31 0001482554 2017-12-01 2017-12-22 0001482554 HFUS:EarlyChildhoodEducationServicesMember 2021-08-01 2022-07-31 0001482554 HFUS:EarlyChildhoodEducationServicesMember 2020-08-01 2021-07-31 0001482554 us-gaap:LeaseholdImprovementsMember 2021-08-01 2022-07-31 0001482554 HFUS:ROUAssetsFinanceLeaseMember 2021-08-01 2022-07-31 0001482554 srt:MinimumMember us-gaap:FurnitureAndFixturesMember 2021-08-01 2022-07-31 0001482554 srt:MaximumMember us-gaap:FurnitureAndFixturesMember 2021-08-01 2022-07-31 0001482554 srt:MinimumMember HFUS:OfficeEquipmentVehiclesMember 2021-08-01 2022-07-31 0001482554 srt:MaximumMember HFUS:OfficeEquipmentVehiclesMember 2021-08-01 2022-07-31 0001482554 srt:MinimumMember HFUS:ComputerSoftwareMember 2021-08-01 2022-07-31 0001482554 srt:MaximumMember HFUS:ComputerSoftwareMember 2021-08-01 2022-07-31 0001482554 HFUS:ShareholderMember 2020-11-23 2020-11-24 0001482554 HFUS:ShareholderMember 2020-11-24 0001482554 HFUS:JointVentureAgreementMember 2019-03-22 0001482554 HFUS:HartfordInternationalEducationTechnologyCoLtdMember HFUS:ShareholderMember 2020-07-31 0001482554 srt:MaximumMember HFUS:JointVentureAgreementMember 2020-06-19 0001482554 srt:MinimumMember HFUS:JointVentureAgreementMember 2020-06-19 0001482554 HFUS:SevenEducationTextbooksMember HFUS:JointVentureAgreementMember HFUS:HartfordInternationalEducationTechnologyCoLtdMember 2019-03-22 0001482554 HFUS:TenHaiDeFuDeMember HFUS:JointVentureAgreementMember HFUS:HartfordInternationalEducationTechnologyCoLtdMember 2019-03-22 0001482554 srt:ChiefExecutiveOfficerMember HFUS:JointVentureAgreementMember HFUS:HartfordInternationalEducationTechnologyCoLtdMember 2021-03-31 0001482554 HFUS:ShanghaiGelinkeChildcareEducationCenterMember 2021-07-31 0001482554 HFUS:ShanghaiSeniorHealthConsultingLtdMember 2019-01-31 0001482554 HFUS:ShanghaiSeniorHealthConsultingLtdMember 2019-02-28 0001482554 HFUS:ShanghaiPasadenaLtdMember 2019-01-31 0001482554 HFUS:ShanghaiPasadenaLtdMember 2019-02-28 0001482554 HFUS:ShanghaiLuoShengInternationalTradeLtdMember 2019-01-31 0001482554 HFUS:HangzhouHartfordComprehensiveHealthManagementLtdMember 2020-12-31 0001482554 HFUS:HangzhouHartfordComprehensiveHealthManagementLtdMember 2020-12-30 2020-12-31 0001482554 HFUS:ShanghaiGelinkeChildcareEducationCenterMember 2020-07-20 0001482554 HFUS:ShanghaiGelinkeChildcareEducationCenterMember 2020-07-19 2020-07-20 0001482554 HFUS:QiaoGardenIntelTravelMember 2020-12-31 0001482554 HFUS:QiaoGardenIntelTravelMember 2020-12-29 2020-12-31 0001482554 us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember HFUS:EducationAndHospitalitySegmentsMember 2022-07-31 0001482554 us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember HFUS:EducationAndHospitalitySegmentsMember 2021-07-31 0001482554 HFUS:HartfordInternationalEducationTechnologyCoLtdMember us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember 2021-08-01 2022-07-31 0001482554 HFUS:HartfordInternationalEducationTechnologyCoLtdMember us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember 2020-08-01 2021-07-31 0001482554 HFUS:SHQiahongMember 2022-07-31 0001482554 HFUS:SHQiahongMember 2021-07-31 0001482554 HFUS:ShanghaiOverseaChineseCultureMediaLtdMember 2022-07-31 0001482554 HFUS:ShanghaiOverseaChineseCultureMediaLtdMember 2021-07-31 0001482554 HFUS:HartfordHotelInvestmentIncMember 2022-07-31 0001482554 HFUS:HartfordHotelInvestmentIncMember 2021-07-31 0001482554 HFUS:HartfordHotelInvestmentIncMember 2021-08-01 2022-07-31 0001482554 HFUS:HartfordHotelInvestmentIncMember 2020-08-01 2021-07-31 0001482554 HFUS:IntellectualPropertiesMember HFUS:HartfordInternationalEducationTechnologyCoLtdMember 2021-08-01 2022-07-31 0001482554 HFUS:IntellectualPropertiesMember HFUS:HartfordInternationalEducationTechnologyCoLtdMember 2022-07-31 0001482554 us-gaap:LicenseMember HFUS:HartfordInternationalEducationTechnologyCoLtdMember 2021-08-01 2022-07-31 0001482554 us-gaap:LicenseMember HFUS:HartfordInternationalEducationTechnologyCoLtdMember 2020-08-01 2021-07-31 0001482554 us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember HFUS:HospitalityMember 2021-08-01 2022-07-31 0001482554 us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember HFUS:EducationMember 2021-08-01 2022-07-31 0001482554 HFUS:CorporateAndUnallocatedMember 2021-08-01 2022-07-31 0001482554 us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember HFUS:HospitalityMember 2022-07-31 0001482554 us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember HFUS:EducationMember 2022-07-31 0001482554 HFUS:CorporateAndUnallocatedMember 2022-07-31 0001482554 us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember HFUS:HospitalityMember 2020-08-01 2021-07-31 0001482554 us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember HFUS:EducationMember 2020-08-01 2021-07-31 0001482554 HFUS:CorporateAndUnallocatedMember 2020-08-01 2021-07-31 0001482554 us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember HFUS:HospitalityMember 2021-07-31 0001482554 us-gaap:DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember HFUS:EducationMember 2021-07-31 0001482554 HFUS:CorporateAndUnallocatedMember 2021-07-31 0001482554 HFUS:HangzhouLongjingQiaoFuVacationHotelCoLtdMember 2022-08-01 0001482554 HFUS:ShangaiLuoShengInternationalTradeLtdMember us-gaap:SubsequentEventMember 2022-08-01 0001482554 HFUS:RelatedPartyMember us-gaap:SubsequentEventMember 2022-08-17 iso4217:USD shares iso4217:USD shares pure iso4217:CNY 0001482554 true FY 10-K/A true 2022-07-31 --07-31 2022 false 000-54439 Hartford Great Health Corp. NV 51-0675116 8832 Glendon Way Rosemead CA 91770 (626) 321-1915 No Yes Yes Yes 5002840 Non-accelerated Filer true true false false Common stock, par value $0.001 par value HFUS 100108000 This Amendment No. 1 to our Annual Report on Form 10-K for the annual period from August 1, 2021 to July 31, 2022, which was filed with the U.S. Securities and Exchange Commission (the “SEC”) on November 14, 2022 (the “Original Filing”), is being filed for the following purposes Simon & Edward, LLP 2485 Rowland Heights, California 15227 12739 1154 1203 14233 309 4499736 975837 4530350 990088 8006 8357 4744153 8006 4752510 4538356 5742598 4481524 3711606 144760 145435 6344721 2681639 10971005 6538680 4190368 10971005 10729048 0.001 0.001 5000000 5000000 0 0 0 0 0.001 0.001 300000000 300000000 100108000 100108000 100108 100108 2173521 2173521 -7400620 -5821519 -16742 -233487 -1288916 -1205073 -6432649 -4986450 4538356 5742598 177913 255655 177913 255655 -177913 -255655 -11857 14806 104317 140 55604 -11717 174727 -189630 -80928 800 800 -190430 -81728 -190430 -81728 -1582152 -2760611 -193481 -589005 -1388671 -2171606 -0.00 0.00 -0.01 -0.02 -0.02 -0.02 100108000 99790192 -1579101 -2253334 267073 -217953 267073 -217953 50328 -39612 216745 -178341 -1362356 -2431675 99108000 99108 2154521 -3568185 -55146 -917489 -2287191 -2253334 -589005 -2842339 1000000 1000 19000 20000 403131 403131 -62098 -62098 -178341 -39612 -217953 100108000 100108 2173521 -5821519 -233487 -1205073 -4986450 100108000 100108 2173521 -5821519 -233487 -1205073 -4986450 -1579101 -193481 -1772582 59310 59310 216745 50328 267073 100108000 100108 2173521 -7400620 -16742 -1288916 -6432649 100108000 100108 2173521 -7400620 -16742 -1288916 -6432649 -1772582 -2842339 122065 85103 104316 162806 403131 -760 70514 -225428 87978 -5327 299588 -24078 -10435 81013 185693 26466 373413 102526 312902 -458993 -17779 27880 27108 -860832 -2381575 27927 15206 30116 145048 168287 -145048 -185682 61750 20000 145000 145000 23156 22049 788673 2407033 972267 2549984 -400 6174 -34013 -11099 54178 65277 20165 54178 800 800 10462 765131 <p id="xdx_80C_eus-gaap--SignificantAccountingPoliciesTextBlock_zJiZxxm8xA17" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1. <span id="xdx_82A_zg1nMqlhzksl">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">This summary of significant accounting policies is presented to assist in understanding the Company’s financial statements. The financial statements and notes are the responsibility of the Company’s management. These accounting policies conform to accounting principles generally accepted in the United States of America (“US GAAP”) and have been consistently applied in the preparation of the financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_ziAdMFBYkaw" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zSfmXQgFk9o4">Organization</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hartford Great Health Corp. was originally incorporated in the State of Nevada on April 2, 2008 under the name PhotoAmigo, Inc. It changed its name to Hartford Great Health Corp. on August 22, 2018 and since then we have been engaged in activities to formulate and implement our business plans.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through its wholly owned subsidiary - Hangzhou Hartford Comprehensive Health Management, Ltd (“HZHF) and HZHF’s <span id="xdx_900_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_c20201231__us-gaap--BusinessAcquisitionAxis__custom--HangzhouLongjingQiaoFuVacationHotelCoLtdMember_ztDV5dZuLOGj" title="Business acquisition, percentage of voting interests acquired">60</span> percent owned subsidiary - Hangzhou Longjing Qiao Fu Vacation Hotel Co., Ltd. (“HZLJ”), and through Shanghai Hartford Comprehensive Health Management, Ltd. (“HFSH”) and its <span id="xdx_90E_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_c20201231__us-gaap--BusinessAcquisitionAxis__custom--ShanghaiHartfordComprehensiveHealthManagementLtdMember_zkHdnZezdlE7" title="Business acquisition, percentage of voting interests acquired">90</span> percent owned subsidiary - Shanghai Qiao Garden International Travel Agency (“Qiao Garden Int’l Travel”), the Company engages in hospitality industry in China. Qiao Garden Int’l Travel was disposed on December 31, 2020, see note 4 Acquisitions, Joint Ventures and Deconsolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company started to engage in early childhood education industry at Hartford International Education Technology Co., Ltd (“HF Int’l Education”). On July 24, 2019 and March 23, 2020, HF Int’l Education established two <span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20200323__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ShanghaiHongkouHaiDeFuDeChildcareCoLtdMember_zlsxsTgNnlub" title="Equity ownership percentage"><span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20190724__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PudongHaojinChildhoodEducationLtdMember_zlfOU6nlJpk5" title="Equity ownership percentage">100</span></span>% owned subsidiaries, Pudong Haojin Childhood Education Ltd. (“PDHJ”) and Shanghai Hongkou HaiDeFuDe Childcare Co., Ltd.(“HDFD”), respectively, to operate the early childhood education service under the brand name of “HaiDeFuDe” in Shanghai, China. On July 20, 2020, HF Int’l Education entered an agreement with two individuals to acquire the whole ownership of Shanghai Gelinke Childcare Education Center (“Gelinke”). Gelinke temporally ceased its operations by the end of August 2021. On August 31, 2021, PDHJ established one <span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20210831__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ShanghaiHdfdZhongliEducationTechnologyCoLtdMember_zXP2qTbLgeE2" title="Equity ownership percentage">96</span>% owned subsidiary, Shanghai HDFD Zhongli Education Technology Co., Ltd. (“Zhongli”), two individual investors hold the remaining <span id="xdx_901_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_c20210831__srt--OwnershipAxis__custom--ShanghaiJingyuEducationTechLtdMember_zqwMNx20TzB3" title="Equity ownership percentage">4</span>% ownership, see note 4 Acquisitions, Joint Ventures and Deconsolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impacted by the government regulation newly implemented in education industry and the restrictions posted by the Chinese government to control the pandemic in China since 2021, to avoid further operation losses, subsequently on August 1, 2022, HFSH entered a contract with a related party, Shanghai Oversea Chinese Culture Media Ltd. (“SH Oversea”), to sell <span id="xdx_904_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_c20220801__us-gaap--BusinessAcquisitionAxis__custom--HangzhouLongjingQiaoFuVacationHotelCoLtdMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ztEvaA00hi05" title="Business acquisition, percentage of voting interests acquired">90</span> percent ownership of HF Int’l Education and its subsidiaries for $<span id="xdx_905_eus-gaap--RelatedPartyTransactionDueFromToRelatedParty_iI_c20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShanghaiOverseaMember__us-gaap--BusinessAcquisitionAxis__custom--HartfordInternationalEducationTechnologyCoLtdMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zTHZC0HtmiLi" title="Related party">900</span> (RMB <span id="xdx_90A_eus-gaap--RelatedPartyTransactionDueFromToRelatedParty_iI_uRMB_c20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShanghaiOverseaMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--BusinessAcquisitionAxis__custom--HartfordInternationalEducationTechnologyCoLtdMember_zwVug3OQJeBj" title="Related party">5,850</span>). On August 1, 2022, HFUS entered a contract with SH Oversea and another individual, to sell <span id="xdx_90E_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_dp_uPure_c20220801__us-gaap--BusinessAcquisitionAxis__custom--HangzhouHartfordComprehensiveHealthManagementLtdMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zDYnrUEcKPCa">100</span> percent ownership of HZHF and its subsidiaries for $<span id="xdx_905_eus-gaap--RelatedPartyTransactionDueFromToRelatedParty_iI_c20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShanghaiOverseaMember__us-gaap--BusinessAcquisitionAxis__custom--HangzhouHartfordComprehensiveHealthManagementLtdMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zBuvDxA6mGk1" title="Related party">1,000</span> (RMB <span id="xdx_901_eus-gaap--RelatedPartyTransactionDueFromToRelatedParty_iI_uRMB_c20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShanghaiOverseaMember__us-gaap--BusinessAcquisitionAxis__custom--HangzhouHartfordComprehensiveHealthManagementLtdMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zQg6WDzy3fhi" title="Related party">6,500</span>). As of July 31, 2022, the asset group in Education segment and the asset group in Hospitality segment classified as assets and liabilities held for sale, and it is the Company’s intention to complete the sales of these assets within the upcoming year.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zomAglyxVfj5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zDuloU45ICHb">Basis of Presentation</span>: </b>The consolidated financial statements include the accounts of Hartford Great Health Corp, its wholly-owned subsidiaries and subsidiaries in which it has a controlling interest. The Company reports noncontrolling interests of the consolidated entities as a component of equity separate from the Company’s equity. All material inter-company transactions between and among the Company and its consolidated subsidiaries have been eliminated in the consolidation. The Company’s net income (loss) excludes income (loss) attributable to the noncontrolling interests.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--UseOfEstimates_zXp6po1B2cqd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zxGkkdMgtAP9">Use of Estimates</span>: </b>The preparation of financial statements in conformity with US GAAP requires the Company’s management to make estimates and assumptions that affect the amounts of assets and liabilities, the identification and disclosure of impaired assets and contingent liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zo98wlUWvilk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zXI6B7LK8d39">Foreign Currency</span>: </b>The accounts of the Company’s foreign subsidiaries are translated in accordance with FASB ASC 830. Foreign currency transaction gains and losses are recognized in other expense, net, at the time they occur. Net foreign currency exchange gains or losses resulting from the translation of assets and liabilities of foreign subsidiaries whose functional currency is not the U.S. dollar are recorded as a part of accumulated other comprehensive loss in stockholders’ equity. The Company does not undertake hedging transactions to cover its foreign currency exposure.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_z9wk5w01trJ" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zhA5v7nTE3ma">Comprehensive Income (loss)</span>: </b>For the year ended July 31, 2022 and 2021, the Company included its foreign currency translation gain or loss as part of its comprehensive income (loss).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_z0EAzO8Mgaxa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_z2lUb9Axjxxe">Fair value measurement</span></b>: Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Accounting Standard Codification (“ASC”) 820, Fair Value Measurements and Disclosures (“ASC 820”), describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value, which are the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 33pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 - Quoted prices in active markets for identical assets or liabilities or funds.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 33pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 33pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s financial instruments consist of cash and cash equivalents, accounts receivable, related party receivable, prepaid and other current receivable, accounts payable, related party payable and other current payable. The carrying amounts of afore-mentioned accounts approximate fair value because of their short-term nature.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_840_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zIchh9uS7kj5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zpjO1JbnVWIj">Cash and Cash Equivalents</span>: </b>The Company maintains cash with banks in the USA and China. Should any bank holding cash become insolvent, or if the Company is otherwise unable to withdraw funds, the Company would lose the cash with that bank; however, the Company has not experienced any losses in such accounts and believes it is not exposed to any significant risks on its cash in bank accounts. In China, a depositor has up to RMB<span id="xdx_901_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_uRMB_c20220731__dei--LegalEntityAxis__custom--PeoplesBankOfChinaFinancialStabilityBureauMember_zwPS0guG1sK5" title="FDIC insured amount">500,000</span> insured by the People’s Bank of China Financial Stability Bureau (“FSD”). In the United States, the standard insurance amount is USD<span id="xdx_909_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20220731_zbM6VoFhh37c" title="FDIC insured amount">250,000</span> per depositor in a bank insured by the Federal Deposit Insurance Corporation (“FDIC”). Financial instruments that potentially subject the Company to significant concentrations of credit risk are cash and cash equivalents and accounts receivable. As of July 31, 2022 and 2021, respectively, none of the Company’s cash and cash equivalents held by financial institutions was uninsured. With respect to accounts receivable, the Company generally does not require collateral and does not have an allowance for doubtful accounts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--PolicyLoansReceivablePolicy_z3IzHEatz6V7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zCssu7R21rbg">Receivables</span>: </b>The Company evaluates the collectability of its receivables based on a number of factors. In circumstances where the Company becomes aware of a specific customer’s or borrower’s inability to meet its financial obligations to the Company, a specific reserve for bad debts is estimated and recorded, which reduces the recognized receivable to the estimated amount the Company believes will ultimately be collected. As of July 31, 2022 and 2021, all balances are collectable based on management’s assessment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zp3pJihOOMFa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zZrjPIyoIANg">Property and equipment, net</span>: </b>Property and equipment, net, are stated at cost. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the assets. The estimated useful lives of property and equipment are as follows:</span></p> <p id="xdx_892_ecustom--ScheduleOfPropertyAndEquipmentUsefulLivesTableTextBlock_zO06drov1mfg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_z1n9urRdHkB7" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Years</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 58%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvements</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20210801__20220731__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zJgXVl7WScEj" style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: right" title="Description of estimated useful lives of property and equipment"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lesser of lease term or estimated useful life</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ROU assets-Finance lease</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20210801__20220731__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ROUAssetsFinanceLeaseMember_z8Ltop4h5kwh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Description of estimated useful lives of property and equipment"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease term</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture and fixtures</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210801__20220731__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zvI60w7LGpc" title="Property, plant and equipment, useful life">3</span>-<span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210801__20220731__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zpsVzzmWTj5d" title="Property, plant and equipment, useful life">5</span></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office equipment and vehicles</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210801__20220731__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeEquipmentVehiclesMember__srt--RangeAxis__srt--MinimumMember_zggjwu4oioJ2" title="Property, plant and equipment, useful life">3</span>-<span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210801__20220731__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeEquipmentVehiclesMember__srt--RangeAxis__srt--MaximumMember_zfbXkf9nGU4k" title="Property, plant and equipment, useful life">5</span></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer software</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210801__20220731__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerSoftwareMember__srt--RangeAxis__srt--MinimumMember_zCWLDdf2pI16" title="Property, plant and equipment, useful life">3</span>-<span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210801__20220731__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerSoftwareMember__srt--RangeAxis__srt--MaximumMember_zSD8nSUScMk8" title="Property, plant and equipment, useful life">5</span></span></td></tr> </table> <p id="xdx_8A1_z65QsKkHQDpb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenditures for repairs and maintenance are charged to expense as incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zrk2MB71qIE8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zGothvJa1sN">Goodwill and Long-lived Assets</span>: </b>Goodwill, which represents the excess of the purchase price over the fair value of identifiable net assets acquired, is not amortized, in accordance with Accounting Standards Codification (ASC) 350, Intangibles—Goodwill and Other. ASC 350 requires that goodwill be tested for impairment at the reporting unit level on an annual basis and between annual tests, if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. These events or circumstances could include a significant change in the business climate, legal factors, operating performance indicators, competition, or sale or disposition of a significant portion of a reporting unit.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has the option to assess goodwill for possible impairment by performing a qualitative analysis to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. A quantitative assessment is performed if the qualitative assessment results in a more-likely-than-not determination or if a qualitative assessment is not performed. The quantitative assessment considers whether the carrying amount of a reporting unit exceeds its fair value, in which case an impairment charge is recorded to the extent that the reporting unit’s carrying value exceeds its fair value. The Company’s goodwill was mainly generated from the acquisitions during the year ended July 31, 2019. We currently have two reporting units - Hospitality and Early Childhood Education. Given the impact of COVID-19 pandemic and the unfavorable operation results, an interim goodwill impairment assessment was performed as of January 31, 2020. Based on the assessment result, management determined that the goodwill generated from acquisitions was fully impaired as of July 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--BusinessCombinationsPolicy_z5etkvuVNfk6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zROeSxa92cI1">Business Combinations</span>: </b>If an acquired set of activities and assets is capable of being operated as a business consisting of inputs and processes from the viewpoint of a market participant, the assets acquired and liabilities assumed are a business. Business combinations are accounted for using the acquisition method of accounting, which requires an acquirer to recognize the assets acquired and the liabilities assumed at the acquisition date measured at their fair values as of that date. Fair value determinations are based on discounted cash flow analyses or other valuation techniques. In determining the fair value of the assets acquired and liabilities assumed in a material acquisition, the Company may utilize appraisals from third party valuation firms to determine fair values of some or all of the assets acquired and liabilities assumed, or may complete some or all of the valuations internally. In either case, the Company takes full responsibility for the determination of the fair value of the assets acquired and liabilities assumed. The value of goodwill reflects the excess of the fair value of the consideration conveyed to the seller over the fair value of the net assets received. Acquisition-related costs that the Company incurs to affect a business combination are expensed in the periods in which the costs are incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_ecustom--NoncontrollingInterestPolicyTextBlock_z5y8YGghz6L5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zKdoFUkTKDR8">Noncontrolling interest</span>: </b>The Company adopted ASC 810, Noncontrolling Interests in Consolidated Financial Statements—an Amendment of Accounting Research Bulletin No. 51, as of January 1, 2009. ASC 810 establishes accounting and reporting standards for ownership interests in subsidiaries held by parties other than the parent, the amount of consolidated net income attributable to the parent and to the noncontrolling interest, changes in a parent’s ownership interest and the valuation of retained noncontrolling equity investments when a subsidiary is deconsolidated. ASC 810 also establishes reporting requirements that provide sufficient disclosures that clearly identify and distinguish between the interest of the parent and the interests of the noncontrolling owner.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--AdvertisingCostsPolicyTextBlock_zR3yjSBoPC38" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zxb7Ek576RUg">Advertising costs</span>: </b>Advertising costs are expensed as incurred. During the year ended July 31, 2022 and 2021, amount of $<span id="xdx_90F_eus-gaap--AdvertisingExpense_pp0p0_c20210801__20220731_zf0ZENoCwYv9" title="Advertising cost">10,540</span> and $<span id="xdx_902_eus-gaap--AdvertisingExpense_pp0p0_c20200801__20210731_zaps6g82gtHj" title="Advertising cost">65,406</span> advertising expenses were incurred, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_842_eus-gaap--IncomeTaxPolicyTextBlock_zXW3n8qBPx07" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zkCnLk9fiHJ1">Income Taxes</span>: </b>The Company accounts for income taxes using the asset and liability method in accordance with ASC 740, Accounting for Income Taxes. The asset and liability method provides that deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using the currently enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company records a valuation allowance to reduce deferred tax assets to the amount that is believed more likely than not to be realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--IncomeTaxExaminationDescription_c20171201__20171222_zr3B1ia4jie6" title="Income tax examination description">On December 22, 2017, the President of the United States signed into law the Tax Reform Act. The Tax Reform Act permanently reduces the U.S. corporate income tax rate from a maximum of 35% to a flat 21% rate, effective January 1, 2018. In addition, the 2017 Tax Act also creates a new requirement that certain income (i.e., Global Intangible Low-Taxed Income (“GILTI”)) earned by controlled foreign corporations (“CFCs”) must be included in the gross income of the CFCs’ U.S. shareholder income. The tax law in PRC applies an income tax rate of 25% to all enterprises</span>. The Company’s subsidiary does not receive any preferential tax treatment from local government. The Company has been in loss position for years and zero balances of tax provisions, deferred tax assets and liabilities as of the reporting periods ended. The tax reforms have no significant impacts on the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zYYRrTxh0Iii" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zBE4AWqSXLp6">Revenue Recognition</span>: </b>The Company adopted ASC Topic 606 Revenue from Contracts with Customers (“Topic 606) on August 1, 2019, applying the modified retrospective method to all contracts that were not completed as of August 1, 2019. The Company is building up its core business upon the completion of multiple acquisitions in March 2019 and impact of COVID-19 pandemic, limited operations occurred during the years ended July 31, 2022 and 2021. The revenue during the years ended July 31, 2022 and 2021 were mainly generated from HZLJ and HF Int’l Education.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue is recognized when control of promised goods or services is transferred to our customers in an amount of consideration to which we expect to be entitled to in exchange for those goods or services. We follow the five steps approach for revenue recognition under Topic 606: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) we satisfy a performance obligation. Billings to customers for which services are not rendered are considered deferred revenue. ASC 606 has no material impacts on the Company’s financial positions. The Company’s revenue is recognized when it satisfies a single performance obligation by transferring control of its products or providing services to a customer. The Company’s general payment terms are short-term in duration. The Company does not have significant financing components or payment terms.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Early childhood education services: HF Int’l Education generates revenue from childhood education classes provided to its customers. The educational services consist of parent-child and bilingual childcare classes. Each contract of educational classes is accounted for as a single performance obligation which is satisfied proportionately over the service period. Tuition fee is generally collected in advance and is initially recorded as deferred revenue and transferred to contract liabilities after trial period. Refunds are provided to parents if they decide within the trial period that they no longer want to take the class. After the trial period, if a parent withdraws from a class, usually only that unearned portion of the fee is available to be returned. For the year ended July 31, 2022 and 2021, $<span id="xdx_905_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210801__20220731__srt--ProductOrServiceAxis__custom--EarlyChildhoodEducationServicesMember_z8xqT94xUkR3" title="Revenue">509,920</span> and $<span id="xdx_902_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200801__20210731__srt--ProductOrServiceAxis__custom--EarlyChildhoodEducationServicesMember_zAqRn4w0ejq7" title="Revenue">435,149</span>, respectively, of revenue were derived from early childhood education classes provided.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hospitality services: HZLJ generates revenue primarily from the room rentals, sale of food and beverage and other miscellaneous hospitality services. The Company recognizes room rental and services daily as services are provided. Under ASC 606, the pattern and timing of recognition of income from hotel facility is consistent with the prior accounting model.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_zH91YYhTsDji" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zMk1LyberF9">Income (Loss) Per Share</span>: </b>Basic earnings per share include no dilution and are computed by dividing net income (or loss) by the weighted- average number of shares outstanding during the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of the Company, assuming the issuance of an equivalent number of common shares pursuant to options, warrants, or convertible debt arrangements. Diluted earnings per share are not shown for periods in which the Company incurs a loss because it would be anti-dilutive. Similarly, potential common stock equivalents are not included in the calculation if the effect would be anti-dilutive. No potentially dilutive debt or equity securities were issued or outstanding during the years ended July 31, 2022 or 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_ecustom--ReclassificationsPolicyTextBlock_zHjKJ3uHJ5gg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zgkkAiB4VA4k">Reclassifications</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain amounts on the prior-year consolidated balance sheet, consolidated statement of operations and cash flows were reclassified to conform to current-year presentation, with no effect on ending stockholders’ equity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zelwnrqv9YJ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zdXYHYAa4Iv8">Recent Accounting Pronouncements</span>.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Recently adopted accounting pronouncements</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes which is intended to simplify various aspects related to accounting for income taxes. The standard is effective for fiscal years, and interim periods within those years, beginning after December 15, 2020, with early adoption permitted. The adoption of ASU 2019-12 had an immaterial impact on the Company’s consolidated statement of operation and consolidated statement of cash flows for the year ended July 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Recently issued accounting pronouncements not yet adopted</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2016, the FASB issued ASU 2016-13, “Financial Instruments—Credit Losses”. The standard, including subsequently issued amendments (ASU 2018-19, ASU 2019-04, ASU 2019-05, ASU 2019-10 and ASU 2019-11), requires a financial asset measured at amortized cost basis, such as accounts receivable and certain other financial assets, to be presented at the net amount expected to be collected based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. In November 2019, the FASB issued ASU No. 2019-10 to postpone the effective date of ASU No. 2016-13 for public business entities eligible to be smaller reporting companies defined by the SEC to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company is evaluating the impact of this guidance on its consolidated financial statements.</span></p> <p id="xdx_853_zL0fvclwp8J9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_840_eus-gaap--OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock_ziAdMFBYkaw" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zSfmXQgFk9o4">Organization</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hartford Great Health Corp. was originally incorporated in the State of Nevada on April 2, 2008 under the name PhotoAmigo, Inc. It changed its name to Hartford Great Health Corp. on August 22, 2018 and since then we have been engaged in activities to formulate and implement our business plans.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Through its wholly owned subsidiary - Hangzhou Hartford Comprehensive Health Management, Ltd (“HZHF) and HZHF’s <span id="xdx_900_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_c20201231__us-gaap--BusinessAcquisitionAxis__custom--HangzhouLongjingQiaoFuVacationHotelCoLtdMember_ztDV5dZuLOGj" title="Business acquisition, percentage of voting interests acquired">60</span> percent owned subsidiary - Hangzhou Longjing Qiao Fu Vacation Hotel Co., Ltd. (“HZLJ”), and through Shanghai Hartford Comprehensive Health Management, Ltd. (“HFSH”) and its <span id="xdx_90E_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_c20201231__us-gaap--BusinessAcquisitionAxis__custom--ShanghaiHartfordComprehensiveHealthManagementLtdMember_zkHdnZezdlE7" title="Business acquisition, percentage of voting interests acquired">90</span> percent owned subsidiary - Shanghai Qiao Garden International Travel Agency (“Qiao Garden Int’l Travel”), the Company engages in hospitality industry in China. Qiao Garden Int’l Travel was disposed on December 31, 2020, see note 4 Acquisitions, Joint Ventures and Deconsolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company started to engage in early childhood education industry at Hartford International Education Technology Co., Ltd (“HF Int’l Education”). On July 24, 2019 and March 23, 2020, HF Int’l Education established two <span id="xdx_90E_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20200323__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ShanghaiHongkouHaiDeFuDeChildcareCoLtdMember_zlsxsTgNnlub" title="Equity ownership percentage"><span id="xdx_907_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20190724__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--PudongHaojinChildhoodEducationLtdMember_zlfOU6nlJpk5" title="Equity ownership percentage">100</span></span>% owned subsidiaries, Pudong Haojin Childhood Education Ltd. (“PDHJ”) and Shanghai Hongkou HaiDeFuDe Childcare Co., Ltd.(“HDFD”), respectively, to operate the early childhood education service under the brand name of “HaiDeFuDe” in Shanghai, China. On July 20, 2020, HF Int’l Education entered an agreement with two individuals to acquire the whole ownership of Shanghai Gelinke Childcare Education Center (“Gelinke”). Gelinke temporally ceased its operations by the end of August 2021. On August 31, 2021, PDHJ established one <span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20210831__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ShanghaiHdfdZhongliEducationTechnologyCoLtdMember_zXP2qTbLgeE2" title="Equity ownership percentage">96</span>% owned subsidiary, Shanghai HDFD Zhongli Education Technology Co., Ltd. (“Zhongli”), two individual investors hold the remaining <span id="xdx_901_eus-gaap--MinorityInterestOwnershipPercentageByParent_iI_pid_dp_c20210831__srt--OwnershipAxis__custom--ShanghaiJingyuEducationTechLtdMember_zqwMNx20TzB3" title="Equity ownership percentage">4</span>% ownership, see note 4 Acquisitions, Joint Ventures and Deconsolidation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impacted by the government regulation newly implemented in education industry and the restrictions posted by the Chinese government to control the pandemic in China since 2021, to avoid further operation losses, subsequently on August 1, 2022, HFSH entered a contract with a related party, Shanghai Oversea Chinese Culture Media Ltd. (“SH Oversea”), to sell <span id="xdx_904_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_c20220801__us-gaap--BusinessAcquisitionAxis__custom--HangzhouLongjingQiaoFuVacationHotelCoLtdMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ztEvaA00hi05" title="Business acquisition, percentage of voting interests acquired">90</span> percent ownership of HF Int’l Education and its subsidiaries for $<span id="xdx_905_eus-gaap--RelatedPartyTransactionDueFromToRelatedParty_iI_c20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShanghaiOverseaMember__us-gaap--BusinessAcquisitionAxis__custom--HartfordInternationalEducationTechnologyCoLtdMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zTHZC0HtmiLi" title="Related party">900</span> (RMB <span id="xdx_90A_eus-gaap--RelatedPartyTransactionDueFromToRelatedParty_iI_uRMB_c20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShanghaiOverseaMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__us-gaap--BusinessAcquisitionAxis__custom--HartfordInternationalEducationTechnologyCoLtdMember_zwVug3OQJeBj" title="Related party">5,850</span>). On August 1, 2022, HFUS entered a contract with SH Oversea and another individual, to sell <span id="xdx_90E_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_dp_uPure_c20220801__us-gaap--BusinessAcquisitionAxis__custom--HangzhouHartfordComprehensiveHealthManagementLtdMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zDYnrUEcKPCa">100</span> percent ownership of HZHF and its subsidiaries for $<span id="xdx_905_eus-gaap--RelatedPartyTransactionDueFromToRelatedParty_iI_c20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShanghaiOverseaMember__us-gaap--BusinessAcquisitionAxis__custom--HangzhouHartfordComprehensiveHealthManagementLtdMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zBuvDxA6mGk1" title="Related party">1,000</span> (RMB <span id="xdx_901_eus-gaap--RelatedPartyTransactionDueFromToRelatedParty_iI_uRMB_c20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShanghaiOverseaMember__us-gaap--BusinessAcquisitionAxis__custom--HangzhouHartfordComprehensiveHealthManagementLtdMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zQg6WDzy3fhi" title="Related party">6,500</span>). As of July 31, 2022, the asset group in Education segment and the asset group in Hospitality segment classified as assets and liabilities held for sale, and it is the Company’s intention to complete the sales of these assets within the upcoming year.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0.60 0.90 1 1 0.96 0.04 0.90 900 5850 1 1000 6500 <p id="xdx_841_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zomAglyxVfj5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zDuloU45ICHb">Basis of Presentation</span>: </b>The consolidated financial statements include the accounts of Hartford Great Health Corp, its wholly-owned subsidiaries and subsidiaries in which it has a controlling interest. The Company reports noncontrolling interests of the consolidated entities as a component of equity separate from the Company’s equity. All material inter-company transactions between and among the Company and its consolidated subsidiaries have been eliminated in the consolidation. The Company’s net income (loss) excludes income (loss) attributable to the noncontrolling interests.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_844_eus-gaap--UseOfEstimates_zXp6po1B2cqd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zxGkkdMgtAP9">Use of Estimates</span>: </b>The preparation of financial statements in conformity with US GAAP requires the Company’s management to make estimates and assumptions that affect the amounts of assets and liabilities, the identification and disclosure of impaired assets and contingent liabilities at the date of the financial statements, and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_842_eus-gaap--ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_zo98wlUWvilk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_867_zXI6B7LK8d39">Foreign Currency</span>: </b>The accounts of the Company’s foreign subsidiaries are translated in accordance with FASB ASC 830. Foreign currency transaction gains and losses are recognized in other expense, net, at the time they occur. Net foreign currency exchange gains or losses resulting from the translation of assets and liabilities of foreign subsidiaries whose functional currency is not the U.S. dollar are recorded as a part of accumulated other comprehensive loss in stockholders’ equity. The Company does not undertake hedging transactions to cover its foreign currency exposure.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--ComprehensiveIncomePolicyPolicyTextBlock_z9wk5w01trJ" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zhA5v7nTE3ma">Comprehensive Income (loss)</span>: </b>For the year ended July 31, 2022 and 2021, the Company included its foreign currency translation gain or loss as part of its comprehensive income (loss).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_843_eus-gaap--FairValueMeasurementPolicyPolicyTextBlock_z0EAzO8Mgaxa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_z2lUb9Axjxxe">Fair value measurement</span></b>: Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Accounting Standard Codification (“ASC”) 820, Fair Value Measurements and Disclosures (“ASC 820”), describes a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value, which are the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 33pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 1 - Quoted prices in active markets for identical assets or liabilities or funds.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 33pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 2 - Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 33pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 2pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s financial instruments consist of cash and cash equivalents, accounts receivable, related party receivable, prepaid and other current receivable, accounts payable, related party payable and other current payable. The carrying amounts of afore-mentioned accounts approximate fair value because of their short-term nature.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_840_eus-gaap--CashAndCashEquivalentsPolicyTextBlock_zIchh9uS7kj5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zpjO1JbnVWIj">Cash and Cash Equivalents</span>: </b>The Company maintains cash with banks in the USA and China. Should any bank holding cash become insolvent, or if the Company is otherwise unable to withdraw funds, the Company would lose the cash with that bank; however, the Company has not experienced any losses in such accounts and believes it is not exposed to any significant risks on its cash in bank accounts. In China, a depositor has up to RMB<span id="xdx_901_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_uRMB_c20220731__dei--LegalEntityAxis__custom--PeoplesBankOfChinaFinancialStabilityBureauMember_zwPS0guG1sK5" title="FDIC insured amount">500,000</span> insured by the People’s Bank of China Financial Stability Bureau (“FSD”). In the United States, the standard insurance amount is USD<span id="xdx_909_eus-gaap--CashFDICInsuredAmount_iI_pp0p0_c20220731_zbM6VoFhh37c" title="FDIC insured amount">250,000</span> per depositor in a bank insured by the Federal Deposit Insurance Corporation (“FDIC”). Financial instruments that potentially subject the Company to significant concentrations of credit risk are cash and cash equivalents and accounts receivable. As of July 31, 2022 and 2021, respectively, none of the Company’s cash and cash equivalents held by financial institutions was uninsured. With respect to accounts receivable, the Company generally does not require collateral and does not have an allowance for doubtful accounts.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 500000 250000 <p id="xdx_848_eus-gaap--PolicyLoansReceivablePolicy_z3IzHEatz6V7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_869_zCssu7R21rbg">Receivables</span>: </b>The Company evaluates the collectability of its receivables based on a number of factors. In circumstances where the Company becomes aware of a specific customer’s or borrower’s inability to meet its financial obligations to the Company, a specific reserve for bad debts is estimated and recorded, which reduces the recognized receivable to the estimated amount the Company believes will ultimately be collected. As of July 31, 2022 and 2021, all balances are collectable based on management’s assessment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--PropertyPlantAndEquipmentPolicyTextBlock_zp3pJihOOMFa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86F_zZrjPIyoIANg">Property and equipment, net</span>: </b>Property and equipment, net, are stated at cost. Depreciation and amortization are computed using the straight-line method over the estimated useful lives of the assets. The estimated useful lives of property and equipment are as follows:</span></p> <p id="xdx_892_ecustom--ScheduleOfPropertyAndEquipmentUsefulLivesTableTextBlock_zO06drov1mfg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_z1n9urRdHkB7" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Years</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 58%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvements</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20210801__20220731__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zJgXVl7WScEj" style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: right" title="Description of estimated useful lives of property and equipment"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lesser of lease term or estimated useful life</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ROU assets-Finance lease</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20210801__20220731__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ROUAssetsFinanceLeaseMember_z8Ltop4h5kwh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Description of estimated useful lives of property and equipment"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease term</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture and fixtures</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210801__20220731__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zvI60w7LGpc" title="Property, plant and equipment, useful life">3</span>-<span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210801__20220731__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zpsVzzmWTj5d" title="Property, plant and equipment, useful life">5</span></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office equipment and vehicles</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210801__20220731__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeEquipmentVehiclesMember__srt--RangeAxis__srt--MinimumMember_zggjwu4oioJ2" title="Property, plant and equipment, useful life">3</span>-<span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210801__20220731__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeEquipmentVehiclesMember__srt--RangeAxis__srt--MaximumMember_zfbXkf9nGU4k" title="Property, plant and equipment, useful life">5</span></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer software</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210801__20220731__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerSoftwareMember__srt--RangeAxis__srt--MinimumMember_zCWLDdf2pI16" title="Property, plant and equipment, useful life">3</span>-<span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210801__20220731__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerSoftwareMember__srt--RangeAxis__srt--MaximumMember_zSD8nSUScMk8" title="Property, plant and equipment, useful life">5</span></span></td></tr> </table> <p id="xdx_8A1_z65QsKkHQDpb" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Expenditures for repairs and maintenance are charged to expense as incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_ecustom--ScheduleOfPropertyAndEquipmentUsefulLivesTableTextBlock_zO06drov1mfg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_z1n9urRdHkB7" style="display: none">SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Years</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 58%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Leasehold improvements</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_987_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20210801__20220731__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zJgXVl7WScEj" style="font: 10pt Times New Roman, Times, Serif; width: 40%; text-align: right" title="Description of estimated useful lives of property and equipment"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lesser of lease term or estimated useful life</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">ROU assets-Finance lease</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentEstimatedUsefulLives_c20210801__20220731__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ROUAssetsFinanceLeaseMember_z8Ltop4h5kwh" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Description of estimated useful lives of property and equipment"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lease term</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furniture and fixtures</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210801__20220731__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MinimumMember_zvI60w7LGpc" title="Property, plant and equipment, useful life">3</span>-<span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210801__20220731__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember__srt--RangeAxis__srt--MaximumMember_zpsVzzmWTj5d" title="Property, plant and equipment, useful life">5</span></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office equipment and vehicles</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_901_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210801__20220731__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeEquipmentVehiclesMember__srt--RangeAxis__srt--MinimumMember_zggjwu4oioJ2" title="Property, plant and equipment, useful life">3</span>-<span id="xdx_90F_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210801__20220731__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--OfficeEquipmentVehiclesMember__srt--RangeAxis__srt--MaximumMember_zfbXkf9nGU4k" title="Property, plant and equipment, useful life">5</span></span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Computer software</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90A_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210801__20220731__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerSoftwareMember__srt--RangeAxis__srt--MinimumMember_zCWLDdf2pI16" title="Property, plant and equipment, useful life">3</span>-<span id="xdx_909_eus-gaap--PropertyPlantAndEquipmentUsefulLife_dtY_c20210801__20220731__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--ComputerSoftwareMember__srt--RangeAxis__srt--MaximumMember_zSD8nSUScMk8" title="Property, plant and equipment, useful life">5</span></span></td></tr> </table> Lesser of lease term or estimated useful life Lease term P3Y P5Y P3Y P5Y P3Y P5Y <p id="xdx_84D_eus-gaap--GoodwillAndIntangibleAssetsPolicyTextBlock_zrk2MB71qIE8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zGothvJa1sN">Goodwill and Long-lived Assets</span>: </b>Goodwill, which represents the excess of the purchase price over the fair value of identifiable net assets acquired, is not amortized, in accordance with Accounting Standards Codification (ASC) 350, Intangibles—Goodwill and Other. ASC 350 requires that goodwill be tested for impairment at the reporting unit level on an annual basis and between annual tests, if an event occurs or circumstances change that would more likely than not reduce the fair value of a reporting unit below its carrying value. These events or circumstances could include a significant change in the business climate, legal factors, operating performance indicators, competition, or sale or disposition of a significant portion of a reporting unit.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has the option to assess goodwill for possible impairment by performing a qualitative analysis to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount. A quantitative assessment is performed if the qualitative assessment results in a more-likely-than-not determination or if a qualitative assessment is not performed. The quantitative assessment considers whether the carrying amount of a reporting unit exceeds its fair value, in which case an impairment charge is recorded to the extent that the reporting unit’s carrying value exceeds its fair value. The Company’s goodwill was mainly generated from the acquisitions during the year ended July 31, 2019. We currently have two reporting units - Hospitality and Early Childhood Education. Given the impact of COVID-19 pandemic and the unfavorable operation results, an interim goodwill impairment assessment was performed as of January 31, 2020. Based on the assessment result, management determined that the goodwill generated from acquisitions was fully impaired as of July 31, 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_848_eus-gaap--BusinessCombinationsPolicy_z5etkvuVNfk6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86B_zROeSxa92cI1">Business Combinations</span>: </b>If an acquired set of activities and assets is capable of being operated as a business consisting of inputs and processes from the viewpoint of a market participant, the assets acquired and liabilities assumed are a business. Business combinations are accounted for using the acquisition method of accounting, which requires an acquirer to recognize the assets acquired and the liabilities assumed at the acquisition date measured at their fair values as of that date. Fair value determinations are based on discounted cash flow analyses or other valuation techniques. In determining the fair value of the assets acquired and liabilities assumed in a material acquisition, the Company may utilize appraisals from third party valuation firms to determine fair values of some or all of the assets acquired and liabilities assumed, or may complete some or all of the valuations internally. In either case, the Company takes full responsibility for the determination of the fair value of the assets acquired and liabilities assumed. The value of goodwill reflects the excess of the fair value of the consideration conveyed to the seller over the fair value of the net assets received. Acquisition-related costs that the Company incurs to affect a business combination are expensed in the periods in which the costs are incurred.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84C_ecustom--NoncontrollingInterestPolicyTextBlock_z5y8YGghz6L5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zKdoFUkTKDR8">Noncontrolling interest</span>: </b>The Company adopted ASC 810, Noncontrolling Interests in Consolidated Financial Statements—an Amendment of Accounting Research Bulletin No. 51, as of January 1, 2009. ASC 810 establishes accounting and reporting standards for ownership interests in subsidiaries held by parties other than the parent, the amount of consolidated net income attributable to the parent and to the noncontrolling interest, changes in a parent’s ownership interest and the valuation of retained noncontrolling equity investments when a subsidiary is deconsolidated. ASC 810 also establishes reporting requirements that provide sufficient disclosures that clearly identify and distinguish between the interest of the parent and the interests of the noncontrolling owner.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_84D_eus-gaap--AdvertisingCostsPolicyTextBlock_zR3yjSBoPC38" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_861_zxb7Ek576RUg">Advertising costs</span>: </b>Advertising costs are expensed as incurred. During the year ended July 31, 2022 and 2021, amount of $<span id="xdx_90F_eus-gaap--AdvertisingExpense_pp0p0_c20210801__20220731_zf0ZENoCwYv9" title="Advertising cost">10,540</span> and $<span id="xdx_902_eus-gaap--AdvertisingExpense_pp0p0_c20200801__20210731_zaps6g82gtHj" title="Advertising cost">65,406</span> advertising expenses were incurred, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> 10540 65406 <p id="xdx_842_eus-gaap--IncomeTaxPolicyTextBlock_zXW3n8qBPx07" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_860_zkCnLk9fiHJ1">Income Taxes</span>: </b>The Company accounts for income taxes using the asset and liability method in accordance with ASC 740, Accounting for Income Taxes. The asset and liability method provides that deferred tax assets and liabilities are recognized for the expected future tax consequences of temporary differences between the financial reporting and tax bases of assets and liabilities, and for operating loss and tax credit carry forwards. Deferred tax assets and liabilities are measured using the currently enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company records a valuation allowance to reduce deferred tax assets to the amount that is believed more likely than not to be realized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_90F_eus-gaap--IncomeTaxExaminationDescription_c20171201__20171222_zr3B1ia4jie6" title="Income tax examination description">On December 22, 2017, the President of the United States signed into law the Tax Reform Act. The Tax Reform Act permanently reduces the U.S. corporate income tax rate from a maximum of 35% to a flat 21% rate, effective January 1, 2018. In addition, the 2017 Tax Act also creates a new requirement that certain income (i.e., Global Intangible Low-Taxed Income (“GILTI”)) earned by controlled foreign corporations (“CFCs”) must be included in the gross income of the CFCs’ U.S. shareholder income. The tax law in PRC applies an income tax rate of 25% to all enterprises</span>. The Company’s subsidiary does not receive any preferential tax treatment from local government. The Company has been in loss position for years and zero balances of tax provisions, deferred tax assets and liabilities as of the reporting periods ended. The tax reforms have no significant impacts on the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> On December 22, 2017, the President of the United States signed into law the Tax Reform Act. The Tax Reform Act permanently reduces the U.S. corporate income tax rate from a maximum of 35% to a flat 21% rate, effective January 1, 2018. In addition, the 2017 Tax Act also creates a new requirement that certain income (i.e., Global Intangible Low-Taxed Income (“GILTI”)) earned by controlled foreign corporations (“CFCs”) must be included in the gross income of the CFCs’ U.S. shareholder income. The tax law in PRC applies an income tax rate of 25% to all enterprises <p id="xdx_840_eus-gaap--RevenueFromContractWithCustomerPolicyTextBlock_zYYRrTxh0Iii" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zBE4AWqSXLp6">Revenue Recognition</span>: </b>The Company adopted ASC Topic 606 Revenue from Contracts with Customers (“Topic 606) on August 1, 2019, applying the modified retrospective method to all contracts that were not completed as of August 1, 2019. The Company is building up its core business upon the completion of multiple acquisitions in March 2019 and impact of COVID-19 pandemic, limited operations occurred during the years ended July 31, 2022 and 2021. The revenue during the years ended July 31, 2022 and 2021 were mainly generated from HZLJ and HF Int’l Education.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue is recognized when control of promised goods or services is transferred to our customers in an amount of consideration to which we expect to be entitled to in exchange for those goods or services. We follow the five steps approach for revenue recognition under Topic 606: (i) identify the contract(s) with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations in the contract, and (v) recognize revenue when (or as) we satisfy a performance obligation. Billings to customers for which services are not rendered are considered deferred revenue. ASC 606 has no material impacts on the Company’s financial positions. The Company’s revenue is recognized when it satisfies a single performance obligation by transferring control of its products or providing services to a customer. The Company’s general payment terms are short-term in duration. The Company does not have significant financing components or payment terms.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Early childhood education services: HF Int’l Education generates revenue from childhood education classes provided to its customers. The educational services consist of parent-child and bilingual childcare classes. Each contract of educational classes is accounted for as a single performance obligation which is satisfied proportionately over the service period. Tuition fee is generally collected in advance and is initially recorded as deferred revenue and transferred to contract liabilities after trial period. Refunds are provided to parents if they decide within the trial period that they no longer want to take the class. After the trial period, if a parent withdraws from a class, usually only that unearned portion of the fee is available to be returned. For the year ended July 31, 2022 and 2021, $<span id="xdx_905_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210801__20220731__srt--ProductOrServiceAxis__custom--EarlyChildhoodEducationServicesMember_z8xqT94xUkR3" title="Revenue">509,920</span> and $<span id="xdx_902_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20200801__20210731__srt--ProductOrServiceAxis__custom--EarlyChildhoodEducationServicesMember_zAqRn4w0ejq7" title="Revenue">435,149</span>, respectively, of revenue were derived from early childhood education classes provided.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"/><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hospitality services: HZLJ generates revenue primarily from the room rentals, sale of food and beverage and other miscellaneous hospitality services. The Company recognizes room rental and services daily as services are provided. Under ASC 606, the pattern and timing of recognition of income from hotel facility is consistent with the prior accounting model.</span></td></tr></table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 509920 435149 <p id="xdx_848_eus-gaap--EarningsPerSharePolicyTextBlock_zH91YYhTsDji" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_865_zMk1LyberF9">Income (Loss) Per Share</span>: </b>Basic earnings per share include no dilution and are computed by dividing net income (or loss) by the weighted- average number of shares outstanding during the period. Diluted earnings per share reflect the potential dilution of securities that could share in the earnings of the Company, assuming the issuance of an equivalent number of common shares pursuant to options, warrants, or convertible debt arrangements. Diluted earnings per share are not shown for periods in which the Company incurs a loss because it would be anti-dilutive. Similarly, potential common stock equivalents are not included in the calculation if the effect would be anti-dilutive. No potentially dilutive debt or equity securities were issued or outstanding during the years ended July 31, 2022 or 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_845_ecustom--ReclassificationsPolicyTextBlock_zHjKJ3uHJ5gg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86C_zgkkAiB4VA4k">Reclassifications</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Certain amounts on the prior-year consolidated balance sheet, consolidated statement of operations and cash flows were reclassified to conform to current-year presentation, with no effect on ending stockholders’ equity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p id="xdx_84B_eus-gaap--NewAccountingPronouncementsPolicyPolicyTextBlock_zelwnrqv9YJ8" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_862_zdXYHYAa4Iv8">Recent Accounting Pronouncements</span>.</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Recently adopted accounting pronouncements</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes which is intended to simplify various aspects related to accounting for income taxes. The standard is effective for fiscal years, and interim periods within those years, beginning after December 15, 2020, with early adoption permitted. The adoption of ASU 2019-12 had an immaterial impact on the Company’s consolidated statement of operation and consolidated statement of cash flows for the year ended July 31, 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">Recently issued accounting pronouncements not yet adopted</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2016, the FASB issued ASU 2016-13, “Financial Instruments—Credit Losses”. The standard, including subsequently issued amendments (ASU 2018-19, ASU 2019-04, ASU 2019-05, ASU 2019-10 and ASU 2019-11), requires a financial asset measured at amortized cost basis, such as accounts receivable and certain other financial assets, to be presented at the net amount expected to be collected based on relevant information about past events, including historical experience, current conditions, and reasonable and supportable forecasts that affect the collectability of the reported amount. In November 2019, the FASB issued ASU No. 2019-10 to postpone the effective date of ASU No. 2016-13 for public business entities eligible to be smaller reporting companies defined by the SEC to fiscal years beginning after December 15, 2022, including interim periods within those fiscal years. The Company is evaluating the impact of this guidance on its consolidated financial statements.</span></p> <p id="xdx_80E_eus-gaap--SubstantialDoubtAboutGoingConcernTextBlock_z9dAmwUKeaxe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 2. <span id="xdx_82F_zQeyA8A0vrbd">GOING CONCERN</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The accompanying financial statements were prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of obligations in the normal course of business. However, Hartford Great Health Corp. has incurred losses since inception, resulting in an accumulated deficit of $<span id="xdx_903_eus-gaap--RetainedEarningsAccumulatedDeficit_iNI_pp0p0_di_c20220731_z1sZH442cXii" title="Accumulated deficit">7,400,620</span> as of July 31, 2022. These conditions raise substantial doubt about the ability of Hartford Great Health Corp. to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In view of these matters, continuation as a going concern is dependent upon several factors, including the availability of debt or equity funding upon terms and conditions acceptable to Hartford Great Health Corp., and ultimately achieving profitable operations. Management believes that Hartford Great Health Corp.’s business plan provides it with an opportunity to continue as a going concern. However, management cannot provide assurance that Hartford Great Health Corp. will meet its objectives and be able to continue in operation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of Hartford Great Health Corp. to continue as a going concern.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> -7400620 <p id="xdx_80D_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zalvMYXDiVXe" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 3. <span><span id="xdx_828_zZJCoz6texw6">STOCKHOLDERS’ EQUITY</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Preferred Stock</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is authorized to issue <span id="xdx_90F_eus-gaap--PreferredStockSharesAuthorized_iI_c20220731_zYkOgzqQhcY4" title="Preferred stock, shares authorized"><span id="xdx_902_eus-gaap--PreferredStockSharesAuthorized_iI_c20210731_zXHQzvjiWc8d" title="Preferred stock, shares authorized">5,000,000</span></span> shares of preferred stock with a par value of $<span id="xdx_908_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20220731_zdadgSOXe945" title="Preferred stock, par value"><span id="xdx_901_eus-gaap--PreferredStockParOrStatedValuePerShare_iI_c20210731_zZqWCI7SDP8d" title="Preferred stock, par value">0.001</span></span> per share. <span id="xdx_909_eus-gaap--PreferredStockSharesIssued_iI_do_c20220731_zGgR0Nj1dRMf" title="Preferred stock, shares issued"><span id="xdx_902_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20220731_zxE4s1oT2qIl" title="Preferred stock, shares outstanding"><span id="xdx_906_eus-gaap--PreferredStockSharesIssued_iI_do_c20210731_zfCx8MztC8f2" title="Preferred stock, shares issued"><span id="xdx_903_eus-gaap--PreferredStockSharesOutstanding_iI_do_c20210731_zhPgneaDH2Vi" title="Preferred stock, shares outstanding">No</span></span></span></span> shares of preferred stock have been issued or outstanding since Inception (April 2, 2008).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Common Stock</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company is authorized to issue <span id="xdx_90A_eus-gaap--CommonStockSharesAuthorized_iI_c20220731_zkGnqcHf2Mx6" title="Common stock, shares authorized"><span id="xdx_905_eus-gaap--CommonStockSharesAuthorized_iI_c20210731_zhhSb5UD8BGe" title="Common stock, shares authorized">300,000,000</span></span> shares of common stock with a par value of $<span id="xdx_90B_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20220731_z1wQCGaidwbf" title="Common stock, par value"><span id="xdx_906_eus-gaap--CommonStockParOrStatedValuePerShare_iI_c20210731_zOen5qYMbv41" title="Common stock, par value">0.001</span></span> per share. On November 24, 2020, the Company issued <span id="xdx_901_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20201123__20201124__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderMember_zcJjakR3FhVe" title="Issuance of common stock, shares">1,000,000</span> shares of common stock to a significant shareholder of the Company at $<span id="xdx_905_eus-gaap--SharePrice_iI_c20201124__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShareholderMember_z9boYoHtF6Cc" title="Share price">0.02</span> per share. The company had a total of <span id="xdx_90B_eus-gaap--CommonStockSharesIssued_iI_c20220731_z59rhgQ1Up1a" title="Common stock, shares issued"><span id="xdx_90B_eus-gaap--CommonStockSharesOutstanding_iI_c20220731_zPfEbgSknaQ6" title="Common stock, shares outstanding"><span id="xdx_907_eus-gaap--CommonStockSharesIssued_iI_c20210731_zY8IWz9cPbh3" title="Common stock, shares issued"><span id="xdx_900_eus-gaap--CommonStockSharesOutstanding_iI_c20210731_zVDcYXZoXgd6" title="Common stock, shares outstanding">100,108,000</span></span></span></span> shares of common stock issued and outstanding at both of July 31, 2022 and 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 5000000 5000000 0.001 0.001 0 0 0 0 300000000 300000000 0.001 0.001 1000000 0.02 100108000 100108000 100108000 100108000 <p id="xdx_807_eus-gaap--BusinessCombinationDisclosureTextBlock_zTqkUbodnEqk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 4. <span id="xdx_823_zLQuZhtCDJZj">ACQUISITIONS, JOINT VENTURES AND DECONSOLIDATION</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Joint Venture – HF Int’l Education</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On March 22, 2019, HFSH entered into a joint venture agreement (the “JV agreement”) with Shanghai Jingyu Education Tech Ltd. (“SH Jingyu”) and one individual investor, to form a new entity - HF Int’l Education to provide childcare education services. HFSH initially owned <span id="xdx_905_ecustom--JointVentureAcquiredOwnershipInterest_iI_pid_dp_uPure_c20190322__us-gaap--TypeOfArrangementAxis__custom--JointVentureAgreementMember_zCILi9zYClW6" title="Joint venture acquired ownership interest">65.0%</span> ownership HF Int’l Education, and reduced to <span id="xdx_908_eus-gaap--MinorityInterestOwnershipPercentageByNoncontrollingOwners_iI_pid_dp_uPure_c20200731__srt--TitleOfIndividualAxis__custom--ShareholderMember__srt--OwnershipAxis__custom--HartfordInternationalEducationTechnologyCoLtdMember_zdCfAD0qKAga" title="Noncontrolling ownership interest">61.0%</span> during the year ended on July 31, 2020 because of equity transactions between noncontrolling shareholders. On June 19, 2020, the board of HF Int’l Education decided to increase registered capital to RMB<span id="xdx_908_eus-gaap--Capital_iI_pn6n6_uRMB_c20200619__us-gaap--TypeOfArrangementAxis__custom--JointVentureAgreementMember__srt--RangeAxis__srt--MaximumMember_z0djZTCcdSo" title="Registered capital">10</span> million from RMB<span id="xdx_901_eus-gaap--Capital_iI_pn6n6_uRMB_c20200619__us-gaap--TypeOfArrangementAxis__custom--JointVentureAgreementMember__srt--RangeAxis__srt--MinimumMember_zaAMO31Lw7D9" title="Registered capital">5</span> million, and three out of four noncontrolling shareholders gave up the subscription rights. <span id="xdx_903_ecustom--NoncontrollingShareholdersDescription_c20210801__20220731_z6mnrafNBks2" title="Noncontrolling shareholders, description">As a result, HFSH held 75.5% of HF Int’l Education and a total of 24.5% equity was held by noncontrolling shareholders. Pursuant to the board meeting held on June 1, 2021, the noncontrolling shareholders sold a total 14.5% equity at zero consideration to HFSH. As a result, HFSH holds 90.0% of HF Int’l Education and $403,131 noncontrolling loss was absorbed by HFSH as a result of the ownership restructure at HF Int’l Education.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Continuous operation losses caused by the market uncertainties including pandemic and government regulations, HF Int’l Education entered agreements to sell the copyrights of seven education textbooks and ten “HaiDeFuDe” registered trademarks owned for RMB<span id="xdx_900_eus-gaap--Capital_iI_pn5n6_uRMB_c20190322__us-gaap--TypeOfArrangementAxis__custom--JointVentureAgreementMember__dei--LegalEntityAxis__custom--HartfordInternationalEducationTechnologyCoLtdMember__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--SevenEducationTextbooksMember_z7xRqq1w7zAa" title="Registered capital">1.2</span> million and RMB<span id="xdx_907_eus-gaap--Capital_iI_pn5n6_uRMB_c20190322__us-gaap--TypeOfArrangementAxis__custom--JointVentureAgreementMember__dei--LegalEntityAxis__custom--HartfordInternationalEducationTechnologyCoLtdMember__us-gaap--IndefiniteLivedIntangibleAssetsByMajorClassAxis__custom--TenHaiDeFuDeMember_znPwTMBXz5Q1" title="Registered capital">1.0</span> million, respectively, to Hartford Health Management (Shanghai) Co., Ltd (“HFHM”) in March 2021 with approval of the board of directors. The CEO of HFHM is a shareholder of the Company who owns more than <span id="xdx_901_ecustom--JointVentureAcquiredOwnershipInterest_iI_pid_dp_uPure_c20210331__us-gaap--TypeOfArrangementAxis__custom--JointVentureAgreementMember__dei--LegalEntityAxis__custom--HartfordInternationalEducationTechnologyCoLtdMember__srt--TitleOfIndividualAxis__srt--ChiefExecutiveOfficerMember_zcVg0WFvLvcd" title="Joint venture acquired ownership interest">5%</span> of the Company’s common stocks.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operation result of HF Int’l Education are included in the Company’s consolidated financial statements commencing on the formation date. The Company classifies the ownership interest held by other four parties as “Noncontrolling interest” on the consolidated balance sheet.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Acquisition of Gelinke</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On July 20, 2020, HF Int’l Education entered an agreement with two individuals to acquire the whole ownership of Gelinke, who engages at early childhood education services in Changning District, Shanghai. The results of operations of the acquired entities are included in the Company’s consolidated financial statements commencing on the acquisition date. The Company has recorded an allocation of purchase price to Gelinke’s tangible and identifiable intangible assets acquired and liabilities assumed based on their fair value at the acquisition date. The Company accounted the acquisition transaction in accordance with FASB ASC 805, Business Combinations, under acquisition accounting method. The related transaction costs were immaterial and included in General and administrative expenses in the accompanying consolidated statements of operations. The acquisition was completed on August 31, 2021. The calculation of purchase price and purchase price allocation is as follows:</span></p> <p id="xdx_891_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_ztmGnwc03PQj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_z8FzPsaL3ze4" style="display: none">SCHEDULE OF RECOGNIZED IDENTIFIED ASSETS ACQUIRED AND LIABILITIES ASSUMED</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49A_20200720__us-gaap--BusinessAcquisitionAxis__custom--ShanghaiGelinkeChildcareEducationCenterMember_zhmAwGmGGOKf" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets Acquired and</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities Assumed</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_pp0p0_maBCRIAz9eJ_zLqQcq1pnU23" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,809</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash_iI_pp0p0_maBCRIAz9eJ_zj15V0TWT0a5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted Cash</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,009</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_iI_pp0p0_maBCRIAz9eJ_zY1TvbCpKBk7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid and Other current receivables</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,696</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_iI_pp0p0_maBCRIAz9eJ_ziYFLUYw71tj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and Equipment, net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,294</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_iNI_pp0p0_di_msBCRIAz9eJ_zY4wD5ulWDK" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unearned revenue</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(78,696</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_40A_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill_iI_pp0p0_maBCRIAz9eJ_zxJiW2ffPEYf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67,712</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iTI_pp0p0_mtBCRIAz9eJ_zAjrDvMik1gc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total consideration<span id="xdx_F4A_zxx19NSKf9Y1">*</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24,824</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span id="xdx_F05_zpPLssj8Av1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span id="xdx_F1D_zR1QoqGlcxGb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFQ09HTklaRUQgSURFTlRJRklFRCBBU1NFVFMgQUNRVUlSRUQgQU5EIExJQUJJTElUSUVTIEFTU1VNRUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--PaymentsToAcquireBusinessesGross_pp0p0_c20200719__20200720__us-gaap--BusinessAcquisitionAxis__custom--ShanghaiGelinkeChildcareEducationCenterMember_zawiY2v3KH63" title="Purchase price">10,462</span> (RMB<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFQ09HTklaRUQgSURFTlRJRklFRCBBU1NFVFMgQUNRVUlSRUQgQU5EIExJQUJJTElUSUVTIEFTU1VNRUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--PaymentsToAcquireBusinessesGross_pp0p0_uRMB_c20200719__20200720__us-gaap--BusinessAcquisitionAxis__custom--ShanghaiGelinkeChildcareEducationCenterMember_zpvcnhxPRUig" title="Purchase price">70,000</span>) payable to the acquiree plus $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFQ09HTklaRUQgSURFTlRJRklFRCBBU1NFVFMgQUNRVUlSRUQgQU5EIExJQUJJTElUSUVTIEFTU1VNRUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--OtherPaymentsToAcquireBusinesses_pp0p0_c20200719__20200720__us-gaap--BusinessAcquisitionAxis__custom--ShanghaiGelinkeChildcareEducationCenterMember_zD5WEe9GoaLh" title="Cash payments to acquire business">14,362</span> (RMB<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFQ09HTklaRUQgSURFTlRJRklFRCBBU1NFVFMgQUNRVUlSRUQgQU5EIExJQUJJTElUSUVTIEFTU1VNRUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--OtherPaymentsToAcquireBusinesses_pp0p0_uRMB_c20200719__20200720__us-gaap--BusinessAcquisitionAxis__custom--ShanghaiGelinkeChildcareEducationCenterMember_z01mpgLP7Vwg" title="Cash payments to acquire business">100,000</span>) cash payment totaled $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFQ09HTklaRUQgSURFTlRJRklFRCBBU1NFVFMgQUNRVUlSRUQgQU5EIExJQUJJTElUSUVTIEFTU1VNRUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_pp0p0_c20200720__us-gaap--BusinessAcquisitionAxis__custom--ShanghaiGelinkeChildcareEducationCenterMember_zl6JsGw0bzu1" title="Total consideration">24,824</span> consideration for the acquisition.</span></td> </tr></table> <p id="xdx_8A6_z9K6GIlPA633" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill is mainly attributable to synergies expected from the acquisition of license, list of customers and teacher workforce. Due to unfavorable operation result of Gelinke during the year ended July 31, 2021, management determined that $<span id="xdx_907_eus-gaap--Goodwill_iI_pp0p0_c20210731__us-gaap--BusinessAcquisitionAxis__custom--ShanghaiGelinkeChildcareEducationCenterMember_z4xnnLktkoik" title="Goodwill">67,712</span> goodwill generated from Gelinke Acquisition was fully impaired.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Other Acquisitions</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January and February 2019, HFSH entered agreements to acquire <span id="xdx_90C_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_c20190131__us-gaap--BusinessAcquisitionAxis__custom--ShanghaiSeniorHealthConsultingLtdMember_zzGi8SWMGhhg" title="Business acquired ownership interest"><span id="xdx_901_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20190228__us-gaap--BusinessAcquisitionAxis__custom--ShanghaiSeniorHealthConsultingLtdMember_zDC6qe8JEkB8" title="Business acquired ownership interest">85</span></span> percent ownership of Shanghai Senior Health Consulting Ltd. (“SH Senior”) and <span id="xdx_90E_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20190131__us-gaap--BusinessAcquisitionAxis__custom--ShanghaiPasadenaLtdMember_zyWqjlUKIXe" title="Business acquired ownership interest"><span id="xdx_900_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20190228__us-gaap--BusinessAcquisitionAxis__custom--ShanghaiPasadenaLtdMember_z15ly8DxF1Ei" title="Business acquired ownership interest">55</span></span> percent ownership of Shanghai Pasadena Ltd. (“SH Pasadena”). On December 31, 2020, HFSH withdrew from the two acquisition agreements. No penalty results from the withdrawn.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In January 2019, HFSH entered agreements to acquire <span id="xdx_900_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20190131__us-gaap--BusinessAcquisitionAxis__custom--ShanghaiLuoShengInternationalTradeLtdMember_zlUmfTXB9eW3" title="Business acquired ownership interest">100</span> percent equity interest of Shanghai Luo Sheng International Trade Ltd. (“SH Luosheng”)  and the agreement has not yet taken effect. On August 1, 2022, HFSH decided to withdraw from the agreement. There was no penalty levied or to be levied due to delayed execution or inexecution.  </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Disposal of subsidiary</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 31, 2020, HFSH disposed its <span id="xdx_90E_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20201231__us-gaap--BusinessAcquisitionAxis__custom--HangzhouHartfordComprehensiveHealthManagementLtdMember_zKmBaBx4NXte" title="Business acquired ownership interest">90</span> percent owned subsidiary - Qiao Garden Int’l Travel to an individual (the “Disposal”). The individual is a relative of the CEO, Qiao Garden Int’l Travel became a related party after deconsolidation. The operation results, assets and liabilities, and cash flows of Qiao Garden Int’l Travel were deconsolidated from the Company’s consolidated financial statements effective on December 31, 2020. The Disposal of Qiao Garden was consummated through a three-party settlement among HFSH, SH Qiaohong and Qiao Garden Int’l Travel (the “Three-Party Settlement”): the original investment RMB <span id="xdx_901_ecustom--InvestmentFromNoncontrollingInterests_pn5n6_uRMB_c20201230__20201231__dei--LegalEntityAxis__custom--HangzhouHartfordComprehensiveHealthManagementLtdMember_zH323UT3ddsg" title="Investment from noncontrolling interest">4.5</span> million plus RMB <span id="xdx_90C_eus-gaap--InvestmentIncomeNet_pn5n6_uRMB_c20201230__20201231__dei--LegalEntityAxis__custom--HangzhouHartfordComprehensiveHealthManagementLtdMember_zsXcJT46IHb7" title="Investment income">0.5</span> million investment income were agreed to returned from Qiao Garden Int’l Travel as a result of the Disposal and settled with a payable due to SH Qiaohong at SHHF, who was a debtor of Qiao Garden Int’l Travel, see Note 14, Related Party Transactions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_890_ecustom--ScheduleOfNetAssetsLiabilitiesDisposedOfSubsidiaryTableTextBlock_zgakyexjneqj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net assets (liabilities) disposed of:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_z4DGmsh02GSa" style="display: none">SCHEDULE OF NET ASSETS (LIABILITIES) DISPOSED OF SUBSIDIARY</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td id="xdx_493_20201231__srt--ConsolidatedEntitiesAxis__custom--QiaoGardenIntelTravelMember_zHAe1BpaM6Uj" style="font: 10pt Times New Roman, Times, Serif; text-align: center">1</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net assets (liabilities) disposed of:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_iI_pp0p0" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">172</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_ecustom--DisposalGroupIncludingDiscontinuedOperationRestrictedCash_iI_pp0p0" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted cash</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29,944</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_ecustom--DisposalGroupIncludingDiscontinuedOperationRelatedPartyReceivable_iI_pp0p0" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related party receivable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">782,224</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_ecustom--DisposalGroupIncludingDiscontinuedOperationRelatedPartyPayable_iI_pp0p0_zIh097ddClPc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related party payable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(98,615</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_407_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_iNI_pp0p0_di_zS2VoBEcQcIk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other current payable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,876</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_402_ecustom--DisposalGroupIncludingDiscontinuedOperationNoncontrollingInterest_iI_pp0p0" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Noncontrolling interest</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(60,812</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_404_ecustom--DisposalGroupIncludingDiscontinuedOperationNetAssetsOfSubsidiary_iI_pp0p0_z9G2GLL3EED7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net assets of the subsidiary, excluding noncontrolling interest</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">649,037</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--DisposalGroupIncludingDiscontinuedOperationConsideration_iI_pp0p0" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consideration</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">753,354</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gain on disposal of the subsidiary</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_pp0p0_c20201229__20201231__srt--ConsolidatedEntitiesAxis__custom--QiaoGardenIntelTravelMember_zBAMTspOR7B4" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain on disposal of the subsidiary"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(104,317</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gain on disposal of noncontrolling interest</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_pp0p0_c20201229__20201231__srt--ConsolidatedEntitiesAxis__custom--QiaoGardenIntelTravelMember_zHDMpW42yAU7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain on disposal of noncontrolling interest"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(60,812</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gain on disposal of the subsidiary, excluding noncontrolling interest</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_pp0p0_c20201229__20201231__srt--ConsolidatedEntitiesAxis__custom--QiaoGardenIntelTravelMember_zvmHXo5IwRTc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain on disposal of the subsidiary, excluding noncontrolling interest"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(43,505</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> </table> <p id="xdx_8AB_z6NlbgmtiQt9" style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_895_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_z4NUJ5tyOZwc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net inflow / (outflow) of cash and cash equivalents in respect of the disposal subsidiary:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B7_zg2KLF5MGfRa" style="display: none">SCHEDULE OF NET INFLOW (OUTFLOW) OF CASH AND CASH EQUIVALENTS OF DISPOSAL SUBSIDIARY</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td id="xdx_491_20201231__srt--ConsolidatedEntitiesAxis__custom--QiaoGardenIntelTravelMember_z3Y5qyCvKBI5" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">1</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr id="xdx_406_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_iNI_pp0p0_di_maDGIDOzAgL_maDGIDOzihM_zqceLZr5BMg6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(172</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_400_ecustom--DisposalGroupIncludingDiscontinuedOperationRestrictedCash_iNI_pp0p0_di_maDGIDOzAgL_maDGIDOzihM_zycdnijhlwuk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted cash</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(29,944</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_409_ecustom--DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalentsAndRestrictedCash_iNTI_pp0p0_di_mtDGIDOzihM_zPzaTsSjjka3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents deconsolidated</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(30,116</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> </table> <p id="xdx_8A8_zK8RdgfffNc6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0.650 0.610 10000000 5000000 As a result, HFSH held 75.5% of HF Int’l Education and a total of 24.5% equity was held by noncontrolling shareholders. Pursuant to the board meeting held on June 1, 2021, the noncontrolling shareholders sold a total 14.5% equity at zero consideration to HFSH. As a result, HFSH holds 90.0% of HF Int’l Education and $403,131 noncontrolling loss was absorbed by HFSH as a result of the ownership restructure at HF Int’l Education. 1200000 1000000.0 0.05 <p id="xdx_891_eus-gaap--ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock_ztmGnwc03PQj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B6_z8FzPsaL3ze4" style="display: none">SCHEDULE OF RECOGNIZED IDENTIFIED ASSETS ACQUIRED AND LIABILITIES ASSUMED</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_49A_20200720__us-gaap--BusinessAcquisitionAxis__custom--ShanghaiGelinkeChildcareEducationCenterMember_zhmAwGmGGOKf" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets Acquired and</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Liabilities Assumed</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40F_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_iI_pp0p0_maBCRIAz9eJ_zLqQcq1pnU23" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 76%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,809</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash_iI_pp0p0_maBCRIAz9eJ_zj15V0TWT0a5" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted Cash</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">25,009</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_iI_pp0p0_maBCRIAz9eJ_zY1TvbCpKBk7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid and Other current receivables</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,696</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_iI_pp0p0_maBCRIAz9eJ_ziYFLUYw71tj" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property and Equipment, net</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,294</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue_iNI_pp0p0_di_msBCRIAz9eJ_zY4wD5ulWDK" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Unearned revenue</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(78,696</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_40A_ecustom--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill_iI_pp0p0_maBCRIAz9eJ_zxJiW2ffPEYf" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Goodwill</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">67,712</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_400_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iTI_pp0p0_mtBCRIAz9eJ_zAjrDvMik1gc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total consideration<span id="xdx_F4A_zxx19NSKf9Y1">*</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">24,824</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 2.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right"><span id="xdx_F05_zpPLssj8Av1" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</span></td><td style="text-align: justify"><span id="xdx_F1D_zR1QoqGlcxGb" style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFQ09HTklaRUQgSURFTlRJRklFRCBBU1NFVFMgQUNRVUlSRUQgQU5EIExJQUJJTElUSUVTIEFTU1VNRUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90F_eus-gaap--PaymentsToAcquireBusinessesGross_pp0p0_c20200719__20200720__us-gaap--BusinessAcquisitionAxis__custom--ShanghaiGelinkeChildcareEducationCenterMember_zawiY2v3KH63" title="Purchase price">10,462</span> (RMB<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFQ09HTklaRUQgSURFTlRJRklFRCBBU1NFVFMgQUNRVUlSRUQgQU5EIExJQUJJTElUSUVTIEFTU1VNRUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_901_eus-gaap--PaymentsToAcquireBusinessesGross_pp0p0_uRMB_c20200719__20200720__us-gaap--BusinessAcquisitionAxis__custom--ShanghaiGelinkeChildcareEducationCenterMember_zpvcnhxPRUig" title="Purchase price">70,000</span>) payable to the acquiree plus $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFQ09HTklaRUQgSURFTlRJRklFRCBBU1NFVFMgQUNRVUlSRUQgQU5EIExJQUJJTElUSUVTIEFTU1VNRUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90E_eus-gaap--OtherPaymentsToAcquireBusinesses_pp0p0_c20200719__20200720__us-gaap--BusinessAcquisitionAxis__custom--ShanghaiGelinkeChildcareEducationCenterMember_zD5WEe9GoaLh" title="Cash payments to acquire business">14,362</span> (RMB<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFQ09HTklaRUQgSURFTlRJRklFRCBBU1NFVFMgQUNRVUlSRUQgQU5EIExJQUJJTElUSUVTIEFTU1VNRUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_906_eus-gaap--OtherPaymentsToAcquireBusinesses_pp0p0_uRMB_c20200719__20200720__us-gaap--BusinessAcquisitionAxis__custom--ShanghaiGelinkeChildcareEducationCenterMember_z01mpgLP7Vwg" title="Cash payments to acquire business">100,000</span>) cash payment totaled $<span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFQ09HTklaRUQgSURFTlRJRklFRCBBU1NFVFMgQUNRVUlSRUQgQU5EIExJQUJJTElUSUVTIEFTU1VNRUQgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90B_eus-gaap--BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_iI_pp0p0_c20200720__us-gaap--BusinessAcquisitionAxis__custom--ShanghaiGelinkeChildcareEducationCenterMember_zl6JsGw0bzu1" title="Total consideration">24,824</span> consideration for the acquisition.</span></td> </tr></table> 1809 25009 4696 4294 78696 67712 24824 10462 70000 14362 100000 24824 67712 0.85 0.85 0.55 0.55 1 0.90 4500000 500000 <p id="xdx_890_ecustom--ScheduleOfNetAssetsLiabilitiesDisposedOfSubsidiaryTableTextBlock_zgakyexjneqj" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net assets (liabilities) disposed of:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B0_z4DGmsh02GSa" style="display: none">SCHEDULE OF NET ASSETS (LIABILITIES) DISPOSED OF SUBSIDIARY</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td id="xdx_493_20201231__srt--ConsolidatedEntitiesAxis__custom--QiaoGardenIntelTravelMember_zHAe1BpaM6Uj" style="font: 10pt Times New Roman, Times, Serif; text-align: center">1</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net assets (liabilities) disposed of:</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40D_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_iI_pp0p0" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">172</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_ecustom--DisposalGroupIncludingDiscontinuedOperationRestrictedCash_iI_pp0p0" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted cash</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">29,944</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40E_ecustom--DisposalGroupIncludingDiscontinuedOperationRelatedPartyReceivable_iI_pp0p0" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related party receivable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">782,224</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_ecustom--DisposalGroupIncludingDiscontinuedOperationRelatedPartyPayable_iI_pp0p0_zIh097ddClPc" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Related party payable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(98,615</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_407_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_iNI_pp0p0_di_zS2VoBEcQcIk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other current payable</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,876</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_402_ecustom--DisposalGroupIncludingDiscontinuedOperationNoncontrollingInterest_iI_pp0p0" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Noncontrolling interest</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(60,812</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_404_ecustom--DisposalGroupIncludingDiscontinuedOperationNetAssetsOfSubsidiary_iI_pp0p0_z9G2GLL3EED7" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net assets of the subsidiary, excluding noncontrolling interest</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">649,037</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_401_eus-gaap--DisposalGroupIncludingDiscontinuedOperationConsideration_iI_pp0p0" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Consideration</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">753,354</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gain on disposal of the subsidiary</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax_pp0p0_c20201229__20201231__srt--ConsolidatedEntitiesAxis__custom--QiaoGardenIntelTravelMember_zBAMTspOR7B4" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain on disposal of the subsidiary"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(104,317</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gain on disposal of noncontrolling interest</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation_pp0p0_c20201229__20201231__srt--ConsolidatedEntitiesAxis__custom--QiaoGardenIntelTravelMember_zHDMpW42yAU7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain on disposal of noncontrolling interest"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(60,812</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gain on disposal of the subsidiary, excluding noncontrolling interest</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98A_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_pp0p0_c20201229__20201231__srt--ConsolidatedEntitiesAxis__custom--QiaoGardenIntelTravelMember_zvmHXo5IwRTc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Gain on disposal of the subsidiary, excluding noncontrolling interest"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(43,505</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> </table> 172 29944 782224 -98615 3876 -60812 649037 753354 -104317 -60812 -43505 <p id="xdx_895_eus-gaap--ScheduleOfCashAndCashEquivalentsTableTextBlock_z4NUJ5tyOZwc" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net inflow / (outflow) of cash and cash equivalents in respect of the disposal subsidiary:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B7_zg2KLF5MGfRa" style="display: none">SCHEDULE OF NET INFLOW (OUTFLOW) OF CASH AND CASH EQUIVALENTS OF DISPOSAL SUBSIDIARY</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 93%; margin-left: 0.5in"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td id="xdx_491_20201231__srt--ConsolidatedEntitiesAxis__custom--QiaoGardenIntelTravelMember_z3Y5qyCvKBI5" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">1</td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"> </td></tr> <tr id="xdx_406_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_iNI_pp0p0_di_maDGIDOzAgL_maDGIDOzihM_zqceLZr5BMg6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 80%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 16%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(172</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_400_ecustom--DisposalGroupIncludingDiscontinuedOperationRestrictedCash_iNI_pp0p0_di_maDGIDOzAgL_maDGIDOzihM_zycdnijhlwuk" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted cash</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(29,944</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_409_ecustom--DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalentsAndRestrictedCash_iNTI_pp0p0_di_mtDGIDOzihM_zPzaTsSjjka3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash and cash equivalents deconsolidated</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(30,116</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> </table> 172 29944 30116 <p id="xdx_80A_eus-gaap--DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock_zvKhr6LMl7dj" style="font: 9pt/9.9pt Times New Roman, Times, Serif; margin: 0"><b>NOTE 5. <span id="xdx_821_zpdWCssDSSe">DISCONTINUED OPERATION</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Impacted by the government regulation newly implemented in education industry and the restrictions posted by the Chinese government to control the pandemic in China since 2021, the Company’s business hasn’t been developed as planned and occurred significant loss from the early child education practice. To avoid further operation losses, subsequently on August 1, 2022, HFSH entered a contract with a related party, Shanghai Oversea Chinese Culture Media Ltd. (“SH Oversea”), to sell <span id="xdx_904_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_c20220801__us-gaap--BusinessAcquisitionAxis__custom--HangzhouLongjingQiaoFuVacationHotelCoLtdMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z8DMAnEuvLTc" title="Business acquisition, percentage of voting interests acquired">90</span> percent ownership of HF Int’l Education and its subsidiaries for $<span id="xdx_902_eus-gaap--RelatedPartyTransactionDueFromToRelatedParty_iI_c20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShanghaiOverseaMember__us-gaap--BusinessAcquisitionAxis__custom--HartfordInternationalEducationTechnologyCoLtdMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zPkDelNQl9l8" title="Related party">900</span> (RMB <span id="xdx_900_eus-gaap--RelatedPartyTransactionDueFromToRelatedParty_iI_uRMB_c20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShanghaiOverseaMember__us-gaap--BusinessAcquisitionAxis__custom--HartfordInternationalEducationTechnologyCoLtdMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_ztBvy4BguBP2" title="Related party">5,850</span>). On August 1, 2022, HFUS entered a contract with SH Oversea and another individual, to sell <span id="xdx_901_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_uPure_c20220801__us-gaap--BusinessAcquisitionAxis__custom--HangzhouHartfordComprehensiveHealthManagementLtdMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z9AGAYg9ui2l" title="Business acquired ownership interest">100</span> percent ownership of HZHF and its subsidiaries for $<span id="xdx_904_eus-gaap--RelatedPartyTransactionDueFromToRelatedParty_iI_c20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShanghaiOverseaMember__us-gaap--BusinessAcquisitionAxis__custom--HangzhouHartfordComprehensiveHealthManagementLtdMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zrgd9lFd8Gm7" title="Related party">1,000</span> (RMB <span id="xdx_907_eus-gaap--RelatedPartyTransactionDueFromToRelatedParty_iI_uRMB_c20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShanghaiOverseaMember__us-gaap--BusinessAcquisitionAxis__custom--HangzhouHartfordComprehensiveHealthManagementLtdMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zXZOzsaxVV6a" title="Related party">6,500</span>).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of July 31, 2022, the assets and liabilities grouped under Education and Hospitality segments classified as assets and/or liabilities held for sale, and it is the Company’s intention to complete the sales of these assets within the upcoming year. The transactions meet the criteria to be reported as a discontinued operation as they constitute significant strategic business shifts for the Company. We have reported, for all periods presented, the financial condition, results of operations, and cash flows of the operation segments as discontinued operations in the accompanying consolidated financial statements.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_zioZMzgmbOK9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">The total assets and liabilities of Education and hospitality segments that are classified as held for sale on the Company</span><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">’</span><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">s consolidated balance sheet as of July 31, 2022, are as follows:</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <br/> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zHSPKyI0nYS7">SCHEDULE OF DISCONTINUED OPERATIONS OF FINANCIAL STATEMENTS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-style: italic; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_499_20220731__us-gaap--StatementBusinessSegmentsAxis__custom--EducationAndHospitalitySegmentsMember__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_zrJbPfP6uQ5f" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">July 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_49A_20210731__us-gaap--StatementBusinessSegmentsAxis__custom--EducationAndHospitalitySegmentsMember__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_zUrnntWsmcp5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">July 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_iB_zUWghte845gb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Current Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_iI_zImwPwDzpZF8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 62%; text-align: left">Cash and cash equivalents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">4,938</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">14,873</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_iI_zIQFX7OF50td" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Prepaid and Other current receivables</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">45,532</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">311,594</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_iI_zUNUK6X280J4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Related party receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">428,519</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">325,555</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_iI_zNYfoTpfi1Fb" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Inventory</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">305,124</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">323,815</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_iI_zw9dFdapergf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Property and equipment, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">582,707</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">585,160</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--DisposalGroupIncludingDiscontinuedOperationRightOfUseAssetsOperatingLease_iI_zrlD4O0uQbBe" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">ROU assets-operating lease</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,836,698</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,837,187</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_iI_zgEUHSPhjDe9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Other assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">296,218</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">321,806</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperation_iTI_z6LvZqsJj9Gb" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Assets held for sale</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,499,736</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,719,990</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_iB_zwNY7NfXXmk7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Current Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--DisposalGroupIncludingDiscontinuedOperationRelatedPartyLoanAndPayablesCurrent_iI_zqUtIDthqF81" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Related party loan and payables</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,321,549</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,332,338</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--DisposalGroupIncludingDiscontinuedOperationContractLiiabilitiesCurrent_iI_zZNvmm3SPrN1" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Contract liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">547,906</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">545,346</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--DisposalGroupIncludingDiscontinuedOperationLeaseLiabilities_iI_zLiMXrrZv7M6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Lease liabilities, current and noncurrent</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,715,688</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,071,767</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_iI_zZkUVPl9zwJf" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Other current payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">401,782</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">553,841</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_iI_z18m5d6Gmsz4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Other liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">357,796</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">368,715</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_iTI_z2ile2E0Mqz8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total Liabilities held for sale</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,344,721</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,872,007</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the years ended July 31, 2022 and 2021, results of operations from HF Intel Education and its subsidiaries, and HZHF and its subsidiary were as follows:</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-style: italic">For the years ended July 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20210801__20220731__srt--ConsolidatedEntitiesAxis__custom--HartfordInternationalEducationTechnologyCoLtdMember__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_zFU9v7T4llol" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">2022</p> <p style="margin-top: 0; margin-bottom: 0">(restated)</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20200801__20210731__srt--ConsolidatedEntitiesAxis__custom--HartfordInternationalEducationTechnologyCoLtdMember__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_zjsOhHqzOoo2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">2021</p> <p style="margin-top: 0; margin-bottom: 0">(restated)</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_406_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_zMYbe5SUfyGg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 62%; text-align: left">Net sales</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">561,262</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">553,459</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_zzNRn41Jjpqc" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Cost of sales</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">677,093</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">722,838</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_iT_z8ik652VLRJ3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">Gross profit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(115,831</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(169,379</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_zBxMM1gKxpX2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Selling, general, and administrative expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,579,922</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,520,817</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--DisposalGroupIncludingDiscontinuedOperationImpairmentExpense_z8kk8LAog1xb" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Impairment</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0785">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">70,514</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOperatingExpense_iT_ziRd5wV7p4Oc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,579,922</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,591,331</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_zeQOuhmoGM6h" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Loss from operations of discontinued operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,695,753</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,760,710</td><td style="text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--InterestIncomeExpenseNet_i01_zr72kzSDUWj6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 30pt; text-align: left">Interest expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(54,730</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(45,692</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--NonoperatingIncomeExpense_i01_zSaL9LgJZGDi" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 30pt; text-align: left">Other Income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">168,331</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">45,791</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_iT_zyD6e4HFVUPl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Loss from discontinued operations before income taxes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,582,152</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,760,611</td><td style="text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod_zDdicAmhqjlb" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0pt; text-align: left; padding-bottom: 1.5pt">Income tax benefit (expense)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0803">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0804">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_iT_zwnLuNbeZz46" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Income (loss) from discontinued operations, net of taxes before gain from sale of discontinued operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,582,152</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,760,611</td><td style="text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_zTnXpbEbPFX6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Loss from sale of discontinued operations, net of taxes</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0809">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0810">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_iT_zaRZQc6lGFzi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Income from discontinued operations, net of taxes</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,582,152</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,760,611</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the years ended July 31, 2022 and 2021, net cash used in discontinued operations - HF Intel Education and its subsidiaries, and HZHF and its subsidiary were as follows:</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"/> <td id="xdx_49F_20210801__20220731__srt--ConsolidatedEntitiesAxis__custom--HartfordInternationalEducationTechnologyCoLtdMember__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_zaVBYp8chAqf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td id="xdx_49A_20200801__20210731__srt--ConsolidatedEntitiesAxis__custom--HartfordInternationalEducationTechnologyCoLtdMember__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_zYEUqINK7z91" style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years ended July 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInDiscontinuedOperationsAbstract_iB_zNr5GfzvEDbj" style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-weight: bold">Cash flow of discontinued operations:</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"> </td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"> </td></tr> <tr id="xdx_40C_eus-gaap--CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_ztAWZZspETc1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 62%; text-align: left">Operating cash flows</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">(656,663</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">(2,455,829</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_zomXoHeZt0y9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Investing cash flows</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(145,048</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(155,566</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInDiscontinuedOperations_iT_z8hlYkOJNQak" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Net cash used in discontinued operations</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(801,711</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,611,395</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 0.90 900 5850 1 1000 6500 <p id="xdx_893_eus-gaap--ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_zioZMzgmbOK9" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">The total assets and liabilities of Education and hospitality segments that are classified as held for sale on the Company</span><span style="font-family: Arial, Helvetica, Sans-Serif; font-size: 9pt">’</span><span style="font-family: Times New Roman, Times, Serif; font-size: 9pt">s consolidated balance sheet as of July 31, 2022, are as follows:</span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <br/> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="display: none; font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8B4_zHSPKyI0nYS7">SCHEDULE OF DISCONTINUED OPERATIONS OF FINANCIAL STATEMENTS</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="font-style: italic; text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_499_20220731__us-gaap--StatementBusinessSegmentsAxis__custom--EducationAndHospitalitySegmentsMember__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_zrJbPfP6uQ5f" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">July 31, 2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td> <td id="xdx_49A_20210731__us-gaap--StatementBusinessSegmentsAxis__custom--EducationAndHospitalitySegmentsMember__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_zUrnntWsmcp5" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">July 31, 2021</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_iB_zUWghte845gb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Current Assets</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_iI_zImwPwDzpZF8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 62%; text-align: left">Cash and cash equivalents</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">4,938</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">14,873</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent_iI_zIQFX7OF50td" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Prepaid and Other current receivables</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">45,532</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">311,594</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_iI_zUNUK6X280J4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Related party receivable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">428,519</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">325,555</td><td style="text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_iI_zNYfoTpfi1Fb" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt">Inventory</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">305,124</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">323,815</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent_iI_zw9dFdapergf" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Property and equipment, net</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">582,707</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">585,160</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_ecustom--DisposalGroupIncludingDiscontinuedOperationRightOfUseAssetsOperatingLease_iI_zrlD4O0uQbBe" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">ROU assets-operating lease</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,836,698</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,837,187</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_iI_zgEUHSPhjDe9" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Other assets</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">296,218</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">321,806</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--AssetsOfDisposalGroupIncludingDiscontinuedOperation_iTI_z6LvZqsJj9Gb" style="vertical-align: bottom; background-color: White"> <td style="font-weight: bold; text-align: left; padding-bottom: 1.5pt">Total Assets held for sale</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">4,499,736</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">5,719,990</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract_iB_zwNY7NfXXmk7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Current Liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--DisposalGroupIncludingDiscontinuedOperationRelatedPartyLoanAndPayablesCurrent_iI_zqUtIDthqF81" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Related party loan and payables</td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,321,549</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td style="text-align: right">1,332,338</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_ecustom--DisposalGroupIncludingDiscontinuedOperationContractLiiabilitiesCurrent_iI_zZNvmm3SPrN1" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Contract liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">547,906</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">545,346</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_ecustom--DisposalGroupIncludingDiscontinuedOperationLeaseLiabilities_iI_zLiMXrrZv7M6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Lease liabilities, current and noncurrent</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,715,688</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,071,767</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_iI_zZkUVPl9zwJf" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Other current payable</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">401,782</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">553,841</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_iI_z18m5d6Gmsz4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Other liabilities</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">357,796</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">368,715</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent_iTI_z2ile2E0Mqz8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Total Liabilities held for sale</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,344,721</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">6,872,007</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"/><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the years ended July 31, 2022 and 2021, results of operations from HF Intel Education and its subsidiaries, and HZHF and its subsidiary were as follows:</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-style: italic">For the years ended July 31,</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49C_20210801__20220731__srt--ConsolidatedEntitiesAxis__custom--HartfordInternationalEducationTechnologyCoLtdMember__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_zFU9v7T4llol" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">2022</p> <p style="margin-top: 0; margin-bottom: 0">(restated)</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" id="xdx_49A_20200801__20210731__srt--ConsolidatedEntitiesAxis__custom--HartfordInternationalEducationTechnologyCoLtdMember__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_zjsOhHqzOoo2" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"><p style="margin-top: 0; margin-bottom: 0">2021</p> <p style="margin-top: 0; margin-bottom: 0">(restated)</p></td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_406_eus-gaap--DisposalGroupIncludingDiscontinuedOperationRevenue_zMYbe5SUfyGg" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 62%; text-align: left">Net sales</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">561,262</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">553,459</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold_zzNRn41Jjpqc" style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1.5pt">Cost of sales</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">677,093</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">722,838</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss_iT_z8ik652VLRJ3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left">Gross profit</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(115,831</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(169,379</td><td style="text-align: left">)</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating expenses:</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense_zBxMM1gKxpX2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Selling, general, and administrative expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,579,922</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,520,817</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--DisposalGroupIncludingDiscontinuedOperationImpairmentExpense_z8kk8LAog1xb" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; padding-bottom: 1.5pt">Impairment</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0785">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">70,514</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DisposalGroupIncludingDiscontinuedOperationOperatingExpense_iT_ziRd5wV7p4Oc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Total operating expenses</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">1,579,922</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">2,591,331</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax_zeQOuhmoGM6h" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left">Loss from operations of discontinued operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,695,753</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,760,710</td><td style="text-align: left">)</td></tr> <tr id="xdx_400_eus-gaap--InterestIncomeExpenseNet_i01_zr72kzSDUWj6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 30pt; text-align: left">Interest expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(54,730</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(45,692</td><td style="text-align: left">)</td></tr> <tr id="xdx_409_eus-gaap--NonoperatingIncomeExpense_i01_zSaL9LgJZGDi" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 30pt; text-align: left">Other Income</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">168,331</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">45,791</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_iT_zyD6e4HFVUPl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Loss from discontinued operations before income taxes</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,582,152</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,760,611</td><td style="text-align: left">)</td></tr> <tr id="xdx_40C_eus-gaap--DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod_zDdicAmhqjlb" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 0pt; text-align: left; padding-bottom: 1.5pt">Income tax benefit (expense)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0803">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0804">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_iT_zwnLuNbeZz46" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; text-align: left">Income (loss) from discontinued operations, net of taxes before gain from sale of discontinued operations</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,582,152</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,760,611</td><td style="text-align: left">)</td></tr> <tr id="xdx_40A_eus-gaap--DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax_zTnXpbEbPFX6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt">Loss from sale of discontinued operations, net of taxes</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0809">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right"><span style="-sec-ix-hidden: xdx2ixbrl0810">-</span></td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr id="xdx_40F_eus-gaap--IncomeLossFromDiscontinuedOperationsNetOfTax_iT_zaRZQc6lGFzi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1.5pt">Income from discontinued operations, net of taxes</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(1,582,152</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,760,611</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the years ended July 31, 2022 and 2021, net cash used in discontinued operations - HF Intel Education and its subsidiaries, and HZHF and its subsidiary were as follows:</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"/> <td id="xdx_49F_20210801__20220731__srt--ConsolidatedEntitiesAxis__custom--HartfordInternationalEducationTechnologyCoLtdMember__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_zaVBYp8chAqf" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td> <td style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center"> </td><td id="xdx_49A_20200801__20210731__srt--ConsolidatedEntitiesAxis__custom--HartfordInternationalEducationTechnologyCoLtdMember__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_zYEUqINK7z91" style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt"> </td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td> <td colspan="6" style="border-bottom: Black 1.5pt solid; font-weight: bold; text-align: center">Years ended July 31,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr id="xdx_404_eus-gaap--NetCashProvidedByUsedInDiscontinuedOperationsAbstract_iB_zNr5GfzvEDbj" style="vertical-align: bottom"> <td style="padding-bottom: 1.5pt; font-weight: bold">Cash flow of discontinued operations:</td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic; text-align: center">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"> </td><td style="font-weight: bold; font-style: italic; padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font-weight: bold; font-style: italic; text-align: center">2021</td><td style="padding-bottom: 1.5pt; font-weight: bold; font-style: italic"> </td></tr> <tr id="xdx_40C_eus-gaap--CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations_ztAWZZspETc1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 10pt; width: 62%; text-align: left">Operating cash flows</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">(656,663</td><td style="width: 1%; text-align: left">)</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 15%; text-align: right">(2,455,829</td><td style="width: 1%; text-align: left">)</td></tr> <tr id="xdx_40E_eus-gaap--CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations_zomXoHeZt0y9" style="vertical-align: bottom; background-color: White"> <td style="padding-left: 10pt; text-align: left; padding-bottom: 1.5pt">Investing cash flows</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(145,048</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">(155,566</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> <tr id="xdx_403_eus-gaap--NetCashProvidedByUsedInDiscontinuedOperations_iT_z8hlYkOJNQak" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-left: 20pt; text-align: left; padding-bottom: 1.5pt">Net cash used in discontinued operations</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(801,711</td><td style="padding-bottom: 1.5pt; text-align: left">)</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left">$</td><td style="border-bottom: Black 1.5pt solid; text-align: right">(2,611,395</td><td style="padding-bottom: 1.5pt; text-align: left">)</td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 4938 14873 45532 311594 428519 325555 305124 323815 582707 585160 2836698 3837187 296218 321806 4499736 5719990 1321549 1332338 547906 545346 3715688 4071767 401782 553841 357796 368715 6344721 6872007 561262 553459 677093 722838 -115831 -169379 1579922 2520817 70514 1579922 2591331 -1695753 -2760710 -54730 -45692 168331 45791 -1582152 -2760611 -1582152 -2760611 -1582152 -2760611 -656663 -2455829 -145048 -155566 -801711 -2611395 <p id="xdx_80B_eus-gaap--RelatedPartyTransactionsDisclosureTextBlock_zrmASaSgm0ub" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 6. <span id="xdx_82C_z05OHI9s6jBj">RELATED PARTY TRANSACTIONS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Related Party Receivables</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of July 31, 2022, $ <span id="xdx_901_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_iI_pp0p0_c20220731_zYg8JIbnutN1" title="Related party receivable">428,519</span> and $<span id="xdx_909_eus-gaap--DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_iI_pp0p0_c20210731_zPUmPxAd8RLg" title="Related party receivable">325,555</span> related party receivables were allocated to current assets held for sales, see Note 5, under “Assets and liabilities held for sale”.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Related Party Payables</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of July 31, 2022 and 2021, amounts of $<span id="xdx_904_eus-gaap--AccountsPayableRelatedPartiesCurrentAndNoncurrent_iI_pp0p0_c20220731__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SHQiahongMember_zDyAGI3u3As4">620,876 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_905_eus-gaap--AccountsPayableRelatedPartiesCurrentAndNoncurrent_iI_pp0p0_c20210731__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SHQiahongMember_zenda5v3egKi">616,159</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">, are payable to SH Qiaohong, respectively. The balances were mainly funding support from SH Qiaohong for operation. The funding support bears no interest and due on demand.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">HFSH had payable balances to Shanghai Oversea Chinese Culture Media Ltd. (“SH Oversea”), an entity managed by the same management team, in the amounts of $<span id="xdx_90B_eus-gaap--AccountsPayableRelatedPartiesCurrentAndNoncurrent_iI_c20220731__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShanghaiOverseaChineseCultureMediaLtdMember_z7Q9T7LY6WMg" title="Accounts payable, related parties">3,531,064</span> and $<span id="xdx_905_eus-gaap--AccountsPayableRelatedPartiesCurrentAndNoncurrent_iI_c20210731__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShanghaiOverseaChineseCultureMediaLtdMember_z9bRrQRT6UJ8" title="Accounts payable, related parties">2,926,782</span> as of July 31, 2022 and 2021, respectively. The payable is funding support from SH Oversea for operation, bears no interest and due on demand.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of July 31, 2022 and 2021, amount of $<span id="xdx_90F_eus-gaap--ShortTermBorrowings_iI_c20220731__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HartfordHotelInvestmentIncMember_ziCqIo7Zfw2j" title="Short term debt">290,000</span> and $<span id="xdx_90F_eus-gaap--ShortTermBorrowings_iI_c20210731__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HartfordHotelInvestmentIncMember_zf1oMJgQSlm1" title="Short term debt">145,000</span>, respectively, borrowed in form of a short-term loan at <span id="xdx_903_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_pid_dp_c20220731__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HartfordHotelInvestmentIncMember_zGoLFFoiYluj" title="Debt instrument, interest rate, stated percentage">5</span>% per annum from a related party, Hartford Hotel Investment Inc., an entity managed by the same management team. $<span id="xdx_90F_eus-gaap--InterestExpenseRelatedParty_c20210801__20220731__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HartfordHotelInvestmentIncMember_zYJUQ5JTx7Zg" title="Interest expense, related party">11,857</span> and $<span id="xdx_90C_eus-gaap--InterestExpenseRelatedParty_c20200801__20210731__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HartfordHotelInvestmentIncMember_z4akWs4bcESe" title="Interest expense, related party">3,856</span> of interest expenses were recorded during the year ended July 31, 2022 and 2021, respectively. The unpaid principal and interest will be due on demand.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The remaining related party payable of $<span id="xdx_908_eus-gaap--AccountsPayableRelatedPartiesCurrentAndNoncurrent_iI_pp0p0_c20220731_zyTgVwz6PMUi">39,583</span> and $<span id="xdx_90D_eus-gaap--AccountsPayableRelatedPartiesCurrentAndNoncurrent_iI_pp0p0_c20210731_zyWSsGBRK7o2">80,477</span> as of July 31, 2022 and 2021, respectively, represents the unpaid portion of operating advances made to the Company by affiliates which are managed by the same management team. These advances do not bear interest and are considered due on demand.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">As of July 31, 2022, $<span id="xdx_90C_ecustom--DisposalGroupIncludingDiscontinuedOperationRelatedPartyLoanAndPayablesCurrent_iI_c20220731_zIW5zgn2nk6k" title="Related party loan and payables">1,317,690</span></span> <span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_907_ecustom--DisposalGroupIncludingDiscontinuedOperationRelatedPartyLoanAndPayablesCurrent_iI_pp0p0_c20210731_zqmkFgwbIj8i" title="Related party loan and payables">1,332,338</span> related party payables were allocated to current liabilities held for sales, see Note 5, under “Assets and liabilities held for sale”.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i><span style="text-decoration: underline">Other Related Party Transactions</span></i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Office space at Rosemead, CA is provided to Hartford Great Health Corp. at no cost by the sole executive officer. No provision for these costs has been included in these financial statements as the amounts are not material.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 428519 325555 620876 616159 3531064 2926782 290000 145000 0.05 11857 3856 39583 80477 1317690 1332338 <p id="xdx_801_eus-gaap--CommitmentsAndContingenciesDisclosureTextBlock_zreDcaGwCLhk" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 7. <span id="xdx_82D_zEPQMBh3pcle">COMMITMENTS AND CONTINGENCIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">There has been below material contractual obligations and other commitments except the lease commitments disclosed in Note 12 Leases.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i><span style="text-decoration: underline">License agreements</span></i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In June 2021, HF Int’l Education and its three subsidiaries: PDHJ, HDFD and Gelinke entered license agreements with HFHM for the rights to use the intellectual Properties (the “IPs”) HFHM owns. The IPs cover in the license agreements are four set of curriculum structure designed and fifteen trademarks including “HaiDeFuDe” registered trademarks purchased from HF Int’l Education. <span id="xdx_904_ecustom--LicenseDescription_c20210801__20220731__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--IntellectualPropertiesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HartfordInternationalEducationTechnologyCoLtdMember_z1gAIQB9CCX9" title="Licencse description">As a return, on a monthly basis, HF Int’l Education and its subsidiaries pays 90% of its tuition revenue generated to HFHM as license usage fee. Due to impacts from the pandemic and new regulations issued by Chinese government in education industry, HF Int’l Education occurred significant loss from operation</span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">. On July 2022, both parties mutually agreed to amend the fee to <span id="xdx_906_ecustom--AmendFeePercentage_iI_pid_dp_c20220731__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--IntellectualPropertiesMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HartfordInternationalEducationTechnologyCoLtdMember_ztZ5apAkf54a" title="Amed fee percentage">20</span>%, the amended rate is retrospectively applicable since June 1, 2021 and recaptured in 2022. As a result, the Company incurred $<span id="xdx_904_eus-gaap--ProceedsFromLicenseFeesReceived_pp0p0_c20210801__20220731__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HartfordInternationalEducationTechnologyCoLtdMember__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zh8HkmxYDL62" title="Incrrued license fees">6,664 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and $<span id="xdx_909_eus-gaap--ProceedsFromLicenseFeesReceived_pp0p0_c20200801__20210731__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--HartfordInternationalEducationTechnologyCoLtdMember__srt--ProductOrServiceAxis__us-gaap--LicenseMember_zQiu8STuMnEl" title="Incrrued license fees">161,783 </span></span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">license fees to HFHM for the year ended July 31, 2022 and 2021 reported under discontinued operation, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> As a return, on a monthly basis, HF Int’l Education and its subsidiaries pays 90% of its tuition revenue generated to HFHM as license usage fee. Due to impacts from the pandemic and new regulations issued by Chinese government in education industry, HF Int’l Education occurred significant loss from operation 0.20 6664 161783 <p id="xdx_80E_eus-gaap--IncomeTaxDisclosureTextBlock_ziK57fUddGR5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 8. <span id="xdx_820_zEo1Tk1iFEu6">INCOME TAXES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We recorded income tax expense of $<span id="xdx_901_eus-gaap--IncomeTaxExpenseBenefit_pp0p0_c20210801__20220731_z9LaOzC4LQM4" title="Income tax expense"><span id="xdx_90D_eus-gaap--IncomeTaxExpenseBenefit_pp0p0_c20200801__20210731_z8roDQLLnVkk" title="Income tax expense">800</span></span> for both of the years ended July 31, 2022 and 2021, due to the loss position for the years since inception.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_89A_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zuFFxkvYUyee" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hartford Great Health Corp.’s deferred tax assets, valuation allowance, and change in valuation allowance are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B8_zmVnDSp6Qenb" style="display: none">SCHEDULE OF INCOME TAX VALUATION</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated tax</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net NOL</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">benefit from NOL</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">carry-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOL</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and other tax</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">valuation</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">deferred</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Period Ending</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">forward</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expires</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">benefits (21%)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">tax asset</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 16%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31-Jul-21</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_c20210731_zzbjGGVie846" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Net NOL carry-forward"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,634,644</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_ecustom--NetOperatingLossExpires_c20200801__20210731_z2lPAb9YSW01" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="NOL expires"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2041</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--DeferredIncomeTaxExpenseBenefit_pp0p0_c20200801__20210731_zMcPq1YL1hNl" style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right" title="Estimated tax benefit from NOL and other tax benefits (21%)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,990,393</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_980_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_c20210731_zJweqzgqfObk" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Valuation allowance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,990,393</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--DeferredTaxAssetsNet_iNI_pp0p0_di_c20210731_zci20MbneC8k" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Change in valuation allowance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(919,938</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iI_pdp0_c20210731_zAAso0fTzlSh" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Net deferred tax asset"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0883">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31-Jul-22</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_c20220731_zmt1fF5TMWP" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net NOL carry-forward"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,400,620</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_ecustom--NetOperatingLossExpires_c20210801__20220731_zI9CJHa3nOCc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="NOL expires"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2042</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--DeferredIncomeTaxExpenseBenefit_pp0p0_c20210801__20220731_zq18ggkd56T3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Estimated tax benefit from NOL and other tax benefits (21%)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,220,186</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_c20220731_zkDVk4CJ0M8j" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Valuation allowance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,220,186</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--DeferredTaxAssetsNet_iNI_pp0p0_di_c20220731_zyADQWwrkANb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in valuation allowance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(229,793</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iI_pdp0_c20220731_zO3sA4ReosW3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net deferred tax asset"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0895">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> <p id="xdx_8A7_zKaPs95g4w64" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_892_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z3rRkyxSIfN2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income taxes at the statutory rate are reconciled to reported income tax expense (benefit) as follows: </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BC_zXmI9GyKpZid" style="display: none">SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal income tax rate</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20210801__20220731_zoEDyjfGwCF6" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Federal income tax rate"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20200801__20210731_zuU5RjYVnG5i" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Federal income tax rate"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State income tax rate</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_c20210801__20220731_zBB1tTv5Wmuf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="State income tax rate"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.8</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_c20200801__20210731_ziZXbUpwgF0f" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="State income tax rate"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.8</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign tax difference</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_c20210801__20220731_zrX5NdolzJSc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Foreign tax difference"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4.8</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_c20200801__20210731_zagyQc3DGXH7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Foreign tax difference"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4.1</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-taxable item adjustment</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_ecustom--EffectiveIncomeTaxRateNontaxableItemAdjustment_pid_dp_c20210801__20220731_zcR3vyzGbJhe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Non-taxable item adjustment"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0911">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_ecustom--EffectiveIncomeTaxRateNontaxableItemAdjustment_pid_dp_c20200801__20210731_zrtHKMgueaji" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Non-taxable item adjustment"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3.2</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GILTI</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_ecustom--EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncome_pid_dp_c20210801__20220731_z5RNAkljtzt4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="GILTI"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0915">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_ecustom--EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncome_pid_dp_c20200801__20210731_zUDB1SrPFpMc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="GILTI"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0917">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_c20210801__20220731_z3zH8savqJic" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Valuation allowance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(25.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_c20200801__20210731_zjXN8nAviGxl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Valuation allowance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(22.5</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Others</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_c20210801__20220731_zEfecTohaY11" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Others"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0923">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_c20200801__20210731_z0V7xvEcaUp4" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Others"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0925">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective tax rate</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_c20210801__20220731_zNnDTv2yqhwk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Effective tax rate"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_c20200801__20210731_zU4oM98UvkAd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Effective tax rate"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> </table> <p id="xdx_8A6_zOSTZFDqxgAf" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">At this time, the Company is unable to determine if it will be able to benefit from its deferred tax asset. There are limitations on the utilization of net operating loss carry-forwards, including a requirement that losses be offset against future taxable income, if any. In addition, there are limitations imposed by certain transactions which are deemed to be ownership changes. Accordingly, a full valuation allowance has been established for the entire deferred tax asset. Other temporary differences and estimated permanent differences are considered immaterial. Open tax years subject to examination by the IRS range from August 1, 2017 to the present. The Company has no uncertain tax positions.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has been in loss position for years since inception and zero balances of deferred tax assets and liabilities as of the reporting periods ended. </span>There was no GILTI tax for the Company for the years ended July 31, 2022 and 2021 due to the operation losses incurred.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> 800 800 <p id="xdx_89A_eus-gaap--ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_zuFFxkvYUyee" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hartford Great Health Corp.’s deferred tax assets, valuation allowance, and change in valuation allowance are as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B8_zmVnDSp6Qenb" style="display: none">SCHEDULE OF INCOME TAX VALUATION</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Estimated tax</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net NOL</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">benefit from NOL</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Change in</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">carry-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOL</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">and other tax</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">valuation</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">deferred</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Period Ending</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">forward</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">expires</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">benefits (21%)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">tax asset</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; width: 16%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31-Jul-21</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_c20210731_zzbjGGVie846" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Net NOL carry-forward"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">6,634,644</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_ecustom--NetOperatingLossExpires_c20200801__20210731_z2lPAb9YSW01" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="NOL expires"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2041</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98B_eus-gaap--DeferredIncomeTaxExpenseBenefit_pp0p0_c20200801__20210731_zMcPq1YL1hNl" style="font: 10pt Times New Roman, Times, Serif; width: 15%; text-align: right" title="Estimated tax benefit from NOL and other tax benefits (21%)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,990,393</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_980_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_c20210731_zJweqzgqfObk" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Valuation allowance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,990,393</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_982_eus-gaap--DeferredTaxAssetsNet_iNI_pp0p0_di_c20210731_zci20MbneC8k" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Change in valuation allowance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(919,938</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iI_pdp0_c20210731_zAAso0fTzlSh" style="font: 10pt Times New Roman, Times, Serif; width: 9%; text-align: right" title="Net deferred tax asset"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0883">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">31-Jul-22</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--DeferredTaxAssetsOperatingLossCarryforwards_iI_pp0p0_c20220731_zmt1fF5TMWP" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net NOL carry-forward"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">7,400,620</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_ecustom--NetOperatingLossExpires_c20210801__20220731_zI9CJHa3nOCc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="NOL expires"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2042</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_989_eus-gaap--DeferredIncomeTaxExpenseBenefit_pp0p0_c20210801__20220731_zq18ggkd56T3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Estimated tax benefit from NOL and other tax benefits (21%)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2,220,186</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_988_eus-gaap--DeferredTaxAssetsValuationAllowance_iNI_pp0p0_di_c20220731_zkDVk4CJ0M8j" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Valuation allowance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,220,186</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_98C_eus-gaap--DeferredTaxAssetsNet_iNI_pp0p0_di_c20220731_zyADQWwrkANb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Change in valuation allowance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(229,793</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td id="xdx_986_eus-gaap--DeferredTaxAssetsLiabilitiesNet_iI_pdp0_c20220731_zO3sA4ReosW3" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Net deferred tax asset"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0895">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> </table> 6634644 2041 1990393 1990393 919938 7400620 2042 2220186 2220186 229793 <p id="xdx_892_eus-gaap--ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_z3rRkyxSIfN2" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income taxes at the statutory rate are reconciled to reported income tax expense (benefit) as follows: </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8BC_zXmI9GyKpZid" style="display: none">SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 90%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 68%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Federal income tax rate</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20210801__20220731_zoEDyjfGwCF6" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Federal income tax rate"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_c20200801__20210731_zuU5RjYVnG5i" style="font: 10pt Times New Roman, Times, Serif; width: 12%; text-align: right" title="Federal income tax rate"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">State income tax rate</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_c20210801__20220731_zBB1tTv5Wmuf" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="State income tax rate"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.8</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_pid_dp_c20200801__20210731_ziZXbUpwgF0f" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="State income tax rate"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.8</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Foreign tax difference</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_c20210801__20220731_zrX5NdolzJSc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Foreign tax difference"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4.8</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_pid_c20200801__20210731_zagyQc3DGXH7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Foreign tax difference"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4.1</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-taxable item adjustment</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_984_ecustom--EffectiveIncomeTaxRateNontaxableItemAdjustment_pid_dp_c20210801__20220731_zcR3vyzGbJhe" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Non-taxable item adjustment"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0911">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_ecustom--EffectiveIncomeTaxRateNontaxableItemAdjustment_pid_dp_c20200801__20210731_zrtHKMgueaji" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Non-taxable item adjustment"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3.2</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">GILTI</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_ecustom--EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncome_pid_dp_c20210801__20220731_z5RNAkljtzt4" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="GILTI"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0915">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_ecustom--EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncome_pid_dp_c20200801__20210731_zUDB1SrPFpMc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="GILTI"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0917">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Valuation allowance</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_c20210801__20220731_z3zH8savqJic" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Valuation allowance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(25.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_983_eus-gaap--EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_pid_dp_c20200801__20210731_zjXN8nAviGxl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Valuation allowance"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(22.5</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Others</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98B_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_c20210801__20220731_zEfecTohaY11" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Others"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0923">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98D_eus-gaap--EffectiveIncomeTaxRateReconciliationOtherAdjustments_pid_dp_c20200801__20210731_z0V7xvEcaUp4" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right" title="Others"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0925">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Effective tax rate</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_c20210801__20220731_zNnDTv2yqhwk" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Effective tax rate"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--EffectiveIncomeTaxRateContinuingOperations_pid_dp_c20200801__20210731_zU4oM98UvkAd" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Effective tax rate"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">0.0</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</span></td></tr> </table> 0.210 0.210 0.088 0.088 -4.8 -4.1 -0.032 -0.250 -0.225 0.000 0.000 <p id="xdx_802_eus-gaap--SegmentReportingDisclosureTextBlock_zALvm71ldz52" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 9. <span id="xdx_82E_zI3rP6G3sU25">SEGMENT INFORMATION (restated)</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company currently operates in following industry segments: hospitality (hotel and travel agency) and early childhood education industry in China.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_893_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zyeAIbXDfcw" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Segment information on assets as of July 31, 2022 and revenue generated during the year ended July 31, 2022, as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B9_zoCwey2rulZi" style="display: none">SCHEDULE OF SEGMENT INFORMATION</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_490_20210801__20220731__us-gaap--StatementBusinessSegmentsAxis__custom--HospitalityMember__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_zSJqmdmv1k8e" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_49D_20210801__20220731__us-gaap--StatementBusinessSegmentsAxis__custom--EducationMember__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_zef3uJfBcPad" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_49E_20210801__20220731__us-gaap--StatementBusinessSegmentsAxis__custom--CorporateAndUnallocatedMember_z23kBbxbZYob" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_49C_20210801__20220731_zuG9z3RYCFYa" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hospitality</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Discontinued Operation)</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Education</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Discontinued Operation)</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate and Unallocated (Continued operation)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zSHVMtdmI7Ve" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 44%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51,342</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">509,920</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0937">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">561,262</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_ecustom--OperatingIncomeLossIncludingContinuedAndDiscontinuedOperations_z5vUL3KqtyR3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating loss</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(129,352</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,566,401</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(177,913</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,873,666</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_401_ecustom--IncomeLossFromContinuingAndDiscontinuedOperationsBeforeIncomeTaxesExtraordinaryItems_ztjDSwAOuNre" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss before tax</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(182,980</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,399,172</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(189,630</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,771,782</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_401_eus-gaap--NetIncomeLoss_zTCQCcWv74l3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net Loss Attributable to Hartford Great Health Corp</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(129,422</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,259,249</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(190,430</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,579,101</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total assets (excluding Intercompany balances)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--Assets_iI_c20220731__us-gaap--StatementBusinessSegmentsAxis__custom--HospitalityMember__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_zPX33lIjFzrb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total assets (excluding Intercompany balances)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">303,703</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--Assets_iI_c20220731__us-gaap--StatementBusinessSegmentsAxis__custom--EducationMember__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_zFEGkbQRxMk9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total assets (excluding Intercompany balances)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,196,033</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--Assets_iI_c20220731__us-gaap--StatementBusinessSegmentsAxis__custom--CorporateAndUnallocatedMember_zgN6zwx6Et39" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total assets (excluding Intercompany balances)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38,620</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--Assets_iI_c20220731_z5N4ZSmfaWC7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total assets (excluding Intercompany balances)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,538,356</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets allocated to held for sale</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--AssetsHeldForSaleNotPartOfDisposalGroup_iNI_di_c20220731__us-gaap--StatementBusinessSegmentsAxis__custom--HospitalityMember__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_zIDV16emNqDc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets allocated to held for sale"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(303,703</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--AssetsHeldForSaleNotPartOfDisposalGroup_iNI_di_c20220731__us-gaap--StatementBusinessSegmentsAxis__custom--EducationMember__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_zlimMMAPReo8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets allocated to held for sale"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,196,033</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--AssetsHeldForSaleNotPartOfDisposalGroup_iNI_di_c20220731__us-gaap--StatementBusinessSegmentsAxis__custom--CorporateAndUnallocatedMember_z7i5P9KQ7X7e" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets allocated to held for sale"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0967">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--AssetsHeldForSaleNotPartOfDisposalGroup_iNI_di_c20220731_zRZIVCb65Bz9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets allocated to held for sale"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,499,736</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Segment information on assets as of July 31, 2021 and revenue generated during the year ended July 31, 2021, as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_49E_20200801__20210731__us-gaap--StatementBusinessSegmentsAxis__custom--HospitalityMember__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_zxTHVth0oIxk" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_49B_20200801__20210731__us-gaap--StatementBusinessSegmentsAxis__custom--EducationMember__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_zETpDmtrom5g" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_490_20200801__20210731__us-gaap--StatementBusinessSegmentsAxis__custom--CorporateAndUnallocatedMember_zcwelD6Lk53k" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_49A_20200801__20210731_z2v2ohzohMkb" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hospitality</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Discontinued Operation)</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Education</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Discontinued Operation)</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate and Unallocated</span></span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Continued operation)</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zpCsXBJUtMO" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 44%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">118,309</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">435,150</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0973">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">553,459</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_ecustom--OperatingIncomeLossIncludingContinuedAndDiscontinuedOperations_zXCQfs1O46W6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating loss</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(172,536</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,588,174</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(255,655</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,016,365</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_401_ecustom--IncomeLossFromContinuingAndDiscontinuedOperationsBeforeIncomeTaxesExtraordinaryItems_zUjnaEqCfqqe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss before tax</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(216,303</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,544,308</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(80,928</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,841,539</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_401_eus-gaap--NetIncomeLoss_z7Csw12Wztj1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net Loss Attributable to Hartford Great Health Corp</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(174,018</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,997,588</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(81,728</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,253,334</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total assets (excluding Intercompany balances)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--Assets_iI_c20210731__us-gaap--StatementBusinessSegmentsAxis__custom--HospitalityMember__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_zI9K3LeDUUQ8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total assets (excluding Intercompany balances)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">384,747</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--Assets_iI_c20210731__us-gaap--StatementBusinessSegmentsAxis__custom--EducationMember__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_zHc7GqD7gf8b" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total assets (excluding Intercompany balances)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,335,244</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--Assets_iI_c20210731__us-gaap--StatementBusinessSegmentsAxis__custom--CorporateAndUnallocatedMember_zRXs84zNtWDg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total assets (excluding Intercompany balances)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,607</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--Assets_iI_c20210731_zNLdT2IvzKt6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total assets (excluding Intercompany balances)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,742,598</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Assets allocated to held for sale</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--AssetsHeldForSaleNotPartOfDisposalGroup_iNI_di_c20210731__us-gaap--StatementBusinessSegmentsAxis__custom--HospitalityMember__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_zTxcSVUW0so5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets allocated to held for sale">(384,747</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--AssetsHeldForSaleNotPartOfDisposalGroup_iNI_di_c20210731__us-gaap--StatementBusinessSegmentsAxis__custom--EducationMember__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_zm2f6d9gIjQl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets allocated to held for sale">(5,335,244</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--AssetsHeldForSaleNotPartOfDisposalGroup_iNI_di_c20210731__us-gaap--StatementBusinessSegmentsAxis__custom--CorporateAndUnallocatedMember_z2vBnfQNATki" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets allocated to held for sale"><span style="-sec-ix-hidden: xdx2ixbrl1003">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--AssetsHeldForSaleNotPartOfDisposalGroup_iNI_di_c20210731_zOK04EU0Ajok" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets allocated to held for sale">(5,719,991</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> </table> <p id="xdx_8A7_z9lLADRgvOt7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/> <p id="xdx_893_eus-gaap--ScheduleOfSegmentReportingInformationBySegmentTextBlock_zyeAIbXDfcw" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Segment information on assets as of July 31, 2022 and revenue generated during the year ended July 31, 2022, as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> <span id="xdx_8B9_zoCwey2rulZi" style="display: none">SCHEDULE OF SEGMENT INFORMATION</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_490_20210801__20220731__us-gaap--StatementBusinessSegmentsAxis__custom--HospitalityMember__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_zSJqmdmv1k8e" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_49D_20210801__20220731__us-gaap--StatementBusinessSegmentsAxis__custom--EducationMember__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_zef3uJfBcPad" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_49E_20210801__20220731__us-gaap--StatementBusinessSegmentsAxis__custom--CorporateAndUnallocatedMember_z23kBbxbZYob" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_49C_20210801__20220731_zuG9z3RYCFYa" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hospitality</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Discontinued Operation)</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Education</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Discontinued Operation)</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate and Unallocated (Continued operation)</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zSHVMtdmI7Ve" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 44%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">51,342</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">509,920</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0937">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">561,262</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_403_ecustom--OperatingIncomeLossIncludingContinuedAndDiscontinuedOperations_z5vUL3KqtyR3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating loss</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(129,352</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,566,401</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(177,913</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,873,666</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_401_ecustom--IncomeLossFromContinuingAndDiscontinuedOperationsBeforeIncomeTaxesExtraordinaryItems_ztjDSwAOuNre" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss before tax</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(182,980</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,399,172</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(189,630</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,771,782</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_401_eus-gaap--NetIncomeLoss_zTCQCcWv74l3" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net Loss Attributable to Hartford Great Health Corp</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(129,422</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,259,249</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(190,430</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,579,101</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total assets (excluding Intercompany balances)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_985_eus-gaap--Assets_iI_c20220731__us-gaap--StatementBusinessSegmentsAxis__custom--HospitalityMember__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_zPX33lIjFzrb" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total assets (excluding Intercompany balances)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">303,703</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_981_eus-gaap--Assets_iI_c20220731__us-gaap--StatementBusinessSegmentsAxis__custom--EducationMember__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_zFEGkbQRxMk9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total assets (excluding Intercompany balances)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,196,033</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98F_eus-gaap--Assets_iI_c20220731__us-gaap--StatementBusinessSegmentsAxis__custom--CorporateAndUnallocatedMember_zgN6zwx6Et39" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total assets (excluding Intercompany balances)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">38,620</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98E_eus-gaap--Assets_iI_c20220731_z5N4ZSmfaWC7" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total assets (excluding Intercompany balances)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">4,538,356</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Assets allocated to held for sale</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--AssetsHeldForSaleNotPartOfDisposalGroup_iNI_di_c20220731__us-gaap--StatementBusinessSegmentsAxis__custom--HospitalityMember__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_zIDV16emNqDc" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets allocated to held for sale"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(303,703</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_980_eus-gaap--AssetsHeldForSaleNotPartOfDisposalGroup_iNI_di_c20220731__us-gaap--StatementBusinessSegmentsAxis__custom--EducationMember__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_zlimMMAPReo8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets allocated to held for sale"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,196,033</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--AssetsHeldForSaleNotPartOfDisposalGroup_iNI_di_c20220731__us-gaap--StatementBusinessSegmentsAxis__custom--CorporateAndUnallocatedMember_z7i5P9KQ7X7e" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets allocated to held for sale"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0967">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_988_eus-gaap--AssetsHeldForSaleNotPartOfDisposalGroup_iNI_di_c20220731_zRZIVCb65Bz9" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets allocated to held for sale"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(4,499,736</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Segment information on assets as of July 31, 2021 and revenue generated during the year ended July 31, 2021, as follows:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; display: none; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_49E_20200801__20210731__us-gaap--StatementBusinessSegmentsAxis__custom--HospitalityMember__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_zxTHVth0oIxk" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_49B_20200801__20210731__us-gaap--StatementBusinessSegmentsAxis__custom--EducationMember__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_zETpDmtrom5g" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_490_20200801__20210731__us-gaap--StatementBusinessSegmentsAxis__custom--CorporateAndUnallocatedMember_zcwelD6Lk53k" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_49A_20200801__20210731_z2v2ohzohMkb" style="font: 10pt Times New Roman, Times, Serif; text-align: right"> </td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif; text-align: center"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hospitality</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Discontinued Operation)</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Education</span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Discontinued Operation)</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corporate and Unallocated</span></span></p> <p style="margin-top: 0; margin-bottom: 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Continued operation)</span></p></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: center; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_40A_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_zpCsXBJUtMO" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 44%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">118,309</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">435,150</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span style="-sec-ix-hidden: xdx2ixbrl0973">-</span></span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">553,459</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_409_ecustom--OperatingIncomeLossIncludingContinuedAndDiscontinuedOperations_zXCQfs1O46W6" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating loss</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(172,536</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,588,174</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(255,655</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,016,365</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_401_ecustom--IncomeLossFromContinuingAndDiscontinuedOperationsBeforeIncomeTaxesExtraordinaryItems_zUjnaEqCfqqe" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Loss before tax</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(216,303</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,544,308</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(80,928</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,841,539</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr id="xdx_401_eus-gaap--NetIncomeLoss_z7Csw12Wztj1" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net Loss Attributable to Hartford Great Health Corp</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(174,018</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1,997,588</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(81,728</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2,253,334</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total assets (excluding Intercompany balances)</span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_986_eus-gaap--Assets_iI_c20210731__us-gaap--StatementBusinessSegmentsAxis__custom--HospitalityMember__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_zI9K3LeDUUQ8" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total assets (excluding Intercompany balances)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">384,747</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_98C_eus-gaap--Assets_iI_c20210731__us-gaap--StatementBusinessSegmentsAxis__custom--EducationMember__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_zHc7GqD7gf8b" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total assets (excluding Intercompany balances)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,335,244</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_989_eus-gaap--Assets_iI_c20210731__us-gaap--StatementBusinessSegmentsAxis__custom--CorporateAndUnallocatedMember_zRXs84zNtWDg" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total assets (excluding Intercompany balances)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">22,607</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td id="xdx_982_eus-gaap--Assets_iI_c20210731_zNLdT2IvzKt6" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Total assets (excluding Intercompany balances)"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,742,598</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: White"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left">Assets allocated to held for sale</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_982_eus-gaap--AssetsHeldForSaleNotPartOfDisposalGroup_iNI_di_c20210731__us-gaap--StatementBusinessSegmentsAxis__custom--HospitalityMember__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_zTxcSVUW0so5" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets allocated to held for sale">(384,747</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_98D_eus-gaap--AssetsHeldForSaleNotPartOfDisposalGroup_iNI_di_c20210731__us-gaap--StatementBusinessSegmentsAxis__custom--EducationMember__us-gaap--DisposalGroupClassificationAxis__us-gaap--DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember_zm2f6d9gIjQl" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets allocated to held for sale">(5,335,244</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_985_eus-gaap--AssetsHeldForSaleNotPartOfDisposalGroup_iNI_di_c20210731__us-gaap--StatementBusinessSegmentsAxis__custom--CorporateAndUnallocatedMember_z2vBnfQNATki" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets allocated to held for sale"><span style="-sec-ix-hidden: xdx2ixbrl1003">-</span></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: left"> </td><td id="xdx_984_eus-gaap--AssetsHeldForSaleNotPartOfDisposalGroup_iNI_di_c20210731_zOK04EU0Ajok" style="font: 10pt Times New Roman, Times, Serif; text-align: right" title="Assets allocated to held for sale">(5,719,991</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: left">)</td></tr> </table> 51342 509920 561262 -129352 -1566401 -177913 -1873666 -182980 -1399172 -189630 -1771782 -129422 -1259249 -190430 -1579101 303703 4196033 38620 4538356 303703 4196033 4499736 118309 435150 553459 -172536 -2588174 -255655 -3016365 -216303 -2544308 -80928 -2841539 -174018 -1997588 -81728 -2253334 384747 5335244 22607 5742598 384747 5335244 5719991 <p id="xdx_807_eus-gaap--ErrorCorrectionTextBlock_z3SxRxwNpwh7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 10. <span id="xdx_82E_zPlZVFpyzOPh">RESTATEMENT</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company restated its Annual Report on Form 10-K for the annual period from August 1, 2021 to July 31, 2022, which was filed with the U.S. Securities and Exchange Commission (the “SEC”) on November 14, 2022 (the “Original Filing”), is being filed for the following purposes:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">(a) for Consolidated balance sheets on Item 8, Financial Statements, of Part II of Form 10-K, to reclass the balance of Non-current assets held for sale, as of July 31, 2022, to Current assets held for sale.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">(b) for Consolidated statements of operations on Item 8, Financial Statements, of Part II of Form 10-K, to separately disclose the </span><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">discontinued operation results for years ended July 31, 2022 and 2021.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The restatements above have been incorporated into the consolidated statements of operation, Note #5 and #9, respectively.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"/> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p id="xdx_806_eus-gaap--SubsequentEventsTextBlock_z78m34lBvFlb" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 11. <span id="xdx_82A_zdpJBhbMd7Ll">SUBSEQUENT EVENTS</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In accordance with ASC 855<i>, “Subsequent Events”</i>, the Company has evaluated subsequent events through the date of issuance of these financial statements and has noted the following subsequent events to be disclosed.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 1, 2022, see note 5, under section “Assets and liabilities held for sale”, HFSH entered a contract with a related party, SH Oversea, to sell <span id="xdx_90E_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_pid_dp_c20220801__us-gaap--BusinessAcquisitionAxis__custom--HangzhouLongjingQiaoFuVacationHotelCoLtdMember_zLR9zpTLvOX4" title="Business acquisition, percentage of voting interests acquired">90</span> percent ownership of HF Int’l Education and its subsidiaries for $<span id="xdx_905_eus-gaap--RelatedPartyTransactionDueFromToRelatedParty_iI_c20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShanghaiOverseaMember__us-gaap--BusinessAcquisitionAxis__custom--HartfordInternationalEducationTechnologyCoLtdMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zN81pIgUKPG5" title="Related party">900</span> (RMB <span id="xdx_900_eus-gaap--RelatedPartyTransactionDueFromToRelatedParty_iI_uRMB_c20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShanghaiOverseaMember__us-gaap--BusinessAcquisitionAxis__custom--HartfordInternationalEducationTechnologyCoLtdMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zKKTav7yWU67" title="Related party">5,850</span>). On August 1, 2022, HFUS entered a contract with SH Oversea and another individual, to sell <span id="xdx_904_eus-gaap--BusinessAcquisitionPercentageOfVotingInterestsAcquired_iI_dp_uPure_c20220801__us-gaap--BusinessAcquisitionAxis__custom--HangzhouHartfordComprehensiveHealthManagementLtdMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zcNOl7US7sJb">100</span> percent ownership of HZHF and its subsidiaries for $<span id="xdx_906_eus-gaap--RelatedPartyTransactionDueFromToRelatedParty_iI_c20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShanghaiOverseaMember__us-gaap--BusinessAcquisitionAxis__custom--HangzhouHartfordComprehensiveHealthManagementLtdMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z124MwHCkSui" title="Related party">1,000</span> (RMB <span id="xdx_90F_eus-gaap--RelatedPartyTransactionDueFromToRelatedParty_iI_uRMB_c20220801__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ShanghaiOverseaMember__us-gaap--BusinessAcquisitionAxis__custom--HangzhouHartfordComprehensiveHealthManagementLtdMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zRmsStdSgYgh" title="Related party">6,500</span>).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 1pt 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 1, 2022, HFSH decided to withdraw from the agreement entered in January 2019 to acquire <span id="xdx_909_eus-gaap--EquityMethodInvestmentOwnershipPercentage_iI_pid_dp_c20220801__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis__custom--ShangaiLuoShengInternationalTradeLtdMember_zuQqpomtQ8la" title="Equity method investment ownership, perentage">100</span> percent equity interest of Shanghai Luo Sheng International Trade Ltd. (“SH Luosheng”). There was no penalty levied or to be levied due to delayed execution or inexecution.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On August 17, 2022, the Company borrowed a note in a total amount of $<span id="xdx_90A_eus-gaap--ShortTermBorrowings_iI_pp0p0_c20220817__srt--TitleOfIndividualAxis__custom--RelatedPartyMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zJPwAGcMklY9" title="Short term debt">30,000</span>, in form of a short-term loan at <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_uPure_c20220817__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember__srt--TitleOfIndividualAxis__custom--RelatedPartyMember_zs4GPqHlQyGl" title="Debt instrument, interest rate, stated percentage">5</span>% per annum from a related party.</span></p> 0.90 900 5850 1 1000 6500 1 30000 0.05 $10,462 (RMB70,000) payable to the acquiree plus $14,362 (RMB100,000) cash payment totaled $24,824 consideration for the acquisition. EXCEL 55 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 56 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 57 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 58 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 106 257 1 true 52 0 false 5 false false R1.htm 00000001 - Document - Cover Sheet http://hartfordhealthcare.org/role/Cover Cover Cover 1 false false R2.htm 00000002 - Statement - Consolidated Balance Sheets Sheet http://hartfordhealthcare.org/role/BalanceSheets Consolidated Balance Sheets Statements 2 false false R3.htm 00000003 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://hartfordhealthcare.org/role/BalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) Statements 3 false false R4.htm 00000004 - Statement - Consolidated Statements of Operations Sheet http://hartfordhealthcare.org/role/StatementsOfOperations Consolidated Statements of Operations Statements 4 false false R5.htm 00000005 - Statement - Consolidated Statements of Comprehensive Loss Sheet http://hartfordhealthcare.org/role/StatementsOfComprehensiveLoss Consolidated Statements of Comprehensive Loss Statements 5 false false R6.htm 00000006 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Deficit) Sheet http://hartfordhealthcare.org/role/StatementsOfChangesInStockholdersEquityDeficit Consolidated Statements of Changes in Stockholders' Equity (Deficit) Statements 6 false false R7.htm 00000007 - Statement - Consolidated Statements of Cash Flows Sheet http://hartfordhealthcare.org/role/StatementsOfCashFlows Consolidated Statements of Cash Flows Statements 7 false false R8.htm 00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Sheet http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Notes 8 false false R9.htm 00000009 - Disclosure - GOING CONCERN Sheet http://hartfordhealthcare.org/role/GoingConcern GOING CONCERN Notes 9 false false R10.htm 00000010 - Disclosure - STOCKHOLDERS??? EQUITY Sheet http://hartfordhealthcare.org/role/StockholdersEquity STOCKHOLDERS??? EQUITY Notes 10 false false R11.htm 00000011 - Disclosure - ACQUISITIONS, JOINT VENTURES AND DECONSOLIDATION Sheet http://hartfordhealthcare.org/role/AcquisitionsJointVenturesAndDeconsolidation ACQUISITIONS, JOINT VENTURES AND DECONSOLIDATION Notes 11 false false R12.htm 00000012 - Disclosure - DISCONTINUED OPERATION Sheet http://hartfordhealthcare.org/role/DiscontinuedOperation DISCONTINUED OPERATION Notes 12 false false R13.htm 00000013 - Disclosure - RELATED PARTY TRANSACTIONS Sheet http://hartfordhealthcare.org/role/RelatedPartyTransactions RELATED PARTY TRANSACTIONS Notes 13 false false R14.htm 00000014 - Disclosure - COMMITMENTS AND CONTINGENCIES Sheet http://hartfordhealthcare.org/role/CommitmentsAndContingencies COMMITMENTS AND CONTINGENCIES Notes 14 false false R15.htm 00000015 - Disclosure - INCOME TAXES Sheet http://hartfordhealthcare.org/role/IncomeTaxes INCOME TAXES Notes 15 false false R16.htm 00000016 - Disclosure - SEGMENT INFORMATION (restated) Sheet http://hartfordhealthcare.org/role/SegmentInformationRestated SEGMENT INFORMATION (restated) Notes 16 false false R17.htm 00000017 - Disclosure - RESTATEMENT Sheet http://hartfordhealthcare.org/role/Restatement RESTATEMENT Notes 17 false false R18.htm 00000018 - Disclosure - SUBSEQUENT EVENTS Sheet http://hartfordhealthcare.org/role/SubsequentEvents SUBSEQUENT EVENTS Notes 18 false false R19.htm 00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Sheet http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesPolicies SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies) Policies 19 false false R20.htm 00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Sheet http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesTables SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables) Tables http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPolicies 20 false false R21.htm 00000021 - Disclosure - ACQUISITIONS, JOINT VENTURES AND DECONSOLIDATION (Tables) Sheet http://hartfordhealthcare.org/role/AcquisitionsJointVenturesAndDeconsolidationTables ACQUISITIONS, JOINT VENTURES AND DECONSOLIDATION (Tables) Tables http://hartfordhealthcare.org/role/AcquisitionsJointVenturesAndDeconsolidation 21 false false R22.htm 00000022 - Disclosure - DISCONTINUED OPERATION (Tables) Sheet http://hartfordhealthcare.org/role/DiscontinuedOperationTables DISCONTINUED OPERATION (Tables) Tables http://hartfordhealthcare.org/role/DiscontinuedOperation 22 false false R23.htm 00000023 - Disclosure - INCOME TAXES (Tables) Sheet http://hartfordhealthcare.org/role/IncomeTaxesTables INCOME TAXES (Tables) Tables http://hartfordhealthcare.org/role/IncomeTaxes 23 false false R24.htm 00000024 - Disclosure - SEGMENT INFORMATION (restated) (Tables) Sheet http://hartfordhealthcare.org/role/SegmentInformationRestatedTables SEGMENT INFORMATION (restated) (Tables) Tables http://hartfordhealthcare.org/role/SegmentInformationRestated 24 false false R25.htm 00000025 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE (Details) Sheet http://hartfordhealthcare.org/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE (Details) Details 25 false false R26.htm 00000026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Sheet http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) Details http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesTables 26 false false R27.htm 00000027 - Disclosure - GOING CONCERN (Details Narrative) Sheet http://hartfordhealthcare.org/role/GoingConcernDetailsNarrative GOING CONCERN (Details Narrative) Details http://hartfordhealthcare.org/role/GoingConcern 27 false false R28.htm 00000028 - Disclosure - STOCKHOLDERS??? EQUITY (Details Narrative) Sheet http://hartfordhealthcare.org/role/StockholdersEquityDetailsNarrative STOCKHOLDERS??? EQUITY (Details Narrative) Details http://hartfordhealthcare.org/role/StockholdersEquity 28 false false R29.htm 00000029 - Disclosure - SCHEDULE OF RECOGNIZED IDENTIFIED ASSETS ACQUIRED AND LIABILITIES ASSUMED (Details) Sheet http://hartfordhealthcare.org/role/ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails SCHEDULE OF RECOGNIZED IDENTIFIED ASSETS ACQUIRED AND LIABILITIES ASSUMED (Details) Details 29 false false R30.htm 00000030 - Disclosure - SCHEDULE OF RECOGNIZED IDENTIFIED ASSETS ACQUIRED AND LIABILITIES ASSUMED (Details) (Parenthetical) Sheet http://hartfordhealthcare.org/role/ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetailsParenthetical SCHEDULE OF RECOGNIZED IDENTIFIED ASSETS ACQUIRED AND LIABILITIES ASSUMED (Details) (Parenthetical) Details 30 false false R31.htm 00000031 - Disclosure - SCHEDULE OF NET ASSETS (LIABILITIES) DISPOSED OF SUBSIDIARY (Details) Sheet http://hartfordhealthcare.org/role/ScheduleOfNetAssetsLiabilitiesDisposedOfSubsidiaryDetails SCHEDULE OF NET ASSETS (LIABILITIES) DISPOSED OF SUBSIDIARY (Details) Details 31 false false R32.htm 00000032 - Disclosure - SCHEDULE OF NET INFLOW (OUTFLOW) OF CASH AND CASH EQUIVALENTS OF DISPOSAL SUBSIDIARY (Details) Sheet http://hartfordhealthcare.org/role/ScheduleOfNetInflowOutflowOfCashAndCashEquivalentsOfDisposalSubsidiaryDetails SCHEDULE OF NET INFLOW (OUTFLOW) OF CASH AND CASH EQUIVALENTS OF DISPOSAL SUBSIDIARY (Details) Details 32 false false R33.htm 00000033 - Disclosure - ACQUISITIONS, JOINT VENTURES AND DECONSOLIDATION (Details Narrative) Sheet http://hartfordhealthcare.org/role/AcquisitionsJointVenturesAndDeconsolidationDetailsNarrative ACQUISITIONS, JOINT VENTURES AND DECONSOLIDATION (Details Narrative) Details http://hartfordhealthcare.org/role/AcquisitionsJointVenturesAndDeconsolidationTables 33 false false R34.htm 00000034 - Disclosure - SCHEDULE OF DISCONTINUED OPERATIONS OF FINANCIAL STATEMENTS (Details) Sheet http://hartfordhealthcare.org/role/ScheduleOfDiscontinuedOperationsOfFinancialStatementsDetails SCHEDULE OF DISCONTINUED OPERATIONS OF FINANCIAL STATEMENTS (Details) Details 34 false false R35.htm 00000035 - Disclosure - DISCONTINUED OPERATION (Details Narrative) Sheet http://hartfordhealthcare.org/role/DiscontinuedOperationDetailsNarrative DISCONTINUED OPERATION (Details Narrative) Details http://hartfordhealthcare.org/role/DiscontinuedOperationTables 35 false false R36.htm 00000036 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative) Sheet http://hartfordhealthcare.org/role/RelatedPartyTransactionsDetailsNarrative RELATED PARTY TRANSACTIONS (Details Narrative) Details http://hartfordhealthcare.org/role/RelatedPartyTransactions 36 false false R37.htm 00000037 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative) Sheet http://hartfordhealthcare.org/role/CommitmentsAndContingenciesDetailsNarrative COMMITMENTS AND CONTINGENCIES (Details Narrative) Details http://hartfordhealthcare.org/role/CommitmentsAndContingencies 37 false false R38.htm 00000038 - Disclosure - SCHEDULE OF INCOME TAX VALUATION (Details) Sheet http://hartfordhealthcare.org/role/ScheduleOfIncomeTaxValuationDetails SCHEDULE OF INCOME TAX VALUATION (Details) Details 38 false false R39.htm 00000039 - Disclosure - SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION (Details) Sheet http://hartfordhealthcare.org/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION (Details) Details 39 false false R40.htm 00000040 - Disclosure - INCOME TAXES (Details Narrative) Sheet http://hartfordhealthcare.org/role/IncomeTaxesDetailsNarrative INCOME TAXES (Details Narrative) Details http://hartfordhealthcare.org/role/IncomeTaxesTables 40 false false R41.htm 00000041 - Disclosure - SCHEDULE OF SEGMENT INFORMATION (Details) Sheet http://hartfordhealthcare.org/role/ScheduleOfSegmentInformationDetails SCHEDULE OF SEGMENT INFORMATION (Details) Details 41 false false R42.htm 00000042 - Disclosure - SUBSEQUENT EVENTS (Details Narrative) Sheet http://hartfordhealthcare.org/role/SubsequentEventsDetailsNarrative SUBSEQUENT EVENTS (Details Narrative) Details http://hartfordhealthcare.org/role/SubsequentEvents 42 false false All Reports Book All Reports [dq-0542-Deprecated-Concept] Concept AccountsReceivableRelatedPartiesCurrent in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. form10-ka.htm 3084, 3085 [dq-0542-Deprecated-Concept] Concept NotesPayableRelatedPartiesClassifiedCurrent in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. form10-ka.htm 3138, 3139 [dq-0542-Deprecated-Concept] Concept RelatedPartyTransactionDueFromToRelatedParty in us-gaap/2022 used in 12 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. form10-ka.htm 3982, 3983, 4637, 4638, 5323, 5324, 5325 [dq-0542-Deprecated-Concept] Concept PropertyPlantAndEquipmentEstimatedUsefulLives in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. form10-ka.htm 4096, 4101 [dq-0542-Deprecated-Concept] Concept AccountsPayableRelatedPartiesCurrentAndNoncurrent in us-gaap/2022 used in 6 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. form10-ka.htm 4894, 4895, 4904, 4917 [dq-0542-Deprecated-Concept] Concept InterestExpenseRelatedParty in us-gaap/2022 used in 2 facts was deprecated in us-gaap/2023 as of 2023 and should not be used. form10-ka.htm 4911 form10-ka.htm ex21-1.htm ex31-1.htm ex31-2.htm ex32.htm hfus-20220731.xsd hfus-20220731_cal.xml hfus-20220731_def.xml hfus-20220731_lab.xml hfus-20220731_pre.xml form10-k_001.jpg http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 61 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form10-ka.htm": { "axisCustom": 0, "axisStandard": 17, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 489, "http://xbrl.sec.gov/dei/2022": 36 }, "contextCount": 106, "dts": { "calculationLink": { "local": [ "hfus-20220731_cal.xml" ] }, "definitionLink": { "local": [ "hfus-20220731_def.xml" ] }, "inline": { "local": [ "form10-ka.htm" ] }, "labelLink": { "local": [ "hfus-20220731_lab.xml" ] }, "presentationLink": { "local": [ "hfus-20220731_pre.xml" ] }, "schema": { "local": [ "hfus-20220731.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/srt/2022q3/srt-sup-2022q3.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022q3/us-gaap-sup-2022q3.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 419, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 50, "http://hartfordhealthcare.org/20220731": 16, "http://xbrl.sec.gov/dei/2022": 3, "total": 69 }, "keyCustom": 35, "keyStandard": 222, "memberCustom": 33, "memberStandard": 13, "nsprefix": "HFUS", "nsuri": "http://hartfordhealthcare.org/20220731", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://hartfordhealthcare.org/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "b", "span", "p", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000010 - Disclosure - STOCKHOLDERS\u2019 EQUITY", "menuCat": "Notes", "order": "10", "role": "http://hartfordhealthcare.org/role/StockholdersEquity", "shortName": "STOCKHOLDERS\u2019 EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000011 - Disclosure - ACQUISITIONS, JOINT VENTURES AND DECONSOLIDATION", "menuCat": "Notes", "order": "11", "role": "http://hartfordhealthcare.org/role/AcquisitionsJointVenturesAndDeconsolidation", "shortName": "ACQUISITIONS, JOINT VENTURES AND DECONSOLIDATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BusinessCombinationDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000012 - Disclosure - DISCONTINUED OPERATION", "menuCat": "Notes", "order": "12", "role": "http://hartfordhealthcare.org/role/DiscontinuedOperation", "shortName": "DISCONTINUED OPERATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000013 - Disclosure - RELATED PARTY TRANSACTIONS", "menuCat": "Notes", "order": "13", "role": "http://hartfordhealthcare.org/role/RelatedPartyTransactions", "shortName": "RELATED PARTY TRANSACTIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000014 - Disclosure - COMMITMENTS AND CONTINGENCIES", "menuCat": "Notes", "order": "14", "role": "http://hartfordhealthcare.org/role/CommitmentsAndContingencies", "shortName": "COMMITMENTS AND CONTINGENCIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000015 - Disclosure - INCOME TAXES", "menuCat": "Notes", "order": "15", "role": "http://hartfordhealthcare.org/role/IncomeTaxes", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000016 - Disclosure - SEGMENT INFORMATION (restated)", "menuCat": "Notes", "order": "16", "role": "http://hartfordhealthcare.org/role/SegmentInformationRestated", "shortName": "SEGMENT INFORMATION (restated)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ErrorCorrectionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000017 - Disclosure - RESTATEMENT", "menuCat": "Notes", "order": "17", "role": "http://hartfordhealthcare.org/role/Restatement", "shortName": "RESTATEMENT", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ErrorCorrectionTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000018 - Disclosure - SUBSEQUENT EVENTS", "menuCat": "Notes", "order": "18", "role": "http://hartfordhealthcare.org/role/SubsequentEvents", "shortName": "SUBSEQUENT EVENTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000019 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "menuCat": "Policies", "order": "19", "role": "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "AsOf2022-07-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000002 - Statement - Consolidated Balance Sheets", "menuCat": "Statements", "order": "2", "role": "http://hartfordhealthcare.org/role/BalanceSheets", "shortName": "Consolidated Balance Sheets", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "AsOf2022-07-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "HFUS:ScheduleOfPropertyAndEquipmentUsefulLivesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000020 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "menuCat": "Tables", "order": "20", "role": "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesTables", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "HFUS:ScheduleOfPropertyAndEquipmentUsefulLivesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000021 - Disclosure - ACQUISITIONS, JOINT VENTURES AND DECONSOLIDATION (Tables)", "menuCat": "Tables", "order": "21", "role": "http://hartfordhealthcare.org/role/AcquisitionsJointVenturesAndDeconsolidationTables", "shortName": "ACQUISITIONS, JOINT VENTURES AND DECONSOLIDATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000022 - Disclosure - DISCONTINUED OPERATION (Tables)", "menuCat": "Tables", "order": "22", "role": "http://hartfordhealthcare.org/role/DiscontinuedOperationTables", "shortName": "DISCONTINUED OPERATION (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000023 - Disclosure - INCOME TAXES (Tables)", "menuCat": "Tables", "order": "23", "role": "http://hartfordhealthcare.org/role/IncomeTaxesTables", "shortName": "INCOME TAXES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000024 - Disclosure - SEGMENT INFORMATION (restated) (Tables)", "menuCat": "Tables", "order": "24", "role": "http://hartfordhealthcare.org/role/SegmentInformationRestatedTables", "shortName": "SEGMENT INFORMATION (restated) (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "HFUS:ScheduleOfPropertyAndEquipmentUsefulLivesTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-012022-07-31_us-gaap_LeaseholdImprovementsMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000025 - Disclosure - SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE (Details)", "menuCat": "Details", "order": "25", "role": "http://hartfordhealthcare.org/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails", "shortName": "SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "HFUS:ScheduleOfPropertyAndEquipmentUsefulLivesTableTextBlock", "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-012022-07-31_us-gaap_LeaseholdImprovementsMember", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "AsOf2022-07-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashFDICInsuredAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000026 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "menuCat": "Details", "order": "26", "role": "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CashAndCashEquivalentsPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "AsOf2022-07-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashFDICInsuredAmount", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "AsOf2022-07-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RetainedEarningsAccumulatedDeficit", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000027 - Disclosure - GOING CONCERN (Details Narrative)", "menuCat": "Details", "order": "27", "role": "http://hartfordhealthcare.org/role/GoingConcernDetailsNarrative", "shortName": "GOING CONCERN (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R28": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "AsOf2022-07-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unitRef": "Shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000028 - Disclosure - STOCKHOLDERS\u2019 EQUITY (Details Narrative)", "menuCat": "Details", "order": "28", "role": "http://hartfordhealthcare.org/role/StockholdersEquityDetailsNarrative", "shortName": "STOCKHOLDERS\u2019 EQUITY (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "span", "span", "span", "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "AsOf2022-07-31", "decimals": "INF", "lang": null, "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "Shares", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "AsOf2020-07-20_custom_ShanghaiGelinkeChildcareEducationCenterMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000029 - Disclosure - SCHEDULE OF RECOGNIZED IDENTIFIED ASSETS ACQUIRED AND LIABILITIES ASSUMED (Details)", "menuCat": "Details", "order": "29", "role": "http://hartfordhealthcare.org/role/ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails", "shortName": "SCHEDULE OF RECOGNIZED IDENTIFIED ASSETS ACQUIRED AND LIABILITIES ASSUMED (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "AsOf2020-07-20_custom_ShanghaiGelinkeChildcareEducationCenterMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "AsOf2022-07-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "USDPShares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000003 - Statement - Consolidated Balance Sheets (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://hartfordhealthcare.org/role/BalanceSheetsParenthetical", "shortName": "Consolidated Balance Sheets (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "span", "link:footnote", "span", "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2020-07-192020-07-20_custom_ShanghaiGelinkeChildcareEducationCenterMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000030 - Disclosure - SCHEDULE OF RECOGNIZED IDENTIFIED ASSETS ACQUIRED AND LIABILITIES ASSUMED (Details) (Parenthetical)", "menuCat": "Details", "order": "30", "role": "http://hartfordhealthcare.org/role/ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetailsParenthetical", "shortName": "SCHEDULE OF RECOGNIZED IDENTIFIED ASSETS ACQUIRED AND LIABILITIES ASSUMED (Details) (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "span", "link:footnote", "span", "td", "tr", "table", "us-gaap:ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2020-07-192020-07-20_custom_ShanghaiGelinkeChildcareEducationCenterMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:PaymentsToAcquireBusinessesGross", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-01to2022-07-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000031 - Disclosure - SCHEDULE OF NET ASSETS (LIABILITIES) DISPOSED OF SUBSIDIARY (Details)", "menuCat": "Details", "order": "31", "role": "http://hartfordhealthcare.org/role/ScheduleOfNetAssetsLiabilitiesDisposedOfSubsidiaryDetails", "shortName": "SCHEDULE OF NET ASSETS (LIABILITIES) DISPOSED OF SUBSIDIARY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "HFUS:ScheduleOfNetAssetsLiabilitiesDisposedOfSubsidiaryTableTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "AsOf2020-12-31_custom_QiaoGardenIntelTravelMember", "decimals": "0", "lang": null, "name": "HFUS:DisposalGroupIncludingDiscontinuedOperationRelatedPartyReceivable", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R32": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "HFUS:ScheduleOfNetAssetsLiabilitiesDisposedOfSubsidiaryTableTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "AsOf2020-12-31_custom_QiaoGardenIntelTravelMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000032 - Disclosure - SCHEDULE OF NET INFLOW (OUTFLOW) OF CASH AND CASH EQUIVALENTS OF DISPOSAL SUBSIDIARY (Details)", "menuCat": "Details", "order": "32", "role": "http://hartfordhealthcare.org/role/ScheduleOfNetInflowOutflowOfCashAndCashEquivalentsOfDisposalSubsidiaryDetails", "shortName": "SCHEDULE OF NET INFLOW (OUTFLOW) OF CASH AND CASH EQUIVALENTS OF DISPOSAL SUBSIDIARY (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "AsOf2020-12-31_custom_QiaoGardenIntelTravelMember", "decimals": "0", "lang": null, "name": "HFUS:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalentsAndRestrictedCash", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R33": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "HFUS:NoncontrollingShareholdersDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000033 - Disclosure - ACQUISITIONS, JOINT VENTURES AND DECONSOLIDATION (Details Narrative)", "menuCat": "Details", "order": "33", "role": "http://hartfordhealthcare.org/role/AcquisitionsJointVenturesAndDeconsolidationDetailsNarrative", "shortName": "ACQUISITIONS, JOINT VENTURES AND DECONSOLIDATION (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:BusinessCombinationDisclosureTextBlock", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "HFUS:NoncontrollingShareholdersDescription", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R34": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "AsOf2022-07-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000034 - Disclosure - SCHEDULE OF DISCONTINUED OPERATIONS OF FINANCIAL STATEMENTS (Details)", "menuCat": "Details", "order": "34", "role": "http://hartfordhealthcare.org/role/ScheduleOfDiscontinuedOperationsOfFinancialStatementsDetails", "shortName": "SCHEDULE OF DISCONTINUED OPERATIONS OF FINANCIAL STATEMENTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "table", "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-012022-07-31_custom_HartfordInternationalEducationTechnologyCoLtdMember_us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember", "decimals": "0", "lang": null, "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationRevenue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R35": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "AsOf2022-08-01_custom_HangzhouLongjingQiaoFuVacationHotelCoLtdMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired", "reportCount": 1, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000035 - Disclosure - DISCONTINUED OPERATION (Details Narrative)", "menuCat": "Details", "order": "35", "role": "http://hartfordhealthcare.org/role/DiscontinuedOperationDetailsNarrative", "shortName": "DISCONTINUED OPERATION (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R36": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "AsOf2022-07-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000036 - Disclosure - RELATED PARTY TRANSACTIONS (Details Narrative)", "menuCat": "Details", "order": "36", "role": "http://hartfordhealthcare.org/role/RelatedPartyTransactionsDetailsNarrative", "shortName": "RELATED PARTY TRANSACTIONS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:RelatedPartyTransactionsDisclosureTextBlock", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "AsOf2022-07-31", "decimals": "0", "lang": null, "name": "us-gaap:AccountsPayableRelatedPartiesCurrentAndNoncurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R37": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-012022-07-31_custom_HartfordInternationalEducationTechnologyCoLtdMember_us-gaap_LicenseMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromLicenseFeesReceived", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000037 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details Narrative)", "menuCat": "Details", "order": "37", "role": "http://hartfordhealthcare.org/role/CommitmentsAndContingenciesDetailsNarrative", "shortName": "COMMITMENTS AND CONTINGENCIES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-012022-07-31_custom_HartfordInternationalEducationTechnologyCoLtdMember_us-gaap_LicenseMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProceedsFromLicenseFeesReceived", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R38": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "AsOf2022-07-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000038 - Disclosure - SCHEDULE OF INCOME TAX VALUATION (Details)", "menuCat": "Details", "order": "38", "role": "http://hartfordhealthcare.org/role/ScheduleOfIncomeTaxValuationDetails", "shortName": "SCHEDULE OF INCOME TAX VALUATION (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "AsOf2022-07-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R39": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-01to2022-07-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000039 - Disclosure - SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION (Details)", "menuCat": "Details", "order": "39", "role": "http://hartfordhealthcare.org/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails", "shortName": "SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-01to2022-07-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-01to2022-07-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000004 - Statement - Consolidated Statements of Operations", "menuCat": "Statements", "order": "4", "role": "http://hartfordhealthcare.org/role/StatementsOfOperations", "shortName": "Consolidated Statements of Operations", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-01to2022-07-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:SellingGeneralAndAdministrativeExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R40": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-01to2022-07-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000040 - Disclosure - INCOME TAXES (Details Narrative)", "menuCat": "Details", "order": "40", "role": "http://hartfordhealthcare.org/role/IncomeTaxesDetailsNarrative", "shortName": "INCOME TAXES (Details Narrative)", "subGroupType": "details", "uniqueAnchor": null }, "R41": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-01to2022-07-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000041 - Disclosure - SCHEDULE OF SEGMENT INFORMATION (Details)", "menuCat": "Details", "order": "41", "role": "http://hartfordhealthcare.org/role/ScheduleOfSegmentInformationDetails", "shortName": "SCHEDULE OF SEGMENT INFORMATION (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-01to2022-07-31", "decimals": "0", "lang": null, "name": "HFUS:OperatingIncomeLossIncludingContinuedAndDiscontinuedOperations", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R42": { "firstAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "AsOf2022-08-17_custom_RelatedPartyMember_us-gaap_SubsequentEventMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShortTermBorrowings", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000042 - Disclosure - SUBSEQUENT EVENTS (Details Narrative)", "menuCat": "Details", "order": "42", "role": "http://hartfordhealthcare.org/role/SubsequentEventsDetailsNarrative", "shortName": "SUBSEQUENT EVENTS (Details Narrative)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "AsOf2022-08-17_custom_RelatedPartyMember_us-gaap_SubsequentEventMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ShortTermBorrowings", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-01to2022-07-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000005 - Statement - Consolidated Statements of Comprehensive Loss", "menuCat": "Statements", "order": "5", "role": "http://hartfordhealthcare.org/role/StatementsOfComprehensiveLoss", "shortName": "Consolidated Statements of Comprehensive Loss", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-01to2022-07-31", "decimals": "0", "lang": null, "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "AsOf2020-07-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000006 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Deficit)", "menuCat": "Statements", "order": "6", "role": "http://hartfordhealthcare.org/role/StatementsOfChangesInStockholdersEquityDeficit", "shortName": "Consolidated Statements of Changes in Stockholders' Equity (Deficit)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "AsOf2020-07-31_us-gaap_CommonStockMember", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-01to2022-07-31", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ProfitLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00000007 - Statement - Consolidated Statements of Cash Flows", "menuCat": "Statements", "order": "7", "role": "http://hartfordhealthcare.org/role/StatementsOfCashFlows", "shortName": "Consolidated Statements of Cash Flows", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-01to2022-07-31", "decimals": "0", "lang": null, "name": "us-gaap:DepreciationAndAmortization", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000008 - Disclosure - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "menuCat": "Notes", "order": "8", "role": "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPolicies", "shortName": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "00000009 - Disclosure - GOING CONCERN", "menuCat": "Notes", "order": "9", "role": "http://hartfordhealthcare.org/role/GoingConcern", "shortName": "GOING CONCERN", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "form10-ka.htm", "contextRef": "From2021-08-01to2022-07-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubstantialDoubtAboutGoingConcernTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 52, "tag": { "HFUS_AdvancesFromRelatedParties": { "auth_ref": [], "calculation": { "http://hartfordhealthcare.org/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Advances from related parties.", "label": "Advances from related parties" } } }, "localname": "AdvancesFromRelatedParties", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "HFUS_AmendFeePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Amend fee percentage.", "label": "Amed fee percentage" } } }, "localname": "AmendFeePercentage", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "HFUS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash": { "auth_ref": [], "calculation": { "http://hartfordhealthcare.org/role/ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 2.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed current assets restricted cash.", "label": "Restricted Cash" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsRestrictedCash", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "HFUS_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill": { "auth_ref": [], "calculation": { "http://hartfordhealthcare.org/role/ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 6.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Business combination, recognized identifiable assets acquired and liabilities assumed, current assets, goodwill.", "label": "Goodwill" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedGoodwill", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "HFUS_ComputerSoftwareMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Computer Software [Member]", "label": "Computer Software [Member]" } } }, "localname": "ComputerSoftwareMember", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails" ], "xbrltype": "domainItemType" }, "HFUS_CorporateAndUnallocatedMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Corporate And Unallocated [Member]", "label": "Corporate And Unallocated [Member]" } } }, "localname": "CorporateAndUnallocatedMember", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "HFUS_DebtsForgivenessPerCourtRuling": { "auth_ref": [], "calculation": { "http://hartfordhealthcare.org/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Debts forgiveness per court ruling.", "label": "DebtsForgivenessPerCourtRuling", "negatedLabel": "Debts forgiveness per court ruling" } } }, "localname": "DebtsForgivenessPerCourtRuling", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "HFUS_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalentsAndRestrictedCash": { "auth_ref": [], "calculation": { "http://hartfordhealthcare.org/role/ScheduleOfNetInflowOutflowOfCashAndCashEquivalentsOfDisposalSubsidiaryDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disposal group, including discontinued operation, cash and cash equivalents and restricted cash.", "label": "Cash and cash equivalents deconsolidated", "negatedTotalLabel": "Cash and cash equivalents deconsolidated" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalentsAndRestrictedCash", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfNetInflowOutflowOfCashAndCashEquivalentsOfDisposalSubsidiaryDetails" ], "xbrltype": "monetaryItemType" }, "HFUS_DisposalGroupIncludingDiscontinuedOperationContractLiiabilitiesCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Disposal group including discontinued operation contract liiabilities current.", "label": "DisposalGroupIncludingDiscontinuedOperationContractLiiabilitiesCurrent", "verboseLabel": "Contract liabilities" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationContractLiiabilitiesCurrent", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfDiscontinuedOperationsOfFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "HFUS_DisposalGroupIncludingDiscontinuedOperationImpairmentExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disposal group including discontinued operation impairment expense.", "label": "Impairment" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationImpairmentExpense", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfDiscontinuedOperationsOfFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "HFUS_DisposalGroupIncludingDiscontinuedOperationLeaseLiabilities": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Disposal group including discontinued operation lease liabilities.", "label": "Lease liabilities, current and noncurrent" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationLeaseLiabilities", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfDiscontinuedOperationsOfFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "HFUS_DisposalGroupIncludingDiscontinuedOperationNetAssetsOfSubsidiary": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disposal group, including discontinued operation, net assets of the subsidiary.", "label": "Net assets of the subsidiary, excluding noncontrolling interest" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationNetAssetsOfSubsidiary", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfNetAssetsLiabilitiesDisposedOfSubsidiaryDetails" ], "xbrltype": "monetaryItemType" }, "HFUS_DisposalGroupIncludingDiscontinuedOperationNoncontrollingInterest": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Disposal group, including discontinued operation, noncontrolling interest.", "label": "DisposalGroupIncludingDiscontinuedOperationNoncontrollingInterest", "verboseLabel": "Noncontrolling interest" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationNoncontrollingInterest", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfNetAssetsLiabilitiesDisposedOfSubsidiaryDetails" ], "xbrltype": "monetaryItemType" }, "HFUS_DisposalGroupIncludingDiscontinuedOperationRelatedPartyLoanAndPayablesCurrent": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Disposal group including discontinued operation related party loan and payables current.", "label": "DisposalGroupIncludingDiscontinuedOperationRelatedPartyLoanAndPayablesCurrent", "verboseLabel": "Related party loan and payables" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationRelatedPartyLoanAndPayablesCurrent", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/RelatedPartyTransactionsDetailsNarrative", "http://hartfordhealthcare.org/role/ScheduleOfDiscontinuedOperationsOfFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "HFUS_DisposalGroupIncludingDiscontinuedOperationRelatedPartyPayable": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Disposal Group, Including Discontinued Operation, Related party payable.", "label": "Related party payable" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationRelatedPartyPayable", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfNetAssetsLiabilitiesDisposedOfSubsidiaryDetails" ], "xbrltype": "monetaryItemType" }, "HFUS_DisposalGroupIncludingDiscontinuedOperationRelatedPartyReceivable": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disposal group, including discontinued operation, related party receivable.", "label": "DisposalGroupIncludingDiscontinuedOperationRelatedPartyReceivable", "verboseLabel": "Related party receivable" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationRelatedPartyReceivable", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfNetAssetsLiabilitiesDisposedOfSubsidiaryDetails" ], "xbrltype": "monetaryItemType" }, "HFUS_DisposalGroupIncludingDiscontinuedOperationRestrictedCash": { "auth_ref": [], "calculation": { "http://hartfordhealthcare.org/role/ScheduleOfNetInflowOutflowOfCashAndCashEquivalentsOfDisposalSubsidiaryDetails": { "order": 2.0, "parentTag": "HFUS_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalentsAndRestrictedCash", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disposal group, including discontinued operation, restricted cash.", "label": "Restricted cash", "negatedLabel": "Restricted cash" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationRestrictedCash", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfNetAssetsLiabilitiesDisposedOfSubsidiaryDetails", "http://hartfordhealthcare.org/role/ScheduleOfNetInflowOutflowOfCashAndCashEquivalentsOfDisposalSubsidiaryDetails" ], "xbrltype": "monetaryItemType" }, "HFUS_DisposalGroupIncludingDiscontinuedOperationRightOfUseAssetsOperatingLease": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Disposal group including discontinued operation right of use assets operating lease.", "label": "ROU assets-operating lease" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationRightOfUseAssetsOperatingLease", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfDiscontinuedOperationsOfFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "HFUS_DisposalOfSubsidiary": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Disposal of subsidiary.", "label": "Disposal of subsidiary" } } }, "localname": "DisposalOfSubsidiary", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "HFUS_EarlyChildhoodEducationServicesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Early Childhood Education Services [Member]", "label": "Early Childhood Education Services [Member]" } } }, "localname": "EarlyChildhoodEducationServicesMember", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "HFUS_EducationAndHospitalitySegmentsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Education and Hospitality Segments [Member].", "label": "Education and Hospitality Segments [Member]" } } }, "localname": "EducationAndHospitalitySegmentsMember", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfDiscontinuedOperationsOfFinancialStatementsDetails" ], "xbrltype": "domainItemType" }, "HFUS_EducationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Education [Member]", "label": "Education [Member]" } } }, "localname": "EducationMember", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "HFUS_EffectiveIncomeTaxRateNontaxableItemAdjustment": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Nontaxable Item Adjustment", "label": "Non-taxable item adjustment" } } }, "localname": "EffectiveIncomeTaxRateNontaxableItemAdjustment", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "HFUS_EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncome": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Effective Income Tax Rate Reconciliation Global Intangible Low Taxed Income", "label": "GILTI" } } }, "localname": "EffectiveIncomeTaxRateReconciliationGlobalIntangibleLowTaxedIncome", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "HFUS_GainLossFromRestructure": { "auth_ref": [], "calculation": { "http://hartfordhealthcare.org/role/StatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Gain loss from restructure.", "label": "Loss from restructure" } } }, "localname": "GainLossFromRestructure", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "HFUS_GainOnDisposalOfSubsidiary": { "auth_ref": [], "calculation": { "http://hartfordhealthcare.org/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Gain on disposal of subsidiary.", "label": "Gain on disposal of subsidiary" } } }, "localname": "GainOnDisposalOfSubsidiary", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "HFUS_HangzhouHartfordComprehensiveHealthManagementLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Hangzhou Hartford Comprehensive Health Management Ltd [Member]", "label": "Hangzhou Hartford Comprehensive Health Management Ltd [Member]" } } }, "localname": "HangzhouHartfordComprehensiveHealthManagementLtdMember", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/AcquisitionsJointVenturesAndDeconsolidationDetailsNarrative", "http://hartfordhealthcare.org/role/DiscontinuedOperationDetailsNarrative", "http://hartfordhealthcare.org/role/SubsequentEventsDetailsNarrative", "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "HFUS_HangzhouLongjingQiaoFuVacationHotelCoLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Hangzhou Longjing Qiao Fu Vacation Hotel Co., Ltd [Member]", "label": "Hangzhou Longjing Qiao Fu Vacation Hotel Co., Ltd. [Member]" } } }, "localname": "HangzhouLongjingQiaoFuVacationHotelCoLtdMember", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/DiscontinuedOperationDetailsNarrative", "http://hartfordhealthcare.org/role/SubsequentEventsDetailsNarrative", "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "HFUS_HartfordHotelInvestmentIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Hartford Hotel Investment Inc [Member]", "label": "Hartford Hotel Investment Inc [Member]" } } }, "localname": "HartfordHotelInvestmentIncMember", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "HFUS_HartfordInternationalEducationTechnologyCoLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Hartford International Education Technology Co., Ltd [Member]", "label": "Hartford International Education Technology Co., Ltd [Member]" } } }, "localname": "HartfordInternationalEducationTechnologyCoLtdMember", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/AcquisitionsJointVenturesAndDeconsolidationDetailsNarrative", "http://hartfordhealthcare.org/role/CommitmentsAndContingenciesDetailsNarrative", "http://hartfordhealthcare.org/role/DiscontinuedOperationDetailsNarrative", "http://hartfordhealthcare.org/role/ScheduleOfDiscontinuedOperationsOfFinancialStatementsDetails", "http://hartfordhealthcare.org/role/SubsequentEventsDetailsNarrative", "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "HFUS_HospitalityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Hospitality [Member]", "label": "Hospitality [Member]" } } }, "localname": "HospitalityMember", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "HFUS_IncomeLossFromContinuingAndDiscontinuedOperationsBeforeIncomeTaxesExtraordinaryItems": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Income loss from continuing and discontinued operations before income taxes extraordinary items.", "label": "Loss before tax" } } }, "localname": "IncomeLossFromContinuingAndDiscontinuedOperationsBeforeIncomeTaxesExtraordinaryItems", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfSegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "HFUS_IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities": { "auth_ref": [], "calculation": { "http://hartfordhealthcare.org/role/StatementsOfCashFlows": { "order": 14.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Increase decrease in operating lease assets and liabilities.", "label": "IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities", "negatedLabel": "Operating lease assets and liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseAssetsAndLiabilities", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "HFUS_IntellectualPropertiesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Intellectual Properties [Member]", "label": "Intellectual Properties [Member]" } } }, "localname": "IntellectualPropertiesMember", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "HFUS_InvestmentFromNoncontrollingInterests": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Investment from Noncontrolling Interest.", "label": "InvestmentFromNoncontrollingInterests", "verboseLabel": "Investment from noncontrolling interest" } } }, "localname": "InvestmentFromNoncontrollingInterests", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/AcquisitionsJointVenturesAndDeconsolidationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "HFUS_InvestmentReturnThroughThreepartySettlement": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Investment return through threeparty settlement.", "label": "Investment return through three-party settlement" } } }, "localname": "InvestmentReturnThroughThreepartySettlement", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "HFUS_JointVentureAcquiredOwnershipInterest": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Joint venture acquired ownership interest.", "label": "Joint venture acquired ownership interest" } } }, "localname": "JointVentureAcquiredOwnershipInterest", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/AcquisitionsJointVenturesAndDeconsolidationDetailsNarrative" ], "xbrltype": "percentItemType" }, "HFUS_JointVentureAgreementMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Joint Venture Agreement [Member]", "label": "Joint Venture Agreement [Member]" } } }, "localname": "JointVentureAgreementMember", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/AcquisitionsJointVenturesAndDeconsolidationDetailsNarrative" ], "xbrltype": "domainItemType" }, "HFUS_LicenseDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "License Description", "label": "Licencse description" } } }, "localname": "LicenseDescription", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "HFUS_NetOperatingLossExpires": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Net operating loss expires.", "label": "NOL expires" } } }, "localname": "NetOperatingLossExpires", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfIncomeTaxValuationDetails" ], "xbrltype": "stringItemType" }, "HFUS_NoncontrollingInterestPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Noncontrolling Interest Policy Text [Block]", "label": "NoncontrollingInterestPolicyTextBlock", "verboseLabel": "Noncontrolling interest" } } }, "localname": "NoncontrollingInterestPolicyTextBlock", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "HFUS_NoncontrollingShareholdersDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Noncontrolling shareholders, description.", "label": "Noncontrolling shareholders, description" } } }, "localname": "NoncontrollingShareholdersDescription", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/AcquisitionsJointVenturesAndDeconsolidationDetailsNarrative" ], "xbrltype": "stringItemType" }, "HFUS_OfficeEquipmentVehiclesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Office Equipment and Vehicles [Member]", "label": "Office Equipment and Vehicles [Member]" } } }, "localname": "OfficeEquipmentVehiclesMember", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails" ], "xbrltype": "domainItemType" }, "HFUS_OperatingIncomeLossIncludingContinuedAndDiscontinuedOperations": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating income loss including continued and discontinued operations.", "label": "Operating loss" } } }, "localname": "OperatingIncomeLossIncludingContinuedAndDiscontinuedOperations", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfSegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "HFUS_PeoplesBankOfChinaFinancialStabilityBureauMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "People's Bank of China Financial Stability Bureau [Member]", "label": "People's Bank of China Financial Stability Bureau [Member]" } } }, "localname": "PeoplesBankOfChinaFinancialStabilityBureauMember", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "HFUS_PudongHaojinChildhoodEducationLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Pudong Haojin Childhood Education Ltd [Member]", "label": "Pudong Haojin Childhood Education Ltd [Member]" } } }, "localname": "PudongHaojinChildhoodEducationLtdMember", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "HFUS_QiaoGardenIntelTravelMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Qiao Garden Intel Travel [Member]", "label": "Qiao Garden Intel Travel [Member]" } } }, "localname": "QiaoGardenIntelTravelMember", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfNetAssetsLiabilitiesDisposedOfSubsidiaryDetails", "http://hartfordhealthcare.org/role/ScheduleOfNetInflowOutflowOfCashAndCashEquivalentsOfDisposalSubsidiaryDetails" ], "xbrltype": "domainItemType" }, "HFUS_ROUAssetsFinanceLeaseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ROU Assets-Finance Lease [Member]", "label": "ROU Assets-Finance Lease [Member]" } } }, "localname": "ROUAssetsFinanceLeaseMember", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails" ], "xbrltype": "domainItemType" }, "HFUS_ReclassificationsPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Reclassifications [Policy Text Block]", "label": "Reclassifications" } } }, "localname": "ReclassificationsPolicyTextBlock", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "HFUS_RelatedPartyMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related Party [Member]", "label": "Related Party [Member]" } } }, "localname": "RelatedPartyMember", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "HFUS_RestructureOfSubsidiary": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Restructure of subsidiary.", "label": "Restructure of subsidiary" } } }, "localname": "RestructureOfSubsidiary", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "HFUS_SHQiahongMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "SHQiahong [Member]", "label": "SHQiahong [Member]" } } }, "localname": "SHQiahongMember", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "HFUS_ScheduleOfNetAssetsLiabilitiesDisposedOfSubsidiaryTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Net Assets Liabilities Disposed Of Subsidiary [Table Text Block].", "label": "SCHEDULE OF NET ASSETS (LIABILITIES) DISPOSED OF SUBSIDIARY" } } }, "localname": "ScheduleOfNetAssetsLiabilitiesDisposedOfSubsidiaryTableTextBlock", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/AcquisitionsJointVenturesAndDeconsolidationTables" ], "xbrltype": "textBlockItemType" }, "HFUS_ScheduleOfPropertyAndEquipmentUsefulLivesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule Of Property And Equipment Useful Lives [Table Text Block]", "label": "SCHEDULE OF PROPERTY AND EQUIPMENT USEFUL LIFE" } } }, "localname": "ScheduleOfPropertyAndEquipmentUsefulLivesTableTextBlock", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "HFUS_SevenEducationTextbooksMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Seven Education Textbooks [Member]", "label": "Seven Education Textbooks [Member]" } } }, "localname": "SevenEducationTextbooksMember", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/AcquisitionsJointVenturesAndDeconsolidationDetailsNarrative" ], "xbrltype": "domainItemType" }, "HFUS_ShangaiLuoShengInternationalTradeLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shangai Luo Sheng International Trade Ltd [Member]", "label": "Shangai Luo Sheng International Trade Ltd [Member]" } } }, "localname": "ShangaiLuoShengInternationalTradeLtdMember", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "HFUS_ShanghaiGelinkeChildcareEducationCenterMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shanghai Gelinke Childcare Education Center [Member]", "label": "Shanghai Gelinke Childcare Education Center [Member]" } } }, "localname": "ShanghaiGelinkeChildcareEducationCenterMember", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/AcquisitionsJointVenturesAndDeconsolidationDetailsNarrative", "http://hartfordhealthcare.org/role/ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails", "http://hartfordhealthcare.org/role/ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetailsParenthetical" ], "xbrltype": "domainItemType" }, "HFUS_ShanghaiHartfordComprehensiveHealthManagementLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shanghai Hartford Comprehensive Health Management, Ltd. [Member]", "label": "Shanghai Hartford Comprehensive Health Management, Ltd. [Member]" } } }, "localname": "ShanghaiHartfordComprehensiveHealthManagementLtdMember", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "HFUS_ShanghaiHdfdZhongliEducationTechnologyCoLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shanghai Hdfd Zhongli Education Technology Co Ltd [Member]", "label": "Shanghai HDFD Zhongli Education Technology Co Ltd [Member]" } } }, "localname": "ShanghaiHdfdZhongliEducationTechnologyCoLtdMember", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "HFUS_ShanghaiHongkouHaiDeFuDeChildcareCoLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shanghai Hongkou Hai De FuDeChildcareCoLtdMember", "label": "Shanghai Hongkou Hai De Fu De Childcare Co Ltd [Member]" } } }, "localname": "ShanghaiHongkouHaiDeFuDeChildcareCoLtdMember", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "HFUS_ShanghaiJingyuEducationTechLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shanghai Jingyu Education Tech Ltd [Member]", "label": "Shanghai Jingyu Education Tech Ltd [Member]" } } }, "localname": "ShanghaiJingyuEducationTechLtdMember", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "HFUS_ShanghaiLuoShengInternationalTradeLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shanghai Luo Sheng International Trade Ltd. [Member]", "label": "Shanghai Luo Sheng International Trade Ltd. [Member]" } } }, "localname": "ShanghaiLuoShengInternationalTradeLtdMember", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/AcquisitionsJointVenturesAndDeconsolidationDetailsNarrative" ], "xbrltype": "domainItemType" }, "HFUS_ShanghaiOverseaChineseCultureMediaLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shanghai Oversea Chinese Culture Media Ltd [Member]", "label": "Shanghai Oversea Chinese Culture Media Ltd [Member]" } } }, "localname": "ShanghaiOverseaChineseCultureMediaLtdMember", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "domainItemType" }, "HFUS_ShanghaiOverseaMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shanghai Oversea [Member]", "label": "Shanghai Oversea [Member]" } } }, "localname": "ShanghaiOverseaMember", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/DiscontinuedOperationDetailsNarrative", "http://hartfordhealthcare.org/role/SubsequentEventsDetailsNarrative", "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "HFUS_ShanghaiPasadenaLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shanghai Pasadena Ltd. [Member]", "label": "Shanghai Pasadena Ltd. [Member]" } } }, "localname": "ShanghaiPasadenaLtdMember", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/AcquisitionsJointVenturesAndDeconsolidationDetailsNarrative" ], "xbrltype": "domainItemType" }, "HFUS_ShanghaiSeniorHealthConsultingLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shanghai Senior Health Consulting Ltd [Member]", "label": "Shanghai Senior Health Consulting Ltd. [Member]" } } }, "localname": "ShanghaiSeniorHealthConsultingLtdMember", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/AcquisitionsJointVenturesAndDeconsolidationDetailsNarrative" ], "xbrltype": "domainItemType" }, "HFUS_ShareholderMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Shareholder [Member]", "label": "Shareholder [Member]" } } }, "localname": "ShareholderMember", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/AcquisitionsJointVenturesAndDeconsolidationDetailsNarrative", "http://hartfordhealthcare.org/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "domainItemType" }, "HFUS_TenHaiDeFuDeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Ten \u201cHaiDeFuDe\u201d [Member]", "label": "Ten \u0093HaiDeFuDe\u0094 [Member]" } } }, "localname": "TenHaiDeFuDeMember", "nsuri": "http://hartfordhealthcare.org/20220731", "presentation": [ "http://hartfordhealthcare.org/role/AcquisitionsJointVenturesAndDeconsolidationDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r489" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r489" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditorFirmId": { "auth_ref": [ "r486", "r488", "r489" ], "lang": { "en-us": { "role": { "documentation": "PCAOB issued Audit Firm Identifier", "label": "Auditor Firm ID" } } }, "localname": "AuditorFirmId", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "nonemptySequenceNumberItemType" }, "dei_AuditorLocation": { "auth_ref": [ "r486", "r488", "r489" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "localname": "AuditorLocation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_AuditorName": { "auth_ref": [ "r486", "r488", "r489" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "localname": "AuditorName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "internationalNameItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r488" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r486", "r488", "r489" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r487" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r475" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r488" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r488" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r490" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r478" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r481" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r477" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/AcquisitionsJointVenturesAndDeconsolidationDetailsNarrative", "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r477" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r494" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r477" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r491" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r489" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r477" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r477" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r477" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r477" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r492" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/AcquisitionsJointVenturesAndDeconsolidationDetailsNarrative", "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r488" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r482" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r483" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r476" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r480" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r479" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r484" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r485" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r493" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://hartfordhealthcare.org/role/Cover" ], "xbrltype": "booleanItemType" }, "srt_ChiefExecutiveOfficerMember": { "auth_ref": [ "r511" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]" } } }, "localname": "ChiefExecutiveOfficerMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://hartfordhealthcare.org/role/AcquisitionsJointVenturesAndDeconsolidationDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ConsolidatedEntitiesAxis": { "auth_ref": [ "r206", "r379", "r380", "r383", "r384", "r410", "r456", "r521", "r524", "r525" ], "lang": { "en-us": { "role": { "label": "Consolidated Entities [Axis]" } } }, "localname": "ConsolidatedEntitiesAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfDiscontinuedOperationsOfFinancialStatementsDetails", "http://hartfordhealthcare.org/role/ScheduleOfNetAssetsLiabilitiesDisposedOfSubsidiaryDetails", "http://hartfordhealthcare.org/role/ScheduleOfNetInflowOutflowOfCashAndCashEquivalentsOfDisposalSubsidiaryDetails" ], "xbrltype": "stringItemType" }, "srt_ConsolidatedEntitiesDomain": { "auth_ref": [ "r206", "r379", "r380", "r383", "r384", "r410", "r456", "r521", "r524", "r525" ], "localname": "ConsolidatedEntitiesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfDiscontinuedOperationsOfFinancialStatementsDetails", "http://hartfordhealthcare.org/role/ScheduleOfNetAssetsLiabilitiesDisposedOfSubsidiaryDetails", "http://hartfordhealthcare.org/role/ScheduleOfNetInflowOutflowOfCashAndCashEquivalentsOfDisposalSubsidiaryDetails" ], "xbrltype": "domainItemType" }, "srt_EquityMethodInvesteeNameDomain": { "auth_ref": [], "localname": "EquityMethodInvesteeNameDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://hartfordhealthcare.org/role/SubsequentEventsDetailsNarrative", "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_MaximumMember": { "auth_ref": [ "r298", "r299", "r300", "r301", "r341", "r415", "r446", "r457", "r458", "r465", "r469", "r474", "r526", "r543", "r544", "r545", "r546", "r547", "r548" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://hartfordhealthcare.org/role/AcquisitionsJointVenturesAndDeconsolidationDetailsNarrative", "http://hartfordhealthcare.org/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r298", "r299", "r300", "r301", "r341", "r415", "r446", "r457", "r458", "r465", "r469", "r474", "r526", "r543", "r544", "r545", "r546", "r547", "r548" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://hartfordhealthcare.org/role/AcquisitionsJointVenturesAndDeconsolidationDetailsNarrative", "http://hartfordhealthcare.org/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails" ], "xbrltype": "domainItemType" }, "srt_OwnershipAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Ownership [Axis]" } } }, "localname": "OwnershipAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://hartfordhealthcare.org/role/AcquisitionsJointVenturesAndDeconsolidationDetailsNarrative", "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_OwnershipDomain": { "auth_ref": [], "localname": "OwnershipDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://hartfordhealthcare.org/role/AcquisitionsJointVenturesAndDeconsolidationDetailsNarrative", "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_ProductOrServiceAxis": { "auth_ref": [ "r262", "r417", "r466", "r473", "r518", "r519", "r527", "r553" ], "lang": { "en-us": { "role": { "label": "Product and Service [Axis]" } } }, "localname": "ProductOrServiceAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://hartfordhealthcare.org/role/CommitmentsAndContingenciesDetailsNarrative", "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_ProductsAndServicesDomain": { "auth_ref": [ "r262", "r417", "r466", "r473", "r518", "r519", "r527", "r553" ], "localname": "ProductsAndServicesDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://hartfordhealthcare.org/role/CommitmentsAndContingenciesDetailsNarrative", "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r298", "r299", "r300", "r301", "r339", "r341", "r342", "r343", "r344", "r414", "r415", "r446", "r457", "r458", "r465", "r469", "r474", "r515", "r526", "r544", "r545", "r546", "r547", "r548" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://hartfordhealthcare.org/role/AcquisitionsJointVenturesAndDeconsolidationDetailsNarrative", "http://hartfordhealthcare.org/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r298", "r299", "r300", "r301", "r339", "r341", "r342", "r343", "r344", "r414", "r415", "r446", "r457", "r458", "r465", "r469", "r474", "r515", "r526", "r544", "r545", "r546", "r547", "r548" ], "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://hartfordhealthcare.org/role/AcquisitionsJointVenturesAndDeconsolidationDetailsNarrative", "http://hartfordhealthcare.org/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails" ], "xbrltype": "domainItemType" }, "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": { "auth_ref": [ "r267" ], "lang": { "en-us": { "role": { "label": "Investment, Name [Axis]" } } }, "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://hartfordhealthcare.org/role/SubsequentEventsDetailsNarrative", "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualAxis": { "auth_ref": [ "r511", "r539" ], "lang": { "en-us": { "role": { "label": "Title of Individual [Axis]" } } }, "localname": "TitleOfIndividualAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://hartfordhealthcare.org/role/AcquisitionsJointVenturesAndDeconsolidationDetailsNarrative", "http://hartfordhealthcare.org/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "auth_ref": [], "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://hartfordhealthcare.org/role/AcquisitionsJointVenturesAndDeconsolidationDetailsNarrative", "http://hartfordhealthcare.org/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Changes and Error Corrections [Abstract]" } } }, "localname": "AccountingChangesAndErrorCorrectionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableRelatedPartiesCurrentAndNoncurrent": { "auth_ref": [ "r142", "r150", "r164", "r507" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount for accounts payable to related parties.", "label": "Accounts payable, related parties" } } }, "localname": "AccountsPayableRelatedPartiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsReceivableRelatedPartiesCurrent": { "auth_ref": [ "r142", "r144", "r180", "r507" ], "calculation": { "http://hartfordhealthcare.org/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.", "label": "Related party receivable" } } }, "localname": "AccountsReceivableRelatedPartiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r43", "r45", "r46", "r181", "r440", "r451", "r452" ], "calculation": { "http://hartfordhealthcare.org/role/BalanceSheets": { "order": 5.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r42", "r46", "r137", "r403", "r447", "r448", "r496", "r497", "r498", "r508", "r509", "r510" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r30", "r472" ], "calculation": { "http://hartfordhealthcare.org/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r345", "r346", "r347", "r508", "r509", "r510", "r535" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss including noncontrolling interests to net cash provided by (used in) operating activities:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdvertisingCostsPolicyTextBlock": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for advertising cost.", "label": "Advertising costs" } } }, "localname": "AdvertisingCostsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_AdvertisingExpense": { "auth_ref": [ "r349" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.", "label": "Advertising cost" } } }, "localname": "AdvertisingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "localname": "ArrangementsAndNonarrangementTransactionsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/AcquisitionsJointVenturesAndDeconsolidationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r146", "r157", "r179", "r203", "r246", "r252", "r258", "r268", "r302", "r303", "r305", "r306", "r307", "r308", "r309", "r311", "r312", "r379", "r383", "r389", "r472", "r522", "r523", "r541" ], "calculation": { "http://hartfordhealthcare.org/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Total assets (excluding Intercompany balances)", "totalLabel": "TOTAL ASSETS" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/BalanceSheets", "http://hartfordhealthcare.org/role/ScheduleOfSegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r175", "r182", "r203", "r268", "r302", "r303", "r305", "r306", "r307", "r308", "r309", "r311", "r312", "r379", "r383", "r389", "r472", "r522", "r523", "r541" ], "calculation": { "http://hartfordhealthcare.org/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total Current Assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsHeldForSaleNotPartOfDisposalGroup": { "auth_ref": [ "r95" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of assets held-for-sale that are not part of a disposal group.", "label": "Assets Held-for-sale, Not Part of Disposal Group", "negatedLabel": "Assets allocated to held for sale" } } }, "localname": "AssetsHeldForSaleNotPartOfDisposalGroup", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfSegmentInformationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsNoncurrent": { "auth_ref": [ "r203", "r268", "r302", "r303", "r305", "r306", "r307", "r308", "r309", "r311", "r312", "r379", "r383", "r389", "r522", "r523", "r541" ], "calculation": { "http://hartfordhealthcare.org/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold or consumed after one year or beyond the normal operating cycle, if longer.", "label": "Assets, Noncurrent", "totalLabel": "Total Non-current Assets" } } }, "localname": "AssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsNoncurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-current Assets" } } }, "localname": "AssetsNoncurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": { "auth_ref": [ "r0", "r1", "r19", "r102", "r173", "r174" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Assets", "totalLabel": "Total Assets held for sale" } } }, "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfDiscontinuedOperationsOfFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "auth_ref": [ "r0", "r1", "r19", "r98", "r102", "r173", "r174" ], "calculation": { "http://hartfordhealthcare.org/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Current assets held for sale" } } }, "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Assets" } } }, "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfDiscontinuedOperationsOfFinancialStatementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Presentation" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "auth_ref": [ "r375", "r467", "r468" ], "lang": { "en-us": { "role": { "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "localname": "BusinessAcquisitionAcquireeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/AcquisitionsJointVenturesAndDeconsolidationDetailsNarrative", "http://hartfordhealthcare.org/role/DiscontinuedOperationDetailsNarrative", "http://hartfordhealthcare.org/role/ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails", "http://hartfordhealthcare.org/role/ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetailsParenthetical", "http://hartfordhealthcare.org/role/SubsequentEventsDetailsNarrative", "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_BusinessAcquisitionAxis": { "auth_ref": [ "r123", "r124", "r375", "r467", "r468" ], "lang": { "en-us": { "role": { "documentation": "Information by business combination or series of individually immaterial business combinations.", "label": "Business Acquisition [Axis]" } } }, "localname": "BusinessAcquisitionAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/AcquisitionsJointVenturesAndDeconsolidationDetailsNarrative", "http://hartfordhealthcare.org/role/DiscontinuedOperationDetailsNarrative", "http://hartfordhealthcare.org/role/ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails", "http://hartfordhealthcare.org/role/ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetailsParenthetical", "http://hartfordhealthcare.org/role/SubsequentEventsDetailsNarrative", "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Business Acquisition [Line Items]" } } }, "localname": "BusinessAcquisitionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/AcquisitionsJointVenturesAndDeconsolidationDetailsNarrative", "http://hartfordhealthcare.org/role/ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails", "http://hartfordhealthcare.org/role/ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetailsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired": { "auth_ref": [ "r122" ], "lang": { "en-us": { "role": { "documentation": "Percentage of voting equity interests acquired at the acquisition date in the business combination.", "label": "Business acquisition, percentage of voting interests acquired", "verboseLabel": "Business acquired ownership interest" } } }, "localname": "BusinessAcquisitionPercentageOfVotingInterestsAcquired", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/AcquisitionsJointVenturesAndDeconsolidationDetailsNarrative", "http://hartfordhealthcare.org/role/DiscontinuedOperationDetailsNarrative", "http://hartfordhealthcare.org/role/SubsequentEventsDetailsNarrative", "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Business Combination and Asset Acquisition [Abstract]" } } }, "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_BusinessCombinationDisclosureTextBlock": { "auth_ref": [ "r128", "r376" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).", "label": "ACQUISITIONS, JOINT VENTURES AND DECONSOLIDATION" } } }, "localname": "BusinessCombinationDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/AcquisitionsJointVenturesAndDeconsolidation" ], "xbrltype": "textBlockItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": { "auth_ref": [ "r126" ], "calculation": { "http://hartfordhealthcare.org/role/ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 1.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": { "auth_ref": [ "r126" ], "calculation": { "http://hartfordhealthcare.org/role/ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 3.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets", "verboseLabel": "Prepaid and Other current receivables" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue": { "auth_ref": [ "r126" ], "calculation": { "http://hartfordhealthcare.org/role/ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 5.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred revenue expected to be recognized as such within one year or the normal operating cycle, if longer, assumed at the acquisition date.", "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Deferred Revenue", "negatedLabel": "Unearned revenue" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesDeferredRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet": { "auth_ref": [ "r125", "r126" ], "calculation": { "http://hartfordhealthcare.org/role/ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.", "label": "Total consideration", "totalLabel": "Total consideration" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails", "http://hartfordhealthcare.org/role/ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetailsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": { "auth_ref": [ "r125", "r126" ], "calculation": { "http://hartfordhealthcare.org/role/ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails": { "order": 4.0, "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.", "label": "Property and Equipment, net" } } }, "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_BusinessCombinationsPolicy": { "auth_ref": [ "r121" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.", "label": "Business Combinations" } } }, "localname": "BusinessCombinationsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Capital": { "auth_ref": [ "r439" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of total capital as defined by regulatory framework.", "label": "Registered capital" } } }, "localname": "Capital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/AcquisitionsJointVenturesAndDeconsolidationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r73", "r74", "r75" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Payable to acquiree" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r70", "r177", "r459" ], "calculation": { "http://hartfordhealthcare.org/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r71" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r64", "r70", "r76" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations", "periodEndLabel": "Cash, cash equivalents and restricted cash at end of period", "periodStartLabel": "Cash, cash equivalents and restricted cash at beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r64", "r141" ], "calculation": { "http://hartfordhealthcare.org/role/StatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net change in Cash, cash equivalents and restricted cash" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashDivestedFromDeconsolidation": { "auth_ref": [ "r60" ], "calculation": { "http://hartfordhealthcare.org/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reduction in cash due to no longer including the former subsidiary's cash in the consolidated entity's cash.", "label": "Cash Divested from Deconsolidation", "negatedLabel": "Disposal of subsidiary" } } }, "localname": "CashDivestedFromDeconsolidation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashFDICInsuredAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.", "label": "FDIC insured amount" } } }, "localname": "CashFDICInsuredAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations": { "auth_ref": [ "r18", "r64" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of investing activities of discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Investing cash flows" } } }, "localname": "CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfDiscontinuedOperationsOfFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations": { "auth_ref": [ "r18", "r64" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) of operating activities of discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Operating cash flows" } } }, "localname": "CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfDiscontinuedOperationsOfFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r38", "r151", "r163" ], "calculation": { "http://hartfordhealthcare.org/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingencies (Note 7)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r106", "r296", "r297", "r453", "r520" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "COMMITMENTS AND CONTINGENCIES" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/CommitmentsAndContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r508", "r509", "r535" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par value" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/BalanceSheetsParenthetical", "http://hartfordhealthcare.org/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/BalanceSheetsParenthetical", "http://hartfordhealthcare.org/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r29", "r107" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/BalanceSheetsParenthetical", "http://hartfordhealthcare.org/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r29", "r472" ], "calculation": { "http://hartfordhealthcare.org/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock - $0.001 par value, 300,000,000 shares authorized, 100,108,000 shares outstanding at both of July 31, 2022 and 2021." } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r47", "r185", "r187", "r194", "r435", "r443" ], "calculation": { "http://hartfordhealthcare.org/role/StatementsOfComprehensiveLoss": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Total Comprehensive Loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": { "auth_ref": [ "r133", "r134", "r139", "r185", "r187", "r193", "r434", "r442" ], "calculation": { "http://hartfordhealthcare.org/role/StatementsOfComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Less: total other comprehensive loss attributable to noncontrolling interest" } } }, "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income (loss)" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtInstrumentInterestRateStatedPercentage": { "auth_ref": [ "r37", "r313" ], "lang": { "en-us": { "role": { "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.", "label": "Debt instrument, interest rate, stated percentage" } } }, "localname": "DebtInstrumentInterestRateStatedPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/RelatedPartyTransactionsDetailsNarrative", "http://hartfordhealthcare.org/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_DeferredIncomeTaxExpenseBenefit": { "auth_ref": [ "r68", "r120", "r360", "r366", "r367", "r506" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.", "label": "Estimated tax benefit from NOL and other tax benefits (21%)" } } }, "localname": "DeferredIncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfIncomeTaxValuationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsLiabilitiesNet": { "auth_ref": [ "r530" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.", "label": "Net deferred tax asset" } } }, "localname": "DeferredTaxAssetsLiabilitiesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfIncomeTaxValuationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r530" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "negatedLabel": "Change in valuation allowance" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfIncomeTaxValuationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "auth_ref": [ "r118", "r531" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.", "label": "Net NOL carry-forward" } } }, "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfIncomeTaxValuationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r357" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfIncomeTaxValuationDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DefinedBenefitPlanDisclosureLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Defined Benefit Plan Disclosure [Line Items]" } } }, "localname": "DefinedBenefitPlanDisclosureLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_DepreciationAndAmortization": { "auth_ref": [ "r68", "r99" ], "calculation": { "http://hartfordhealthcare.org/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationAndAmortization", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax": { "auth_ref": [ "r5", "r7", "r9" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.", "label": "Gain on disposal of the subsidiary" } } }, "localname": "DiscontinuedOperationGainLossFromDisposalOfDiscontinuedOperationBeforeIncomeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfNetAssetsLiabilitiesDisposedOfSubsidiaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax": { "auth_ref": [ "r5", "r6", "r7", "r8", "r9", "r16", "r51", "r166" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Loss from operations of discontinued operations" } } }, "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfDiscontinuedOperationsOfFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax": { "auth_ref": [ "r5", "r6", "r21" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from operations classified as a discontinued operation. Excludes gain (loss) on disposal and provision for gain (loss) until disposal.", "label": "Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax", "totalLabel": "Income (loss) from discontinued operations, net of taxes before gain from sale of discontinued operations" } } }, "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfDiscontinuedOperationsOfFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax": { "auth_ref": [ "r5", "r7", "r9", "r21" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of (gain) loss recognized for the (reversal of write-down) write-down to fair value, less cost to sell, of a discontinued operation.", "label": "Loss from sale of discontinued operations, net of taxes" } } }, "localname": "DiscontinuedOperationProvisionForLossGainOnDisposalNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfDiscontinuedOperationsOfFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod": { "auth_ref": [ "r6", "r21", "r533" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) attributable to income (loss) from operations classified as a discontinued operation. Excludes tax expense (benefit) for gain (loss) on disposal and for provision for gain (loss) until disposal.", "label": "Income tax benefit (expense)" } } }, "localname": "DiscontinuedOperationTaxEffectOfIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfDiscontinuedOperationsOfFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation": { "auth_ref": [ "r7", "r9", "r21", "r533" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit) on gain (loss) not previously recognized resulting from the disposal of a discontinued operation.", "label": "Gain on disposal of noncontrolling interest" } } }, "localname": "DiscontinuedOperationTaxEffectOfIncomeLossFromDisposalOfDiscontinuedOperation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfNetAssetsLiabilitiesDisposedOfSubsidiaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember": { "auth_ref": [ "r2", "r3", "r4" ], "lang": { "en-us": { "role": { "documentation": "Component or group of components classified as held-for-sale or disposed of by sale and representing a strategic shift that has or will have a major effect on operations and financial results. Includes a business or nonprofit activity on acquisition classified as held-for-sale.", "label": "Discontinued Operations, Held-for-sale or Disposed of by Sale [Member]" } } }, "localname": "DiscontinuedOperationsHeldForSaleOrDisposedOfBySaleMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfDiscontinuedOperationsOfFinancialStatementsDetails", "http://hartfordhealthcare.org/role/ScheduleOfSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupClassificationAxis": { "auth_ref": [ "r173" ], "lang": { "en-us": { "role": { "documentation": "Information by disposal group classification.", "label": "Disposal Group Classification [Axis]" } } }, "localname": "DisposalGroupClassificationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfDiscontinuedOperationsOfFinancialStatementsDetails", "http://hartfordhealthcare.org/role/ScheduleOfSegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DisposalGroupClassificationDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "localname": "DisposalGroupClassificationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfDiscontinuedOperationsOfFinancialStatementsDetails", "http://hartfordhealthcare.org/role/ScheduleOfSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": { "auth_ref": [ "r0", "r1", "r19", "r102" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net", "verboseLabel": "Related party receivable" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/RelatedPartyTransactionsDetailsNarrative", "http://hartfordhealthcare.org/role/ScheduleOfDiscontinuedOperationsOfFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent": { "auth_ref": [ "r0", "r1", "r19", "r98", "r102" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Accounts Payable, Current", "verboseLabel": "Other current payable" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfDiscontinuedOperationsOfFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent": { "auth_ref": [ "r0", "r1", "r19", "r97", "r102", "r173", "r174" ], "calculation": { "http://hartfordhealthcare.org/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.", "label": "Non-current assets held for sale" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents": { "auth_ref": [ "r0", "r1", "r19", "r102" ], "calculation": { "http://hartfordhealthcare.org/role/ScheduleOfNetInflowOutflowOfCashAndCashEquivalentsOfDisposalSubsidiaryDetails": { "order": 1.0, "parentTag": "HFUS_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalentsAndRestrictedCash", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.", "label": "Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents", "negatedLabel": "Cash and cash equivalents", "verboseLabel": "Cash and cash equivalents" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfDiscontinuedOperationsOfFinancialStatementsDetails", "http://hartfordhealthcare.org/role/ScheduleOfNetAssetsLiabilitiesDisposedOfSubsidiaryDetails", "http://hartfordhealthcare.org/role/ScheduleOfNetInflowOutflowOfCashAndCashEquivalentsOfDisposalSubsidiaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.", "label": "Consideration" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfNetAssetsLiabilitiesDisposedOfSubsidiaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold": { "auth_ref": [ "r17", "r174" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of costs of goods sold attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Cost of sales" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfDiscontinuedOperationsOfFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense": { "auth_ref": [ "r17" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of general and administrative expense attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Selling, general, and administrative expenses" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfDiscontinuedOperationsOfFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss": { "auth_ref": [ "r17", "r174" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gross profit attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Gross Profit (Loss)", "totalLabel": "Gross profit" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfDiscontinuedOperationsOfFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent": { "auth_ref": [ "r0", "r1", "r19", "r98", "r102" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Inventory" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationInventoryCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfDiscontinuedOperationsOfFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOperatingExpense": { "auth_ref": [ "r17" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of operating expense attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Disposal Group, Including Discontinued Operation, Operating Expense", "totalLabel": "Total operating expenses" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOperatingExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfDiscontinuedOperationsOfFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets": { "auth_ref": [ "r0", "r1", "r19", "r98", "r102" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Other assets" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfDiscontinuedOperationsOfFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities": { "auth_ref": [ "r0", "r1", "r19", "r98", "r102" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Other Liabilities, Current", "negatedLabel": "Other current payable", "verboseLabel": "Other liabilities" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfDiscontinuedOperationsOfFinancialStatementsDetails", "http://hartfordhealthcare.org/role/ScheduleOfNetAssetsLiabilitiesDisposedOfSubsidiaryDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent": { "auth_ref": [ "r0", "r1", "r19", "r98", "r102" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as prepaid and other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Prepaid and Other Assets, Current", "verboseLabel": "Prepaid and Other current receivables" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationPrepaidAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfDiscontinuedOperationsOfFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent": { "auth_ref": [ "r0", "r1", "r19", "r98", "r102" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Current", "verboseLabel": "Property and equipment, net" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfDiscontinuedOperationsOfFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationRevenue": { "auth_ref": [ "r17", "r174" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue attributable to disposal group, including, but not limited to, discontinued operation.", "label": "Net sales" } } }, "localname": "DisposalGroupIncludingDiscontinuedOperationRevenue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfDiscontinuedOperationsOfFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "auth_ref": [ "r25", "r105" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "DISCONTINUED OPERATION" } } }, "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/DiscontinuedOperation" ], "xbrltype": "textBlockItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r195", "r212", "r213", "r214", "r215", "r216", "r221", "r222", "r225", "r226", "r227", "r228", "r387", "r388", "r436", "r444", "r461" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Basic and Diluted" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareBasicAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net loss per common share:" } } }, "localname": "EarningsPerShareBasicAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r79", "r80" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Income (Loss) Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": { "auth_ref": [ "r537" ], "calculation": { "http://hartfordhealthcare.org/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of exchange rate changes on cash" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Effective tax rate" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r204", "r353", "r368" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Federal income tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r529", "r532" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.", "label": "Valuation allowance" } } }, "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": { "auth_ref": [ "r529", "r532" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.", "label": "Foreign tax difference" } } }, "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": { "auth_ref": [ "r529", "r532" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.", "label": "Others" } } }, "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "auth_ref": [ "r529", "r532" ], "lang": { "en-us": { "role": { "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).", "label": "State income tax rate" } } }, "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r107", "r170", "r189", "r190", "r191", "r207", "r208", "r209", "r211", "r217", "r220", "r229", "r269", "r327", "r345", "r346", "r347", "r362", "r363", "r386", "r391", "r392", "r393", "r394", "r395", "r398", "r403", "r447", "r448", "r449" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_EquityMethodInvestmentOwnershipPercentage": { "auth_ref": [ "r88" ], "lang": { "en-us": { "role": { "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.", "label": "Equity ownership percentage", "verboseLabel": "Equity method investment ownership, perentage" } } }, "localname": "EquityMethodInvestmentOwnershipPercentage", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/SubsequentEventsDetailsNarrative", "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_ErrorCorrectionTextBlock": { "auth_ref": [ "r218" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting error correction.", "label": "RESTATEMENT" } } }, "localname": "ErrorCorrectionTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/Restatement" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair value measurement" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinanceLeasePrincipalPayments": { "auth_ref": [ "r401", "r402" ], "calculation": { "http://hartfordhealthcare.org/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow for principal payment on finance lease.", "label": "Finance Lease, Principal Payments", "negatedLabel": "Principal payments on finance lease" } } }, "localname": "FinanceLeasePrincipalPayments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r282", "r284", "r285", "r287", "r418", "r419" ], "lang": { "en-us": { "role": { "documentation": "Information by major type or class of finite-lived intangible assets.", "label": "Finite-Lived Intangible Assets by Major Class [Axis]" } } }, "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r90", "r93" ], "lang": { "en-us": { "role": { "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": { "auth_ref": [ "r400" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.", "label": "Foreign Currency" } } }, "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FurnitureAndFixturesMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.", "label": "Furniture and Fixtures [Member]" } } }, "localname": "FurnitureAndFixturesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": { "auth_ref": [ "r68" ], "calculation": { "http://hartfordhealthcare.org/role/StatementsOfCashFlows": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.", "label": "Gain (Loss) on Disposition of Property Plant Equipment", "negatedLabel": "Loss on disposal of property and equipment" } } }, "localname": "GainLossOnSaleOfPropertyPlantEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_GainOrLossOnSaleOfStockInSubsidiary": { "auth_ref": [ "r499", "r500", "r504", "r549", "r552" ], "calculation": { "http://hartfordhealthcare.org/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) on sale or disposal of equity in securities of subsidiaries.", "label": "Gain (Loss) on Disposition of Stock in Subsidiary", "negatedLabel": "Disposal of subsidiary, including noncontrolling interest" } } }, "localname": "GainOrLossOnSaleOfStockInSubsidiary", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_Goodwill": { "auth_ref": [ "r178", "r270", "r432", "r464", "r472", "r513", "r514" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Goodwill [Default Label]", "verboseLabel": "Goodwill" } } }, "localname": "Goodwill", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/AcquisitionsJointVenturesAndDeconsolidationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": { "auth_ref": [ "r89", "r92" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.", "label": "Goodwill and Long-lived Assets" } } }, "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GoodwillImpairmentLoss": { "auth_ref": [ "r68", "r271", "r276", "r281", "r464" ], "calculation": { "http://hartfordhealthcare.org/role/StatementsOfCashFlows": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.", "label": "Impairment loss" } } }, "localname": "GoodwillImpairmentLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperations": { "auth_ref": [ "r53", "r69", "r131", "r212", "r213", "r214", "r215", "r224", "r227" ], "calculation": { "http://hartfordhealthcare.org/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.", "label": "Net (loss) income from continuing operations Attributable to Hartford Great Health Corp" } } }, "localname": "IncomeLossFromContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity": { "auth_ref": [ "r129", "r132" ], "calculation": { "http://hartfordhealthcare.org/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.", "label": "Less: net income from continuing operations attributable to noncontrolling Interest" } } }, "localname": "IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r50", "r145", "r153", "r169", "r246", "r251", "r257", "r260", "r437", "r463" ], "calculation": { "http://hartfordhealthcare.org/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "totalLabel": "(Loss) income before income taxes" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r132", "r203", "r210", "r246", "r251", "r257", "r260", "r268", "r302", "r303", "r305", "r306", "r307", "r308", "r309", "r311", "r312", "r388", "r389", "r463", "r522" ], "calculation": { "http://hartfordhealthcare.org/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperations", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.", "label": "Net (loss) income from continuing operations" } } }, "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": { "auth_ref": [ "r49", "r152", "r154", "r165", "r195", "r210", "r212", "r213", "r214", "r215", "r222", "r225", "r226", "r388", "r436" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.", "label": "Continuing operations" } } }, "localname": "IncomeLossFromContinuingOperationsPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": { "auth_ref": [ "r5", "r6", "r7", "r8", "r9", "r21", "r166", "r174", "r371" ], "calculation": { "http://hartfordhealthcare.org/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "totalLabel": "Income loss from discontinued operations, net of income taxes" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfDiscontinuedOperationsOfFinancialStatementsDetails", "http://hartfordhealthcare.org/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest": { "auth_ref": [ "r5", "r6", "r7", "r8", "r9", "r16", "r21", "r129", "r132" ], "calculation": { "http://hartfordhealthcare.org/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Less: net loss from discontinued operations attributable to noncontrolling Interest" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": { "auth_ref": [ "r5", "r6", "r7", "r8", "r9", "r16", "r21", "r132" ], "calculation": { "http://hartfordhealthcare.org/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.", "label": "Net loss from discontinued operations Attributable to Hartford Great Health Corp", "verboseLabel": "Gain on disposal of the subsidiary, excluding noncontrolling interest" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfNetAssetsLiabilitiesDisposedOfSubsidiaryDetails", "http://hartfordhealthcare.org/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": { "auth_ref": [ "r51", "r166", "r168", "r195", "r223", "r225", "r226", "r550", "r551" ], "lang": { "en-us": { "role": { "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.", "label": "Discontinued operations" } } }, "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfDiscontinuedOperationsOfFinancialStatementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "auth_ref": [ "r1", "r10", "r11", "r12", "r13", "r14", "r15", "r20", "r22", "r23", "r24", "r103", "r104" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "Disposal Groups, Including Discontinued Operations [Table]" } } }, "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfDiscontinuedOperationsOfFinancialStatementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Abstract]" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r204", "r354", "r355", "r359", "r364", "r369", "r372", "r373", "r374" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/IncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationDescription": { "auth_ref": [ "r117" ], "lang": { "en-us": { "role": { "documentation": "A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings.", "label": "Income tax examination description" } } }, "localname": "IncomeTaxExaminationDescription", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r205", "r219", "r220", "r244", "r352", "r365", "r370", "r445" ], "calculation": { "http://hartfordhealthcare.org/role/StatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income tax expense", "totalLabel": "Income Tax Expense" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/IncomeTaxesDetailsNarrative", "http://hartfordhealthcare.org/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxPolicyTextBlock": { "auth_ref": [ "r188", "r350", "r351", "r355", "r356", "r358", "r361" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.", "label": "Income Taxes" } } }, "localname": "IncomeTaxPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxesPaidNet": { "auth_ref": [ "r72" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.", "label": "Income taxes paid" } } }, "localname": "IncomeTaxesPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInBrokerDealerRelatedReceivablesPayablesNet": { "auth_ref": [ "r67" ], "calculation": { "http://hartfordhealthcare.org/role/StatementsOfCashFlows": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in receivables or payables that result from buying and selling securities for the firm's own account or from acting as an agent or intermediary in the sale of securities.", "label": "Increase (Decrease) in Broker-Dealer Related Receivables (Payables), Net", "negatedLabel": "Related party receivables and payables" } } }, "localname": "IncreaseDecreaseInBrokerDealerRelatedReceivablesPayablesNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r416", "r503" ], "calculation": { "http://hartfordhealthcare.org/role/StatementsOfCashFlows": { "order": 12.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Contract liabilities" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInInventories": { "auth_ref": [ "r67" ], "calculation": { "http://hartfordhealthcare.org/role/StatementsOfCashFlows": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.", "label": "Increase (Decrease) in Inventories", "negatedLabel": "Inventory" } } }, "localname": "IncreaseDecreaseInInventories", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOtherAccountsPayable": { "auth_ref": [ "r67" ], "calculation": { "http://hartfordhealthcare.org/role/StatementsOfCashFlows": { "order": 13.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligations classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Increase (Decrease) in Other Accounts Payable", "verboseLabel": "Other current payable" } } }, "localname": "IncreaseDecreaseInOtherAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherCurrentLiabilities": { "auth_ref": [ "r503" ], "calculation": { "http://hartfordhealthcare.org/role/StatementsOfCashFlows": { "order": 15.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in current liabilities classified as other.", "label": "Other liabilities" } } }, "localname": "IncreaseDecreaseInOtherCurrentLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r67" ], "calculation": { "http://hartfordhealthcare.org/role/StatementsOfCashFlows": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r67" ], "calculation": { "http://hartfordhealthcare.org/role/StatementsOfCashFlows": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid and Other current receivables" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": { "auth_ref": [ "r283", "r286" ], "lang": { "en-us": { "role": { "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.", "label": "Indefinite-Lived Intangible Assets [Axis]" } } }, "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/AcquisitionsJointVenturesAndDeconsolidationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": { "auth_ref": [ "r91", "r94" ], "lang": { "en-us": { "role": { "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company." } } }, "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/AcquisitionsJointVenturesAndDeconsolidationDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_InterestExpenseRelatedParty": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of interest expense incurred on a debt or other obligation to related party.", "label": "Interest expense, related party" } } }, "localname": "InterestExpenseRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNet": { "auth_ref": [ "r156" ], "calculation": { "http://hartfordhealthcare.org/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of operating interest income (expense).", "label": "Interest (expense) income, net", "verboseLabel": "Interest expense" } } }, "localname": "InterestIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfDiscontinuedOperationsOfFinancialStatementsDetails", "http://hartfordhealthcare.org/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestPaidNet": { "auth_ref": [ "r196", "r199", "r200" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.", "label": "Interest paid" } } }, "localname": "InterestPaidNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_InvestmentIncomeNet": { "auth_ref": [ "r55", "r57" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.", "label": "Investment income" } } }, "localname": "InvestmentIncomeNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/AcquisitionsJointVenturesAndDeconsolidationDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseholdImprovementsMember": { "auth_ref": [ "r100" ], "lang": { "en-us": { "role": { "documentation": "Additions or improvements to assets held under a lease arrangement.", "label": "Leasehold Improvements [Member]" } } }, "localname": "LeaseholdImprovementsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r34", "r203", "r268", "r302", "r303", "r305", "r306", "r307", "r308", "r309", "r311", "r312", "r380", "r383", "r384", "r389", "r462", "r522", "r541", "r542" ], "calculation": { "http://hartfordhealthcare.org/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "TOTAL LIABILITIES" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r32", "r149", "r161", "r472", "r505", "r512", "r536" ], "calculation": { "http://hartfordhealthcare.org/role/BalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r36", "r176", "r203", "r268", "r302", "r303", "r305", "r306", "r307", "r308", "r309", "r311", "r312", "r380", "r383", "r384", "r389", "r472", "r522", "r541", "r542" ], "calculation": { "http://hartfordhealthcare.org/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total Current Liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current Liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent": { "auth_ref": [ "r0", "r1", "r19", "r98", "r102", "r173", "r174" ], "calculation": { "http://hartfordhealthcare.org/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.", "label": "Current liabilities held for sale", "totalLabel": "Total Liabilities held for sale" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/BalanceSheets", "http://hartfordhealthcare.org/role/ScheduleOfDiscontinuedOperationsOfFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "verboseLabel": "Current Liabilities" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfDiscontinuedOperationsOfFinancialStatementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent": { "auth_ref": [ "r0", "r1", "r19", "r97", "r102", "r173", "r174" ], "calculation": { "http://hartfordhealthcare.org/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.", "label": "Long-term liabilities held for sale" } } }, "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LicenseMember": { "auth_ref": [ "r528" ], "lang": { "en-us": { "role": { "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.", "label": "License [Member]" } } }, "localname": "LicenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_MinorityInterest": { "auth_ref": [ "r40", "r148", "r160", "r203", "r268", "r302", "r305", "r306", "r307", "r311", "r312", "r389" ], "calculation": { "http://hartfordhealthcare.org/role/BalanceSheets": { "order": 6.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).", "label": "Noncontrolling interest" } } }, "localname": "MinorityInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.", "label": "Noncontrolling ownership interest" } } }, "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/AcquisitionsJointVenturesAndDeconsolidationDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_MinorityInterestOwnershipPercentageByParent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.", "label": "Noncontrolling Interest, Ownership Percentage by Parent", "verboseLabel": "Equity ownership percentage" } } }, "localname": "MinorityInterestOwnershipPercentageByParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "percentItemType" }, "us-gaap_NetCashProvidedByUsedInDiscontinuedOperations": { "auth_ref": [ "r64" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Increase (decrease) in cash associated with the entity's discontinued operations.", "label": "Net Cash Provided by (Used in) Discontinued Operations", "totalLabel": "Net cash used in discontinued operations" } } }, "localname": "NetCashProvidedByUsedInDiscontinuedOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfDiscontinuedOperationsOfFinancialStatementsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInDiscontinuedOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flow of discontinued operations:" } } }, "localname": "NetCashProvidedByUsedInDiscontinuedOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfDiscontinuedOperationsOfFinancialStatementsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r198" ], "calculation": { "http://hartfordhealthcare.org/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r198" ], "calculation": { "http://hartfordhealthcare.org/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r64", "r66", "r69" ], "calculation": { "http://hartfordhealthcare.org/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r52", "r69", "r155", "r167", "r174", "r183", "r186", "r191", "r203", "r210", "r212", "r213", "r214", "r215", "r219", "r220", "r224", "r246", "r251", "r257", "r260", "r268", "r302", "r303", "r305", "r306", "r307", "r308", "r309", "r311", "r312", "r388", "r389", "r463", "r522" ], "calculation": { "http://hartfordhealthcare.org/role/StatementsOfComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Loss", "verboseLabel": "Net Loss Attributable to Hartford Great Health Corp" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfSegmentInformationDetails", "http://hartfordhealthcare.org/role/StatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "Recent Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NoncashInvestingAndFinancingItemsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Non-cash investing and financing activities:" } } }, "localname": "NoncashInvestingAndFinancingItemsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NoncontrollingInterestDecreaseFromDeconsolidation": { "auth_ref": [ "r109", "r135" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of the reduction or elimination during the period of a noncontrolling interest resulting from the parent's loss of control and deconsolidation of the entity in which one or more outside parties had a noncontrolling interest.", "label": "Investment from noncontrolling interest" } } }, "localname": "NoncontrollingInterestDecreaseFromDeconsolidation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_NoncontrollingInterestMember": { "auth_ref": [ "r129", "r327", "r508", "r509", "r510" ], "lang": { "en-us": { "role": { "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.", "label": "Noncontrolling Interest [Member]" } } }, "localname": "NoncontrollingInterestMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_NonoperatingIncomeExpense": { "auth_ref": [ "r56" ], "calculation": { "http://hartfordhealthcare.org/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "label": "Other (expense) income, net", "verboseLabel": "Other Income" } } }, "localname": "NonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfDiscontinuedOperationsOfFinancialStatementsDetails", "http://hartfordhealthcare.org/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_NotesPayableRelatedPartiesClassifiedCurrent": { "auth_ref": [ "r33", "r143", "r507" ], "calculation": { "http://hartfordhealthcare.org/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount for notes payable (written promise to pay), due to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Related party loan and payables" } } }, "localname": "NotesPayableRelatedPartiesClassifiedCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingCostsAndExpenses": { "auth_ref": [], "calculation": { "http://hartfordhealthcare.org/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Excludes Selling, General and Administrative Expense.", "label": "Operating Costs and Expenses", "totalLabel": "Total operating cost and expenses" } } }, "localname": "OperatingCostsAndExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r246", "r251", "r257", "r260", "r463" ], "calculation": { "http://hartfordhealthcare.org/role/StatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating Loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock": { "auth_ref": [ "r77", "r78", "r84", "r140" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.", "label": "Organization" } } }, "localname": "OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "auth_ref": [ "r41" ], "calculation": { "http://hartfordhealthcare.org/role/StatementsOfComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Foreign currency translation adjustments" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": { "auth_ref": [ "r41", "r44", "r390", "r397" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.", "label": "Foreign currency translation adjustment" } } }, "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r48", "r107", "r184", "r187", "r192", "r391", "r396", "r398", "r433", "r441", "r496", "r497" ], "calculation": { "http://hartfordhealthcare.org/role/StatementsOfComprehensiveLoss": { "order": 1.0, "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).", "label": "Other Comprehensive Income (Loss), Net of Tax", "totalLabel": "Total other comprehensive loss" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r132", "r133", "r136", "r184", "r187" ], "calculation": { "http://hartfordhealthcare.org/role/StatementsOfComprehensiveLoss": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "totalLabel": "Total Other Comprehensive Loss Attributable to Hartford Great Health Corp" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfComprehensiveLoss" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Comprehensive income (loss), net of income tax" } } }, "localname": "OtherComprehensiveIncomeLossTaxAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfComprehensiveLoss" ], "xbrltype": "stringItemType" }, "us-gaap_OtherIncomeAndExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other Income (Expense)" } } }, "localname": "OtherIncomeAndExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OtherNotesPayableCurrent": { "auth_ref": [ "r35" ], "calculation": { "http://hartfordhealthcare.org/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of long-term notes classified as other, payable within one year or the normal operating cycle, if longer.", "label": "Other current payable" } } }, "localname": "OtherNotesPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherOperatingIncomeExpenseNet": { "auth_ref": [], "calculation": { "http://hartfordhealthcare.org/role/StatementsOfOperations": { "order": 3.0, "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.", "label": "Other income, net" } } }, "localname": "OtherOperatingIncomeExpenseNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherPaymentsToAcquireBusinesses": { "auth_ref": [ "r58" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with other payments to acquire businesses including deposit on pending acquisitions and preacquisition costs.", "label": "Cash payments to acquire business" } } }, "localname": "OtherPaymentsToAcquireBusinesses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetailsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForPreviousAcquisition": { "auth_ref": [ "r502" ], "calculation": { "http://hartfordhealthcare.org/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Cash outflow representing an adjustment to the purchase price of a previous acquisition.", "label": "Payments for Previous Acquisition", "negatedLabel": "Cash used in Acquisitions" } } }, "localname": "PaymentsForPreviousAcquisition", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquireBusinessesGross": { "auth_ref": [ "r58", "r377" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.", "label": "Purchase price" } } }, "localname": "PaymentsToAcquireBusinessesGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetailsParenthetical" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r59" ], "calculation": { "http://hartfordhealthcare.org/role/StatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_PolicyLoansReceivablePolicy": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for policy loans receivable, including the basis for determining the amount reported for loans made to policyholders against and secured by future policy benefits. May also disclose the range of interest rates charged to policyholders on such loans.", "label": "Receivables" } } }, "localname": "PolicyLoansReceivablePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r28", "r314" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/BalanceSheetsParenthetical", "http://hartfordhealthcare.org/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/BalanceSheetsParenthetical", "http://hartfordhealthcare.org/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r28", "r314" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/BalanceSheetsParenthetical", "http://hartfordhealthcare.org/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r28" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/BalanceSheetsParenthetical", "http://hartfordhealthcare.org/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r28", "r472" ], "calculation": { "http://hartfordhealthcare.org/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock - $0.001 par value, 5,000,000 shares authorized, no shares issued and outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r495" ], "calculation": { "http://hartfordhealthcare.org/role/BalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid and Other current receivables" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r61" ], "calculation": { "http://hartfordhealthcare.org/role/StatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from issuance of common stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromLicenseFeesReceived": { "auth_ref": [ "r65" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash received from licensees for license fees during the current period.", "label": "Incrrued license fees" } } }, "localname": "ProceedsFromLicenseFeesReceived", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromMinorityShareholders": { "auth_ref": [ "r63" ], "calculation": { "http://hartfordhealthcare.org/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from a noncontrolling interest. Includes, but is not limited to, purchase of additional shares or other increase in noncontrolling interest ownership.", "label": "Contribution from noncontrolling interest" } } }, "localname": "ProceedsFromMinorityShareholders", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromPreviousAcquisition": { "auth_ref": [ "r501" ], "calculation": { "http://hartfordhealthcare.org/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash inflow representing an adjustment to the purchase price of a previous acquisition.", "label": "Cash proceeds from Acquisitions" } } }, "localname": "ProceedsFromPreviousAcquisition", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromRelatedPartyDebt": { "auth_ref": [ "r62" ], "calculation": { "http://hartfordhealthcare.org/role/StatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from a long-term borrowing made from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth. Alternate caption: Proceeds from Advances from Affiliates.", "label": "Proceeds of related party notes payable" } } }, "localname": "ProceedsFromRelatedPartyDebt", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProductInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Product Information [Line Items]" } } }, "localname": "ProductInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ProductLiabilityContingencyLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Product Liability Contingency [Line Items]" } } }, "localname": "ProductLiabilityContingencyLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ProductLiabilityContingencyTable": { "auth_ref": [ "r300", "r516", "r517", "r518" ], "lang": { "en-us": { "role": { "documentation": "Information and financial data about the reasonably possible loss or the recognized and additional reasonably possible loss from product liability related to an individual product.", "label": "Product Liability Contingency [Table]" } } }, "localname": "ProductLiabilityContingencyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/CommitmentsAndContingenciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ProfitLoss": { "auth_ref": [ "r174", "r183", "r186", "r197", "r203", "r210", "r219", "r220", "r246", "r251", "r257", "r260", "r268", "r302", "r303", "r305", "r306", "r307", "r308", "r309", "r311", "r312", "r378", "r381", "r382", "r388", "r389", "r437", "r463", "r470", "r471", "r498", "r522" ], "calculation": { "http://hartfordhealthcare.org/role/StatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.", "label": "Net (loss)", "verboseLabel": "Net loss including noncontrolling interests" } } }, "localname": "ProfitLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfCashFlows", "http://hartfordhealthcare.org/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "auth_ref": [ "r101" ], "lang": { "en-us": { "role": { "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.", "label": "Long-Lived Tangible Asset [Axis]" } } }, "localname": "PropertyPlantAndEquipmentByTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": { "auth_ref": [ "r96" ], "lang": { "en-us": { "role": { "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).", "label": "Description of estimated useful lives of property and equipment" } } }, "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Property, Plant and Equipment [Line Items]" } } }, "localname": "PropertyPlantAndEquipmentLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r101", "r162", "r438", "r472" ], "calculation": { "http://hartfordhealthcare.org/role/BalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsNoncurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/BalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": { "auth_ref": [ "r101", "r454", "r455" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.", "label": "Property, Plant and Equipment, Policy [Policy Text Block]", "verboseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "auth_ref": [ "r100" ], "lang": { "en-us": { "role": { "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "localname": "PropertyPlantAndEquipmentTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PropertyPlantAndEquipmentUsefulLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.", "label": "Property, plant and equipment, useful life" } } }, "localname": "PropertyPlantAndEquipmentUsefulLife", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r340", "r406", "r407" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests." } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/CommitmentsAndContingenciesDetailsNarrative", "http://hartfordhealthcare.org/role/DiscontinuedOperationDetailsNarrative", "http://hartfordhealthcare.org/role/RelatedPartyTransactionsDetailsNarrative", "http://hartfordhealthcare.org/role/StockholdersEquityDetailsNarrative", "http://hartfordhealthcare.org/role/SubsequentEventsDetailsNarrative", "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionDueFromToRelatedParty": { "auth_ref": [ "r304", "r305", "r306", "r310", "r311", "r312", "r507", "r538" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Receivables to be collected from (obligations owed to) related parties, net as of the balance sheet date where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth.", "label": "Related party" } } }, "localname": "RelatedPartyTransactionDueFromToRelatedParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/DiscontinuedOperationDetailsNarrative", "http://hartfordhealthcare.org/role/SubsequentEventsDetailsNarrative", "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Related Party Transaction [Line Items]" } } }, "localname": "RelatedPartyTransactionLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Related Party Transactions [Abstract]" } } }, "localname": "RelatedPartyTransactionsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r340", "r406", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429", "r430", "r431", "r540" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/CommitmentsAndContingenciesDetailsNarrative", "http://hartfordhealthcare.org/role/DiscontinuedOperationDetailsNarrative", "http://hartfordhealthcare.org/role/RelatedPartyTransactionsDetailsNarrative", "http://hartfordhealthcare.org/role/StockholdersEquityDetailsNarrative", "http://hartfordhealthcare.org/role/SubsequentEventsDetailsNarrative", "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": { "auth_ref": [ "r404", "r405", "r407", "r408", "r409" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "RELATED PARTY TRANSACTIONS" } } }, "localname": "RelatedPartyTransactionsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/RelatedPartyTransactions" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestructuringCostAndReserveLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Restructuring Cost and Reserve [Line Items]" } } }, "localname": "RestructuringCostAndReserveLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/DiscontinuedOperationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r31", "r108", "r159", "r450", "r452", "r472" ], "calculation": { "http://hartfordhealthcare.org/role/BalanceSheets": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Accumulated deficit", "negatedLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/BalanceSheets", "http://hartfordhealthcare.org/role/GoingConcernDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r170", "r207", "r208", "r209", "r211", "r217", "r220", "r269", "r345", "r346", "r347", "r362", "r363", "r386", "r447", "r449" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r237", "r238", "r250", "r255", "r256", "r262", "r263", "r265", "r336", "r337", "r417" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfSegmentInformationDetails", "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r328", "r329", "r330", "r331", "r332", "r333", "r334", "r335", "r338", "r460" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": { "auth_ref": [ "r123", "r124", "r375" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.", "label": "Schedule of Business Acquisitions, by Acquisition [Table]" } } }, "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/AcquisitionsJointVenturesAndDeconsolidationDetailsNarrative", "http://hartfordhealthcare.org/role/ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetails", "http://hartfordhealthcare.org/role/ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedDetailsParenthetical" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of cash and cash equivalents.", "label": "SCHEDULE OF NET INFLOW (OUTFLOW) OF CASH AND CASH EQUIVALENTS OF DISPOSAL SUBSIDIARY" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/AcquisitionsJointVenturesAndDeconsolidationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r119" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "SCHEDULE OF INCOME TAX VALUATION" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": { "auth_ref": [ "r111", "r112", "r113", "r114", "r115" ], "lang": { "en-us": { "role": { "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans. Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).", "label": "Schedule of Defined Benefit Plans Disclosures [Table]" } } }, "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": { "auth_ref": [ "r1", "r10", "r11", "r12", "r13", "r14", "r15", "r20", "r22", "r23", "r24", "r103", "r104" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.", "label": "SCHEDULE OF DISCONTINUED OPERATIONS OF FINANCIAL STATEMENTS" } } }, "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/DiscontinuedOperationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "auth_ref": [ "r116" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.", "label": "SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION" } } }, "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/IncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfProductInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule detailing quantitative information concerning products or product lines by product or product line.", "label": "Schedule of Product Information [Table]" } } }, "localname": "ScheduleOfProductInformationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "auth_ref": [ "r101" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.", "label": "Property, Plant and Equipment [Table]" } } }, "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfPropertyAndEquipmentUsefulLifeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock": { "auth_ref": [ "r127" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the amounts recognized as of the acquisition date for each major class of assets acquired and liabilities assumed. May include but not limited to the following: (a) acquired receivables; (b) contingencies recognized at the acquisition date; and (c) the fair value of noncontrolling interests in the acquiree.", "label": "SCHEDULE OF RECOGNIZED IDENTIFIED ASSETS ACQUIRED AND LIABILITIES ASSUMED" } } }, "localname": "ScheduleOfRecognizedIdentifiedAssetsAcquiredAndLiabilitiesAssumedTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/AcquisitionsJointVenturesAndDeconsolidationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": { "auth_ref": [ "r143", "r144" ], "lang": { "en-us": { "role": { "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.", "label": "Schedule of Related Party Transactions, by Related Party [Table]" } } }, "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/RelatedPartyTransactionsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": { "auth_ref": [ "r289", "r290", "r291", "r292", "r293", "r294", "r295" ], "lang": { "en-us": { "role": { "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.", "label": "Schedule of Restructuring and Related Costs [Table]" } } }, "localname": "ScheduleOfRestructuringAndRelatedCostsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/DiscontinuedOperationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "auth_ref": [ "r85", "r86", "r87", "r89" ], "lang": { "en-us": { "role": { "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "Schedule of Segment Reporting Information, by Segment [Table]" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfSegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "auth_ref": [ "r85", "r86", "r87", "r89" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.", "label": "SCHEDULE OF SEGMENT INFORMATION" } } }, "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/SegmentInformationRestatedTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentDomain": { "auth_ref": [ "r234", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r260", "r265", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r292", "r295", "r464", "r553" ], "lang": { "en-us": { "role": { "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "localname": "SegmentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfDiscontinuedOperationsOfFinancialStatementsDetails", "http://hartfordhealthcare.org/role/ScheduleOfSegmentInformationDetails" ], "xbrltype": "domainItemType" }, "us-gaap_SegmentReportingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Segment Reporting [Abstract]" } } }, "localname": "SegmentReportingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SegmentReportingDisclosureTextBlock": { "auth_ref": [ "r234", "r235", "r236", "r246", "r249", "r254", "r258", "r259", "r260", "r261", "r262", "r264", "r265", "r266" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.", "label": "SEGMENT INFORMATION (restated)" } } }, "localname": "SegmentReportingDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/SegmentInformationRestated" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Segment Reporting Information [Line Items]" } } }, "localname": "SegmentReportingInformationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfSegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "auth_ref": [ "r54" ], "calculation": { "http://hartfordhealthcare.org/role/StatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingCostsAndExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.", "label": "Selling, general and administrative" } } }, "localname": "SellingGeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Price of a single share of a number of saleable stocks of a company.", "label": "Share price" } } }, "localname": "SharePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "perShareItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_ShortTermBorrowings": { "auth_ref": [ "r27", "r147", "r158", "r472" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Reflects the total carrying amount as of the balance sheet date of debt having initial terms less than one year or the normal operating cycle, if longer.", "label": "Short term debt" } } }, "localname": "ShortTermBorrowings", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/RelatedPartyTransactionsDetailsNarrative", "http://hartfordhealthcare.org/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "monetaryItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r77", "r201" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementBusinessSegmentsAxis": { "auth_ref": [ "r172", "r234", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r260", "r265", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r288", "r292", "r295", "r464", "r553" ], "lang": { "en-us": { "role": { "documentation": "Information by business segments.", "label": "Segments [Axis]" } } }, "localname": "StatementBusinessSegmentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfDiscontinuedOperationsOfFinancialStatementsDetails", "http://hartfordhealthcare.org/role/ScheduleOfSegmentInformationDetails" ], "xbrltype": "stringItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r39", "r107", "r170", "r189", "r190", "r191", "r207", "r208", "r209", "r211", "r217", "r220", "r229", "r269", "r327", "r345", "r346", "r347", "r362", "r363", "r386", "r391", "r392", "r393", "r394", "r395", "r398", "r403", "r447", "r448", "r449" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfNetAssetsLiabilitiesDisposedOfSubsidiaryDetails", "http://hartfordhealthcare.org/role/ScheduleOfNetInflowOutflowOfCashAndCashEquivalentsOfDisposalSubsidiaryDetails", "http://hartfordhealthcare.org/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r207", "r208", "r209", "r229", "r417" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/ScheduleOfNetAssetsLiabilitiesDisposedOfSubsidiaryDetails", "http://hartfordhealthcare.org/role/ScheduleOfNetInflowOutflowOfCashAndCashEquivalentsOfDisposalSubsidiaryDetails", "http://hartfordhealthcare.org/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r28", "r29", "r107", "r108" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Issuance of common stock, shares" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfChangesInStockholdersEquityDeficit", "http://hartfordhealthcare.org/role/StockholdersEquityDetailsNarrative" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r28", "r29", "r107", "r108" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Issuance of common stock" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders\u2019 Equity (Deficit)" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/BalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": { "auth_ref": [ "r129", "r130", "r138", "r170", "r171", "r190", "r207", "r208", "r209", "r211", "r217", "r269", "r327", "r345", "r346", "r347", "r362", "r363", "r386", "r391", "r392", "r398", "r403", "r448", "r449", "r505", "r512", "r536" ], "calculation": { "http://hartfordhealthcare.org/role/BalanceSheets": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.", "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total Stockholders\u2019 Deficit" } } }, "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/BalanceSheets", "http://hartfordhealthcare.org/role/StatementsOfChangesInStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r110", "r202", "r315", "r316", "r317", "r318", "r319", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r385" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "STOCKHOLDERS\u2019 EQUITY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StockholdersEquity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.", "label": "Subsequent Event [Line Items]" } } }, "localname": "SubsequentEventLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r399", "r412" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/DiscontinuedOperationDetailsNarrative", "http://hartfordhealthcare.org/role/SubsequentEventsDetailsNarrative", "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTable": { "auth_ref": [ "r399", "r412" ], "lang": { "en-us": { "role": { "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.", "label": "Subsequent Event [Table]" } } }, "localname": "SubsequentEventTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/SubsequentEventsDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r399", "r412" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/DiscontinuedOperationDetailsNarrative", "http://hartfordhealthcare.org/role/SubsequentEventsDetailsNarrative", "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r399", "r412" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/DiscontinuedOperationDetailsNarrative", "http://hartfordhealthcare.org/role/SubsequentEventsDetailsNarrative", "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesDetailsNarrative" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Subsequent Events [Abstract]" } } }, "localname": "SubsequentEventsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r411", "r413" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "SUBSEQUENT EVENTS" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/SubsequentEvents" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubstantialDoubtAboutGoingConcernTextBlock": { "auth_ref": [ "r26" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.", "label": "GOING CONCERN" } } }, "localname": "SubstantialDoubtAboutGoingConcernTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/GoingConcern" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_TypeOfArrangementAxis": { "auth_ref": [ "r534" ], "lang": { "en-us": { "role": { "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]" } } }, "localname": "TypeOfArrangementAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/AcquisitionsJointVenturesAndDeconsolidationDetailsNarrative" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r81", "r82", "r83", "r230", "r231", "r232", "r233" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/SummaryOfSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Weighted average shares outstanding:" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r221", "r227" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Basic and diluted" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://hartfordhealthcare.org/role/StatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 5 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r105": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "360", "URI": "https://asc.fasb.org/topic&trid=2155823", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r106": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2410-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2417-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e2439-114920", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Subparagraph": "(a)-(d)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "37", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4845-128472", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r128": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "805", "URI": "https://asc.fasb.org/topic&trid=2303972", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568447-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "4A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4568740-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613673-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4613674-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "4I", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "4B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(13))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(20))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04.10)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(16)(a)(1))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(24))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.17)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(11))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)(2)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(15))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(3)(b))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(21))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(23))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "5B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.12-04(a))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "5C", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1278-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "5D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(j)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "26", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/subtopic&trid=2122178", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "40", "Topic": "205", "URI": "https://asc.fasb.org/subtopic&trid=51888271", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "34", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "280", "URI": "https://asc.fasb.org/topic&trid=2134510", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(19)(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(f)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)(1)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(1)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(1))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(b)(2))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 5.P.4(d))", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721494-107759", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a)(5))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(a)", "Topic": "720", "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "35", "Subparagraph": "(b)", "Topic": "720", "URI": "https://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.22(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=109227538&loc=d3e44648-109337", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=128092470&loc=d3e4946-128472", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)(1)", "Topic": "805", "URI": "https://asc.fasb.org/extlink&oid=126975305&loc=d3e6927-128479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=125521441&loc=d3e30755-110894", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32262-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721503-107759", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "830", "URI": "https://asc.fasb.org/topic&trid=2175825", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r409": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "850", "URI": "https://asc.fasb.org/topic&trid=2122745", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124437977&loc=d3e55792-112764", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r413": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org/topic&trid=2122774", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r418": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "926", "URI": "https://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r419": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "340", "Topic": "928", "URI": "https://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r421": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r422": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r423": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(10)(1))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(25))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r435": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(c)(1)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=117337116&loc=SL5958568-112826", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(19))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(21))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Subparagraph": "(d)", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "958", "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r456": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "360", "Subparagraph": "(SX 210.12-28(Footnote 4))", "Topic": "970", "URI": "https://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r457": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r458": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r459": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r460": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r461": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r462": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r463": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r464": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=122137925&loc=d3e14258-109268", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r465": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r466": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r467": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r468": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(a)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r469": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r470": { "Name": "Accounting Standards Codification", "Paragraph": "4J", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r471": { "Name": "Accounting Standards Codification", "Paragraph": "4K", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r472": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r473": { "Name": "Accounting Standards Codification", "Paragraph": "13H", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117783719-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r474": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r475": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r476": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r477": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r478": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r479": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r480": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r481": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r482": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r483": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r484": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r485": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r486": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r487": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r488": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r489": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(13))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868656-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r490": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r491": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r492": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r493": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r494": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r495": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r496": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r497": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r498": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r499": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(7)(c))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r500": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(b)(9)(a))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r501": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r502": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r503": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r504": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r505": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r506": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r507": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(k)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r508": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r509": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(14))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r510": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r511": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r512": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r513": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r514": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(h)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r515": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r516": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r517": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r518": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r519": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r520": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r521": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r522": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r523": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r524": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r525": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r526": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r527": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r528": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r529": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.13)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r530": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r531": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r532": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r533": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r534": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "808", "URI": "https://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r535": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r536": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r537": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r538": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r539": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r540": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r541": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r542": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r543": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r544": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r545": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r546": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r547": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r548": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r549": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(13)(g))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7(a),(b))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r550": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r551": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r552": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r553": { "Name": "Accounting Standards Codification", "Paragraph": "4H", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.7)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.8)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "3A", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "3B", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "250", "URI": "https://asc.fasb.org/topic&trid=2122394", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8813-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "350", "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "15", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126982154&loc=d3e400-110220", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905813&loc=d3e1205-110223", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2510-110228", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2473-110228", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" } }, "version": "2.2" } ZIP 62 0001493152-23-020868-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-020868-xbrl.zip M4$L#!!0 ( -!9S%:6M0E%'00 'HB * 97@R,2TQ+FAT;>U:;6_: M2!#^CL1_F"(E:B7>3^U)X"(!AIC*"5SP54J_+?;:WF;9I>MU*?GUM[8Q&(C: MRYV3A@0^8+S,SL[,,\^LUF/-L"[-3K&@&8.NKJX0?31K9)F#CE9+KNK?VOIO MK3?6;V!JW9B#CR67,]F"1GTAP2)S', 57L(UGR-63@;*,,6"N"4U44V=/'1> M&^9(>(15)%^T0(EO!F9<2CY?CTG\0U80)1YK@8V9Q*+4T8;C*RN[7L5%M5E\C]=BDV'^J[Q@GB^S-GVP0^? MS(@L%IJ-:N.G+AR&,=&8&U)Y>I9"DA,#:;%PG@(EC& M_OARTKVZ.8%VH#GK]=4+PGS@ 2 @)) G)["')"[#DH?4*188E[&<)#*42@ "%0;B$ALQN56ZJK[DE+&Z M/5/Q8V":TTFW/[JZ^%BJE^+[25?7T_L'I]62.-*/1.MG;9AQH9"HV IWM B4 M0>FO4KQ+:M;UPQ?XCH540-$T_$G02NMM5[/T_VSSGQ_.'C'LEGYHXGKAYME6 M^CZQ!WO2;)X]1<&5BE.)L5S 6%%-**8*$CC$EH2SG:*K_%)?U\\(]R?".B=D M'QU-[B;6C9C-Q8(+%$&H@/U-**Y+1UH2>Q39M]"HOE=+!)P2Y]_7V[RS/K/G M[,?FP(L%3GW$/!^1=V!*IPIOSZGS+>1M8S@U MSD7\\]WQ5L_4N7)B8=\G##UK)CP6_*,HLBRN!HC"P GM9!>QL.TS3KFWRF9" MGU?WLR'2<"Z"Z"8S_Y0A1YTAS+OS>9@8D^9+?, 3V,?JL/8='U:,\EYF?#&& MQY\%:2A>?1:8G'E?HP/\7P1Q&(;P&:TKA<$EIE%EB!,@@[_YZ83_$>,_"1V% M>5H#N (_NKV%7"7#+0P4_T?$PU'&2 382 M>$/XZH;P^E _8?]BL+_ E+#;+.);SO?CL&]8OQ8]@7_$X$?L30SYXBO64W+_ M66##^@WX:_'7!'XM?A#?R;T12K'[/!M/3VCS<5O[IE*!(<'4:<%$'8O::N*W M$#,[FM"&\2*B4] "$P42*I64"_KHMGCV6D&'WFZKWGXMDWQQ;Z0/&B>1ZL,';2FEM)J*11J63#!K4323B!U= M3M2B=T>2ETFB=T[^ 5!+ P04 " #06#9PYFPH>0V%*K6]UZ^FG)[IP-_K@XKM-.T_V'N\WT=N?DJO<7N1W\=='_?6LD(W-(VJW8D $/F2:7 M;$9N9$@CSUWPR"U3?+0%':'K==;/L'O3H(*/HT/BL\@P=41>*NN(A%2->=0P M,CXDT'QQ82B-D:&]MG7<^7QU.EO]2.N(Y"=!\?&D4J4[)\?]^PD?U\-)[LM_8(V&\FC-Q2-:01TXVK>\'FI.L;O+/7:NU5.@V% M:_&;&$RCH%Z[203T:^_31OL3@2ND?1#@UR0*F')V@],5-QR:]>_]"8W&+#.^ M_=O^I\TJ?B Y;_5_$@UK:;[FW2K5/O? BU(SE&44(%N6&Q5+!F(_)9 MJA Z-/[5[.(2/J/*C*0*R!?%J"%GC HS(:=2Q;OKDUT)KGW,!=M&U7.PS $= M47AK]Q\'U8;YWFZ]=D(UN ]\%<[)721G@@5CYCE_*N?(0(+42!KB@P#*(X#N M.6"V40DCVE##0M /_4O!#EC8'&)@1!&U%9$A-P1RG&VWWJ!>BYC/M*9JCFU" M>L=L%E@(U7 M &U@3($,,4N//E=^$D*S"+JGZ6,VX?Z$Z 0_EOUG3+%4"%H0 M+P*#@&Y60 ADZA7T"&\_Q$5,Z!/V9\?ONXW'\J M+AD9\0@M@KY5$_(2,B9SD)7L3'7 M1@'W(Q0O.L5!32\7@#K39JDNZO'S!.$3]'01D]\X"#]!$ Y6'/:KTE\3>:33 M,$MY#V*)="7*MMZQWCPG5&%''4,<\*%@Z%_"(%J'@NL)]L!F(6 IXBG^#KCV MA=0)]$.455*X (J5]%D ER$ MB%@ @81Z*)BA2#GJ/7!-MM9LFO\Y7YR)%V1 MBUP<@"#(Y0+:Q1'[S9X!]V3 MBSXY[5]<7'=[O?/++[]OM;;L[]OK[FGV.QU_Q@,S07FMO[V:$#ZD@V#DX*;\ M1$TQ/GTJLH4#XG$?JC/HE9>5&M;:W3O@T1;NB_6.*Q%4F?>VZ<["=:]5K@!F MJE2QQS2(9D&ZQ_C"/\MHGH<'#]F63Q/,FB_L4DX/8$A#!K#@;$A)ETP4C 9) M:\JU3870BD5V4"P'EW0OGXD5$]3BC"-=Y=18HHJ7IG24Q"'[@I5:"AY08Z=@ MJ'G J>(X-=P124LD(APVTB2DNMD10I!(P MN]:\):$$%'7\-,^KX=N084-(]M"?!4)\F!HL8%DL^^FJIPR<:)B $YMJRS?ERJP MIB$"DS&+H'82@)]PA\6(XM@DB8S#2$!['@/WW*#D!B6_#TKZCZ'DFS: JU2Q M/Z4B0<)3'A/8:(3G3E-8=;I@=V)1[#[/(].?Z89%.4U6-V,L*,(H0.NTVT,9 MRL0\KNX+:'$Y=>A"-,/MI-'SFX)DF&U4V0S"G$- ^2/49 -5&ZCZ+E 5O']" MY];J&P$"CQ[2W2A[IQ"R7KS3518UH:*5OI\HA(%@0BBU@>MXT@D#:PA$ M\C6!&A'TV"[N4DZ7$2 E<*8UT>F4^ !)]CP&CVKLD9RS>,>9,*%Z49@CV[+( MR@++AGE)/19,=4X$OV,B/5D+T ,L.0&\/8$Q1I**$P MP_L!!P6MD&U82\ ;8&W @H(ON/N5P07[FG PP$)#$MEG?_3.9FM\0PZ^^];X MNZECNJ(DUN-6BGUL$!81'E7YG,%:3VN1Q:[SC-$[K!?I#F]GS=86!!GJ0!=-1LD28?P9>2)4RZSP/R 8RD ARUY9"&Z==) M""L(YMU.4TJI"H_+?X@4N@&H#P)0[W\[NAO-2Q)T!?S! P1@EO8 X-CGCU)D M\AP3Y]%4BBE#.A[1<,[LXFTG$CFL>]DN18BDI*IMT7@L*/ M]+SG.P"X'@3.8;WVSR1BI+WGD;W6WOY/\:SM*^?>?AY4CE2=](>Q>J<&(?7BAZ%6.AJY4-(=C437)S M==LG9U>77\B?WJUPK>%\KI M4B5O_3X+H@)(>8_H]+'0_D.J"8K^TFB0SYR)X)!< Z\\@JY?$RB0LFUTSO_=Z;/6LK_.]* YZ +2YV*4/Q!+;9J;VED>0C3#O9S M2+-"93M-F(ML6G*3V<39=#/V0596$U]7=N\OXVO._P-02P,$% @ T%G, M5J('U$U(" 33< H !E>#,Q+3(N:'1M[5MM;]LX$OYNP/^!%V 7"2#' M=M+<81-O *=.M[G+-4%B+-"/M$3;W%"D2E)V?+_^9DA)EEWE18US2*[NA]22 MR.$,9^;APZ'4^SS\]^5IL]'[?-X?P/\$__6&%\/+\]->V_\/3]O9X][9U> K MN1U^O3S_?6>LI#TFW4YBR9#'S) O;$YN5$QEX&\$Y)9I/MZ!CM#U.N]GV;UM M4<$G\IB$3%JF3\AS99V0F.H)ERVKDF/2*2Y'REH5PYV=T]ZGJR_#LHZM,8VY M6!P_)=FU-?P_S"NR<_JK')GDI-=&@3 ;UVMVU-79Z5LV7O/)U&Y2X=[9Z?G] ME(^X;38.N_L'O?;9Z8/J_ZQN>%#G5>?X*=FP=SXR;?F8A]1R)9L--28?IYR- MR21J#(^9?M1S[\GBZU2;E$H(2*N@78B&D\/. 0';[9216ZI'5#+3 MNKH7;$'ZH<4G!YW.X\'[XMQ[%6.IC)J-FU1 O^XA;74_$+A#ND<1_DQEQ+2W MF86IYI9#L_/[<$KEA.6&=W\[_/!39&W9CK]2 UFQJ&_(AE6^")J-VRF3D]97 M/H7,!,<$,,F8L@MP'+7'6[?4,"2QWYN"*I#-6=/=SRS9H,P+,J4S1C2;<39G M$3B>&]*7,@5TOF&)TI"HDGQ2.H8.K7^U^YBWGZFV8Z4C\H=FU)+/C H+(:1T MLK\^V2\&LC>YME8&3J$RZ8*$3H'!'* 0!7?V_W&4;)0!'>PW&V?4@-O 1_&" MW$DU%RR:L,#[47L'1@JD2F5)" (HEX#3"P!HJU-&C*66Q: ?^I6"#9#,N#*/ M*4*T)BKFEL!BYMJM-V@V) N9,50OL$U,[YB#_$*H@7L1: -C"J1_^3H8,9IU!(S92,A9J;/&0UFW!C-9 [0O&F5QS4#$J!9W)MENJB'C]'\#W M/8LX?.7@^P#!-UQQU*_:?$O5B&6B%H1_MCO.1=J,] M?[WG;%V/<&B#O.!A"O@F@W;8/[L\)Q_/+R^O^X/!Q9<_?M_I[+CKV^O^Q_PZ M&W_.(SM%>9U?-LM>AS?U)VF&L1E2D2<-B,="4F\XJ"\K,ZRS?W#$Y0X6M@:G M&Q&T,>_MTKW"=3^J7 7$;%+% 3,@FD59D?"9_QQ[>1H: F16(4UQI7QFEWIZ M !L:,8 $;T-&L%2J8318J&;4>NF8&1XQ*GF.#7X[ZCB>K@L.+!R..1!>J5I:?/L6.R] MGZIZRB2I3@ TC=M5A:'2D3,-T9=,F(2]D@#LA"XR'2##+.5%0BB@WNT_PQN\R*$_4T62V\ M.$"$48#.&5\O&:G4/JSN,^AP/75H(9IAZ6C\=.&/C/*BE%L]F'<(*'^"FFQA M:@M3KPY3T9N'J8'/TQ>" QXM9-4G]Z02KIY=V:J+F+"+56&8:H2 TL:N0H58 M&0OW\?02!C80B.1;"OM"T&.WNDL]7<: DL"5UD1G4Q("'+GS%CR*<4=MWN(] M;\*4FF(SCBS+H2J+' OF-?4H&.J""'['1'90LR8\^$%/_2#1?O>P^_Z.9HY> M4AUW1\11C@_!!_GY785Z-(VX5=H4.Q]W V3& M,;>6L4=HT4C!1@R?1QP4=$)V(8> *T!.0"+!#ZQTY3#!OJ4<#'"0D$KW\H[9 MVY; MX3@YRR!]T5-?,>RB7O?#Q((CZ-"SB#/L[U'45V>,WJ'^P-?7' [!%=P M<6\;Y*>P5?!13YD'#\M\;==^W)1DY!KX T!9#]S= ? MQKU/E*%2X)DWES,E9@SIMZ23[+THG3$D%B="+1@\G4^5YT2TC'DUR; 2&]DB M[;]G0'@KV@T@#(Z;C7^FDI'N04 ..@>'F]4UM_]'D' $"P;3K5 )01,#2N>_ MZN!B"4X]Z.ID]RY.VZ9-UMY4[K4O2A'_ G,>T;WJ!?I"C68CT^-_KX/[ MB*+9J/B*HJ3+YC!@+7)?F+*YF+^U6N039R(Z)M> M"?0]EL*=!%3\H1<)6[S M=4PN*6PN6ZWL6ZW>X.+/?/BUA?WO^/[U4]&&B_^&$N\[=K+Z=43M4/@^LWRF MED)C!=Q[;9B+?%I*D]G&V?0SMFG/M_%S./]]''Y&]U]02P,$% @ T%G, M5K3\W!U#! XQ< @ !E>#,R+FAT;>U8[6_:.!C_CL3_\!S2JDTBA)?K M=(,,B0(%-@X0<#?UHTDYP02F%;UQT]H:I\ !+;CW\OCQ_' M:#^;#;=.ST%UOM3;-S,>YR^+_A2Z#I4 MRJ&&.5O1"$;T!J9R140QO5&$&57,+^! '#K)QFEZJRW"V5+4P:5"4]6 GXW5 M@!512R8L+<,ZE+>7"ZFU7.&=0M.Y'(_FNQ@MGZP87]SP>BSG!NTM>L66@CPG8N6AV;P.V8#J?JU4=^Z)Y-/#?%?P^ MI=3/(W/*?'@F=-I4:>8SEV@F13XG?9A@9^DQ%RZ9(,)EA,.4AE)I6*Q!!Q3: M :,^=&^I&VOVA<+8Q_%4 1'>\Y'%<,SG[B3(2$YB%<5$:- 2Q[M&-7A7?@LH MG-%F1M2""!I9XUM.U]!RM6FIELL_7@ O56A#_I\XPG1<;VXRX5$3L%8M5<*C M%J>9Y)2O\SE?JL2W,%:AC# $NN7*5T:/KD<>LL$*<8UD5I"Q'=E 3M>2K5"9:V/=BNCO9D&,H77E"B@2-.# M#S%?0ZU21!&JU7O8TH@9-+0GYM@U,82A.8D?IKNBUS%3=(79D5B6R5ZIO29O MML*C@(II,[![ZP9$+&FF?N5=[?=$SRTE)A#H*JF".)_0A!DKF$CMV3#U"5.( M)U0T,C,733OA'),95ZRQ QM"A!(EKH*_M0DC>BR);2;%7C%/@HKJ0RPH5*K)\JEMC9AW#D%O%,MV@@M.W,]0*9TCB4ARYCUFD[FC]>3; M[Z!I1W9*9CJ>=:$_'O7@4VO4<^Q!*DWM;5 MH _M_LMN<:*%:!90L;2N6) B; K.@Q)I,&R,L4[@[_W MILIBOPWU]JCQW?J'\]^=>'9/./LGH/OU]/#HLG?$.2QO=XM@/[51F_M9P*F? MC-@FTT[HP]TN,\RQ48M,EATQ;:-FJMA_<=0V+^G3M_;FY?Y74$L#!!0 ( M -!9S%9#5L9O5S, /L] 0 9F]R;3$P+6M?,# Q+FIP9^UZ=UR3:;KV M:R^,HM)&$#(#@DK+J!05)&L!!$0$I4:((R(EA(PB/66M" QF+1"%@2A%2H , M)00()$,?0$2Z$$@D"$A)HR2!M"_NF=VS>^9\>V:_/[_?>9,WO_=YWG(_UWU? M=TNB^*#X".QR=G!R -:M6P=<5;X !0,X VQ8O_[+6[EM5+XW;=VT:>/&3=NW M;-F\]:OM7WVELEU%9=0WU M+P]9MT%YS\9-VS9MVJ:^0V6'^K^]*7X!=F\%+J^';EBG#ZS?O6[#[G6*%@ $ M .LVK?OK!ORVK5NO7./F+5NW;5=17D#>!:Q?MV'#^HT;OJQ:>1:M/ ]LW+UI MS[>'3VU6<_]^B_Y-]2-WGKS>:G"ZO%'#HY>__^BU6W>W;=?4^GJOMJ'1@8.' MC"TLK:R/'3]QYJR]@^,Y)^=+ESV]O'U\_0*O!]T(#@D-B[P=%1T3&Q=_[_Z# MAXF/DI*?/GN>EHY_\3(C)S45H4B\NO8%USI@P[J_;?\MKMU*7.LW;MRP M<WKSGE/N6[V^JZ1^YLU7]])/7Y8W;#(YZ\#6NW>K= MKKG?8L)0\ 7:7Y'],6!W_Y^0_1W8?^(:!;[:L$YIO V[ 0@@NY23?'"=5;)5 MLBMSY<[-25?MGE;-;!V\^YVHKD(]MHHNJR$$S[.T47O[^&%R?B1ZTT_.2YT_ MYUJ-OV-@PBJ>\CCGZ$><#QT*V>5NKP[\][M[S8 9QS#),&WW-**<2&$A[5^I M4(NLO?RG:PMF^\]H#'[2['=;;*ET+N[#4EWQ+?%H\B>K(\P_X2L4 )$2YQF$ M%.\XN:7+ !JE0SP>E>*]5-T#XF*'I/.+V(;9R_2)[WKIE7)F71KA@W6XQ'O4 MNW-\MBYUPU/_QW>3?ZT5&!&"PRB1 :=V$&6,I'S/)/I'SPB=SV4Y3E>#,JPE M9:F+Y&\&:NT],B\^9%H]]=KM0(C+JBX>Q%49K@>UY^^+OPP)<1,68=[3Q\-0 M>4OZB(%,HM6.L"'V-'OTD ;7K#-ITFLU9XR*C_)0 /?[SRSF/Y,$_++?K,)+ MXHQ*E0WEP4Q390,1)9\&2XU"GAQ(99YE)I?1CRB N+ &5K)%J9W0QB5S'@HO MLINJ[R^F8G\)>7_\.J+7\W5],MLPW9J9*O+%)A.$#QA_2BK,208._LO]611@ MIIY91 L"[)(/OEJ?'/S23?EYR%K5#_ [F/=JD]+2P%_W9Q95?[?/<_< +8DC MIG4B;??I)P ML=^,>V P*J6GMK;_VEDZ!QNUIP:G*H[T%->6PO5,!1?*AN(-B;)CO1F6^LD]H]NU462>DM(,FSX4I&X0W)6G"F\*T[+983T MCC%F-44";%#H8?1L$#/3$"_I5@"OANE)OD3<[YRA -KP2317 MN]:A XN0N^R+K#D*-KI^U"+L^U!9L ;XT=H5WN[[/8<'%A_KO>[6WBV!P.OI M'ROGWR)FG0\GKRJ "3HG;@*B*[;V$!@N:]&T^Q<./!Y\,Z#A[&*B #:>+Y@) M$Q7.^.;Z!JX.XF^1H]O.RTYS/%A*3#RS#VY^OS3 MD%)=)H78K ! FD*=Z$9YEPT6)+&LY3L*[_=CCOG,/9L==95GR7Z:>X8N-#$X MBMU>1VB )AR_M;0/,[IOC'(R.FO .UFZ0_8*/^E 9L,M^"O3N)TXJ]::&D37 M@7>S9'J= @"/DT(YEPXNXO/]:BV3^_^-!?U.W&/ 9+"M@P8!LW MV;5.VQ'QIOMUUT91C&9VH'W=Y=5KJS3?,+>M9,K]J!VWACU[P64K+(JKK1;K M>@*.;%\I@AHR9"P\4D2$3RJ 5I+8@[;>[IODMI.G)[@YY&2FDY7)404@-(9' M3L0D\VS1? 5P5J Q]3P>,90/GR%75'.26=$%(XN2-E; =$ ;[#J?"ML<2W$I MISY4 .>LH^N:&7#M+%KVNVZ3TE\2'F7*WB0]FY*##_:ASKZ_,63YJV6JEG-] M?Q68HVMQ?M(E>L?^ ,RLO)MB6OQC2A9];1/ZC!"SFKOPL5JF "R#%R:E[;7E31*-TNH2#DNBLO/GR9.F?=0R00N M]G-4$=&)C7"Y9&+95FM)QCWBE&DO]@8EG?]JL2!M"J$ TF%&'&H:;24A'?]Q MW.!L?8T2:9>+#9&TLG1&D3_4> '-( MVHM;RTJOW?4*>5*>D:L>(L4F3C@Q&+"H"M'Q9@(+'L;A]%R =^]EL]TC%] MJA95=&W5MD%BAVQ8L@Q#H66OS3&J8D*SGU%F;C-Q'+Y%)R@K9Y%VVUX!O">. M?9]:G^=K)V1E$#\LMF>^Z#S^/-C6\9D7G[,DEC- M7W9(3E#FBQ(B'2EQ\=/;7TD16!$F3"!??;[;N+!RSB\6N5S@\PJF'Q#D]BR: M)2(VB!L$+JYBZXEMJ%-%S3=CD#-Y*D@D)>$HML&/I8KRAPNV-,8[/GI5G?&. MY?[G*_;(FZ+>4 DXAJG*466B[$12%3V= BE$8'U?ZED05AW-0I3S5]YJ[JXT MV5_1:'+4W]8=S0+?GJ7(&^8KAFP-B $H#X%#Z<:;K:&:3\+*5].=(-GS0ERZ M$;*N2ZDL5E0P.YBS+5=Z5"!*E'Y[\PUS[D1V*:5+8C1>CD2G4&^2?,.KK6YY MX0([P9Q#E_'->LC$Q> >;4L2;JKOFJ\Y.0&RG*4_^/U#0_ODS7?!9*MQ.I-) M7QAVXLM5O_81)S=:0AL\N&VW!Z[]Q"Q><#.>\!B7\YC7%0"-^%C@S>F>0'XE M3G'O9?/EY84=@3;0#@L[C]P35D.,I>%\Z;=BV00L55,$^E#1O8-3S,WN7+%R M3I'QA.FDN45BM2T/6*5&JC[2Q+?Z[3:,0FN"O6 'V$>%Z M'9\:8@?W48G@A>+D[\" 4]DN_-/#L0$<$IB=BK[5;Q:R&'/#@\;2I0K?Z]G@'#Q M\7>>_CKBS4#)@NEMG09]J GQ6%E$?5[62Y9HGB(AM)AX# N?JHTR&..(_@C$ MIWK$I4N2HQT:I?5:L!N^*+J0!>).$ >,Q$ZY_J&"4U@S.?'F7L^[QTF-UEO(21MTK$Q&,[ M(R6V9S%[MTWV/,+7.3Y&Z7[DF'3YGVG10Y7&G>#Z?'/'NM)8 :A90H=ML5K- MM0^JZ=&4BC%3D28\:/,(IGLC=#K&0W*!)41[3Y7"U&)5702>TT\2HI\RYOS. MD\P><"H7TM?/ESAR5$%W9\+,"P*4I ,\8 M<"98&:3!Z;.W.$F&']?"D0VI]99Q MP:VJJ:,*X![FF]C*LV1Z^=FJ/E-N569"BBLKM"';V_X."SN.("S(YI835.]@ M0/WUOL'L_74#! ]RS1+[B'^Z*RO8QXHCY[9*JGK44%OY,RF6/;OFZHA,?UIM M@5%:W(9S-+>_E-9&I])-3%",XD#CFT]NI8:>3<-\-^L7D8]\$S912@Z"VT"7 M4V:2W\U-8:/4K"50[+(JS_,@-D15Y9SH?3@M>7JP]-(";^?(=?C+@(.>EW\B M(AUT8!&C9-5?%,!.L_'\MSRL\D:_+M/A2&3"2[.TI]N"5C$W7%E2+[C1L#"4 MCTZM^KEDE)1Y4Z/.M ?EYQEK%,=.@U85B=0+:S^CL M6!*$[T:-7T!RO<^\0AE5\]]0OX_,FZO+LYJ-BT/'(S$,$ICN^CXE;%=6M<]YUQLP1IF.>*]'>;#"GL[Q577XFW1X_;:, [E9S,+:A_#GFM]4# MB/T5*><'S*JHP6.9I.!T5O@7^LXP+>W[/9&%[5%Q<8C"EQRNL-[;:W9JOP!%-^&L M0L7H8@5P*TC^WD6P@7U]-+@QZU*;7/M"Y:-)8_%[:!(J%K3)#=!S)UE!: 3:R=JUGXP/OH! M=DH8Q]QKY:*/U>JNKB1A=HAC+C]MLLU>+BPQ#^='"7_]TA#\K(B4-%!R7-RB;E MF4=#&Z^2CA<)I>15WXF&+1?%W8(REO-0U+8](J^!()>NZM5Q3VO>B ( W-+I M7I!$C=5[;)WG8F^)A[__T3BK-5B2W7N& IAY1E, LG7S=!5A2=PQ1L">[/9M M K6V806@'L4 ;XYU(UZ(+;<+L&$;9%TCMLEU^)1^:2BB- M]QSEJ-DI&QZE\&@P#\+$BN"&\G8^]@)Y@+SU=;T@K2FN+AIWA)OH_E#JKATR,&RP,6%0U]'BPK_X=#=K[(K*FIWRQ>G25 MQ8[AH'-0E\4)V F"^#0X?PB9<]AQ(]7P7)!\D;-*\;I!G#@9/&&]@"CT"1,N M0L/T]@]>BZJ0'\M=U9E6 '3/06/46#UK=_/>8TL)D/@#-S_24YE'$X500?!C M\DD'ZR':$&)YM>^=Q@=&KS7"MJ9)9Z(Z2S&Y8B'/W/^:WX@\6OJSABQ:Z\F.7 NY$K#!R MA'^!MD4;#LPM9"J $=BS2(QEF[QWEP)HVB'Y5FS37.[09?:^RN$L3(A2.ED[ M$3Q);T*$8H.PB;M#TY^.*8# LWBM(?Z;:3 8)7QD$S MY*[6!O=KC$6PY"TAKIC.V?U1@GN@ #;;Z:!.GNX/.])S[Z>?Y04(_0-JK.:7Z0\AT;J*QM0>!LV'"?.E0.Q M9YJJ>RNXZ4Q-'V_QU10%D-P:+CU5(]!J(HQ FJ-INH]#"ES@/N"R;Q)1U>7G MJ/FW841$R:?7Q]JE#N\C"PX%P*Z_%\=(7.%VYH*8^V9ERSHZ:*U6;(C\G28> M8;:LHB5X1VBBF_G+:FQ/CT)^85 MT+CB .@H]I<8'E*VF1;/OHK-<8'ZU/M'(4R]XV_P5LKCJ)#'#2I"?KV\IT^J,G%,;WKJV\?0)%W* M4:N!NE3(S(=5EAHB>;'>H7 M<,5Z PLE[;V.I$XGM;@\QZ_NC-"C\UL'\U/KT[--V"UH.JT*N?/LB03.6 M<%$\+G&-W$TGPS,-[)\VS-HR<79 ,U>I =XZYL"3?P) M61:4D(99"%B3IBO])8 G ()4=T#]8&[A[)VUA]2ZR[J_G16?JV% .F1 M]ZLI -1PJO0B_Z2H$;1.:C0HQ>-;UL_-7Z:A,U^\8U[*H4C29OV0C:FP9E Y M+\EC=-2IWI.]]9DGS=._KSYAL)XDF<3*A(-[4NWS_>H2U1 ML5AD5W6=*C"&;=*1[(BM7CPX;KZ2,HOPGEJEQ9RC+^L.>MP/U/,(]+CU/+A; MZ(3Y&G5;S!!@[4\X_+F7"6N/)6%+&^K=#+/;T5P)FR>>%A?M]GR+KE)"G)"'W!%PF+ ME[(2PA3 9*')-.X>=M:T85I4CSC:438SNYUITZ71U/8]<;%S25Z;2/Q_H"EB16*"N"F+: MX+J7K@Q9=.D>/94,TV]?F)/,("-B*7:>6MGS4X!!5LN(IJ_ZI-AH8:#SIX:?XAPOY 7Z76G'S[LH !45H;CB#B8!O1(V&G>7TH*98F>'9Q( N5&54=%W"6R55F+HDW M4@+Z;)UM+.Y@TQ]ICH9GN"7>\.W;*D1XA\*PS^G,$?^"A32^=[-V8F/W 9]A MJ67!G%_:IT5EBSE4S"72PTC=\BFT9?#WFS/A&@TEAQF-VAP?MFMAKFS4Q MG M\=RY>6+*W/=M@[VAV0_9A?_J6P VMLJ^+5\]>S/PCJ:)#TB*FKX7LY:**[^N M+/E,Z\MM2J:85?=RH$/X6'&[6-EM#E@_'6C^M# M5>]4V31XS%RHH5=6D;.YLQPAAGNP/Y+PDBX8#7Z("@HL"ZE>NU^]Y5QYFG[Z M(.^\\].2E-KH":)/U\2Q_*^77)BV+K_0=Z&0JO>EWQ95%YB3]%X38;/:Q2=S MR*WDKBYC!NWH8LX)\REE0QQ_H)6D"Z=MDS=75_ATCD.93E%%3GI33ENEC\O(%W_U _'@P^/ ':MJ*#VXL* M'R;[1QA!Q1:Z1G.Z=LC5Q Y3M^EB; P/Q?)C6\"T_<7@B^*4R-=CHZ/C 5)[ MJT0*_17 HKXN3\K YX7V@,:!<)=3!]R9'8>(VRZ/P>D<0.'EFD M"U"#FI63;JHA1^:>,"T.V^=3QCXC.%OLIX$%PEN7&OZ HZYVOL)'=.I7]]JY8(&L:5B]Z:D)]-)CZR M(#Q*Q^A*@@@?"%?ZPS_Z?K,Z59G=.!4SK@#\+_&\\V,SV4+\QP8UMT&RJNI< M1\&8<^:;Y!%?A*;CZ-.N)13UI3+"3U>_$;1E1I6&Q4>EEHR2WSTM%G$BBIEG MU,>(2X&1'+F&?,4N1 $D;NM)G-/;D7(IVW7[=0'X@R6DTKBA MM,DRMTME/[U5S:Z'2^&3G7*E%\1W2E"&]8(6K71K^LCPK=*A3&2!7 B--1\/ M^L!0=IE/EL 29TA#P!,BZEK?PDKJA@M]R_XN+<@2!XJ37=IZBXMGN^^G>[RC M.C(5 ,WOY_86TC;4GQYHCZP$5?;+>XL-0A7 M[70X._._TA<0L](4D6%$L@V M+!P_JDMY((6&%L)TM=%.!X;MWM8]\[7%7.F%GN-4WL).TA_$(9N.!0X^:[\H MYAQE.PR;!SXQ9XBZX V8KD_8_I/T&$0\_GX41ZLU8R=A$NX9@N!9K*0?BE"# MEX"P2@_?<6L1A>'G.B)_Z#*^,N84K)'365QJS(R0V$1(BDEDN2C?L8'GWT^.X:I*>#:&)MZ3(R?0@W T16<%E8"S[20*.>X2IQ" M3M!RAB@9_L.C3(3QTH6JWHFTH0F>X8@PH; :&XE\RVHBC_I(K_*'BL /S/3+ MJ2RV4X1^U7B(EV$(997*^/(C@;+D\;(U%"";Y>:"];,9,9G[4X6%.2\>C+)N MI%U[&<^%93WCH>=(B;3W:@;NEFY(FH8/'BR#:GL8)IW]>1B>. MZKK8:R0-J;O; Q9KPQT* (0-;("Q"2UPDMKGT:D'=YFM>]R0T3C1$RN>/WDE M23V+>,XS[4"WFO'S7"_;"CM'L;M$%;>-Y1\6\,U0*6_%,@E_ >IC;8\ \Z]\ MAZWOD!X2P;ODWV+:Y'KB,(J>B6"XQ:;[=$=^:! %>MUEW '&-8B0<&1SLLT, MV%>8#WH:@@,ML%&5T_RV)QOQ?=4O2 AE;C/-&>,:IBD]N"K?^=C<$^',ZWO= MY;4[M DC?5/3MB="ZT\)^EO7D(G+NH>^K[HG SGWFD$FF4VJ/+K\_CL%@*') MQ"K\#>?$ALIRRUR7LC;5IP *PL[7=\D[%4!4&.P.9/UMY%W:/A>X/Z6NN^G+ MR0B"1:EL4#Z'K0P@40M+YX>F<17YW!9!2.]/;P1?)T5>.,UY\W9>FQN19ABG M#'EF:MX"ZT8%L#/0VPPCD5X@@*I%: G4!F)>J4@-OMK<F5K'G* M2U^-<'HMH40&U2J=%]1",IVM UL=6'TF]H4\S.J8LJ,,DSEJ9_K->5$N*0EP M%PW'K*G5^SHT3U/R7^B[I)#"V#KD5V57MH8'I3-'7L;DN)AW)S,P M""IQ6E4O-)3/4Q8D^^@54:[7NEH@(WZV=3?F9Z?2V?N*G6>5<3:!3/-G-=)( M?I^M]70$0Y3B4'Q&*[F[O94(]>T%71U?.6>GD[$V!ZV=LL=W)H5GV1;6%RQ6GT!/R85KG^4:8R$G"MI) M0,!G;6$Y^[("N.\LD9R>O)@!?9 \F]W+2*"L%4%GQK4DH.@GP34'6@E :/;! MFO=MY4'!)8;L#\Z$X-A^CME#'S]_:HRT:Y'+"[AC6;4'U>>HPY$O#K_%[!7# MBZ4.@@.MND>6/'%N_)>"SH">D.J(B#*_K:6&GKZ^0N.C^NC!\<6A"TD"&\\] ML8'-UO',5RA/K99,(OIT1SW+,EP;2DGI5@!O=+3-Z(VB@[N7<0^EGJ]CEYJB MLPWZK[MP-&.S?0Z$R->*@I!I]/%"6P.!2C/FQ-W!*KB8-S379.9L.-I!&_(* M\AYE<2U1]_A>(HG)+W25\'J;DGFUV$92Q*NA*ITD0XFM7\S:&9?I7Y3>Y$RH M"\*R@^5F*UKWI4[LTBT3S"1$()KX(?1BK$ES*DIX&)(9'#:\6,II<:F4(96. MM]YSM7"O"")$5[17+@@6) Q473-_)J7>>C(EU<_,X&+%X(T^),B-=@Z#K;P" M9B711\N,(?MB QM!6^K/L)$J84_%B<[]WV>SC1(ZD+X%(\^3?"G6;Q?HHO'8 MS7FTS_FT M2%"FR6"&":J:SU, M](GW>X*-((?'D^#WBHIHB)0I.+8RN8A)HC_$PTDJ*;$ M3>AT7V""M>8)R)JG<^-V/2;VTY6HH2[3UU[^F5;!8F/('C'!/C%@ +$"TIJO M"[YOP)]SF;!I.+&&7>XJ78I;J"!UVW[NVE/B*H4TV[>A8<)CJ!Z+YKU87OAJ MT0W*0^3*DY),K-)A)UWA;$JRU.2C DC29'XW:&FFTTJ1[^CC+A//.L7(* ME M%%"PO1QB';'B1O6N]RZ,S="U8=.3$2N\74;Y$^-()_FO%)"ZN L%58 MM"?6RI\ANGAT_B(".8(//QJ'(#_;SM N"_UN':#H.%S^;\$G]\ ME321Z5E'?JCBV\<*&B@C'#E%CZ\LD#RGJT2Y[8X5^?'M[A#%."C>T1_:DEY! M3AMO@862_]PJ](R#AI<4T:=B5C/^;%?C$XXP"M&T"0DB1,89%Y/ (AJ,340$ M;TFK[,!URKFC8M8O[]9P.+N=\]F'!LEG&URM _I>#7!GTE C5QL8$2\+ LO>O M:L6_-]$C*0-74H#6L/1,PH3,P)M2.V@JVF86:-;6_D$2.\J 3B'HT?@VO6/\ M@COW3#L+7!XR:<+'PVM\/8Z"7?H>/>: MEBRC;TU!%_@6R$,UY& %D'Z>P<9F\K"_'-P[+F8TCL:T\1)["D;#8K0CTHCZ M57BOP_?3?>C4)7"7_X&[4E!!K%JSE[;FD_6,#SXMY6>SE#4?4DB< 3]B[2HA M(S5CW_#;.JKZ#CL695<=>33488W4>Z-'M6EE9I'G%*?C4N#8.)8=DG MZM]C3,3W? >C&JQ;]73ZEEVZ7$QT7GHQ5=K(OA'K6^@F2&P:?B8W<^%)AUY$ MX,*JZ=67E*K=E=@J$,'Y2(M!SWSZWL#Q]&B51 8UX(>K-\!=4[25>; M%V*.B;/R0[4;>$GD5!?[@0B+CJK,V2'_;3D4U_0*9)^F.P[@=DD/C^I$]>U#TZ#N$L[W_]PX0\/#HN[A% M1W"I.2;;7!S#/JEZX;M\;GZ@60GR>-/FVR:UQ![4&3[<=W@9FUC=WQ%J>\+L M?ETT\0UY($FCQ8.1=[YSCDHI8T*8I00<#3Q4KY4OOC;C0(-;-0PO+,\.?N/D MSTZ3(XJ[1,6Z\$D-4C-IAR-QOI089F5-F%6Y:?G3Q9/U"7W@0_BI,4EF=$\# M)49D$KL$'3]FG& 7&JE1?Y1/\GYOR0E89/?;TRGU@B-S?)V*Q2XX0/&AM"YB M2:L0P71903MH^^V>?6$9"$Y']B&S,H]06VIM?[>GHS_5?0#,E S"+H@+]%Y/ M[L V.[V:V^#1.PE-4D/!Z$G]J%NM2]+.M_DG,WG7*"3;Z^EVFHF^=?U@3H9/ MFKQ9>".=;10T7MYG-@Y)?G-E;*RUS6(U[D*D*W]GP1OI]6GT'R M35IRB%>]O>"91Z8R>#Q8D>TQ"#:3%^2/,L^@OS=.Q9MG2DLEUFAEK;[D'3E) MTG3*@P=H]9H*2X6UJ/?[2ZCIQW*2IM+HS-%,[,?+DQP#?6SD064WYV9=(X9. MEH+.X<[W7FJFI%N?F!JJC PFNMW\Q.#BNY.WIJE->R()8N\?BI99]RBTW>(_ M,P]F7DRMDB!/[A-A9"D)8H6UN&$&X?? M^[OFF@ZEF+HB-K7_1;23(;\QCL-/P;(P*]%/')9J!CRT:YR @UOT:YC^56_)LY2O(:9Y\N> MA%E[./>H+Y;UC%<0$:MH>"W?#:?E)[ JS>F"C':79F47P6\3*3W563Y&RDKJ M$U8:77_#+37@>/]UP?GA6TQHV%\Z(H8PFO3>7'(:PF\2?K*$RN)X+*QZ8AND M%K7%SE=>'[R(,\5Y\JV;&KR=Q*$3K!US&2U"7,$L=H1R,?0M#AFYB& MM5(5 MP*FRW?0;#:<1=L? $>'@TNYL?+Y_Z!)WD53"T1!M05#3LL:ALJRT&%=Q1VE8 M@*XXDN@[/CIVBA2;NDQ]9ECK)']WGAI#DE;@PUUJ$RRC0;MH!^P+YDYL?O8Z MS.LI,^Q$RH>Q[HBN'X34J^FPET=%]"C*M (((_ ,]&M#WD$FCF>I?NQ)LK 6 M>V\;,(LZ)S4PZ[\R=N7=O(F]J=N>LP1P=[DOYH:$8)B:7-63@M!F%6?C@!XQBR=T O\R/?I:]%I5,0!2L>+-.E.GL/$%B<(D@?]**7'$1Y:_/[YB!^1:SH V2F\F3))46/[,%]-P?Z_%)I-"?-B5 M5O62)"5WXQOV;9]\'@X 4)MAI-^C6%8V-+MP[NH4BH1#9/'.=9(-L: M Q(?=9/KX\1Q_LH1'B2V5([(:P\-5L_3R3\0WJ+K7IF!)V"[%$!S9XD"^.Q8 MHP :,[ "=>Q_&=->0U>=Y$--V,-"84@WZHP"4#7^\I=1O4D%L#E4 ;2X_WYF M93NK$S0J=INV8WR@BA"K](;3#N4_%;-I^Q5 8IJO GB/NZD [EDH /;!W\T< MDCE0%A.%-*U57'4].; 6/UV @#F+<7(]3V4E_C/-_$PI3 M"AVE4A"KA=N)L#W_%2"GFSCK,+A,>J0 )J:\L,L&8]B/W1!Q,N2?1G9*U9V1P+9)VQD8 M/VQT*EEPX#^,FO";41W_>>@V9TE_#B'SZ6_1E*D"")@Y[S1%ZEJ4,=,$X']Y MH^, ''L0"Y_ OI!$AJVYD]$F;(B2!@395M'?:? /(_R R5\OA[R0A.8ZS#54 M]U>3\E&._X9EORAYL5]2I5^,[OVWE&Q%RC#''B'^2STHF8W7M)C[!_C&@CN98"U?^!+'^W?H+%#=JW?\ E M#ZX]0$ZI_X,P_\%<#1E'_T \^DWO:DHR53K V:!_ MP7-NVQB=-0@R^_/Y[M)V^ M67I88#1A-%Q:4//&WOP$N^(DA*]P]_0NVQ*PH]LG8X] M*#UB5RQP;-;5:LVPP^==D;T9;7;-4$GQ*7FS6&T!FZ/SLG+R!<'W+M#CE(EW M<2O9;,\2QZK'/+JBPL(C%UO_F"7FH%[_S=^T_\D#JY0S.__3 VT=E?K.5EG% MY97)-XD]7$XZC)MQ2R;KDZ'1$L/^EO>.IK3P(DW6BC-OR6KLLKL4X*?2[@7F M66CAK81=-[5=(]$6E!W[%, \.]274G%"*4%BN410!A2*>;\.&&55RQ[=&/-F@MV!#YI2V]BF6_Z;G[&=%5\I^MT_8H %8$BV]< M3-^"LAWUI&6=8/K+,BYGC$[/S>;75-]^UGU)O71I1RGLL%*-I9#/9_ZF1<(_ M*UE>\$BN1!YZ%?MB+6+^8T^BT3W[.YO&ZT+][LW]C,[^^&;^C7FWB0*(H\5\ M^6]KI!_?'%?FJ-T34FX;*7M]@ (S]L0'&LGFYL4> &O3%?MP%B:V[63$Z?>_>J]A*JWETAQ2ZPXQ&2,8QZ5!:;E)=3F6E=5?R*O(W=U(^^!\=X&^B[;X@ MPX9>5?KZ4?O><)3-F\:"V:'>D9$_40,?JH\2_6R]6V"_8]S"%\;]C=R7T8YJ MTC>$T1K('PA$L/]GYZ>V@AZ@R'PWX8=[D]8M<-5MK1.^MZOKDGTQ \,=YN-) M5"Z'5"CX#$_//^Z!-\4Y/-3/-K)='ND2$QKU]@D"1UU*/VM'D/8;[+9BN MG*W9YQ6(4A-C":M[JE2EFLIJL:77WO.X4_B[^/:;WY_"B3WHRN//3E^F5;[]OW^FG)9JGODKS'V+ M7+UWNO?DZB0E[+4]*(BR5/X5*\Z 3#A+E<>O#RBGQ::)"B I)_GXU-C)GVRV M2 _!E./E_6*L MCT%P4@L, VI7T9G'93SO-]E>M1LU=7XDLX%JWZ^_7]-\HX M.(/_0:FY_V9]OP>A[MYC/K$P\>'W"\S]'8B#N=G^S2/-/_]^?8Z_!^'N^+]* M_E\E__^BY)21YHI_:\E_6'&8_U7R_\CD+\>?G=]#^-#_0%?[5U7HO[O''VZR M PT]8*9-H$'G&Y*@08-9SV\Z6\MX+_]D.QQLK_&CR.9S7NYKQJ^ ]]??/<2JHP83%>DHS?(AC'9&SC 7MF\GQ)":D!)4)BM-AF?OU[SNEN M+2S>(FPPFGN?&0-2KV=?/_V_VY'%KKGKF8[]VU:Y6-IBW-8=P[0'OVT%?G][ M?^O_'>9SGX8^/ ?/VMYO6T/?'W]X__[FYJ9X4RTZ[N!]^>#@X/TM/K,E'OIP M._>Y2JE4?O_WV6E7'_*1MFW:GJ_9.@]?LDS[Y^+Q\=?PT9YKF8E'\1LU2?7] MS-#PJQ&]$']X][WX,?&H/_?1FGC45X^:GK-3*>_=M0[Q1/C"[:)GR[AFV"'_ M^W/G-'KC#PM@>: M-@X?[FM>CQZ4/R1&E=]M>\%X;/$1M_V%[^$S].X_5?6VY_IWOBE_GWH+QG,= MBWMS9Z)?$DLT?'?;GXRY-W_[\/-[_!G?*6V7RMN5\"IT)[!]=S+_?.6/B:E@ MO7,WD7CHY/BJ&SXUU%P?H,$8MAF/[<)K;E["I+::+3[]M^?S6?R]HQWM\ M[[T<]M/_;&^S8Y-;Q@?6Y?Y'=JZ-^ =V:]Q^9*TC^N-[J?+Y^U7W/Y6C+_7Z M!?P'E\>VMQ_Z=K7Z'3?]??YFOZO-/F+$G2J^52[ME\I/>;W6^,X!/V G\/]- M&\YRTH!#V-(F'YCMV)Q^-&\_ M(%IS%^D%?3(-@]M$/? C/'@.H.2:NB ,MWX'V<*QZXP0GY 3E+24>18BV=;A\;<[9CQV-1U9 MN1Q*,KL/1W WCJ=97UPG&+=LW0I0V(-O<66F'7"C/>8N"0%US^.^=^[8>N"Z ML(*MQ.KK7KL?7[%I_+8%$%8Q$39+I3W@*X%MBF!]LTP*"#R>U=:A6 MKI;Y@*6?FEK/M$S?Y##U(_;QQ!T<'*2^@X8S&ID^WJ97MXT&K70 C?LZ#%+ M*Y=J+[ZT\J*E[::^M L0 CG=5KG\8DM:=$KE]+ #)9@/ M7S33;ML*)]K];M#S3,/4W,G6@TG.U!+W]E,_-4!39\1/'<_#=0@8"P#,0DSU MZK[OFKW UWH6OW00<>$A$)U!NQ@(,O_D_1RD#YA+VT])[.<. #K86P),.WW3 MQ]T\;$W?Y8O?D70X-F'"&1_UN#N]VDHM?5+ZY-76#V9UUS XJ)=I,^,Z;I;G@>,]BAP M 9R%9$*D$,1$^N6Q&^R RFC:W&AJK@TC>HMVDSYE6L9N?N&ZTD>796PP2VEATC$\3HPE1OH/F@_][*[7R%=>^F)6BFN^W%$;"\]UI?B'AZ( M[7OI<;HT+^#)R)VB7$7[>;#0]RM8L)^RO)K"HA^' OO5E=O ^%_?V?E5OYT MX-]/7W%=M (2RQV7FP.[0=J_/KE$'X;6/@JEJ.7UJ\?25/Y7F M5\CKKM<\SCN!?YV;,^Q3(.0(G6@JJ2/ LO>U.-@KY*^RKSL#3Z, M>E4KZ8E"SW9U3T:^2OK$;UELZ9?0,7V3R/-O\Y$(NCXRUB^C;#5]X8H\!B[N MK&UW-0MU83(1V;_N.JCNIFPS.>(]'R]@ #=B<\^[P%L*7+\3(+EY^C)3UL3Q M2)4S(&9E>/+Z]M+GL6J)ZLY!'!ISUY]<6)KM-_\)S/%HQDWZF!6G3VV_.(YQ M8UI6:S363!=7=Y_P=O<*E^(WT3DWZ-HO7'YM.H%7U^$L/?,^5G?74G?*Z?/I M"VU"'E[ I517FKYKK:%YPR- =P]8_B/EA[N7NA1/5'C_9Z;MN*8_H?B?H6,9 MW'V@57UFI=7T!=#X2M'BCQ&R[7Y,NGCRL5;31WPE1:(L<,Z?3)-V=E]F:?=? M<(I<,L(:DIB:MV-N@RP%S,=KB=@7XW/@GSO^-TZ+?O)A[J5L1FW9B.)(DT 2 M"ES[14R+KL2[4Q:(B8+,U(1LWC4"G/R^Y/K0=RQE,&LZI;PC1,90LYZ['.^&6 <2?F+\K M-@(_]S]/\)OYPN?>$FRVZW^XG ROF/BV]F$/0+]N!+[R9:WBZ M^Z7TN?QSGNZL+76U3C=]XC]W<8 MTC[!%8?!_\@95N"((*A M:0>6V-%\?@X+TFXQ2J_E\U%DT7FJT'&0B#F]("O ,M;=0;5(AZ,E\/QB.3V, M@/V#"7DZ=&WB.&^*5I^^EMAY[N5?D/DBX8GYQ)PK8'[(9,BQ&4/5D\\5! MPG:_:ANX__PK*4*26GZ'7W,@TBH"%Q_ZR_2'#6(!W&W>2@$=*1'\O_%H/MQP MW+$#])_7;>,*&(CEZ.B(F$_M#ZKI&Y@$#8VQ'E#D+H"U325!W$56G[:7W?3W MDM9M+>3YC]MABOIL&K?U"WLIEYZF2>"743(6;HU2&[BM5A?P %'689]F'7%9GG6+SU0$<0/V/BZF];GCD:6USD=9U[AMJ)?DOJ/IC<0KZOO$ M27 M\D@7GW-$,\KK=[8BY=\_C#803B%_2?60JMNEVG9E;WT/26Y@J8>TGEB:A*2] M94-2>=T/J;S,0UHH6Z[7<24H?^DIE+_\#)2_=&_@R4N=>G20?( :2.P'^9,! MB[D=6Z9NRA049I@CC.+ RC91&@R<&=GC_PDP9]P9C1V;@01-W_O=D3B; 0-WGL&&P<.",*7- (3YF]\P"'AX M!.9F ,6#SV/#X.3.G-#- (V[CF SH&'-9/-G/J3[T\DV T]62J@J[X-XS M(7MUA>R7@(=,R%XE(?M%*$(F9*^=D/T2<)()V:LJ9+^(*3R3)%]:DEQQZ_XO MEGK8#"!:*5%TW0$JDV5?7)9==Q#*A.$U$8;7'= R:7JEI.GU *?'%.O8#!A: M+2%\]8(K?['\R68 T>H*X6L(4)D0OEI"^!J"4":$KZ,0OH: E@GAJRN$KQXX M326W9:+WZD12/$?&1"8YK[CD_,+PD F^+R[XOC1%R.36]9!;7QA.,K%SI<3. M9X:&TG:YDB@79 _^'3K!J6,/?L!9_&%JSG'PIR;*!9TX/K=BE8+6'3P^!YZ) MQ71C!4 %8%")EL>=Q0O"B;S#YX23[A .9ZB9JKQ4@IB>4 _I,\W6!H1\&P(O M3SN35P\WI>IVI3H#-X!3/YW@1#./^'%PQ!M#TS*PZ_@KH"Z>ZW_HPCJ, ,M+ M"\YSQOVA8T2E/F>_Y1Q;5<\#IP<>$HO!SKJ6I=*?\AP-X=O&7WCOT,X'\N\NQCBA@/1 MH\_K!2F1O.J7 *>O(!Y.@L3)O H(:M_8W/6&YG@.2-RUYU<.!17A#7B:TA0J MWMAEA/\3(")>P[_6&UI>1J5ZE"T@>=R7DS%/6@'FWL?+JO]QG]-S0++"[?8U MH#W7),"F4$KX5<)ZAY,U$2L;BF9(HJB@]WD2_V4.Z4P<;[I0?A_^/?H*,R1\ M;B141/)Q=H37C6H/8RMI6UXRR'Y6]I*!_6O@,!DJKBHJQNLJ7W!G;''OLV;_ M;/<;0]/6CN%_MFYJ5M<7G0HFGP.7:\%Z8Y+!S0^G? !2#JTW;A][Y F\5D>@ MB$LL[Z$S .,2Q5^5RII5,(J'ZZG-/"I<3^U[.>%Z]U78;VJN-9DUTW:Y>VWJ M?,W#=]"4=.$ZL"F_[<0X9B7H4R^NTKT2C$"%W<3K9 M#8(HHE5W'$(&3H^C4,>!:U/#5SCP8_.66K]*(P$PC.]GIFV.@M$& 9AZ>/'! MI*-W(SON@-XOI\6/BS23 SPV\&>6]WR9?+F]7JN%?.['P!Y=,A]Q]'5#ZE/"$Y F\L!6>+NIQ M$"3O=#D0%"7;97"S4G"3S)HK+SEK!3-CJMN5B@* KXZ)HK5-IH^!R\GI\#I M ;E9NU]W760S.$[LUN_8]LO=O[J;I0;KE))2SPSX_T)(]KH"# H?EZ:/V4PM MVS"O32/0K%\C$0^==EX6S%(BJ9=(LYZE\=GN=OG@ 33K]8GK2Z-BZRBE)^$. M86*EX.XUV3A6#NY>TK3QO'#W"!GM5Q*HE 3 K[D=>_36[SG.SU<2?_.B4+PX M0/C%DZ5 SN%]P"B?GYK7'-%DH6;95!NE^>0Z4=+EM.J[(QVPXMA=8OFD/UMY(^#CXN.<07I9;EY\! M,BK;E?T,,M8-,O#67H)F7&B>!O>B;1@LS&Q[,^E"=ONKCBD:0?<:,,RZ$WOA%O&L>-V-8NW77AD['CP<__S!+]9;PB<:?VEV)LZ MH'BAJ(<<9;JA!.*P->N+ZP1CBAB W] -HNF9."Q M/N"Q$E:V#%!6%%!>B8TI@Z]U@*_5L[#<1[_( V]QW0\T2Y:<-,.JQIM78RJL M,__H7.^[#C)=*^6346:%*U6M.)6>KT-DN)/AS@K@SO.VB5R.P_G4U.&JUMS% MM5I ]I 5+VZC%S8[BU],QA6>S3^<(42&$*].V8C%E&UZ.,1CPO)FCBV+>G@- M?&-Q)VA%Z#(D>4+L:H8B&X B#<<=.W"ZV ?P"F0#R]%1CM@<<+_S #)@>H@' M.!-&,F'D%9EG[LD5RV \DR5>)81GHL JB0+/;(Q>;'O+N'O&W3.+W'UHDHD' MF7B0H45!T?<4XLA@/),E7B6$9Z+ *HD" MSY] AL+&=,W:4\<>_##M 18U.P[^U 1Z473Z*XKI?%BUXX>=Q1!<\\IO:BN+IR%$6 3J2: M,$J4_M QH@22V6\Y/]=&?#J9=L4+P#\?B)?W%!#'@_BF9+^YE[JNH'Q? _+9 M>/ >L[V+!/ 1<<\P8^.YY,$(!W9D#18\X@^DUSALU M-ND1MYV1:=\W[?WG,CWOO('5[XE3>,"!7L T]US9&/Y\\H5USC[?"W2-\V\/ M'/^3>?O!18J!JM;0'+.^ZXPZO._]MG6LZ3X0M-V=W2WF._([Q_%MD*3H^[VM MPT_OI]X7@XIO/2=P=>[A5_3-D -WP@/^]!X.%?Z+__=IS#Q_8@%1[0.N?6#E MTMAGET!V/';.;UC'&6EV07Q18%W T?Y'ABBYK5GFP/[ =(X,\",;:>[ M+=] M9_R!P1#A%SW'!^Y W\%RO;%FQ^?;[FLCTYI\N&]&>M8S_^5B@5N'__>_Y=W2 MQT_O<4 XA3'MYM/_;&^S8Q,4U@^L UQ^^T(;<+:]??@)]JNFO3$-?XC#E/ZS ME?BAY[AP/&('GRU-_\EVX"BH5-E')G]4NQ&_EXNUZ(GX$N,KQ*.6_XXM[WUB M?6M\$=-7L-:[4'>VKGO9IY%ZAU?GK?JYT>L^7?CI'[^IZGP$&C]N=,U@_#8G,_]:X_7Y0JGSG M!C>WMX\F(/EX"I+KM@W:;(>/'=>?#]'M_M^CLY]M MK<:?#M%]QQUI_F];YJW_H> 8K5UF[P\JUM\8[UCYFER=-%K&: MB,O4&Y?X<_F@NO-ZD D.2$'Q*]K2L>/F<_Z0L[[IZ9K%)EQS&5 -;K!I@-^= M O@+LCHTA?M_/L3_<7S6OK$.NJV_:JE /!8^'L%[0T.;X$JY/0_P$PN;1=P= MN8]&X,( _C%M_!N,=N=6G-/VT)DX7X?:(/6M)+>Q:%U;AU\#:\+02S,7APLS M-_9YZL:B(8_A&V_^1H___-T"2O57>;*7(M^=FGJ+K%L+&?!#^?(:XUYJTM[* M,<;&M(B'">OD\;J+.7[3^Y^KC4E@_-#39(Y]S?+FG1\U.QE_?)W\,62.?@@L3-C:R=;(ON,_S'?$'QEM6L6] %@VG-'( M]- 5E,_U38LS.R /$0'J%/$J2>+5))?-,3Q]'@A_\SRBI7WM?/OOSKK4-5(89]<;GF,]$#=,\YHVYCFYO@YEPC;[']"&<%7??O69L\[4>$$:=6Q9\KYOVX+>MTA9] M'FN&H3X_>K\QCU'H"-(=R]+&'BQ(_26<@I]\]_$37&.I.] LU*&*0U->QD^^ M\>0U[QS\9]EP.(=8?$X0BY:MRX!!8%X47]AP MMW)PW'6*2G[GV=?/MJ]NGGQJ36K" K<,:O+Z[5RN7 M=Q\(1O O=Z6HRI(Y&F&=6)[C,@>4%I?]"%S3,TPJ%0=L;FE8MK*HM>0S;Q4[ MQ6Y1K*\Y&EO.!(/%-A8&S3@7B$#1'6BV^2]]^6XM[G6-0#!)+,4RSYWBNSE0 M"/]!$6]YDNNLW)I)K2^*VW'18LEB1#,A1M0-P\54!_&?4]/FY?DB1/FT9&FG MS;-A]>GNH6D18L[D6X?[^]6*.-LO%K<-8(=_:9,'NU&.YNVN 7^VW4OGQIZ_ MMZ[>^&/'./O\K9.>>#0S]=9AQ_'XB&O&@S>S-V\S)#VTW0N0\8&*+] L>HW* MYR\_:GO=]M.M$H]6+>8O<.NP : .@]EFIE>L(D$XG@=E%PYSUI M_-OZ^H_W[>*SEC;6)&;?.CPH[^V5,F5BKF K3TS*<'TV=@'IS+%F,7[+]< W MK]%L!F(']S*1+NW#!P@5BT,XW1A);CUMJ7>(0LBDZR[7%M.ZBW+E=%#["^2? M- (* J3U)5OVT#56^>S_4F3!]R_2-^TA=<),US83JF& MS!='Z@+7=4WLZ#TYWYJXN*"!6P=GCL+*!(+8VO3O98,PQZ'8;;CPS?_!*8+6.0[ MC&(]7(KN\M@X<+T 'X0? )W()EZNHH4R_$1A6Q+C$,W8VAW7-&KM)U#K3\<* M;%]S*<3$71#^^3?(EC]'I?K?^L_44&IJ8J('"X43B4SLW&%A1-Z&X5495_FB M^'4SY.1"0E00+(J]+;\CC#*89EDA6L7QKN1 5-.' M5A$N\*#$#&WB%>\Q'MG=3P<'6F^QHX% M+TP@:S1&G#FB[)G/2>$35)- 9,BS[O8E>XL'O/>15:J58BB>FA0A-<8(J03F MNESGI*\\&7WSN6G\%4L.L9)[[V9Q[G@JA"8\"3P(B0(+$K2^_&EI-?WXOY]Y M:C@W?_X,YU8/YY1@:9B>;CE8>0+AV^! ^ZDD# &5Z8"A@@E, M>,#19""42I/HP-AU;B?(C$U;N&%PI9XJ6N>QR'^/:X%3<7D?%F3K' ?"HCRL MU6J%^SB&,1@FTN*0FCUA6IAM2HN,/U+,5*2E ?)7S0Y M,[GJN4"0TI4( BQ M4"[IR:IS*)THZ6O6V@34V4/-"8T_P$%T9S2V.+(%CP/D&2HU\)^ PF#%\-I@ M + 'H$*>(1<"R M=863:(*Q63CQ.Y(-W]P=K'T1]"Q3/[8("CA1AS9SF5\0?]3! ,\3W2NGCHE70S^6/ZK&9 M!]3OR)WD,S.+8'(-\ME\3ADSRY7>=D7A>ESK6T/8C**.XE%&TU%(C][%PD"C M1$#2:D4=J8""VE3P,B:BIGD1IPBS8IVS^# M)*<2CUU;]I;JT3[$:A=N9J7# M#](^EFF&?#"3D.ER['FA3(FUHSLA0=MC,'"G7I@:G"_S$KN"+XC5S3"'>SQ ]+*J MESS_CH-C<]=N]7=+%ZF$HBVJI#)G/?<54ME8O&W",0Q(#,'E#5SGQA\NO/!D MEI-Z]0N]U!#O+$BXK5NWIY>=GW_PISO\'GSQ<]?U& !8T:N:C8:*(#466[06 MLMCJZPF@$<-07,+2%&:@C4;H$>P^!R=:?:)VC7WA TL)#EO)T34;-0"7U79-]@?8LB5':3\@G.7*K6-;]V+ M?TXZ?Y6? 6#CZ\FB5.(K?+;XM=N+1YE\F(XR^>5+R=*N M?EFD?EC)ZE4(%Z=V"F&@/M?0Z(U]JE(20^5]AB=!9_#,D?EK=!FN9H0J4',QFL,A-$BVXXO?D/C(I!$A1ZI76VB59K.XNOT#$ MN;9&\3 MD)^(WLR7>GX?MX.+G^;QW^T?*41/3,^Y166\5)(S>10+@!.N=#R^*15+I7+T MQ7*U\]7/_E,K+#T[T*AD$DD,!1EF_#C58S"E>O0D565=05 OI@CJ M,KI$9)=V**OUX#W(6I1P*S*:Q0E\,KRA!4[)+O+.1"1V&+9#@KZ(H)&!-IQZ M\%$VD7P%&ZIY/AM31(A.>AM6GOXP8^-(I@H(J""@$!VVVM&J,!)F; I;7;54 MJ^Q]_[?_U;@\MIQA9]*?]KDEX4L,QF*CW1\]<]=:YH;35+=+M>W*W@/#:5KG MQ[& &M5/#)30 O"K0JFT,*HFGU,WUD\&.L5O4-S$F39AE3T*SZJN8N?E7+G;?VKB1>WKP># '/O2&JAL63[$15E+HQH&$4MLO[( MMPR#Y7-7Q6XQGN6'$:.ANRVJQL[>XM0RE+3;;,B@T7>XQ'/G6K3Q+>^(^1(/ MMUT3+AX6?$R9>>K% CH">QSE+EI2/J?VUP<:[MS@#Z 8C1UO8?)->E#^X=D M? UQ\M>7? =E?:N]$S??<&R2$RA6M*=9&N:R>$..]@F ,4K>V2\ $*G@AVZ8 M#5- L5WFO."?(#%4#7S/O,@*98S!7?IC+DH>?J+,.7QL8:1H 9,@-- M!/>D3IAP= \EM=PMZI M^4]@&FA+P;-O:&/3)VXN>U1CEI:H\"RA;T\5?53:P2+H/M-LD.(1-$.3TA' M1B"8,TY6!QX[\5"T0' -01JPP1!19OA01\(-/-)6P'0WJ =C1*0X=-N82X9) MBC>.^Y-"A>4V'[83"OIQ30_=0T; <0ZM!Q($P\@T2:S#,KG+2(K* '@. !L2 M@.7W9?3QW130C2G)NS;13!KZ+>N=2+*VUI++TR]3+)Y_36ES?^H':ZP"N%*E=JIE:E\TSL9#RA_6 MD\:&[KHG7>:W?;IG\TCUKVL'Z."='8F%*0,)->-&E;6 M$PQK6X<7G?9%LW/9:F9PM]ZDL+J>(+B[=7C:_%(_90"(C6;SJ'7^)8/$-:2 M.^L)?GM;AV>@@[!N_;AY^8T=M;J-TW;WJI.1P[4DAYGUY9597U:)V"4MRIE) M^75!6D;15G>MJP]GTW[Q6<@C]_EJ$[A(FJNMIS2W#])U MC^5+K-ML7'5::Z4=[V7$^L)DV4DLN?U+TVT5LM0X"YISE?=;@L(+A)3>.#T6[=%M#0" MW$;[_ BHJ7P&E.RKTTMZ!&V0=?QA;<#Z(".S\T"Z7EQ'F*[L;!W^<54_OP08 M_+-)P D?05P0GV-6(5;_W+ZZ9%+*0$_BVD!LN;KI"GP$I_OK27HK6X<1,>T" M=#;7RV-83C& XLG"P,H3T8.UI*'EZM8AZ$_G7X!(M@2#![I9_])I"B!E?[4N M3UB]T6A? 9T]![9_KCZUSK_0\S$)-Z2X:P/;E10%W74GKP?K*0:400S ,/5. M^U2:!- G>;16WJ"7 M3I-RC,H ML.;?S<85F1/;Q\>M1A._0QVCT>Y(V4WHV7\&)@NIZ) M6.7]K<,(-AOMLXOF>7>]](QJ.3,K/@ ^US-)H7R /G *P_C&VG^= ^$\:5V@ MTQ!HZ&6]=!\18GO>J8_5$I; MAPJ,"4*![")X=Q,P>]FI TENT(\%:5D7<@5KG1\U@6 ?-==):D@3CE^3G+N> M.125,F:1M"XV^S\"1+O&A':C7>59UI^IN4_O^'RS\QN M^:J +J-H*[;6UP1<*TK18O+<>F915"IH$#II?6ZM4639BDAL\#VNXK>MRJ-+ M_&7T8X7HQXK<(TA'4[A9W3KLMKZJ%(FN8 M,\/1 _$5]AG13)L;HFRYZ3%7-*'27 Y?^:+!B.8Q+QC!1E2O*/P5RY?;7.>> M!]];$^RP.;:XSXOLPN*:Q[&V.98P=T0;U;O7(1I4.5A)77=<6 'U<8%G.*RK M-Q%C8;%L7 N_'9H]T_?"F3PN>E7('V 0@]\RS1=?PGJI>+I)#7AI=]CT0 M7 MS"S3\\4SV-,E'#YK!CF_7'GU(VL+"/N X\KNQ1_9G]B7> .KF=]1.U=V6XT= MICK&C^QR,H;YZZ[6,_6/[%P;<7'4YPX>8"51KUR]14U=TZV4O@XG_/AZ\5FQ M][O0_]%$+ZSHA,DZS2_USA$Y MJ=O^#/[=-V^W?\',](U;7B4&7#PYJQ7SN\8+>#VRE M@MW_3.^G$%0"H)DN+M6/BRX]$!H,[&M$[0&Y9?*^_-$#.6\7UX815(R/Z M-=[E1781M";YG':MF1;14)@Z>J7(8)DL\*CQX V0312B]"$*,/+4:.9KKLZH MH+[GMV/8R,S7&FQ"-\?8+W[Z)R&IA5_G<_+[L:79L\,#;(SFC>(-G< RIK^U MS)_MHV(DIBH/:#*8/OY7(3XDPSHT@>Z8P%. MJ-IIR [PIG0-B1W\@(V*5:]*((F&V4=%$$F.:VH6J(K4OE@I6T1$I/('^IC) M"6+N CA;MP*#%U@O(#TUGT-5U *JY%,/MU3[^C[/?3]*!'_X+A(2^?W6KC2L MJ# \FD=_K<-+130<(0D_C8%2O+V#W;V#I!'Z99U(1/W9(_X!2<0RX( ]4"* MR@5,+/:EG6MCO6-A578.--9]QJY$&"<]W])\H$/WD0M%'QP#W12=B=!6@/4$M)X/=#'8%[*H. MZ+KC^1Y!*0#39!Z<&MS2)L1+\5GFP-6[@9V1P0R4%"@A""$W';N.$>B9L/6* M@*-I7YNN8Z/@@SWN'P,FR(N$I]SE@T (X2&E89XVX@RM)V2'9OR6O-@N$2 + MC2U$AD;DPL^@Z95 4YH2ES0:3PJL;]JAZ1<5P(&K^MM+^["F_Q.8GI"Q/N)C M&3QM*#Q=.TB'(NV/ST"8$*?'KJGSX@R8_&H99+MU]?Z*Y/C V(Y_[ FS.9R=RL"?*=DN'A.D MWE=10?+K&S[]8.#% H>N=STAC;14<_BI;G_%HS-(S2JH,L M:;%*@55*I?UP>2U@Z12J]4Y$@]#;-NK$%T/'=^HC<^ 4&#Q59"U?.KA N_$] M\1#H/VH7+'X(^9PX!9PW&,#1PZPXT[!Z;B,'K>< MFPV,74F9D+1!8KHV^NR[*OQAB !5IBA$*(/C=HKG*N34PI\1S= MU"QF<__&<2G"![%CC)C+O*'FXC1AT::HT M%GS<S#'OP[=(*(C^ \+@?6X)G7 M/)^37/4L# DNL%/0RQ0#._GOR?$[ D#\*S2?[)8P&E,G%G''I*>./?B!4/B' MJ3GL.&!_:C+X\\3QN05K*=)TQ7PNFO#TJV+ !1GF*3;:Q8,9:N:"K;#Y.XE$ MA9/C[DG(VHG-P5,#4^" MBV%Z8T>&D!]QG8]Z('Y4RR@FH+" Z6@V7 +;8?68W;3 OCI I]B?<"( >D": M\*2., R+C#BTZPUD^,\3(:T@P?,!Q"E.5 (%7CW77,Q@')J6,70<@W$C"".I M)8"@@*B0(PFES?#A2ZX/;<=R!I,0_6(H$H>F?"Y\2P%LD2$6@9QLPM%0F.R0 M6P;;JQ5K_R$$C_)>[#L.P;B&(P\9A(75,'A"!PP5Q&#@<$I+_W+OM^%RE M<";3$X?8FS"0,RA) <0/C$:Z8_&PDK;-O@9P Y4=$OT/:(HSS=6'K%)5:+YP M/=Q#HYKI#1',8%HTO4W3BZNB;0KN(90590K4HH@[%0MNZ!H;GC>I?L.-Y\C(Q4F M)=M13K%,#$A<,2E?Y+=RQ5Z0D_,D)H7G]X4#&/R,GUITG0V:,;P$^6B(MJ!# MRY=]/D)M%E%7YY1BA&PP$BP(#*.,Y%!,J93I!.1GR4?@WWC="6!R;,X.=F=@ M":Y-;02$#KA<]M\AP(-EWDV:(KB2C\=89Q)93/L:EH'I(X@BM >7(Z%!U-F) M4:>(]^5S=S,_EO&^9Y.')>$BF%I,M!1:17GZA%0ATYN1 =E;!74 ,0!4TR+A MR5F'-1<3%Y0/3$QL![GOTEF26!89,2P,?56N4+7!Z!0+M'62&F.]!:C@0S-4'.T7TO>@% "0X"]%2BS@ YL6 2 MX)!>@*(YD":DQ:CY#E!@H'@5$HUF1*$[@,C1*203K60#F]+18! +=T.K"4EA MD7T&&2*,&AX%>..42ZD.1@2NT/K[G/95P<,)^42E(@1\&=]"T>J,,MZ IT=W MQ+3QV()ER.S,KP%04$E?,VJS)$F[#S*5A-L)$V\Q:HFH$L(DJ%-Z M(!))68_[-VA.C:11H:>J(',0X .\4A0R\1?,E76Q%$C;AML&E17SP&S@B0!+ MD1D6OM9(I 48() *E^A0TC# BA>SY9)(XVL_N:V2(5WR Q?$G[@3VZ%D85<3 MUF#-IV@910: =)%^&"T!E%]EVF5DV:68>HS04@J)% Z4GH*)%_WPQ_#A0,>* M*_W VD#P%?\NIAR3@^4(,%V5#R;+L!$O9]'K=, B0=D&-$"NCI2@[P"^8W*1 MP',#A '+&0NOB,"@KFD[VU?%;A'T-Q([XH::) ;WT?8*C%#S4D_\S.ZN#NI- MTMI1MWUSNS[ DS\CPQ?I4A>N,W"U46$]=O49C0TNY@O BR[F@4#KL?N&K"[,Z=G@LAS:O8Y#:FD=R%G_P7;);X<$^8O@$.B MJW)--GDD 7,@*H7-*B= 2,XXJ,Z@7>KLR/10(<]*>BV*0*QE$8BI1B#N9!&( MJQ*!N%[X6L95/K]79*AYPI4.^I1&"C6:+CTI%Z-A1BA.\WQG!2'/D39EPQ/ M3#VRE/@:ZD>4&V>3/0;]9YKKHA.6+$RB1))<0SXG?+%HP@A3$.+SD3E*BH.C MB-#[,6?M*)1(MH6J.19R"2I78F+IMZ>5Z)B2[!C2$H)6(&D"R>=TD%;_!?5/ M#JCTQBN;:HQ0C!)]Z?30UP('Q4>$ M>6M('Q=*AO$K2@9I%?CT(A$XGXL@CB4@[B-[@H#YD0XH],=/&./ %EEH&,X3!,*P#DBR61N5\0K.$:>MX&(0^&!0 8\1- M-5==6A2YZ"J=*_J:P!I@SYJJ.(+H37,"G.]R5TDRN=C5 @T3A1Y Q/5H M[($C?,D&'P%OH&IFTD4^LS(9\"FJKI%\1>9KGPI?()F2]53( CX&[F@3V>JC MZ7 (" I:"6NH:H+*PJBYRM ?.ZK8;LAL&J-H\MAP!_\A (?NQRBMF1+I9+7,6VF'^,5"4L!:C9MH,D@TCLF39AH>-R MOC.A'[BX.3P2HB7)U]N 8R1[,*:T?8Z*<&8\M'A^:A@%[9\9 +!2AP\(_ M(T,5IW/GIC8=7XPRIH>.'B*VX9L84;'=P.A*-648:BS!8?:^,>+X!J46^"^] MN@W,TW+TGP0@*!!1[(A_XP"C ](SI(OY,H4ZA9@SBJIG+$;K&X1M&%<7/IXA M<-V8?_SCE*4])&$&UTV#!*Y\#K0$8%)$K80M$='JW@4 PL71)8*@EB '-AR\ M# D44^MR:KA/58*.A& *(O" 6>-*8 BS%PC/5Q^KE?=@'O)/" (AQ0J9U.]% M0689)UR&3(BE '4-!9.D>R:R%6.X 1:R5U<6\]F$OJIK%:% /A<)->+R-2 I M48X29)8)@K0QO$&*P&8]K5C830JDB51$A=T%U](J@26!?P+Y^:>*!] M]%CJ?CC^S=#4AS08%EH,+)_*QY*[#>C#9ONDGE5-#XD]-C@8H^,;65M@F"(V M!X5\X<^G.#HJ_8I5E2C +>AAN50"(P,X'[S7,Y"O0-['M2'5=M:V8J#A!.9YP$(=[3B[]O4."71Q/\SE@EBJSQ^8# M!XX7/I$4J478BMCK4TE3Q5IZIAW;/3:J )CB?LAU0CE4'@L)9HL&8\RJT&[U,*:F_"6N@/ MVJQ\W1%2#338-#_B*NYF.V*7#0%/3AV1AQ8P377)K.'EDXO"7- !%J;F4%WAC M,TND"&>2<>Z&C!.8 MJN"=U2([;7ZIGR(';32;V)\R8Z'+(9_M*$FUK$P+"W,,1:MHC>GFM8E-(BC; M$JFJ<&98@#@6YJMB\J=H#^G8I:%,S9*!C+06]'U0I)6F8WVR*()*!P07[270ER%42/P&9MY$6KIT MH$("2_$&2$)CS4')LTIQ4!8?"(*J@Z@$%^+%8R2 ,5H@F,FP!Y%D2K$FU1!$ MXYW0PWZ@TU/1)/E<;!89#NO([J.B]3A2_Y^V %%-FH66CT&EH+,"(( MH,7F1D$FX8LF>]A@E'RT-]2(CTQR6MAP3T:<,#0EX#2QMZ)@(1160J=:V$^E MR,[1QWWW6D78Q43](O#+)5^RJ)CE4-@5N:$-JL 3GDOB\+%ZEM@%EV,RS;B& MD;C(_-Q )%FNMK@WI2WN%-E9Z[S)NO7CYN4W=M3J-D[;W:O.IJJ.Z9H[?(#[ M1#(Z(HOR[Z[RTE_2/;N7N6=3=<_N9N[957'/OK[*VRM2&3TKC?[2HO>LJ+$_ M)6K40-2H=WYO7K+C=H>\*NUSUOSCJG7YK<@ZS=/Z);EQT6?W\B%U<=1HG]6ZSR]K'\B76;3:N.JW--7.G?'UG% 2**=:A'W(SS_6Y MXI;1;.!@"1NR'83-S%W-$#4NW+F1F@U,8+19ESKNR/0"GXI-_1,XOLC,:%\V MF+A.[\XP0LV6)7-X.*T,!8YB"E4TM Q\)A554X\9#O?4$PL"GH6=I,M!6XZL MG,U;V7T8=V-2'2!Q'IKAD &E$X D4:X-M@^D@AC5Q/-D;E^?L@%E4+=RVH^Y M304_X7 *RD^/)SD.7"S/0V6!^#66J$K&35.'-&AGECP1&R*EJ8V36V. M<%8+C4;PN\W>U(HE*GTKJDJB'BPB0FW&;[FK8YO3^U\K*$-"/H_A+H^Q;)F-N:::[84I2*AFDP^!Q;?/ IMF@@6,QC):UX5C]53TP0?VUGPG M 8'U7.$JH_,>:3\YQ8-K\#4)Y09'IXX* M058QQ/="TV5^RSP%XO(.LH+CHT%D4EN\06$KN&#?LRU[J' MQM0QS06[XE@H5@LS\+ ;+UFO[EJPS$BP0- !<.W%@+JG>2953A*D<#YD:88H>2IN3(2_)VY=U)Z6^"CO?Q%2HK$= MZ_FAU7$&%^=@;'B>4T!5Q#(LZO#H"H:852"NFY84L73A'(Y'&0RNAI'9Y MHK ;G9RY<"!]5PN,J<-(8 (P!E%ELB",UQ;5O/9E34^R#8LC]\@#(JY$N$DH M[U.PID0 FMI(?$JJJZSRY"4A%"J^D&5SS! MX\D&L@G@]BBS"\@Q7B'*>";2;I@X2J**ITS_ MNA!');$,T\: V%#6K("57M@\$E])5 W']!H<54PIQU9-VD-TCC5J%]",V>]B M AB4G'V*55@HC4I681 9EA49)XN&5>T_8GWH,=L3J 2F9TG<0X5C!H9$2'-4*"6F+Y(F M^:94+.]&>HE0X:*46B$11D)*0; +JB A)5(0O6$"3&Q'P<\Q*'_1Q,0YZ<=$ ML8?P"NNB*G13X7*SA$7S[EKT&@+:HVSE#]_%PZSJ6V3<3J5YL["";BEK>61I MO]]+(R;M85F:Q]IFI5T_M3LZ!N*N.K5C68<[NS4_>,7R9L,SH-TO$;1@L=$U MP,7CU[]M5:9=+LNYDO3-^Z?.S=K>PUHM]C4!S0GPE;6]"/)"IDR:@2? C0U< M+ >%?,%Q/S!WT'M;*>T4*M7]0J56>S>'?#_RL"1SV=W_S[()M>OY8K%_"!'C MSLM^Q-(K_WDN)'OJ"LM+/MLW:1UEN3*U4C)]I+E4E$]36^V2C_4!S"$#T]<* MI@>U-0;39^)&?PU-G_\Z"UKFX73)9)0FWUE9+%YMU%U]KK+RK"2#O SRUH@[ MI*^K+/.<+K%K5<8G7CNVEJKKAJT9Y+T&R"L72Z5U@[Q,BPB-5YC\.JL56MDL^II"3**=)!;E[#Q(+G*=*TGQ5I2K5( MTUY6I&E5BC2M'[ZFR=XN,+\OGQ/E1; *1\;IEL/IC@(>50A8E*E7B+=KI21+ MC7)J-5]5S,1"I);IR;RX<\TSM'\8U="P-97,&N6BF230^[)VN8 MZPI+_1=S_[TYY50\54Y%E!J/U36,C1]+.99II8(38T&8L-'K5%JIR"*5A5_R M.5E0X?Z",>RM7&2WV9!K>Q'H@6CK[%#! M>%'^():0CZ4'=-?L134G8-^R((BH)>+*J@S1J%1]1@\0.(#]RHH<-(N0<+@Y M]L-^A&H%"_:+B\_GJ(:#ZEB3F(P.$@%Y:N5X)9IKJ/3LL*[.HI(1M*6P&:(J M/@>C?#LY!)IHE"$PL7+4M_B/1ML6AM,,!581?'$54QD'UAL<$/AR'ENF4I M#$>5Q2!HA\,?FB.J:3L-1I0@'=]*N,>H":TJ-?R8#;-HOP:?VFD^-[-5CU/C M][!$0U@*@CJ_8Y)N>&F8MBMR]H>BC'4$+W>#,@U#M2;"&KZ +[C_\((!OJE@ M1-@#4TXZ74=(;(C?(A&S!1F4]0N(,&"^NZAN;()92IX+]!B/ M'=-&U&W^@42J^4] !=(*2G3PY6T ]>.R@M5L*8A+@5>V;HZC!C. /S FM46G M#'YL*E(NETNL 0,!/[^@B?.Y1N#"0OZW7 )U_0Q[V?@:.^%4]@:^.&>U6KE2 M$A5C?.PR8O'QT+%!A@E(UX<)WNZ6*^] X3_8/BB5=HOB1E8?UE=_A8"-1R8R M;:2/%Z" ZY--1,=GZD% "&G+\HFZI"3DU7W)^:D,%W4T MHHZD2']$@P4X!^3SN%2NN5*,I@6J-A\%40@M4D=DRYUH+5@>C&KHA%6S7L"O$SJ>X)DZR#Q3J7JF]C//5.:96DU5:Y;!EJ<8 M[![VG#BO?VE2!V]I>>Q2FZNK;K?5/J?F$O#$Z;=NBWI+1&RXT3X_:EVJ9SK- M[M7I)3V"S97K^,/&,.EG;X^ !255M4G4;@/A\1$JHV9-L!XVQ7"$=;BI/NEX M; E#=]S_(!TJ/%&ZF#@PE8X/U=98Q60R47E2JT2G%)J+;T$C1=^1M"2;\+ W MY=R8HP.C9 !RP)PV@E/=_,*^?%%%U0EHL/$^A/E<<@0,C"F"-,"\(16A[>& MFB$]7#\".^[BPHV#3H^:]L(]@SC"/:$9"Z=%_.!,58)S,T6/-*E6&SC/M+XK WR$[L8.KY3'YD#I\!:MDY(*AS89/O.Y^@IP#&U,C9G M83A+,$"W7H7F*>\+M!=-7V N&TU?9&ND#C+<'F@#L6A9\AJ]YS )TD+40D0A M:W,DJ:0H!1UVOT6#&U(KC_NR]T"/ PG.L/W7L-T\K(ORYZ*IBR.ZXE"[&:5= M#ARA4<*UNO:G]^:AU"HW\.B?1[A >P-V9$91(68^E&TEI%E<2 ?NR)-BH^1^ MH=U^/A>=Y?8AJU9V=3Y]]11)@'>OK DD:]C4GAK[X&H#5QL/992&C +!9BL] MC&SU<06&$_3\6"^-Z:91J@+_# 0F0*^(+;EM39CUPW>%(=Y4@1PJ9$,Z"]!D M,1J'<0WS5ZZY7(EQ$5&==WXQUP.*@(Z?D$@V$!_2CNZS-!$^TU;29B9Q+#.. M?4KL%SWAA?4/HVU,SPM$K,W=H>U3[1IL=L1U&1]?5I+!P6ZA=%":^Z*,9!,: MDYK33\;0O"D52Y58!S-TI6G8MDRSXXTQWI0+!T#)]F$6ZE S-F'AM*0P9+\B M0O9+T\9.G#:?BXU5QL7>L5,*K*,V1&;?U+%G6ZQSB(J)4N/#?J:VL('4XEFZ M3H2P5]E7L)>X"%U:JT] W/T7%--(QL5'X/ZX[6'?-RGK1ARGP$Y](XSJ//GO MR;$*ZR0 .]-KN'4L0<_D$G]86H..P[8GYHN MS ,GP&$L&*=(TQ=C\Y]^G3=_2Q)&LY+F M?I#843@^;>0+,&20_%MHZU7QOOG8VNG'[(\P1]@MKR#.3T:]@#B _,MC>[5B[3_, MN;%AUT-S+,YY/KC3">&VT1KGD0#O.K 6!^.+%KU$)(O$#\&/D6(MG"!JKHJH MC-X-6IG!(D HL(O P.LZT1P@I'A-EC%T'"-V)DE*=G%TDB2@;5 88GP#%H2/ M@" DX@%U-2+CX8#"BX4 9F./SH@*5Q416GA!B4U%5!FV\)-XDGG$CX,C+C:B MH\@37GM(?XZ.CT):3%':J#.)WJ#"?AL:3T!O! +/I8(%:_ QJ4*-'+/MQO"H M0+"NQ6ZJ-']7\9NRA:JJQ?LQ"@/OC4,]EJY-(] L0@3)E&1 -, =3P)<>"I? MN&7:/^-G$@SD0^&EWL4> JY:^'46=LQ+E/K1Q2D5<)MY!5)%]>4'.^Y>[#L/^H,*"!K2HR.H>]3M% M:WJ!OI)H=H"@O!BU1"A80OX.9U+QZ^AU3YPMNV,'&4M:@O7V&)N2S\.&H19V MGQ8XP>TALB0 0L<070 C).QCX^LAJC2C4/A"Z\7 U4:R*V=H"=*8#04 MT3#(4)$$13>4B0Y$G$6X.J2F9;H;F#*A@L-$L*2P-:[P=X<+]#&I0B8GJ*[; M'IP)EUU1(YL5'GC/<7[B[D6;5I%*!M?"::X!L<:)$Z!Q!R=PN9W88Y25X8PG MLC.I_ JI6#@^DBL^]H7H!T,B>2JR;FB!OHL X_Y[?!#8LN.A2L%&BY$368QF MKBRZJ)!N2A8879NF_R1;M[P_98!?<$O8%!A&*##59-4DJQG,52M%TY&AR76" MP1#-:-@3D[O*0HBD&QZ7!/L2:>O0Y->BC_H=])JT_)A'(9^C1)=8IW4@6D[@ MZLG)B53"$S_@2O0H"X["@VR9Q*;60EH\G:B(_UVXECGG*NA?[&#%)=Q0)M"8 MZ[[PK&J^C^ES@^M%[R8H&(%L M&1YM9VH/?;C)9=#AS2'I#XNT*I>R4*M40ZT.LE"K+-3JI:G3LR6^*T=4V"0\ ML&5L#?$[(](K8&:#CTR]$-,RB-&!F"_SQJ7$%N,"I*=AEBHEO0*7H/R2/K:; M%8(0L!KLEAV*&);C>=2.61GZT&-WOR*FM#!/J&&AR6'&T!>S,!10UYRV^YV< MA4H5"I4G9VCET$& 0#T<&5^,W?Z?-@+\P?@DRP(VB4H)YJ-S-+.@1!=O-H_9 MQ(M8<4SDI>1BO EIOUDL=?>IO(!0F:+\Z<[9YW*QT88+@$(XV,D$ 4(#T)(]=Z=LSQX_GIF1;>0@ (%,_$Z8H%C(YPQA2"%](O3Z2^HLM"2TN&PW,#6!C2EW- HB M$A!!T8$8KABO5T(O;)NH'(4!X:G(9($DXY?RJ-VHBQ,,LQA!W3TM_BNV0O"(A>P]A[& M1T2!K4/!58#8HXTQI@=NGMTI[U-N50XV,.8A!HR>Q'M+/*,D5$"P7!)C,1']P\JA=)N M544R3:\.C /#8":& M,3TO9J#I)M(BL58T&)EPG2;R=*YK* 7%XB]"_QVM,^ZKPR-!6JW<&Z&8; \R M_OR,=01ZW J-C"+F4#HZ94J@$#B5N&O#@H"S<@O>D,Q5%0HPT:"FRUHX;\HU M"KLILK]$#;'(-^EQ_E/&WN%D+MG[U*32/CD-*2H\TG(T6TJS&-B7Q=\L._XF MBOV*2S;D/9L;#$9.UGA\55SKZ=)CH>(#E#7-:B$AS41>M-5=\K;&>,BN[4]NG,2BL/#(&455/*('ZG=AVRP?5*M4TD@;$5],K)S$=0 + M^)LN"(%*_H)N7EH(7!9F4N%C @O0Z$0!AAAIS*GBAZXL3W+<*,="Z_?-6QZK MUT9F)C@B/"&+#SB9EL3LY!NFJA9DAI$WFKF(ET07'Q2 RI8=?YK/+2\ -1.5 M%HM*).F@^!*_89EB(&H R0(^Y((W>,_'BDPBU(-H"(5& QE&Q2%P->'@%G56 MPW)+DC[+@IMX[5BO*,JH1,D)R:!V[;CB82R=5*!ZK%BU34K9?-#0O&$^=VPY-Z)X;KG\D7U#$U!S5GL31$-F+2]XJ+R9]H94F4)4 M?*P>YD.N\H*7;2J56V*GLTUR8T("YC,DG:H5J90]^%R-* M2^/4(#N%TMY^/E<0\=H8/14W.$8F.GIXM["SNQL.J)8XUB8D120?+I?@*"KX M=#*\7CX-,@R7(<&Q+6*9Z/@@@$^EI0X V$%V#CT70FT+?\*VE8* M^SM NZL'#\/:_5JA7 +E_A0F 5G;<]R>\F+'$E)(NY9.]#<[\'P9ESI @1P& M$BE+PD.0S&(!O-DI5,M[A?M77\CG!HYCD'QN A\R73)[X.9II+U2H8:-B1Y& M7)+XM+]7.-C;BY.6*7P[. !"MR\1,Y^;2US*I<).M?8@TE+=JQ9VRM6'D99J MN5(X /*R@++D<_-(R_3:X!IW#ZH/HBSETOX3*$L^-Y^TB.GW@%<O>*G3M%-"_N;I9Q/9H\=.6=6J&TLY^H*S=/14.N MF5"\B9>#UD4"VUWS"(>QB')R,>C3$2YC8-FF0V]MI@J^$C)\)>D(B;R<%RID M&&4P-(6/5>L!!3+9C;V4UK4X^%95FA 1[[+20IC"2Z*R;*5 =3 QX)UNM%+8 M$P-W3\+*#ODE"$U-U(Z8F= (_G+%:*I3+NR+1:P&H*5@4 M06!ORKO[A)'=!AM6>=P7-L9*M5"N[:IH-*GL1[VMI&$Q<](_9V&9%(&S?!]P5@H[ MI;U"J1J")Y/0*2/\?QD\*R)X9)SH1Z-ZJF* E,X51$J_ HA4!PH@E15K^1"Y M^L"7LB^^25$=61S_B[0]"RW]TE<@JA7COT+;:Z+LL*@%,*](NDP"$)U, U'! MV B#W,D0#RA>*NQ62G&>F<^]J15 1BW4R@=1F4-^32W.%#&A&@X&#%@(:R@C ME< 4@L"-NY95T+,W!,JQC?$\(GA(R;%^C'IEO.39@"W>&1)K:HRI+RS%-F$' M7RY#W\.LC84-W,+$"!G/%W\C! .@'^&X>/&Q=["I, Z#'BRR?RPNCB'D,U$7 M;21;/-]52T-X/6!/*EPWD6])4;HRIY(\)^;(I&!?F6\Y-X-:5+&Z,V6.J73 MF>P]@$!B MO'44>&5-L>$%;1!B AWT8(R"NX,<\'<*#\ ,C M"N26.URTT^H7D3*C1B=* IX$#'SA0 MYV0-S4NL.) L8=$]R>?@<0^?CNH#UN>)=N2-#Y>%1;(P_V4"BI*O_>2JT3OE M2!+5 &("G$]5ZA"%Q> QBK[PG1LJ2S_$@J"T/8](A%?,YRX3\RA"$V8!C((2LL' _I+E M$B2\R\J14IK7H^NAW#9Y.Y0-/A:V$0=5#"QE#)IHK$2G<->1C=(3"D,^ARJ* M[&%CL','N%6YRD[I$1 #0%LCTRG;0R4KFHN*+CC44 =3*[GW;O, XX&1=94L MLB[=R+IR%EF71=:]ILBZ3[W#CK"_)/LX>=N_EF[(@)>_1>T/]99W@GNOG:/D ME];W+.V*S7A68E/:E#\P==[ACY&].8JNIXB\O;W" 3#=^SSWA:DH@EJ-*B7% M3,+B=T1Y2EG',#U1WUO&$<0+'CFSRZ+^,)$]ELII*O_.6)N@:UY)$GU.W7OC M1G1'ETXBTV9778K61\,UA>LK0SR67833P\^AO32T-J8JN*^AF^6Y@%4DH;1L M@!;.WDJ ?1<#6!(WY;T6A(4CJD=2+A?VRO<'O4P!:WEOI[!7V2/ H^%-FOZ> M&-,0>!-+>EB("WICR-R# *ARCD)SF():.3264Z'C>%" PMRA52[2/6E+A7@U MQ3>(PJ4=^8KT-LD0 AFI<..:/M\&>3Z1_B+QR>(#+"7(?5\Z(AXAKV?8]BS8 M=HZA2Y3])DI0TAT$5%TH9/,1ZL'3(B5M\<.QW"A"K /,&RO=CX_8D#2&D/N MQI4H?/PN]&/4\T+!G=9SKM/UJ63 \T#@P7:KCBJP'4&$(-%($K3;")3^HL;Q M%HQI8+)U;;]2*-QX\N2;VFZY4-FM*+\O1D15=PKE\CZ"CW C*)

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ຯ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end